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Summary 
 
Background:  
Lipoprotein(a) [Lp(a)] is composed of a low-density lipoprotein (LDL) particle and a glycoprotein molecule 
known as apolipoprotein(a) [apo(a)]. Apo(a) exists in several differently-sized isoforms and is responsible 
for the unique properties of Lp(a). Although Lp(a) has been known for the past 40 years its relationship 
with coronary heart disease (CHD) has not been characterized in sufficient detail. Whether Lp(a) causes 
CHD is not clear. Furthermore, the role of apo(a) isoform variation and other sources of Lp(a) 
heterogeneity (e.g., level of oxidized phospholipids) in Lp(a)-disease association has not been determined.  
 
Objectives: 
To characterize in detail the association of circulating Lp(a) levels with the risk CHD 
To assess the nature of Lp(a)-CHD association using an integrative genetic study 
To explore the role of Lp(a) heterogeneity in its association with CHD 
 
Data sources: 
1. The Emerging Risk Factors Collaboration (ERFC) database (36 studies, 127,000 participants) 
2. The European Prospective Investigation of Cancer – Norfolk (EPIC-Norfolk) study (2200CHD cases, 
2200 controls) 
3. The Pakistani Risk of Myocardial Infarction Study (PROMIS) (1800 MI cases and 1800 controls) 
4. Systematic quantitative reviews of published epidemiological studies 
 
Results: 
ERFC data - Analyses of cross-sectional data on up to 127,000 participants (predominantly of European 
descent) demonstrated that Lp(a) is generally not strongly correlated with known CHD risk factors. Weakly 
positive correlations were observed with LDL-cholesterol, apolipoprotein B100 and fibrinogen. Levels were 
over 2-fold higher in Blacks compared to Whites. Analyses of available data on repeat measurements in 
6600 participants demonstrated that Lp(a) values have very high long-term within-person consistency 
(regression dilution ratio ~ 0.9). Outcome data involved 9300 incident CHD events, 1900 ischaemic 
strokes and 8100 nonvascular deaths. The risk ratio for CHD per 1SD higher Lp(a) concentration, adjusted 
for age, sex, lipids and other conventional vascular risk factors, was 1.13 (95% CI, 1.09-1.18). The 
corresponding risk ratios for ischaemic stroke and nonvascular death were 1.10 (1.02 – 1.18) and 1.01 
(0.98-1.05), respectively. Data were too limited to assess association in nonwhites. 
 
PROMIS data – the adjusted odds ratio for MI in South Asians was comparable to that of Europeans. 
 
EPIC-Norfolk genetic data - The odds ratio for CHD per 1-SD higher Lp(a) concentration, after adjustment 
for cardiovascular risk factors, was 1.37 (1.20-1.56).  Tagging SNPs rs10455872 and rs11751605 (minor 
allele frequency: 8% and 18%, respectively) were associated with 207% (95% CI, 188 - 227%) and 38% 
(31 - 46%) higher Lp(a) concentrations per copy of minor allele, respectively. These SNPs accounted for 
35% and 5% of the variation in circulating Lp(a) levels, respectively, and were associated with an odds 
ratio for CHD of 1.34 (1.14-1.58) and 1.17 (1.04-1.33), respectively. The observed SNP-CHD associations 
were consistent with expected odds ratios corresponding to the Lp(a) effect of the SNPs. 
 
Systematic reviews – meta-analysis of published data from 40 studies (11,300 cases, 47,000 controls) 
demonstrated that people with smaller apo(a) isoforms have about a 2-fold higher risk of CHD 
or ischemic stroke than those with larger isoforms. Meta-analysis of published data from 10 studies 
(1500 cases, 10,200 controls) showed that people in the top third of baseline distribution of oxidized LDL 
levels have a 1.8-fold higher risk of CHD than those in bottom third. 
 
EPIC-Norfolk biomarker data – Levels of oxidized phospholipids were strongly correlated with Lp(a) 
concentration (r = 0.7, p-value < 0.0001). One SD higher concentration of oxidized phospholipids was 
associated with an adjusted odds ratio for CHD of 1.31 (1.15-1.49). The risk ratio was no longer significant 
after adjustment for Lp(a) concentration (1.08; 95% CI, 0.91-1.29). 
 
Conclusion: 
Lp(a) concentration is specifically, continuously and independently associated with the risk of ischaemic 
vascular outcomes. Available evidence supports the causal role of the particle in CHD. Lp(a) appears to 
induce vascular damage through causal mechanisms that involve apo(a) isoforms and oxidized 
phospholipids. A comprehensive study of markers of Lp(a) heterogeneity should help to understand the full 
impact of Lp(a) on cardiovascular diseases. In addition, further study is needed in nonwhites to assess the 
relevance of the factor to vascular disease risk in these populations. 
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PREFACE 
 
The aim of this thesis was to investigate in detail the association of lipoprotein(a) 
with risk of vascular disease. The work is presented in 10 chapters each 
assessing different aspects of the association. During my doctoral studies, I have 
also conducted research on other topics relevant to cardiovascular disease, 
including on markers of dysglycaemia and on the use of ‘statins’ in primary 
prevention – brief description of these projects and/or list of publications that 
arose from these works are presented in the appendices 
 
This dissertation is the result of my own work and includes nothing which is the 
outcome of work done in collaboration except where specifically indicated in the 
text. 
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Chapter 1: Introduction 
 
Chapter summary 
Coronary heart disease (CHD) continues to be the leading cause of premature death 
and disability despite advances in preventive and therapeutic strategies over the past 
50 years. In parallel with measures to control established cardiovascular risk factors, 
there is a need to identify novel risk markers that may have therapeutic or 
preventive utility. Lipoprotein(a) [Lp(a)] is one such novel marker that is receiving 
increasing attention as a potential causal factor and therapeutic target in CHD. Lp(a) 
is composed of a low-density lipoprotein particle and a glycoprotein molecule known 
as apolipoprotein(a) [apo(a)], which exists in several differently-sized isoforms. 
Although Lp(a) has been known for the past 40 years, its relationship with CHD has 
not been characterized in sufficient detail. Whether Lp(a) causes CHD is not clear. 
Furthermore, the role of apo(a) isoform variation and other sources of Lp(a) 
heterogeneity in its association with CHD has not been determined.  
 
This thesis aims to: i) characterize the association of Lp(a) with the risk of vascular 
disease more reliably and in more detail than has been previously possible through 
re-analysis of worldwide epidemiological data; ii) assess the nature of the association 
between Lp(a) and CHD risk using an integrative genetic study; and iii) investigate 
factors that may contribute to Lp(a) heterogeneity using published and newly 
generated epidemiological data. This chapter describes the biology and epidemiology 
of CHD and Lp(a), and provides the rationale for subsequent chapters. 
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Background 
Coronary heart disease (CHD) is the leading cause of premature death and disability 
globally.1 The worldwide annual death toll from CHD was about 6 million in 1990, 
which increased to over 7 million in 1999.2;3 Coronary disease was the fifth major 
cause of disability-adjusted life years (DALYs) in 1990.4 Although mortality from CHD 
in Western countries has been decreasing for the past three decades, it still remains 
the leading cause of death in this part of the world.5-8 In the developing world on the 
other hand, where infectious diseases have been the major causes of death, there is 
now an alarmingly increasing trend in incidence of CHD mortality.3;4;9 By 2020, it is 
expected that CHD will be the leading cause of death in all regions of the world, 
including Sub-Saharan Africa.4 It is projected that CHD mortality will reach 9 million 
by 2020, and, together with stroke, CHD is expected to be the leading cause of 
DALYs.2;4;10 
 
What is coronary heart disease? 
Coronary heart disease is the most common form of heart disease. It is caused by 
coronary atherosclerosis, a chronic progressive inflammatory disorder of the 
coronary arterial wall that is characterized by focal lipid-rich deposits called 
atheroma. The atheroma remain clinically silent until they become large enough to 
impair arterial perfusion or until ulceration or disruption of the lesion results in 
thrombotic or embolic occlusion of the affected vessel.1;11;12 The major 
manifestations of CHD are stable angina, acute coronary syndrome (which includes 
unstable angina and myocardial infarction), heart failure, arrhythmia and sudden 
cardiac death. Myocardial ischaemia is the common underlying cause of these clinical 
conditions. Stable angina results from a fixed atheromatous stenosis of the arterial 
lumen, while the acute coronary syndrome is due to disruption of atheroma leading 
to thrombosis and arterial spasm. Heart failure, arrhythmia and sudden death occur 
as sequelae of the myocardial ischaemia and/or necrosis.1;13  
Pathogenesis of coronary heart disease1;11;12;14-17 
The pathogenesis of CHD can be divided into four stages, namely: early 
atherosclerosis, stable atherosclerotic plaque, advanced atherosclerosis and unstable 
coronary artery disease (Figure 1.1).  Early atherosclerosis is thought to begin with 
vascular endothelial dysfunction which can result from a multiplicity of insults such 
as high blood pressure, smoking and altered arterial shear stress. This leads to 
activation of monocytes which migrate into the arterial wall to become macrophages. 
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These macrophages ingest oxidized low-density lipoprotein (LDL) particles from 
plasma to become lipid-laden foam cells. Extra-cellular lipid pools appear in the 
arterial wall when these foam cells die and release their contents. The ensuing 
inflammation causes recruitment of smooth muscle cells which proliferate to form a 
fibrous cap around the macrophages and the extra-cellular lipid pool. This leads to 
the formation of a stable atherosclerotic plaque.  Further changes that the plaque 
undergoes depend on the balance between inflammatory and repair processes. The 
inflammatory process is mediated by macrophages and other inflammatory cells such 
as neutrophils and mast cells, while smooth muscle cells mediate the repair process. 
If the latter predominate, the plaque continues to be stable and remains 
asymptomatic until it becomes large enough to obstruct arterial flow. With 
predominance of inflammatory factors on the other hand, the plaque becomes active 
and the fibrous capsule of the atheroma becomes gradually denuded, leading to 
formation of an advanced atherosclerotic plaque. An advanced plaque may be 
complicated by ulceration, which triggers platelet aggregation and thrombosis, 
resulting in an unstable coronary artery disease.   
 
Components of coronary heart disease 
The stages of CHD described above involve several processes that contribute to the 
initiation and progression of an atherosclerotic plaque and determine its final 
outcome. The main components are: (i) endothelial injury and activation, (ii) 
monocyte recruitment and foam cell formation (i.e., fatty streak formation), (iii) lipid 
accumulation, inflammation and vascular smooth muscle proliferation (i.e., plaque 
formation, atherogenesis), (iv) more intense inflammation and thinning of the plaque 
capsule (i.e., plaque progression), and (v) plaque rupture and thrombosis (i.e., 
thrombogenesis). 
 
Risk factors for coronary heart disease 
From the complex etiopathogenic process described above it is clear that CHD is a 
multi-factorial disease. Epidemiological studies of various designs (e.g., twin studies, 
migrant studies) have indicated interplay of multiple genetic and environmental 
factors in occurrence of the disease.18-20 As in other multifactorial conditions, myriad 
genetic and environmental factors act in various degrees and combinations to cause 
individual cases. Figure 1.2 is a simplified model illustrating the multifactorial 
nature of CHD. 
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Beginning with the Framingham Study over 50 years ago epidemiological studies 
have sought to identify risk factors and predictors of CHD and other cardiovascular 
diseases.21-25 Such work has helped to discover and establish the relevance of 
several classical risk factors such as smoking, diabetes, and elevated blood pressure 
and blood cholesterol levels. This has made possible the development of preventive 
and therapeutic strategies with consequent reduction in CHD morbidity and mortality 
in places where the measures were implemented. However, despite the importance 
of such classical risk factors, a significant proportion of the inter-individual and inter-
population variation in CHD risk remains unexplained, highlighting the need for 
discovery of additional novel risk factors.26-29 Study of novel cardiovascular risk 
factors can be useful in a number of ways: (i) it can provide insight into the 
aetiopathogenesis of CHD; (ii) it can help to better identify of people who are at 
increased risk of CHD; and (iii) it can lead to identification of new therapeutic targets 
that might help to increase the efficacy of existing measures. Several novel blood 
based markers, including lipoprotein(a), have been proposed as potentially important 
risk factors for CHD.26;30-32 
 
What is lipoprotein(a)? 
Lipoprotein(a) [Lp(a)] is an LDL like particle that was discovered in 1963 by Kare 
Berg.33 Using hyper-immune rabbit anti-sera, Berg demonstrated the presence of a 
unique antigen within the human β-lipoprotein band (β-lipoprotein band refers to one 
of the bands observed on gel electrophoresis of human plasma, and it contains 
lipoproteins: Figure 1.3). This newly discovered antigen within the human 
lipoprotein particles was named Lp(a) factor – “Lp” referring to “Lipo-protein” and “a” 
referring to its antigenic nature. Berg noted that not all of the subjects carried this 
antigen system and accordingly classified them as Lp(a+) and Lp(a-).33 Later, family 
studies showed that the presence of this antigen was genetically determined.34 
Therefore, Lp(a) was initially considered to be a qualitative trait with an autosomal 
dominant mode of inheritance. Later on the quantitative nature of the factor was 
discovered and it became clear that the “Lp(a+)” individuals were those with very 
high circulating Lp(a) levels.35-37 
 
The structure of lipoprotein(a) 
Lp(a) is composed of an LDL particle which, through its apolipoprotein B100 (apo 
B100) moiety, is covalently bonded to a glycoprotein molecule known as 
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apolipoprotein(a) [apo(a)] (Figure 1.4).  Treatment of Lp(a) with reducing agents 
yields a lipoprotein particle that is essentially indistinguishable from LDL and lipid-
free apo(a). Apo(a), which is found in Lp(a) particles in a 1:1 molar ratio with apo 
B100, confers the unique attributes that distinguish Lp(a) from LDL.
38-42 Apo(a) is 
structurally homologous to the plasma clot lysis factor plasminogen. Like 
plasminogen, it is characterized by the presence of loop-like repeating units known 
as kringles (so called because of their resemblance to Scandinavian pastries of the 
same name).38;39;41-43 Apo(a) is comprised of two kringle domains, kringles IV and V 
(named after the corresponding domains in plasminogen), and a serine protease 
domain. There are 10 different classes of kringle IV (KIV) domain designated as 
apo(a) KIV types 1-10. KIV types 1 and 3-10 (as well as kringle V and the protease 
domain) are present in a single copy in each individual; whereas the KIV type 2 
(KIV2) exists in identically repeated copies that vary in number from three to over 
40 copies (Figure 1.5).38-41 This copy number variation confers marked size 
heterogeneity to apo(a) molecules; the molecular weight of apo(a) isoforms ranges 
between 200 and 800 kilodaltons (KD) in the general population. KIV type 9 contains 
an unpaired cysteine residue involved in disulfide linkage with the apo B100 molecule 
in LDL to form an Lp(a) particle.39;41;44 A number of weak lysine-binding sites are 
present on each of apo(a) KIV types 5-8, which are thought to be involved in the 
initial noncovalent interactions between apo(a) and apo B100 molecules that precede 
the disulfide bond formation.39;42;45 Apo(a) is a highly glycosylated molecule with 
carbohydrates comprising about 30% of its weight. Each kringle contains at least one 
N-linked glycosylation site, whereas inter-kringle sequences contain at least six O-
linked glycosylation sites.38-40;45 
 
Regulation of blood lipoprotein(a) levels 
Production and clearance 
Apo(a) is primarily synthesized by the liver. Once secreted by the hepatocytes 
apo(a) interacts with LDL to form Lp(a) particles, as described above. Although the 
exact site of this interaction is unknown, it is thought to be on the surface of 
hepatocytes.39;43;44;46;47 Circulating Lp(a) levels have high inter-individual variability – 
up to a 1000 fold difference in concentration has been observed between 
individuals.39-41 This high variability is thought to be mainly determined by the rate of 
apo(a) production which in turn is under strong genetic regulation.38-41;48;49 
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The clearance of Lp(a), on the other hand, is not well understood.50 Fragments of the 
apo(a) molecule have been found in urine, and studies in individuals with renal 
disease have shown that circulating Lp(a) levels tend to rise with a decrease in renal 
function.51-53 However, whether the kidneys play a significant role in apo(a) excretion 
is disputed as some researchers have estimated that renal excretion accounts for 
only 1% of total Lp(a) clearance.50;54;55 Similarly, the role of the liver in Lp(a) 
clearance has not been resolved.  Results from clinical and genetic studies have 
shown that Lp(a) levels are not affected by LDL-receptor activity, suggesting that the 
large apo(a) molecule might introduce a charge or steric interaction affecting the 
binding potential of apo B100 in Lp(a) to the LDL-receptor (apo B100 is responsible for 
LDL-receptor-mediated uptake of LDL particles in the liver).41;49;56  A recent study in 
mouse models suggested that the liver may account for a significant proportion of 
Lp(a) clearance through mechanisms that are unrelated to LDL receptors.55 However, 
these results will need to be confirmed by human studies. 
 
Family-based studies have shown that Lp(a) levels are highly heritable with 
calculated heritability estimates ranging between 75% and 98%.39;57-59 The genetic 
element responsible for this heritability has been mainly localized to chromosome 
6q26-27 (the LPA gene locus).58;60;61 The gene is reported to account for up to 90% 
of the genetic variation in circulating Lp(a) levels.48;58;60;62 Other loci found to be 
associated with Lp(a) levels in some recent linkage studies include regions on 
chromosomes 13q22-31, 11p14-15 and 1q23.58;60 
 
The LPA gene 
The LPA gene (also known as APO[a] gene) codes for the apo(a) molecule. It spans a 
region of 130 kilobases (kb) in the short arm of chromosome 6 adjacent to the 
plasminogen gene. Due to its strong homology to the plasminogen gene it is 
considered to be part of the plasminogen gene superfamily.38;39;43;63;64 Several 
polymorphisms within the gene have been reported to correlate with circulating Lp(a) 
levels; these include, (i) the KIV2 copy number variation (CNV),39;48;65;66 (ii) the 
pentanucleotide repeat,39;66-68 and (iii) several single nucleotide polymorphisms 
(SNPs).69-71 
 
The KIV2 CNV exists in over 40 allelic forms. Located in a functional region of the 
LPA gene, this polymorphism is responsible for the apo(a) isoform variation 
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described above.39;41;43;48 The effect of the polymorphism on blood Lp(a) 
concentration has been widely studied in various populations using both genotyping 
and phenotyping methods. The studies showed that Lp(a) levels are inversely 
correlated with the number of KIV2 repeats.48;65;66;72 In vivo studies suggest that 
these associations may be due to an effect of the size polymorphism on the rate of 
apo(a) production.73 The amount of variation in circulating Lp(a) levels that is 
explained by the KIV2 polymorphism varies in different ethnic groups. It has been 
reported that the polymorphism accounts for 40-70% of the variation in Lp(a) level 
in Caucasians, but about 20% of that in Blacks.39;48;72 
 
The pentanucleotide repeat polymorphism ([TTTTA]n) is located 1.4 kb upstream of 
the first exon of the LPA gene, which suggests a possible role in the regulation of 
gene transcription.63;74;75 This polymorphism has fewer alleles compared to the KIV2 
polymorphism. Alleles with 4 to 12 repeats of the ‘TTTTA’ sequence have been 
reported in different studies, although alleles with 8 to 11 repeats are much more 
frequent.67;70;76-79 The polymorphism has been reported to account for 10-14% of the 
inter-individual variation in circulating Lp(a) levels among Caucasians, independent 
of the KIV2 polymorphism.75;80-82 This effect, as for the KIV2 polymorphism, appears 
to be ethnicity-specific.80;82 
 
Over 200 SNPs have been reported for the LPA gene, some of which have been 
assessed for association with circulating Lp(a) levels. Generally, fewer and smaller 
studies have been carried out to date to determine these associations. The +93 c>t 
and +121 g>a polymorphisms near the transcription start site (rs1853021 and 
rs1800769, respectively), the +1 g>a polymorphism at the splice donor site in KIV 
type 8 (rs41272114), and the M4168T polymorphism in KIV type 10 (rs1801693) are 
among the most studied SNPs.68-71;74;76-78;82-85 The first three polymorphisms have 
been reported to be associated with circulating Lp(a) levels in many of the studies. 
Whether these SNPs have a functional effect on Lp(a) levels independent of the KIV2 
CNV is not clear. 
 
Lipoprotein(a) and the acute phase 
Although Lp(a) concentration is under strong genetic regulation, various studies have 
shown that the levels may be altered by the acute phase response.86;87 Like other 
acute phase reactant proteins, Lp(a) levels have been reported to increase 
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significantly following acute myocardial infarction or surgical procedures, or during 
active phases of chronic inflammatory diseases such as rheumatoid arthritis.87-89 
Comparison of the rise in Lp(a)  and C-reactive protein (CRP) levels in response to a 
stressful event (eg, myocardial infarction, surgical procedure) showed that changes 
in Lp(a) levels follow a slower course.89 The observed acute phase responsiveness of 
Lp(a) is thought to be due to the presence of several interleukin 6 (IL-6) responsive 
elements in the promoter region of the LPA gene.63 Consistent with this explanation, 
in vitro studies have shown that apo(a) mRNA expression is subject to positive 
regulation by IL-6.90  
 
The acute-phase role of Lp(a), however, is controversial, as several authors have 
failed to confirm the elevation of Lp(a) levels following stressful events.91 These 
findings indicate potential diversity between individuals in Lp(a) responsiveness to 
acute phase reaction. Some authors have suggested that regulation of Lp(a) levels 
by IL-6 depends on the apo(a) size polymorphism, with Lp(a) and IL-6 levels 
showing significant correlations in individuals with larger, but not smaller, apo(a) 
isoforms.91 
 
Proposed pathogenic mechanisms  
Although Lp(a) was discovered over 40 years ago, its physiological and pathological 
functions are still largely unknown.39;42;92 One of the reasons is the absence of 
suitable animal model for laboratory study of the particle, as Lp(a) is only found in 
humans, Old World Primates such as baboons, and the hedgehog.41;42 With regard to 
physiological functions, there are suggestions that Lp(a) might play role in removal 
of oxidized phospholipids from blood vessels, arising from observations that oxidized 
phospholipids accumulate in Lp(a) particles.42;92;93 Furthermore, it has been shown 
that Lp(a) contains lipoprotein-associated phospholipase A2 (LpPLA2), a hydrolytic 
enzyme attached to lipoproteins in plasma, which is thought to participate in 
breaking down oxidized phospholipids that attach to the particle.93;94 On the other 
hand, observations that Lp(a) tends to localize to damaged tissues and that its levels 
appear to change in response to the acute phase have led to speculations that the 
particle might have a physiological function in wound healing through delivery of 
cholesterol and promotion of inflammation.38;92  
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Based on findings from in vitro studies and studies on transgenic animals, several 
mechanisms have been proposed for the possible role of Lp(a) in  CHD pathogenesis 
(Figure 1.6). The apo(a) molecules appear to play a central role in the pathologic 
effect of Lp(a) by modifying the properties of the particles. The proposed pathogenic 
mechanisms include: 
i. Lp(a) may promote pro-atherogenic processes because of its similarity to 
LDL particles, and capacity for interaction with fibrin and tissue matrix 
components in vessels walls.38;95 Studies examining atherosclerotic 
plaques from human blood vessels have demonstrated Lp(a) deposits in 
the lesions. The accumulation of Lp(a) in atherosclerotic plaques could 
contribute to the growth of atheroma. Lysine-binding residues in KIV type 
10 and other domains in apo(a) are thought to increase the localization 
and concentration of Lp(a) in vessel walls through interaction with fibrin 
and tissue matrix components such as glycosaminoglycans.39;42   
ii. Lp(a) has been shown to inhibit the plasmin-mediated activation of  
transforming growth factor-β (TGF-β).42;96 This effect may enhance 
migration and proliferation of vascular smooth muscle cells as TGF-β is an 
inhibitor of human smooth muscle cell proliferation. 
iii. Lp(a) is thought to promote inflammatory processes by inducing monocyte 
chemotactic activity of vascular endothelial cells.97 Lp(a) has also been 
shown to cause increased secretion of the pro-inflammatory cytokine IL-6 
from monocytes, and of vascular adhesion molecule 1 and E-selectin from 
cultured coronary artery endothelial cells.98 In addition, Lp(a) may 
promote inflammation by preventing the activation of TGF-β, a cytokine 
with the ability to suppress inflammatory responses.42 
iv. Lp(a) particles in vessel walls contain a significant amount of oxidized 
phospholipids.41;99 Although it has been proposed that Lp(a) may have a 
physiological role in removing oxidized phospholipids from vessel walls, 
accumulation of an excess amount of oxidized phospholipids in the particle 
may promote endothelial damage, inflammation and formation of foam 
cells.93;99;100 Furthermore, it has recently been hypothesized that LpPLA2 
molecules present in Lp(a) particles might modify the inflammatory effect 
of oxidized phospholipids by splitting them into free oxidized fatty acids 
and lysophospatidylcholine.93-95;101 
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v. Lp(a) may promote pro-thrombotic processes by interfering with the 
activity of plasminogen.38;39;41 Various in vitro and animal studies have 
shown that Lp(a) prevents the action of tissue-type plasminogen activator 
and increases the endothelial secretion of plasminogen activator inhibitor 
2, thus preventing the activation of plasminogen to plasmin.39;102 In 
addition, apo(a) may act as a competitive inhibitor of plasminogen owing 
to the structural similarity between the two molecules.38 
 
Epidemiological studies of lipoprotein(a) 
Measurement of lipoprotein(a) concentration – assay and analytical variability 
Lp(a) can be measured using either quantitative or semi-quantitative assays.  Semi-
quantitative assays use an electrophoresis-based method to identify individuals with 
high Lp(a) concentrations. Such individuals show a characteristic band known as the 
`sinking pre-beta lipoprotein’ on serum electrophoresis.35;38 Participants can, 
therefore, be classified as having a “definite”, “trace” or “absent” band by visual 
inspection of the pre-beta band region.35 Except for their use in a few early 
epidemiological studies, such semi-quantitative methods have largely been replaced 
by quantitative ones. 
 
Quantitative assays are largely based on immunochemical methods, and may be 
divided into several categories based on the assay principle implemented.103;104 The 
major contemporary immunochemical assays are: enzyme-linked immunosorbent 
assay (ELISA),105-107 immunoturbidimetric assay (ITA),108;109 immunonephelometric 
assay (INA),110;111 and immunoradiometric assay (IRMA).112 Earlier methods include 
less sensitive and more labour-intensive methods such as immunodiffusion, 
radioimmunoassay and electroimmunoassay.103;113-115 The basic principle underlying 
these techniques is quantification of antibodies reacting with specific epitopes in the 
Lp(a) particle. 
 
The concentration of Lp(a) is expressed as mass per unit volume (e.g. mg/dl) or as 
molar concentration (e.g., µmol /l).116 Given the marked intermolecular weight 
variation between apo(a) molecules, the former approach requires an assumption of 
an average mass for Lp(a) particles.32;116 This is considered unsatisfactory because 
the distribution of KIV2 alleles differs between populations.117  The expression of 
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Lp(a) concentration as mass per unit volume in several epidemiological studies is, 
therefore, one area of difficulty in the characterization of Lp(a) in populations.   
 
Another measurement difficulty related to the variable number of KIV2 repeats is 
that antibodies directed at epitopes in the KIV2 region would have differential 
immuno-reactivity depending on the number of repeats, i.e., such antibodies will 
have higher affinity for molecules with a larger number of repeats and vice versa. 
This will result in over- or underestimation of Lp(a) levels for individuals with larger 
or smaller number of KIV2 repeats, respectively – an assay characteristic known as 
“apo(a) isoform sensitivity or dependence”.103;104;118-120 In 2000, an Lp(a) assay 
standardization program supported by the National Heart, Lung and Blood Institute 
assessed the isoform sensitivity pattern of assay systems from 16 manufacturers and 
six research laboratories.120;121 The study revealed that apo(a) isoform sensitivity 
was an important problem. One approach to overcoming this problem is through use 
of assay systems that employ antibodies directed at epitopes located outside the 
KIV2 repeat region. Although such antibodies have already been developed they 
have not been widely used in epidemiological studies.118 
 
Determination of the cholesterol content of Lp(a) particles is another approach to 
quantitative measurement of blood Lp(a) concentration.122;123 Assays based on this 
method can employ various techniques to capture Lp(a) particles, such as 
electrophoresis, ultracentrifugation or use of substances with high affinity for apo(a) 
molecules (e.g., lectin), followed by quantification of the cholesterol content of the 
trapped particles.  This method is not affected by apo(a) isoform variability. It is 
possible to estimate the concentration of Lp(a) particles from the Lp(a) cholesterol 
values using a regression-based conversion factor.41;117    
 
Comparison of measurements of Lp(a) concentration done in different circumstances 
(such as different assay systems, different laboratories, different populations, etc.) 
shows a very high degree of variability.121;124 This lack of comparability in measured 
Lp(a) values has been mainly attributed to the use of different standard materials 
that vary in isoform composition, inadequate optimization of assay systems, and use 
of assay systems that are isoform-dependent.41;118;124 To address the issue of 
standardization, the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) Working Group on Lp(a) proposed an international reference 
 12 
material in 2000,125  which was accepted by the World Health Organization in 
2003.126 However, a further study by the IFCC showed that use of the reference 
standard material only will not be sufficient to achieve harmonization of Lp(a) values 
among different assay systems highlighting the significance of isoform sensitivity 
(and other factors such as optimization) in Lp(a) measurement variability.41;103;120 In 
addition, it has been reported that storage conditions and duration of sample storage 
may affect measured Lp(a) values.42;127-131 Sample storage can have a particularly 
serious effect on the validity of epidemiological studies if degradation of Lp(a) 
selectively affects samples with higher levels or those with certain isoform 
composition, as suggested by some investigators.127-129  
 
In summary, the following factors relating to assay method and sample handling 
characteristics are thought to contribute to between-study differences in measured 
Lp(a) values (biological variability in Lp(a) levels will be discussed in Chapter 4): 
i. A reference material for calibration of assay systems was not available until 
2000. 
ii. Several assay systems used by epidemiological studies have been found to be 
isoform sensitive. 
iii. Most studies expressed Lp(a) concentration as mass per unit volume instead 
of molar units. 
iv. Epidemiological studies differ in sample handling and storage conditions, such 
as storage temperature, duration of storage, number of thawings, etc. 
v. Cross-reactivity of anti-apo(a) antibodies with plasminogen was an issue for 
earlier assay methods. 
 
 Lipoprotein(a) concentration and the risk of coronary heart disease 
The association between Lp(a) and CHD has been assessed by several studies of 
various designs, among different populations. Retrospective case-control studies 
involving cases with a spectrum of coronary outcomes such myocardial infarction, 
symptomatic angina or angiographically determined coronary stenosis have shown 
consistently that Lp(a) is associated with the risk of CHD.100;132-136  However, it is not 
possible to make an accurate assessment of the association using these studies due 
to potential limitations of retrospective case-control studies such as selection bias 
and difficulty in assessing temporal relationships between exposure and outcome 
(i.e., difficulty ruling out the possibility of reverse causality). Moreover, in case-
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control studies of acute coronary syndrome the concentration of Lp(a) in cases is 
likely to be highly elevated in response to the acute phase, distorting the magnitude 
of an observed association.  
 
Several prospective population-based epidemiological studies have assessed the 
association between Lp(a) and the risk of CHD.32;137 Prospective studies provide a 
more robust tool for assessing the relationship between Lp(a) and CHD risk since 
they are not subject to some biases in retrospective studies. Selection bias is not 
likely to cause a problem since the source population from which the non-CHD cases 
are drawn is well defined. Lp(a) concentrations in cases are less likely to be 
influenced by the presence of disease than in retrospective case-control studies as 
levels are typically determined several years before development of the outcome. 
Similarly, prospective studies of acute coronary syndrome are not affected by the 
acute phase avoiding potential biases. The prospective nature of the design, 
however, means that there is a need for a prolonged follow-up of a large cohort to 
accrue sufficient CHD cases enabling informative assessment of the association.  
 
The relative risk estimates reported in the prospective studies were more modest 
than those typically observed in the retrospective case-control studies and some 
notable prospective studies failed to detect a significant association between high 
Lp(a) concentrations and the risk of CHD.138-145 Some prospective studies reported 
that there is a threshold in the relationship between Lp(a) concentration and the risk 
of CHD, and that the association was more important among individuals with higher 
LDL cholesterol levels.146-152 Consequently, in 2003, a National Heart, Lung, and 
Blood Institute Workshop on Lp(a) and cardiovascular disease recommended that 
individuals with Lp(a) levels above the 75th percentile should be considered to be at 
increased risk for cardiovascular disease, particularly when they have high or 
borderline cholesterol levels.119 Individual studies were, however, rarely sufficiently 
powered to assess the shape of the relationship or make precise estimates of relative 
risk within population subgroups, such as people with high rather than low LDL 
cholesterol levels. The following section reports data from a large prospective study 
of Lp(a) concentration and the risk of CHD. 
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The Reykjavik study –large scale prospective data 
Study population 
The Reykjavik study was initiated in 1967. All men born 1907-1934 and all women 
born 1908-1935, who were resident in Reykjavik, Iceland and its adjacent 
communities on December 1st 1966, were identified in the national population 
register and invited to participate in the study. Five stages of recruitment, between 
1967 and 1991, yielded 8888 male and 9681 female participants with no history of 
myocardial infarction (72% response rate). Nurses administered questionnaires, 
made physical measurements, recorded an electrocardiogram, and collected fasting 
venous blood samples. Serum was stored at -20°C until assay. All participants were 
monitored by central registries for occurrence of major cardiovascular morbidity 
(based on MONICA criteria) or cause-specific mortality (based on a death certificate 
with International Classification of Diseases codes 410-414), with a loss to follow-up 
of only about 0.6% to date. A total of 2459 men and women recorded either non-
fatal myocardial infarction or coronary death between study entry and the censoring 
date. One or two controls were frequency matched to cases by calendar year of 
recruitment, sex, and age (in five-year age bands) from among all participants who 
did not develop CHD during follow-up, giving a total of 3969 controls. The study 
protocol was approved by the national bioethics committee and the data protection 
board of Iceland. All participants gave informed consent. Two-thousand four-hundred 
and eighteen incident CHD cases and 3921 controls had available Lp(a) 
measurements. 
 
Lipoprotein(a) measurement 
Lp(a) levels were measured in serum samples, by laboratory staff unaware of 
participants’ disease status, using an enzyme immunoassay [ELITEST-Lp(a)] and an 
assay standard from Hyphen BioMed (Paris, France). This ELISA based system, which 
uses a monoclonal anti-Lp(a) antibody for capture and a polyclonal anti-Apo(B) 
antibody for detection, is not affected by apo(a) isoform variation. The intra- and 
inter-assay coefficients of variation were 4.2% and 4.7%, respectively. Repeat Lp(a) 
measurements were made in the 372 participants who provided paired samples, at a 
mean interval of about 12 years.  
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Statistical analyses 
To minimize impact of pre-existing disease, principal analyses were restricted to the 
2047 patients and 3921 controls without evidence of CHD or stroke at the baseline 
examination (i.e., participants with electrocardiographic abnormalities and/or 
previous history of myocardial infarction, angina or stroke were excluded from the 
main analyses, although they were retained in subsidiary analyses). Lp(a) values 
were natural log transformed to achieve an approximately symmetrical distribution. 
Unconditional logistic regression was used to calculate odds ratios (and 95% 
confidence intervals), progressively adjusted for possible confounding factors (Stata 
Corporation, version 9.2, USA). The shape of the association between Lp(a) levels 
and CHD risk was investigated using groups defined by fifths of the baseline values 
of Lp(a) in controls; the corresponding 95% CIs were estimated from floated 
variances that reflect the amount of information underlying each group (including the 
reference group). Subgroup analyses by sex, smoking habits, blood pressure, 
concentrations of serum lipids and CRP, and type of CHD outcome, were also pre-
specified.  
 
Results 
As would be expected, levels of established cardiovascular risk factors at the baseline 
examination were higher in patients with CHD than in controls (Table 1.1). Baseline 
loge Lp(a) levels were higher in patients with CHD than in controls and weakly - 
though significantly - correlated with total cholesterol (r=0.12; 95% CI, 0.09 to 
0.15), loge triglycerides (r=-0.12; -0.16 to -0.09) and tissue plasminogen activator 
antigen (r=-0.09; -0.12 to -0.06). No significant correlations were detected between 
baseline loge Lp(a) levels and various established and emerging cardiovascular risk 
factors such as age, sex blood pressure, body mass index (BMI), CRP and albumin. 
 
In a comparison of individuals with Lp(a) in the top third with those in the bottom 
third of baseline values, the odds ratio for CHD was 1.61 (95% CI, 1.41-1.84) after 
adjustment for age, sex and calendar year of recruitment (Table 1.2). This odds 
ratio was little changed following further adjustment for several established 
cardiovascular risk factors (i.e., smoking, blood pressure, total cholesterol, 
triglycerides, BMI and diabetes) and inflammatory markers (e.g., CRP). Subsidiary 
analyses yielded adjusted odds ratios for CHD of 1.77 (1.57-1.99) in a comparison of 
extreme fifths, and of 1.23 (1.16-1.31) for 1 standard deviation higher loge Lp(a) 
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concentrations. The odds ratios for CHD appeared to increase continuously with 
increasing Lp(a) concentrations (Figure 1.7); however, further work is needed to 
determine whether a straight or curvilinear line better describes the association. The 
association of Lp(a) levels with CHD risk did not vary materially in a range of 
subgroups based on individual characteristics, notably sex, lipid concentrations, CRP, 
and fatal versus non-fatal CHD outcome (Figure 1.8).  
 
Literature-based meta-analyses of prospective studies 
Danesh et al reported a meta-analysis of 18 prospective studies of general 
populations that were published before 2000.137 In a pooled analysis of 4,000 cases 
that involved only within-study comparisons, the combined relative risk of CHD for 
individuals in top vs. bottom thirds of baseline Lp(a) concentrations was 1.7 (95% 
CI, 1.4 – 1.9). An updated meta-analysis of 31 prospective studies published through 
2008,35;36;138-169 including the Reykjavik study, involved a total of 9870 CHD cases; 
the corresponding combined relative risk was 1.45 ( 1.32-1.8; Figure 1.9). There 
was moderate heterogeneity observed across the studies (I2=43%; 95% CI, 12%-
63%), which was in part explained by differences in period of publication (p=0.004) 
and type of blood sample (p=0.003) (Figure 1.10). Subgroups defined by other 
characteristics pre-specified for investigation, notably study size, sample storage 
characteristics and Lp(a) assay isoform sensitivity, were not significantly different 
(P>0.10 for each characteristic; Figure 1.10). There was no strong evidence for 
publication bias on a funnel plot or Egger test (p=0.23).  
 
While the evidence from literature-based meta-analyses of prospective studies 
suggests the potential importance of Lp(a) in CHD, it does not provide sufficient 
detail to allow assessment of the marker’s utility in cardiovascular disease prevention 
and treatment. For example, it is not possible to determine, from a literature-based 
meta-analysis, whether Lp(a) is associated with CHD throughout the range of 
concentrations (similar to blood pressure and LDL cholesterol), or whether Lp(a) is 
particularly important in specific subgroups of individuals (such as those with high 
LDL cholesterol levels). Re-analysis of individual participant data from a 
comprehensive set of prospective epidemiological studies (i.e., individual participant 
data meta-analysis) can help overcome several of the limitations of individual studies 
or literature-based meta-analyses of individual studies (discussed in Chapter 2).  
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Sources of Lp(a) heterogeneity 
Initially thought to be a blood antigen with a dichotomous trait, the complexity of 
Lp(a) was not fully appreciated when it was first discovered. Later, researchers 
realized that Lp(a) is a quantitative trait like several other markers measured in 
blood. It was then demonstrated that Lp(a) particles show marked size heterogeneity 
due to their content of differently sized apo(a) isoforms. Further study revealed 
various factors that contribute to differences between Lp(a) particles, including the 
oxidized phospholipid content of the particles, the lysine-binding activity of the 
apo(a) moiety, and the size and density of the LDL moiety. The advances in 
understanding of the structural and functional complexity of Lp(a) imply that simple 
measurement of plasma Lp(a) levels may not capture the full impact of the factor on 
cardiovascular disease risk, highlighting the need for concomitant measurement of 
the various markers of Lp(a) heterogeneity. A description of how our understanding 
of the relationship between cholesterol and atherosclerosis progressed in the past 
100 years provides a good analogy to the evolving model of Lp(a)-CHD association. 
The initial model proposed by Anitschkow was that cholesterol is the cause of 
atherosclerosis.170 It was later identified that cholesterol can have `bad’ or `good’ 
vascular effects depending on whether it is contained in LDL or HDL particles, 
respectively. Currently ongoing research suggests that not all LDL particles are 
equally toxic: small, dense LDL particles are thought to confer greater atherosclerotic 
risk.171 
 
i) Apolipoprotein(a) isoforms  
As discussed under the section on structure, Lp(a) is made of apo(a) molecules 
which exist in several differently sized isoforms. Apo(a) isoform variation is an 
important source of Lp(a) heterogeneity accounting for important differences in size 
of Lp(a) particles. Studies have shown that apo(a) isoforms are inversely correlated 
with Lp(a) levels (i.e., smaller apo(a) isoforms are associated with higher Lp[a] 
concentration and vice versa).48;72;172 Hence, smaller apo(a) isoforms would be 
expected to be associated with the risk of CHD to the extent that is predicted from 
the association between apo(a) isoforms and Lp(a) concentration, and between Lp(a) 
concentration and risk of CHD. Consistent with this hypothesis, several studies have 
reported positive associations between smaller apo(a) isoforms and CHD risk.66;173-176 
In the few studies that assessed apo(a) isoforms and Lp(a) concentrations 
concomitantly, the association of apo(a) isoforms  with risk of CHD persisted even 
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after taking into account the effect of apo(a) isoforms on Lp(a) concentrations.176-178 
This apparent independent association of apo(a) isoforms with the risk of CHD has 
led to suggestions that smaller apo(a) isoforms may be more pathogenic than larger 
ones.119 Limited observations suggest that smaller apo(a) isoforms may have 
increased capacity to bind oxidized phospholipids, localize to the vessel wall and 
promote thrombogenesis.95;179-181 Thus, determination of both Lp(a) concentration 
and apo(a) isoform size would likely provide a better picture in assessment of Lp(a)-
associated vascular risk than measurement of Lp(a) concentration alone.  
 
ii) LDL particle size 
LDL particle size is another contributor to Lp(a) heterogeneity. Lp(a) is a composite 
particle formed by covalent linkage between an LDL particle and an apo(a) molecule. 
Limited experimental data suggest that the type of LDL particle that binds to apo(a) 
molecules depends on the predominant apo B100 particle circulating in blood.
182-185 
Thus, individuals with a high concentration of small, dense LDL particles will be 
expected to have Lp(a) particles of comparable size and density.95 Small, dense LDL 
particles are believed to have greater pathogenic effect in blood vessels due to a 
greater propensity for retention in the arterial wall and increased susceptibility to 
oxidative stress.171 Similarly, an Lp(a) species containing small, dense LDL particles 
are thought to be more toxic than those containing a large-buoyant LDL particles. A 
small case-control study involving 200 participants recently reported that individuals 
who concomitantly had small apo(a) isoforms and high concentration of small, dense 
LDL particles had the highest risk of coronary disease.176 In the study, small-apo(a) 
isoforms and high small, dense LDL concentration appeared to have a synergistic 
effect on vascular risk. Therefore, in assessing the cardiovascular risk associated 
with Lp(a), the density of the LDL constituting the particles should receive 
consideration in addition to blood Lp(a) concentration and apo(a) isoforms size.  
 
iii) Oxidized phospholipids 
Oxidized phospholipids are lipid molecules that have been modified through a 
multiplicity of oxidative processes in the body. The potential of oxidized 
phospholipids to cause damage to vessel walls has been recognized from 
observations in several in vitro and in vivo studies.186-191 As discussed under the 
section on pathogenic mechanisms, oxidized phospholipids tend to accumulate within 
Lp(a) particles, and Lp(a) particles with a larger content of oxidized phospholipids 
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are likely to cause greater vascular damage.94;192-194 The amount of oxidative 
byproduct carried by the Lp(a) particles depends on the level of circulating oxidized 
phospholipids. Thus, the blood concentration of oxidized phospholipids may influence 
the vascular toxicity of Lp(a) particles. A recent preliminary study found that the 
association between Lp(a) and the risk of cardiovascular disease was stronger among 
individuals with higher concentrations of oxidized phospholipids.94;193 This suggests 
that concentration of oxidized phospholipids is likely to be an important source of 
heterogeneity in Lp(a) particles. Hence measurement of oxidized phospholipids may 
provide a useful adjunct in assessing the role of Lp(a) in cardiovascular disease.  
 
iv) Lysine-binding activity 
As discussed under the section on pathogenic mechanisms, lysine-binding residues in 
apo(a) increase the localization of Lp(a) particles in blood vessel walls through 
interaction with fibrin and tissue matrix components.39;42  Functional studies have 
shown that not all apo(a) molecules have equal lysine-binding activity. For instance, 
a non-synonymous mutation within the region coding for the KIV type 10 domain of 
the apo(a) molecule has been shown to result in a defective lysine-binding activity.40 
In addition, it has been demonstrated in vivo that the lysine-binding activity of 
apo(a) molecules may be increased by the phospholipolytic activity of LpPLA2.
40;93 A 
preliminary report based on a small case-control study of 200 participants showed 
that lysine-binding activity was higher in CHD cases with small apo(a) isoforms.180 In 
addition, individuals with higher lysine-binding activity and smaller apo(a) isoforms 
had the highest risk of coronary disease in the study. Thus, limited evidence appears 
to suggest that study of lysine-binding activity of apo(a) molecules (along with 
factors that potentially modify their functionality, such as LpPLA2 activity) may 
contribute to the understanding of Lp(a) heterogeneity. 
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‘Mendelian randomization experiment’ 
Determining the nature of the association between Lp(a) and CHD can have 
important therapeutic and preventive implications. However, it is not possible to 
make causal inferences using data from traditional observational epidemiological 
studies due to the inherent limitations of these studies, such as residual confounding 
and reverse causation.195;196 Residual confounding refers to the persistence of 
confounding after making statistical adjustment for confounders in multivariate 
models. It occurs because not all relevant confounders have been (or can be) 
measured in observational studies, and even adjustment for measured confounders 
is usually incomplete due to measurement error. Uncertainties about temporal 
relationships between two associated variables make it difficult to determine the 
direction of an observed association, i.e. whether it is causal or reverse causal.    
 
‘Mendelian randomization’ is an application of genetic epidemiology that utilizes the 
fact that allocation of genes from parents to offspring occurs randomly at conception, 
to tackle the two important challenges to causal inference in traditional epidemiology 
– residual confounding and reverse causation.195-198 If a genetic polymorphism 
affects the levels of a risk factor for a certain disease then it will result in differences 
in the levels of the risk factor between individuals that have different variants, or 
alleles, of that gene. Therefore, the polymorphism will be related to the disease risk 
to the extent predicted by its influence on the levels of that risk factor. And as genes 
are allocated randomly at conception, the relationship between these genotype-
determined differences in the risk factor and disease would be expected not to be 
materially affected by confounding or subsequent development of overt disease 
(reverse causation). Moreover, as the effect of genetic factors may persist 
throughout the life of the individual, such genotype-determined differences are likely 
to be representative of long term exposures. Therefore, by triangulating the 
associations, in this instance, between (i) circulating Lp(a) levels and coronary 
disease outcomes, (ii) LPA gene polymorphisms and circulating Lp(a) levels, and (iii) 
LPA gene polymorphisms and CHD outcomes, it should be possible to determine 
whether a causal association is likely (this approach is discussed further in Chapter 
7). This approach has been successfully applied to the study of other emerging risk 
markers including fibrinogen.196 
 
 
 21 
Aim of thesis 
Key areas of uncertainty 
From the discussions above it is apparent that several issues need to be resolved in 
our understanding of the relationship between Lp(a) and CHD risk in order to 
determine the potential relevance of the marker to disease prevention (both at the 
individual and population level). The following are key areas of uncertainty in current 
knowledge about the particle: 
1. The physiological role of Lp(a) in humans is not known. 
2. A considerable proportion of the genetic variability in Lp(a) concentration 
remains unexplained by the known variants (i.e., the KIV2 and 
pentanucleotide repeat polymorphisms, and some SNPs), particularly in 
nonwhites.  
3. The biological mechanisms underlying the associations between blood Lp(a) 
concentration and  CHD risk are not well understood. 
4. There is limited knowledge about non-genetic factors that regulate 
circulating Lp(a) levels. 
5. Data on within-person variability in Lp(a) levels is limited. 
6. An accurate and precise estimate of any independent association between 
Lp(a) concentration and CHD risk, that takes into account within-person 
variability in exposure and confounders, is not available. 
7. The shape of the association between Lp(a) concentration and CHD risk has 
not been determined reliably. 
8. Information on the associations of Lp(a) with CHD within clinically important 
subgroups of populations, such as males and females or individuals with 
different levels of LDL-cholesterol, is limited. 
9. Actual values of clinically relevant blood Lp(a) levels have not been 
determined (mainly due to challenges in Lp(a) measurement, 
inconsistencies in relative risk estimates and between-population differences 
in Lp(a) concentrations). 
10.  Relevance of Lp(a) to CHD risk prediction has not been determined. 
11.  The nature of the association between Lp(a) and CHD risk is not certain 
(i.e., whether the observed association between Lp(a) concentration and the 
risk of CHD represents a causal relationship is not established).  
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12.  The role of apo(a) isoform variation and other sources of Lp(a) 
heterogeneity (e.g., levels of oxidized phospholipids) in the Lp(a)-CHD 
association has not been determined. 
13.  The association of Lp(a) concentration with clinical outcomes other than 
CHD is not well studied. 
 
Objectives of thesis 
1. To characterize the associations of Lp(a) concentrations with the risk of CHD 
and, secondarily, with the risk of other vascular and non-vascular outcomes, 
in more detail than has been possible before.  
2. To determine if Lp(a) provides any incremental value to coronary risk 
prediction beyond what can be achieved using established cardiovascular 
risk factors. 
3. To identify SNP variants that influence Lp(a) levels and determine their 
association with CHD outcome, to help assess the nature of the Lp(a)-CHD 
association using a ‘Mendelian randomization experiment’ framework. 
4. To determine the association with cardiovascular outcomes of two important 
sources of Lp(a) heterogeneity: apo(a) isoforms and levels of oxidized 
phospholipids. 
 
Thesis outline 
Chapter 2 describes the methods used to establish the Emerging Risk Factors 
Collaboration (ERFC) database, which contains individual level data from over 100 
prospective epidemiological studies of cardiovascular diseases. The chapter also 
describes the design of individual-participant data meta-analysis of Lp(a) 
concentration and the risk of vascular disease, based on a 36-study subset of the 
ERFC. (Reports in Chapter 3-5 are based on data from this 36-study subset.) 
Chapter 3 reports on the cross-sectional correlates of Lp(a) levels with several lipid 
and nonlipid factors recorded in the ERFC. Chapter 4 reports on the long-term 
within-person variability of Lp(a) levels using data on serial measurements available 
in the ERFC. Chapter 5 provides detailed characterization of the association of Lp(a) 
concentration with vascular outcomes (and secondarily non-vascular deaths), 
including assessment of  the shape, independence, and specificity of the association. 
Chapter 6 reports on a preliminary assessment of the association of Lp(a) with the 
risk of myocardial infarction among South Asians, using a retrospective case-control 
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study. Chapter 7 reports an integrative genetic study of a comprehensive panel of 
SNPs at the LPA locus in relation to Lp(a) concentration and CHD risk, to help judge 
whether Lp(a) is a likely causal factor in CHD. Chapter 8 reports on the association 
between apo(a) isoforms and the risk of vascular disease using meta-analysis of 
published data. Chapter 9 reports on the relationship between oxidized 
phospholipids, Lp(a) concentration, and the risk CHD, using meta-analysis of 
published data, and new measurements in a prospective study. Chapter 10 
summarises the findings of the thesis, discusses the strengths, limitations and the 
potential implications of these findings, describes ongoing work on the project, and 
makes suggestions for future work. Appendix 1 lists the publications that I have 
authored during my doctoral studies. Appendix 2 lists various research projects and 
training activities that I have been involved with during my study. 
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 Table 1.1: Baseline characteristics of patients with coronary heart disease and controls in the Reykjavik study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Values for questionnaire items, except age, are given as number (percentage). 
‡ Median (inter-quartile range) values for CRP, triglycerides and Lp(a) were 1.41 mg/l (0.67-3.05 mg/l), 93 mmol/l (70-128 mmol/l) and 
9.4 mg/dl (3.0 – 23.2 mg/dl). 
 
 
Cases 
 
Controls  
Characteristics  N Mean (SD)† 
 
 N Mean (SD)† p-value 
Questionnaire        
Age (years)  2047 55 (9)  3921 56 (9) <0.001 
Male sex   2047 1463 (71)  3921 2710 (69) 0.06 
Current cigarette/pipe/cigar smoker  2047 1232 (60)  3921 1913 (49) <0.001 
Current cigarette smoker  2047 842 (41)  3921 1246 (32) <0.001 
History of diabetes  2047 52 (2.5)  3921 62 (1.6) 0.01 
Physical measurements        
Body mass index (kg/m2)  2041 26 (4)  3894 25 (4) <0.001 
Systolic blood pressure (mmHg)  2046 146 (22)  3902 142 (20) <0.001 
Diastolic blood pressure (mmHg)  2045 90 (11)  3901 87 (11) <0.001 
Forced expiratory volume (L/sec)  2023 2.85 (0.86)  3834 2.86 (0.86) 0.499 
Metabolic and inflammatory markers        
Log C-reactive protein (log mg/l)‡  2024 0.51 (1.10)  3869 0.25 (1.12) <0.001 
Fasting glucose (mmol/l)  2034 4.61 (1.06)  3888 4.53 (0.75) <0.001 
Serum creatinine (mg/dl)  2028 1.01 (0.25)  3889 0.99 (0.50) 0.213 
Uric acid (µmol/l)  2044 310 (71)  3914 300 (70) <0.001 
Haemoglobin (mmol/l)  2029 9.2 (0.8)  3890 9.1 (0.81) <0.001 
von Willebrand factor (IU/dl)  2037 115 (47)  3900 112 (46) 0.011 
Lipid factors        
Total cholesterol (mmol/l)  2046 6.9 (1.2)  3915 6.4 (1.2) <0.001 
Log triglycerides (log mmol/l)‡  1937 0.15 (0.45)  3676 0.03 (0.44) <0.001 
Log lipoprotein(a) (log mg/dl)‡  2047 2.07 (1.61)  3921 1.74 (1.73) <0.001 
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Table 1.2:  Relative odds of coronary heart disease in participants without known coronary disease at baseline† in a 
comparison of extreme thirds of baseline Lp(a) levels. 
  
 
  No. of cases  No. of controls  
Adjusted for age, 
sex and period 
Adjusted for the 
preceding and 
other established 
CHD risk factors* 
Adjusted for the 
preceding and 
C-reactive protein‡ 
  Bottom 
third 
Middle 
third 
Top 
third 
 Bottom 
third 
Middle 
third 
Top  
third 
 Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
Odds ratio 
(95% CI) 
All individuals  538 655 854  1311 1303 1307  1.61 (1.41-1.84) 1.60 (1.38-1.85) 1.58 (1.37-1.84) 
Males  403 463 597  950 905 855  1.64 (1.40-1.92) 1.71 (1.44-2.03) 1.66 (1.40-1.98) 
Females  135 192 257  361 398 452  1.56 (1.21-2.00) 1.40 (1.07-1.81) 1.43 (1.10-1.87) 
 
†
Individuals with evidence of ECG abnormalities, previous myocardial infarction or history of angina at the baseline survey were excluded from analyses.  
*Established CHD risk factors included systolic blood pressure, smoking status, total cholesterol, log triglycerides, BMI, and diabetes.  
‡
Because of missing values, the model with further adjustment for CRP levels involved 1911 CHD cases and 3592 controls 
Note: period refers to 5-year calendar periods of recruitment The odds ratio (95% CI) for CHD without excluding those with evidence of coronary disease 
at baseline was 1.62 (1.40, 1.86) for top third vs. bottom third Lp(a) level comparisons (adjusted for age, sex, period, smoking status and other 
established CHD risk factors). 
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Figure 1.1: Schematic diagram of the pathogenesis of coronary heart disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collection of Medical Illustrations, Elsevier Inc 
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Figure 1.2: Schematic diagram illustrating the multifactorial nature of coronary heart disease 
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Figure 1.3: An illustration of the different human plasma proteins seen on an 
electrophoresis gel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Interlab Srl, 2009 
 
 
Note: Lp(a) particles show beta-mobility on electrophoresis 
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Figure 1.4: Diagrammatic model for components of the Lp(a) particle 
 
 
 
 
 
 
  
  Courtesy of Dr. Reeta Gobin, University of Cambridge 
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Figure 1.5: Diagrammatic illustration of the different apo(a) domains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Apo(a) is made of KIV, KV and protease domains. KIV consists of 10 distinct classes, 
numbered from 1-10; the second class of KIV (KIV2) is found in variable number of repeated 
copies (which vary between three and 50). 
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Figure 1.6: A diagrammatic representation of proposed pathogenic mechanism for Lp(a) 
 
 
 
 
 
 
      Adapted from: Annuard et al. Clin Lab Med. 2006  
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Figure 1.7:   Odds ratios for CHD by fifths of baseline Lp(a) concentration in the 
Reykjavik study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Odds ratios were adjusted for age, sex, systolic blood pressure, smoking status, history 
of diabetes, body mass index, total cholesterol and triglycerides.  Confidence intervals were 
calculated using floating-variances. 
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Figure 1.8:   Odds ratios of CHD by levels of several individual characteristics 
available in the Reykjavik study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Odds ratios are for comparison of individuals in top vs. bottom thirds of the distribution 
of baseline Lp(a) measurements, and were adjusted for age, sex, systolic blood pressure, 
smoking status, history of diabetes, body mass index, total cholesterol and triglycerides. Sizes 
of data markers are proportional to the inverse of the variance of the relative risks.   
Interaction p-value was nonsignificant for all the subgroups. 
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Figure 1.9: Forest plot of 31 prospective studies of Lp(a) and the risk of CHD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Relative risks are for comparison of individuals in top vs. bottom thirds of the 
distribution of baseline Lp(a) measurements. Sizes of data markers are proportional to the 
inverse of the variance of the relative risks. There was significant heterogeneity across the 
studies: p=0.007; I2 = 43% (95% CI, 12-63%). 
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Figure 1.10: Investigation of heterogeneity between 31 prospective studies of Lp(a) 
concentration and CHD risk, using available study-level characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Relative risk were for comparison of individuals in top vs. bottom thirds of the 
distribution of baseline Lp(a) measurements. Sizes of data markers are proportional to the 
inverse of the variance of the relative risks.  There was significant heterogeneity between subgroups 
defined by publication period (p = 0.004) and type of blood sample (p=0.003), but not for the other 
subgroups (p>0.1 for each). 
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Chapter 2: The Emerging Risk Factors Collaboration 
 
Chapter summary 
The Emerging Risk Factors Collaboration (ERFC) is a collaboration of 110 prospective 
epidemiological studies that have recorded information on circulating lipid and/or 
inflammatory markers, other characteristics, as well as major cardiovascular 
outcomes and/ or cause-specific mortality. This chapter describes the methods used 
to establish the ERFC, and the data available for Lp(a) analyses. Thirty-six studies in 
the ERFC provided data on at least one measurement of Lp(a) concentration. This 
subset, involving over 126,000 participants without known preexisting vascular 
disease at baseline, comprises about 90% of relevant incident cardiovascular cases 
reported in Western studies.  Analysis of individual participant data from these 
studies in a systematic meta-analysis should help characterise the relationship 
between circulating Lp(a) levels and the risk of vascular and nonvascular outcomes 
in more detail and precision than has been possible before. 
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Background 
As discussed in Chapter 1, several prospective epidemiological studies have 
reported a positive association between Lp(a) and the risk of CHD.1-3 Individual 
studies, however, were generally not sufficiently powered to make detailed 
characterisation of the relationship, i.e., they were not able to (i) determine the 
magnitude of the association precisely, (ii) make reliable assessment of the shape of 
the association, or  (iii) determine the association by levels of various clinically 
relevant characteristics (such as by sex or age).  Literature-based meta-analyses, 
using published data from these studies, showed that Lp(a) has moderate 
association with CHD helping to prioritize the factor for further investigation.1-3 
However, as such analyses are based on study level data only they cannot enable 
detailed assessment of the association as described above. Nor can literature based 
meta-analyses allow consistent adjustment for potential confounders as studies differ 
in their approach to selecting covariates. 
 
Re-analysis of individual data from a comprehensive set of relevant prospective 
studies can help to overcome the shortcomings encountered by individual studies 
and literature-based meta-analyses. The Emerging Risk Factors Collaboration (ERFC) 
is an individual participant meta-analysis of data on over 1.3 million participants 
from 110 prospective studies in predominantly Western populations, with the aim of 
making a comprehensive and detailed assessment of several lipid and inflammatory 
markers [including Lp(a)] in relation to various clinical outcomes.4   
 
Objectives of the Emerging Risk Factors Collaboration 
The primary objectives of the ERFC are: (i) to assess, in people without known 
cardiovascular disease at the initial examination, the age- and sex-specific 
associations of each of Lp(a), triglycerides, high-density-lipoprotein cholesterol 
(HDL-C), non-HDL-C, apolipoproteins-AI and-B100, CRP, albumin and the leucocyte 
count with first ever confirmed non-fatal myocardial infarction (MI) or coronary 
death, before and after making appropriate allowances for within-person variability; 
(ii) to determine to what extent the separate associations with CHD are independent 
of possible confounding factors and to assess any joint effects (i.e., effect 
modification); (iii) to determine any incremental predictive value of the markers for 
CHD, either separately or in combination, beyond that provided by established risk 
factors; and (iv) to enable detailed exploration of potential sources of heterogeneity 
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for each marker, involving both cohort-level characteristics (such as assay methods, 
features of study design, geographical location) and personal characteristics (such as 
age, sex, and levels of several established risk factors). The secondary objectives 
are: (i) to investigate the markers in relation to new onset stroke, other 
cardiovascular conditions, and nonvascular mortality; (ii) to assess the cross-
sectional correlates of the markers; and (iii) to determine the patterns and 
correlates of within-person variability of each marker over time.  
 
Study design 
Identification and selection of studies 
Studies were identified either in previously published meta-analyses,1;2;5-8 or through 
updated computer-assisted literature searches of databases, scanning of reference 
lists, hand-searching of relevant journals and correspondence with authors of 
relevant reports. To be eligible for inclusion in the ERFC, studies were required to 
have: (i) prospective design (i.e., cohort studies, case-cohort or nested case-
control); (ii) data available from baseline measurements of at least one of the 
relevant markers; (iii) at least 1 year of follow-up; (iv) participants not selected on 
the basis of having preexisting vascular disease; and (v) information on cause-
specific mortality and/or major cardiovascular morbidity collected during follow-up.  
Details of information sought from studies 
For each individual, data were sought on age at baseline, sex, as well as (where 
available) several socio-demographic, lifestyle, biophysical and biochemical 
characteristics measured at baseline and subsequent surveys (Table 2.1). Data 
were collected on features of study design (e.g., population sampling framework, 
geographical location), different blood storage and handling conditions, assay 
methods, methods used to characterize baseline evidence of vascular disease and 
criteria used to diagnose incident outcomes. Individual data on the occurrence, 
during follow-up, of non-fatal cardiovascular outcomes and cause-specific mortality, 
and on the dates of occurrence were obtained from each study; in addition, 
information on the date of last follow-up was obtained. Precise details of the 
diagnostic criteria used for the definition of cases were sought from each study (as 
were data on the completeness of follow-up in the cohort studies). Attribution of 
death was based on the primary cause provided (or, in its absence, the underlying 
cause provided). 
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Data transfer, checking and harmonization 
Data were transferred from the individual studies to the coordinating centre using 
any machine-readable medium and in any format convenient to the collaborator(s). 
The data obtained from each participating study were checked for internal 
consistency by the coordinating centre and any queries then referred back, in 
confidence, to the study collaborator(s). The data were then harmonized to a 
standard format for incorporation into a central database to be used for pooled 
analyses. Information on categorical variables, such as alcohol consumption status, 
physical activity and smoking status, were systematically re-coded to maximise 
comparability among studies. The definition of incident outcomes for the principal 
analyses was based on events classified according to the International Classification 
of Diseases (ICD) (Table 2.2) or, where this was not available, on study-specific 
classification systems. The content of the data was unchanged by this process, and 
computer-generated detailed summary tabulations based on the converted data 
were reviewed and approved by each collaborator. 
 
Study management 
Anonymised data on individual participants provided by each of the studies have 
been stored securely on a computer database at the coordinating centre. The data 
provided from each study, have remained entirely the property of the principal 
investigators of that study, and have been held in strict confidence by the 
coordinating centre. Only the coordinating centre has had direct access to the 
combined dataset, and investigators have retained the right to withdraw their data 
from some or all of the meta-analyses. The coordinating centre (based in the 
Department of Public Health and Primary Care at the University of Cambridge and 
the MRC Biostatistics Unit in Cambridge, with strategic input from the Clinical Trial 
Service Unit at the University of Oxford), has been responsible for the collection, 
harmonization, maintenance and pooling of datasets provided by principal 
investigators, and for helping to lead analyses and interpret the results. The study 
protocol was published after being circulated to collaborators for comments and 
agreement. Similar procedures have been followed for subsequent manuscripts 
arising from the collaboration. 
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Lipoprotein(a) data in the ERFC 
Ensuring comprehensiveness of lipoprotein(a) data 
As the ERFC encompassed several factors, a separate search was performed to 
ensure the comprehensiveness of the database with respect to Lp(a). Prospective 
studies that had collected Lp(a) measurements were identified through electronic 
searches of databases, scanning of the reference lists of relevant articles and 
discussion with collaborators (Figure 2.1). Electronic searches, not limited to the 
English language, were preformed in MEDLINE and EMBASE for studies published 
between January 1970 and March 2009 using terms related to Lp(a) [e.g., 
lipoprotein(a), Lp(a), apolipoprotein(a), apo(a)] and cardiovascular disease 
outcomes (e.g., cardiovascular disease, coronary heart disease, myocardial 
infarction, stroke). Studies were considered for inclusion if they fulfilled the general 
ERFC inclusion criteria and measured Lp(a) using quantitative assay methods. 
 
Thirty-six eligible prospective studies provided data,3;9-43 including 12 that had not 
previously published their findings.32-43 These studies, involving over 145,000 
participants, comprise about 90% of relevant CHD cases identified in Western 
studies. Several smaller studies (collectively comprising about 10% of relevant 
known incident CHD cases) could not supply data.44-52 A few studies were excluded 
because they did not use quantitative Lp(a) assay methods.53-55  
 
Characteristics of contributing studies 
The general characteristics of the 36 studies contributing Lp(a) data to the ERFC are 
provided in Table 2.3. These largely Western studies selected their participants 
from approximately general populations using a variety of sampling methods. Most 
baseline surveys were carried out in the 1990s generally on middle aged or older 
participants. A few studies were entirely comprised of male or female participants. 
Blood was collected from participants mainly in the fasted state, and plasma or 
serum was isolated. A few studies used fresh samples to measure Lp(a) levels; 
however, most stored samples for a variable period of time, generally at 
temperatures of -700 centigrade or less, before measurement (Table 2.4). Two 
studies used in-house assays, 32 used commercially available assays and 2 did not 
specify the assay used to measure Lp(a) concentration. Assay methods used include, 
enzyme-linked immunosorbent assay (ELISA) in 21 studies, immuoturbidimetry or 
nephelometry assay (ITA, INA) in 9 studies, immunoradiometry (IRMA) in 3 studies 
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and enzyme immunodiffusion (EID) in 1 study. Twenty-four studies used assays that 
were not sensitive to apo(a) isoform variation (Table 2.4). The approach used to 
determine whether an assay is isoform sensitive is described in Chapter 5. Studies 
generally expressed Lp(a) concentration either as the total weight of the particle or 
as the weight of the protein mass (i.e., apo(a) and apo B100 mass) per unit volume. 
Where studies explicitly stated that Lp(a) concentration was expressed as total 
protein mass, individual values were multiplied by a factor of 3 to obtain the 
corresponding concentration expressed as the total weight of the particle. For one 
study which expressed Lp(a) concentration in molar units, values were converted to 
mg/dl using a conversion factor provided by the authors.  
 
In registering fatal outcomes, most contributing studies used International 
Classification of Diseases coding to at least 3 digits and ascertainment was based on 
death certificates. Twenty-eight studies also used additional information from 
medical records, autopsy reports, and/or other supplementary sources to classify 
deaths (Table 2.5). Twenty-nine studies used standard definitions of MI based on 
Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) or World 
Health Organization criteria. Twenty-five studies reported diagnosis of stroke on the 
basis of typical clinical features and characteristic changes on brain imaging, and 
most attempted to provide attribution of stroke subtype.  
 
Summary of available lipoprotein(a) data 
After exclusion of participants with known preexisting CHD or stroke at time of 
baseline survey, at least one measurement of Lp(a) concentration was available on a 
total of 126,634 individuals from 36 studies. Resurvey data were available on 6597 
individuals from 7 studies, each of whom provided at least 2 repeat Lp(a) measures. 
Concomitant information was available on Lp(a), age, sex, systolic blood pressure, 
smoking habits, history of diabetes, BMI, triglycerides and total cholesterol in 
106,645 participants from 30 studies. 96,113 participants from 26 studies had 
concomitant data on all the preceding characteristics plus HDL-C. 
 
The distribution of Lp(a) concentration was highly skewed to the right within each 
study population (Figure 2.2). Normal distributions were achieved by natural 
logarithmic (i.e., loge) transformation of Lp(a) values (Figure 2.3).  The overall 
pooled average Lp(a) value was 10.7 mg/dl (geometric mean), and the pooled 
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standard deviation was 1.25 loge mg/dl. The median values of Lp(a) concentration 
ranged between 3.0 mg/dl (inter-quartile range [IQR], 1.1-6.7 mg/dl) and 26.5 
mg/dl (IQR, 11.8-45.0 mg/dl) across the studies (Figure 2.4). The overall median 
in the combined studies was 12.6 mg/dl (IQR, 4.9-32.1 mg/dl).  
 
Conclusion 
The Emerging Risk Factors Collaboration (ERFC) is a collaboration of 110 prospective 
epidemiological studies that have recorded information on circulating lipid and/or 
inflammatory markers, other characteristics, as well as major cardiovascular 
outcomes and/or cause-specific mortality. Thirty-six studies in the ERFC provided 
available data on at least one measurement of Lp(a) concentration. This subset, 
involving over 126,000 participants without known pre-existing vascular disease at 
baseline, comprises about 90% of relevant incident cardiovascular cases reported in 
Western studies.  Analysis of individual participant data from these studies in a 
systematic meta-analysis should help characterise the relationship between 
circulating Lp(a) levels and the risk of vascular and nonvascular outcomes in more 
detail and precision than has been possible before. 
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Table 2.1: List of core variables sought in the Emerging Risk Factors Collaboration 
 
From baseline examination 
• Date of baseline survey 
• Unique (but anonymous) participant identifier 
• Date of birth (or age at baseline) and sex 
• Unique identifier for case-control matched sets for studies in which controls are 
‘individually matched’ to cases 
 
Clinical and biochemical measurements made at baseline examination 
• Ethnicity 
• Smoking and alcohol use (current / ex / never; amount / duration etc.) 
• Use of cardiovascular medications (current and past use, in as much detail as possible, 
including anti-hypertensive drugs, ‘statins’, fibrates) and other medications (e.g. 
hypoglycemic agents, hormone replacement therapy) – also, treatment allocation made in 
randomized controlled trials  
• Use of postmenopausal hormone therapy or oral contraceptives 
• Prior history of coronary heart disease (in particular myocardial infarction and angina), 
stroke, transient ischemic attack (TIA), peripheral vascular disease (PVD)  and diabetes 
• Systolic and diastolic blood pressure 
• Weight, height, waist and hip circumference 
• Physical activity and socio-economic status 
• Total, high- and low-density lipoprotein cholesterol (including particle size and numbers, 
where available); triglycerides; lipoprotein (a); apolipoprotein-AI and -B (including 
information about fasting status at the time blood samples were taken); lipoprotein-
associated phospholipase A2 mass and activity levels 
• Inflammatory markers (including C-reactive protein, fibrinogen, albumin, interleukin-6 and 
the  leucocyte count) 
• Creatinine, uric acid 
• Haemostatic factors (including von-Willebrand factor, fibrin D-dimer) 
• Metabolic factors (including fasting glucose, post load glucose, glycosylated haemoglobin 
and insulin) 
 
From re-survey examinations 
• The unique (but anonymous) participant identifier used for baseline visit 
• Date of the visit (or, if not available, age at visit) 
• Data on baseline items that were collected at repeat surveys (particularly established risk 
factors and other biochemical markers)  
 
Non-fatal events during follow-up 
• Myocardial infarction and date of MI 
• Stroke (including subtype if available: e.g. ischaemic / haemorrhagic) and date of stroke 
• Other subsidiary cardiovascular outcomes: e.g. angina, PVD, coronary artery bypass 
grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), congestive heart 
failure 
• Dates of censoring for end of follow-up for non-fatal events 
 
Fatal events during follow-up 
• Date last known to be alive (if not recorded as dead) 
• Date of death (or, if not available, age at death) 
• Underlying cause of death (preferably coded according to some specified version of the 
three-digit International Classification of Diseases (ICD); but if a three-digit ICD code is 
not available then whatever code the study already uses) 
• Date of censoring for end of follow-up for fatal cases 
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Table 2.2: Definition of major outcomes to be considered in the ERFC 
  
ICD version Outcome 
ICD-9 ICD-10 
Myocardial infarction 410, 412 I21, I22 
Coronary heart disease (CHD) 410-414 I20–I25 
Ischaemic stroke 433, 434 I63 
Haemorrhagic stroke 431 I61 
Other cerebrovascular diseases 
(including unclassified stroke†) 
430, 432, 435-438 F01, G45, I60, I62, I64-
I69 
Other cardiovascular event 093, 391, 393-405, 415-
417, 420-429, 440-444, 
446-453, 458, 459, 745-
747, 798 
I01, I05-I15, I20, I26-I28, 
I30-I52, I70-I82, I87,I95,  
I97-I99, Q20-Q28, R96   
Nonvascular event 001-092, 094-390, 392, 
454-457, 460-744, 748-779, 
800-999, E800-V82 
A00-F00, F02-H95, I00, 
I02, I83-I86, I88, I89, 
J00-Q18, Q30-Q99, S00-
Z99 
Unknown causes of death 780-797, 799 R00-R95, R98, R99 
 
 
Note: Corresponding ICD-6, 7 or 8 codes were used for studies that recorded outcomes using earlier 
ICD versions. †Unclassified stroke refers to ICD codes I64 (ICD-10), 436 (ICD-9) or earlier ICD 
equivalents, or strokes not specified as ischemic or haemorrhagic in study specific codes.  
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Table 2.3: Some baseline characteristics of prospective studies contributing Lp(a) data to the ERFC. 
 
 
*Numbers are before exclusion of participants with known prior CHD or stroke at baseline survey, therefore add up to > 126000. †For studies that published on their 
Lp(a) data; ‡ Fasting status at blood sampling; FHS: Framingham Heart Study. Note: the acronyms for the study names are provided in Chapter 2 appendix  
Study, 
publication year† 
 
Country Population source / sampling Baseline 
year 
No. of 
participants* 
Age range 
(yrs) 
% Males Fasting status‡ / 
duration 
Blood 
sample 
Cohort studies 
AFTCAPS USA Population screening / complete 1990-93 966 45-73 85 Fasted / > 8 hrs serum 
ARIC USA Household listings/Random 1987-89 15162 44-66 45 Fasted / > 8 hrs Plasma 
ATTICA Greece Population register / Random 2000-1 2682 35-89 52 Fated / > 8 hrs Serum 
BRUN, 1999 Italy Population register / Random 1990 895 40-79 51 Fasted / > 8 hrs Plasma 
CHARL USA Household listing / Random 1960-61 234 27-94 48 NS NS 
CHS1,  2003 USA Medicare lists / Random  1989-93 5166 65-100 42 Fasted / > 8 hrs Plasma 
COPEN, 2008 Denmark Population register / Random 1991-94 9613 21-98 44 Non-fasted Serum 
DUBBO, 2002 Australia Electoral roll / Complete 1988-89 2720 59-98 44 Fasted / > 8 hrs Serum 
EAS, 2001 Scotland GP list / Random 1987-88 1010 55-76 51 Fasted/ > 8 hrs Serum 
FINRISK92, 2005 Finland Population register / Random 1992 2344 24-64 47 Fasted / 4-8 hrs Serum  
FRAMOFF, 1996 USA Offspring & spouse to FHS / Complete 1991-95 2856 26-84 45 Fasted / > 8 hrs Plasma 
GOH Israel Population register / Random 1969-73 933 28-58 49 Fasted / > 8 hrs Plasma 
GRIPS, 1997 Germany Occupational / Complete 1982 5999 39-59 100 Fasted / 4-8 hrs Serum 
KIHD  Finland Population register / Random 1984-89 2572 42-61 100 Fasted / > 8 hrs Serum 
NHANES3 USA Census list / Cluster 1988-1994 10338 0-90 48 Fasted / > 6 hrs Serum 
NPHSII, 2001 UK GP list / Complete 1989-94 2432 49-64 100 Non-fasted Serum 
PRIME, 2002 France, Northern 
Ireland 
General Population  /  Quota 1991-94 8255 49-64 100 Fasted /  > 8 hrs Plasma 
PROCAM, 1996 Germany Occupational / Complete 1975-2001 3732 12-78 69 Fasted / > 8 hrs Serum 
QUEBEC, 1998 Canada Population register / Random 1985-86 2492 45-76 100 Fasted / > 8 hrs Plasma 
SHS, 2002 USA Tribal rolls / Complete 1989-92 4204 45-74 41 Fasted / > 8 hrs Plasma 
TARFS  Turkey Household listings / Random 1990 1710 20-100 49 Fasted /  > 8 hrs Plasma 
ULSAM  Sweden Population screening / complete 1970-74 1913 49-73 100 Fasted / > 8 hrs Serum 
WHITE2  UK Civil servant / Complete 1985-88 8021 34-56 67 Fasted /  NS Serum 
WHS, 2006 USA Health professionals / Complete 1993-2004 27792 39-90 0 3/4 Fasted / >8 hrs Plasma 
WOSCOPS, 2000 UK Heart screening clinic / Complete 1989-91 4920 45-64 100 Fasted / > 8 hrs Plasma 
ZUTE The Netherlands Population register / Random 1990 424 69-90 100 Non-fasted  Serum 
Nested case-control studies (individually matched) 
BUPA, 1994 UK Medical centre list / Complete  1975-82 1573 35-64 100 Fasted / NS Serum  
FIA, 1998 Sweden Population register / Random 1985-99 1524 29-77 73 Fasted / 4  hrs Plasma 
FLETCHER, 2007 New Zealand Occupational, electoral roll / Complete, 
random 
1992-94 915 34-86 79 Non-fasted Plasma 
HPFS USA Occupational / Complete 1994 791 47-81 100 2/3 Fasted / NS Plasma 
MRFIT, 2001 USA Population screening / Complete 1973-76 736 35-58 100 Fasted / > 8 hrs Plasma 
NHS, 2005 USA Occupational / Complete 1990 705 43-70 0 Fasted / Variable Plasma 
Nested case-control studies (frequency matched) 
BRHS UK GP lists / Random 1978-80 1839 40-59 100 Non-fasted Serum 
GOTO33, 1993 Sweden Population register / Complete 1983-84 143 49-51 100 Fasted / > 8 hrs Serum 
REYK,  2008 Iceland Population register / Complete 1967-91 6673 33-81 48 Fasted / > 8 hrs Serum 
USPHS, 1993 USA Occupational / Complete 1982 809 40-84 100 Non-fasted Plasma 
Total*    145,093     
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Table 2.4:  Some blood handling, storage and assay characteristics at first measurement of Lp(a) in 
studies contributing to the ERFC. 
 
*Refers to whether assay is affected by apo(a) isoform variation. NS: not stated; C: capture; D: detection; MAb: Monoclonal 
antibody; PAb: Polyclonal antibody: ELISA: Enzyme linked immunosorbent assay; ITA: Immunoturbidimetric assay; IRMA: 
Immunoradiometric assay; INA: Immunonephelometric assay; EID: Electroimmunodiffusion;  
Note: the acronyms for the study names are provided in Chapter 2 appendix
Study 
 
Storage 
duration 
Storage 
temperature 
Assay method 
(source) 
Assay 
Standard 
Antibody used Isoform 
sensitivity* 
AFTCAPS NS NS NS NS NS NS 
ARIC 1 week -1 yr Frozen, -70 0C ELISA (In-house) In-house Anti-apo(a) PAb No 
ATTICA < 1 week Fresh ITA (NS) NS NS NS 
BRUN <1 week Fresh ELISA (Immuno) In-house C: Anti-apo(a) PAb               
D: Anti-apo(a) Ab 
No 
CHARL 1-5 yrs Frozen, -70 0C ELISA (Terumo) Manufacturer D: anti-Lp(a) MAb Yes 
CHS1 1 week-1 yr  ELISA (Genetech) In-house D: Anti apo(a) MAb Yes 
COPEN 1 week-2 yrs Frozen, -80 0C ITA (DAKO) Manufacturer Rabbit anti-Lp(a) Pab Yes 
DUBBO < 1 week Fresh ELISA (Biopool) Manufacturer C: Anti-Lp(a) PAb                   
D: Anti-Lp(a) MAb 
No 
EAS 5-10 yr Frozen, -50 0C ELISA (Biopool) Manufacturer C: Anti-Lp(a) PAb                    
D: Anti-Lp(a) MAb 
No 
FINRISK92 1 week- 1 yr Frozen, -70 0C IRMA (Pharmacia) Manufacturer Two site anti-apo(a)  MAb No 
FRAMOFF 1–5 yrs Frozen, -80 0C ITA (DiaSorin SPQIII) Manufacturer NS Yes 
GOH <1 week Fresh ITA (K-Assay) Manufacturer Goat anti-Lp(a) antisera Yes 
GRIPS 5-10 yrs Frozen, -90 0C ELISA (Immuno) Manufacturer C: Anti-apo(a) PAb                
D: Anti-apo(a) MAb 
No 
KIHD  2-6 yrs Frozen, -20 0C IRMA (Pharmacia) Manufacturer Two site anti-apo(a)  MAb No 
NHANES3 1 week–1 yr Frozen, -20 0C ELISA (Strategic 
Diagnostics) 
Manufacturer C: Anti-Lp(a) MAb                
D: Anti-Lp(a) PAb 
Yes 
NPHSII  1 week-1 yr Frozen, -80 0C ELISA (Biopool) Manufacturer C: Anti-Lp(a) MAb                 
D: Anti-Lp(a) PAb 
No 
PRIME <1 week Fresh ELISA(In-house) NS C: Anti-Apo(a) Mab           
D: Anti-ApoB MAb 
No 
PROCAM <1 week Fresh EID (Behringwerke) Immuno Rabbit anti-Lp(a) antisera No 
QUEBEC 5-10 yrs Frozen, -70 0C ELISA (Biopool) CDC C: Anti-Lp(a) MAb             
D: Anti-Lp(a) PAb 
No 
SHS NS NS ELISA (Terumo) Manufacturer C: MAb; D: Pab Yes 
TARFS  NS Frozen, -75 0C INA (Behring) NS NS No 
ULSAM  > 10 yrs Frozen, -150 0C IRMA (Pharmacia) Manufacturer Two site anti-apo(a)  MAb No 
WHITE2  NS Frozen, -80 0C ITA (NS) NS NS Yes 
WHS >10 yrs Frozen, -150 0C ITA (Denka Seiken) Manufacturer Anti-Lp(a) PAb No 
WOSCOPS 1-5 yrs Frozen, -70 0C ELISA (Innogenetics) NS C: Anti-apo(a)  Mab             
D: Anti-apoB PAb 
No 
ZUTE NS Frozen, -20 0C NS NS NS NS 
BUPA >10 yrs Frozen, -40 0C ELISA (Biopool) NS C: Anti-Lp(a) Pab                    
D: Anti-Lp(a) MAb 
No 
FIA 6-19 yrs Frozen, -80 0C ELISA (Hypehn Biomed) In-house Mono-specific  anti-apo(a) PAb No 
FLETCHER >10 yrs Frozen, -70 0C ELISA            
(Hyphen Biomed) 
Manufacturer C: Anti-apo(a)  MAb                 
D: Anti-apoB PAb 
No 
HPFS 5 -10 yrs Frozen , -130 0C ITA (Denka Seiken) Manufacturer Anti-Lp(a) PAb No 
MRFIT >10 yrs Frozen, -50 0C ELISA (Strategic 
Diagnostics) 
Manufacturer C: Anti-Lp(a) Mab                  
D: Anti-Lp(a) PAb 
Yes 
NHS, 5-10 yrs Frozen , -130 0C ITA (Denka Seiken) Manufacturer Anti-Lp(a) PAb No 
BRHS >10 yrs Frozen, -20 0C ELISA (Hyphen Biomed) Manufacturer NS No 
GOTO33 5-10 yrs Frozen, -70 0C ELISA (Biopool) Manufacturer C: Anti-Lp(a) PAb               
D: Anti-Lp(a) MAb 
No 
REYK >10 yrs Frozen, -20 0C ELISA (Hyphen Biomed) Manufacturer C: Anti-apo(a)  MAb           
D: Anti-apoB PAb 
No 
USPHS >10 yrs Frozen, -80 0C ELISA (Biopool) Manufacturer C: Anti-Lp(a) Mab                 
D: Anti-Lp(a) Pab 
No 
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Table 2.5: Characterisation of baseline and incident cardiovascular disease outcomes in studies contributing Lp(a) data to ERFC. 
Nested case-control studies (individually matched) 
BUPA ++ ++ NS NS * NA NA NA NA NA  o o CC CC CC CC 
FIA ++ - - - **    NA NA  o o CC CC CC CC 
FLETCHER +NC + +NC - *       o o CC CC CC CC 
HPFS + + + - **    NA NA   NC o CC CC CC CC 
MRFIT ++ ++ - - **       o  CC CC CC CC 
NHS + + + - **    NA NA   NC o CC CC CC CC 
Nested case-control studies (frequency matched) 
BRHS ++ ++ - ++ *    NS NS  o o CC CC CC CC 
GOTO33 ++ - - - **       o o CC CC CC CC 
REYK ++ ++ ++ - **        o CC CC CC CC 
USPHS + - - - **    NA NA  o o         
 
- : Not recorded; +: Self-report only; ++: Self-report supplemented by objective criteria (e.g. Electrocardiogram, Physical examination); *: Death certificate only; **: Death 
certificate supplemented by medical record; 0: Feature not included in criteria;  : Feature included in criteria; ‡ These cohorts did not have any of the endpoints in the 
subsets in which Lp(a) values were measured; SAH: Subarachnoid haemorrhage; †not including SAH; NS: Not stated; NC = reportedly measured but data not contributed to 
the ERFC; NA = not applicable, where cohorts contributed data on fatal endpoints only; CC = Lp(a) data for these studies were provided in a nested case-control design for 
CHD endpoints. Note: the acronyms for the study names are provided in Chapter 2 appendix 
Study name Coronary disease assessed at baseline Definition of endpoints Classification of endpoints 
  
_Death_ 
 
____Nonfatal MI____ 
 
_Nonfatal Stroke_ 
 
__________MI_________ 
 
_____________Stroke_____________ 
 
 MI Angina 
Coronary 
revascularization 
Heart 
failure  
Clinical 
feature ECG 
Cardiac 
markers 
Clinical 
feature 
CT/MRI 
imaging Definite Probable Silent Ischemic Hemorrhagic† SAH Unclassified 
Cohort studies 
AFTCAPS ++ ++ - - **       - NC     
ARIC ++  ++ NC ++  - **               
ATTICA + + + + * - - - - - - - - - - - - 
BRUN ++ ++ ++ NC ++ NC **       o o   o o 
CHARL ++ ++ - - **   o  o   o     
CHS1 ++ ++ ++ ++ **        NC  NC   o  
COPEN ++ ++ - - **       o o     
DUBBO ++ ++ ++ - **       NS o     
EAS ++ ++ - - **         NC     
FINRISK92 ++ ++ ++ NC - **       o o     
FRAMOFF ++ ++ - ++NC **       o      
GOH ++ - - - ** NA NA NA NA NA   NC o     
GRIPS ++ ++ NC ++ NC - **        o     
KIHD  ++ ++ ++ ++ **        NC o     
NHANES3 + - - + *        o o   NC  NC  NC    
NPHSII ++ ++ ++ NC +NC **        NC  NC     
PRIME ++ ++ + - **       o o     
PROCAM ++ - - - **        NC    o  
QUEBEC ++ ++ - - **       o  o o o  
SHS ++ NC ++ NC ++ NC ++ NC **        NC o     
TARFS ++ ++ ++ NC - *   o  o  o   o o  
ULSAM ++ ++ ++ ++ **       o o     
WHITE2 ++ ++ NC ++ NC ++ NC *       o o     
WHS + + + - **       o o     
WOSCOPS ++ ++ ++ NC ++ NC **         NC o o o  
ZUTE ++ ++ ++ NC ++ NC **       o o     
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Figure 2.1: Flow diagram for identification of prospective studies of Lp(a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
94 potentially relevant articles retrieved 
3 studies that did not use quantitative 
methods to assay Lp(a) were excluded
9 studies involving approximately 1000 CHD 
cases (~10% of the potentially available cases 
for analyses) were not able to provide data
2748 excluded based on titles and/or 
abstracts due to not fulfilling the inclusion 
criteria (no relevant Lp(a) data, cross-
sectional or retrospective case-control 
design, study sample entirely diseased 
population, reviews, animal studies, etc.)
58 did not fulfil the inclusion criteria 
or were duplicate publications
2842 citations identified through electronic search 
and search of the reference list of relevant articles 
12 additional studies that had not previously published 
their findings were identified through discussion with 
collaborators which, along with the 36 studies identified 
in literature, gave a  total of 48 relevant studies
36 studies provided data for the current analyses
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Figure 2.2: Histogram of untransformed Lp(a) values in each of 36 prospective studies contributed data to the ERFC. 
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Figure 2.3: Histogram of loge transformed Lp(a) values in each of 36 prospective studies contributed data to the ERFC. 
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Figure 2.4: Box plot of untransformed Lp(a) values in each of 36 prospective studies contributed data to the ERFC. 
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Chapter 2 appendix: List of acronyms for studies contributing Lp(a) data to the ERFC 
 
AFTCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) 
ARIC (Atherosclerosis Risk in Communities Study) 
ATTICA (ATTICA Study) 
BRHS (British Regional Heart Study) 
BRUN (Bruneck Study) 
BUPA (British Union Provident Association) 
CHARL (Charleston Heart Study) 
CHS (Cardiovascular Health Study) 
COPEN (Copenhagen City Heart Study) 
DUBBO (Dubbo Study of the Elderly) 
EAS (Edinburgh Artery Study) 
FIA (First Myocardial Infarction in Northern Sweden) 
FINRISK92 (Finrisk Cohort – 1992) 
FLETCHER (Fletcher Challenge Blood Study) 
FRAMOFF (Framingham Offspring Cohort) 
GOH (The Glucose Intolerance, Obesity and Hypertension Study) 
GOTO33 (Goteborg Study – 1933) 
GRIPS (Göttingen Risk Incidence and Prevalence Study) 
HPFS (Health Professionals Follow-up Study) 
KIHD (Kuopio Ischaemic Heart Disease Study) 
MRFIT (Multiple Risk Factor Intervention Trial 1) 
NHANES III (National Health and Nutrition Examination Survey III) 
NHS (Nurses’ Health Study) 
NPHS II (Northwick Park Heart Study II) 
PRIME (Prospective Epidemiological Study of Myocardial Infarction) 
PROCAM (Prospective Cardiovascular Münster Study) 
QUEBEC (Quebec Cardiovascular Study) 
REYK (Reykjavik Study) 
SHS (Strong Heart Study) 
TARFS (Turkish Adult Risk Factor Study) 
ULSAM (Uppsala Longitudinal Study of Adult Men) 
USPHS (U.S. Physicians Health Study) 
WHITEII (Whitehall II Study) 
WHS (Women’s Health Study) 
WOSCOPS (West of Scotland Coronary Prevention Study) 
ZUTE (Zutphen Elderly Study) 
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Chapter 3: Cross-sectional correlates of lipoprotein(a) 
 
Chapter summary 
As circulating Lp(a) levels are under strong genetic control they are believed to be 
largely uninfluenced by lifestyle and biophysical and biochemical factors. This 
chapter reports the cross-sectional associations of Lp(a) with several characteristics 
recorded in up to 127,000 participants in the ERFC without cardiovascular diseases 
at the baseline survey. As expected, Lp(a) levels were highly variable between 
participants, but were only modestly associated with available individual traits, 
including several known cardiovascular risk factors. The identified correlates were 
weakly associated with Lp(a) concentration and together accounted for only 8% of 
the total variation in circulating Lp(a) levels (in contrast to other lipid factors where 
up to 28% of variation in levels are explained by known correlates). Levels were 
materially higher in Black individuals, perhaps reflecting differences in population 
genetic structures. Lp(a) concentration was modestly associated with non-HDL-C, 
apo B100 and HRT, perhaps indicating the possibility of modulation of levels through 
lipid or hormonal factors. Overall, the findings strengthen the notion that the high 
inter-individual variation in Lp(a) concentration is largely due to genetic factors. Due 
to the limited and weak correlation of Lp(a) with other traits, the potential for 
confounding in epidemiological studies of Lp(a)-CHD association should be lower 
than that seen in markers with more extensive correlations (eg, C-reactive protein). 
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Background 
As discussed in Chapter 1, circulating Lp(a) levels are mainly determined by the rate 
of apo(a) production, which in turn is under strong genetic control. Family based 
studies have shown that Lp(a) levels are highly heritable with genetic factors 
accounting for 75% to 98% of the overall variation.1-5 Consequently, it is generally 
thought that Lp(a) concentration is largely independent of various lifestyle, 
biophysical and biochemical factors. Consistent with this hypothesis, studies have 
reported that Lp(a) levels are uncorrelated (or very weakly correlated) with several 
known cardiovascular risk factors such as alcohol consumption, smoking status,  
blood pressure, BMI, HDL-C, apolipoprotein AI and fasting blood glucose.6-12  
 
However, owing to its structural composition and biological properties, Lp(a) shows a 
degree of correlation with some biochemical and physiological variables such as LDL 
cholesterol, apo B100, fibrinogen, and sex hormones.
7;10;13-18 For example, LDL-
cholesterol and apo B100 have been shown to be significantly, albeit weakly, 
correlated with Lp(a) levels (r~0.1), which is consistent with the LDL content of 
Lp(a) particles.10;15 Similarly, the observed correlation between Lp(a) concentration 
and coagulation factors such as fibrinogen  could be due to an effect of Lp(a) on the 
haemostatic  system.8;10;13 
 
The correlates of Lp(a) have generally not been reliably determined, in part due to 
lack of adequate power in individual studies, limitations in Lp(a) assays, differences 
in patterns of correlations between males and females, and between-population 
differences in Lp(a) levels and distributions. For example, while some studies have 
reported significant correlations between Lp(a) concentration and smoking status, 
BMI or systolic blood pressure,6;13;16 others have failed to demonstrate the existence 
of such relationships.7;8;10 Similarly, contradicting observations have been made 
about the association between Lp(a) levels and physical activity, with studies 
reporting both positive and negative correlations.19-21 
 
Reliable characterization of the relationships of Lp(a) concentration with various 
factors will help to: (i) asses the scope for confounding in epidemiological studies of 
the associations of circulating Lp(a) levels and disease risk, (ii) better understand 
the biology of Lp(a) and its inter-relationship with various haemostatic, 
inflammatory, hormonal and lipid factors, which in turn can help to clarify potential 
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pathophysiological mechanisms in disease causation, and (iii) identify possible non-
genetic determinants of Lp(a) levels which could be subject to therapeutic 
interventions in attempts to modify Lp(a) concentrations. This chapter presents the 
cross-sectional associations of Lp(a) levels with various socio-demographic, lifestyle, 
biophysical and biochemical factors using data on up to 127,000 participants from 36 
studies. Such extensive data should enable more detailed and reliable determination 
of the associations of Lp(a) with several individual and study level characteristics, 
under different circumstances (e.g., by sex) than has previously been possible in any 
single study. 
 
Methods 
Summary of available data  
The data harmonisation procedures of the ERFC and characteristics of the 36 studies 
that measured Lp(a) levels are described in Chapter 2. Descriptive statistics were 
calculated for a range of covariates measured at the baseline surveys of the 
contributing studies. for continuous variables the overall mean was obtained by 
pooling the study-specific means using a random-effects meta-analysis model and 
overall variance was calculated as the weighted-average of the study-specific 
variances; categorical variables were summarized as raw counts and proportions.    
  
Assessment of cross-sectional correlations  
The statistical methods used for the analysis of cross-sectional correlates of Lp(a) 
generally followed those published by the Fibrinogen Studies Collaboration.22 For the 
continuous variables, study-specific (or study- and sex- specific) Pearson correlation 
coefficients with loge Lp(a) levels were pooled using random-effects model meta-
analysis (standard errors of the coefficients were calculated after normalization of 
the distributions by Fischer’s z-transformation). To avoid confounding by study when 
comparing estimates for males and females, sex-specific correlations were calculated 
using only data from studies that included both sexes. Positively skewed variables 
(e.g., Lp(a), triglycerides, CRP) were loge transformed to approximate symmetrical 
distributions. The magnitude of association between Lp(a) and other risk factors was 
estimated by  regressing loge Lp(a) values on each factor using linear mixed models 
that included random effects at the study level to account for potential heterogeneity 
in the magnitude of association across studies. Multivariable models were adjusted 
for study, age, and sex, while allowing the effects of Lp(a), age, and sex to vary 
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randomly across studies.  (To determine the sex-specific associations of the 
correlates, analyses restricted to male or female participants only were performed 
using data from studies that included both sexes).. For the continuous variables, 
standardized regression coefficients were then calculated by multiplying the 
regression coefficient from the mixed models with the standard deviation of the 
corresponding correlate.  The percentage difference in Lp(a) concentration per 1 SD 
higher level of correlate was calculated by exponentiating the standardised 
regression coefficients. For the categorical variables, the percentage difference in 
Lp(a) concentration in comparison with the reference category was obtained by 
direct exponentiation of the regression coefficients from the mixed models. Changes 
in coefficients of determination (R2) in nested multivariable models were used to 
quantify the proportion of variation in loge Lp(a) levels explained by each correlate 
over and above the effects of study, age and sex. The multivariable models were 
further extended by mutually adjusting the correlates for each other and assessing 
the amount of variation that is explained by the combined association.22 
  
Linear mixed models were also used to assess shapes of cross-sectional associations 
of Lp(a) with its correlates. To allow assessment of the shape of association without 
imposing any particular shape implied by specific models, continuous variables were 
divided into tenths based on the overall distribution and fitted in the regression 
models as dummy variables.  The fixed effects in each model were: study, age, sex, 
age2, age*sex, age2*sex, factor-tenth, factor-tenth*age, and factor-tenth*sex 
(where “*” denotes interaction). Coefficients that were allowed to vary randomly 
across studies were: age, sex, age2, and factor-tenth entered as continuous variable 
(which constrains individual study departures from the overall shape to depend 
linearly on the level of the risk factor. Categorical variables were modelled similarly, 
except dummy variables were also used in the random part since there was no 
natural monotonic ordering of the categories.22 From each  fitted  mixed  model,  
overall  adjusted  means  and  95  percent  confidence intervals  of  loge  Lp(a)  by  
sex  within  the  tenths  of  continuous markers,  or category  for  categorical  
variables, were  obtained with age  fixed  at  age 50  years (age was adjusted to 65 
years in subsidiary analyses). These adjusted mean (95 percent CI) values were 
exponentiated and plotted against the mean marker value within each tenth to 
assess the shape of association. An inverse-variance weighted quadratic polynomial 
was superimposed across the adjusted means to aid in interpretation of the shape.  
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Correction of lipid measures for Lp(a) cholesterol  
Lp(a) consists of LDL particles which contribute to measured total and LDL 
cholesterol values. Measured total and LDL-cholesterol values were therefore 
corrected for the cholesterol content of Lp(a), which was calculated assuming that 
cholesterol accounts for approximately 15% of the total Lp(a) mass.23 (This is a 
conservative estimate of Lp[a] cholesterol content as some Lp(a) compositional data 
have shown higher values.) 9;24 
 
Z-transformation 
As the average Lp(a) levels varied materially across the studies even with the log-
transformation, parallel analyses were conducted with the loge Lp(a) distributions 
standardised within each study (i.e., z-transformed to a mean of 0 and an SD of 1) 
and results were compared with untransformed analyses. With such standardisation, 
the study specific dummy variables used to model the study effect on loge Lp(a) 
levels were not necessary for the z-transformed analyses. Similarly, coefficients of 
determination obtained from such models did not include study effect. 
 
Correction for measurement error  
Measurement error can weaken the observed correlations between Lp(a) and the 
various covariates, as well as contribute to part of the Lp(a) variation that remains 
unexplained in multivariable models. Data on repeat measurements for Lp(a) and 
the other markers, available in subsets of the participants (Table 3.1), were used to 
make corrections for measurement error. Regression calibration models were used 
to predict the long-term usual levels of the error prone covariates (discussed in 
Chapter 5).25 Associations of Lp(a) with the various risk factors were then re-
assessed using the predicted usual levels.  
 
Study level characteristics 
Study level characteristics are variables that assume only a single value for all 
participants of a given study. Such variable typically include geographical location of 
study, blood handling and storage characteristics, assay methods and principles 
used, study size, and date of publication. To assess the association of such study-
level characteristics with Lp(a) concentration, meta-regression models of mean 
study loge Lp(a) values on the respective variables were used.
26  
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All analyses were performed using Stata Statistical Software, Release 10 (StataCorp 
LP, College Station, Texas, USA). 
 
Results 
Table 3.2 provides descriptive summaries of the baseline characteristics of the 
participants included in Lp(a) analyses. Analyses involved data from up to 126,634 
participants in 36 studies without known cardiovascular disease at baseline survey.  
The mean age of participants at baseline was 57 (SD, 8) years and 52% were men 
(19 studies consisted of both male and female participants, 15 studies of only male 
participants and 2 studies of only female participants). Forty-seven percent of the 
participants were European and 50% North American. Among the 26 studies that 
provided individual level information on ethnicity, the majority of the participants 
(93%) were of European ancestry.  
 
Lipoprotein(a) levels 
There was a 7-fold variation in mean Lp(a) values across the studies; the studies 
with the highest and lowest Lp(a) levels had geometric means of 22.3 and 3.3 
mg/dl, respectively (Table 3.3). Little of this between-study variation in Lp(a) levels 
was explained by available study-level characteristics including fasting status of 
participants (fasted vs. non-fasted; r2 = 0%, p = 0.41), type of blood sample 
(plasma vs. serum; r2 = 0%, p = 0.81), sample storage duration (< 1 week vs. 1 
week – 1 year vs. > 1 year; r2 = 0%, p = 0.48), storage temperature (fresh, vs. ≤ - 
700C vs. > -700C; r2 = 7%, p = 0.13), type of assay method principle (ELISA vs. ITA 
or INA vs. Other; r2 = 8%, p = 0.10), or isoform sensitivity of assay method 
(isoform sensitive vs. insensitive; r2 = 0%, p = 0.98) (Figures 3.1, 3.2, 3.3). 
 
Within-study (between-person) variations in Lp(a) concentrations were much higher 
than between-study variations. After excluding the extreme 1% observations within 
each study, Lp(a) levels varied between 20 and 990 fold within the individual 
studies. Between-study variation accounted for only 10.6% of the overall variance in 
Lp(a) levels. 
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Association with categorical variables 
Lp(a) levels were materially different between Black and White ethnic groups, Blacks 
having more than 100% higher Lp(a) concentration than Whites. Levels were 12% 
(95% CI, 8% to 16%) higher in women and 11% (95% CI, 4% to 17%) lower in 
people with diabetes (Table 3.4). Lp(a) levels were 14% (95% CI, 4% to 24%) 
lower in post-menopausal women known to be taking hormone replacement therapy 
(HRT) at baseline survey, while the use of lipid-lowering medications (i.e., ‘statins’, 
‘fibrates’, niacin or other lipid-lowering drugs) did not appear to be associated with 
Lp(a) levels. Lp(a) concentration was not significantly different between current 
smokers and non-current smokers, between current alcohol drinkers and non-
current drinkers, or between individuals who were physically active and those who 
were less physically active. The observed associations (or lack thereof) were similar 
for male and female participants. In the multi-variable models, which were adjusted 
for study, age and (where appropriate) sex, the individual categorical traits 
explained only a small fraction of the variation in circulating Lp(a) levels: ethnicity 
(2.7%), sex (0.2%), history of diabetes (0.1%) and use of HRT (0.4%).  
 
Association with non-lipid markers 
Circulating Lp(a) levels were not importantly correlated with baseline age (r=0.01). 
Levels were also uncorrelated with systolic or diastolic blood pressure (r = 0.00 and 
r = 0.01, respectively). Significant but very weak inverse correlations, which appear 
exclusive to male participants, were observed with BMI, waist-hip ratio and fasting 
blood glucose (r=-0.02, -0.04 and -0.04, respectively; Table 3.5). In males, Lp(a) 
levels were lower by 5% per 1-SD higher BMI, by 6% per 1-SD higher waist-hip 
ratio and by 8% per 1-SD higher fasting blood glucose (Table 3.6).  In the multi-
variable models, which were adjusted for study, age and sex, the individual non-lipid 
markers explained little of the variation in circulating Lp(a) levels: BMI (0.3%), 
waist-hip ratio (0.45%), and fasting blood glucose (0.28%). Figure 3.4 is a plot of 
mean Lp(a) levels by sex against mean values in tenths of the correlates, suggestive 
of linear associations across the range of observed values, and potential qualitative 
interactions with sex for BMI.  
 
Association with lipid markers 
Lp(a) levels were positively correlated with apo B100, LDL-C and non-HDL-C 
concentrations (r = 0.11 , for each), and inversely correlated with loge triglycerides 
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concentrations (r= -0.05) (Table 3.5). Lp(a) levels were higher by 15% per 1-SD 
higher apo B100, by 16% per 1-SD higher LDL-C, by 14% per 1-SD higher non-HDL-C 
and by  6% per 1-SD lower loge triglycerides concentration (Table 3.6). Individually, 
apo B100, LDL-C, non-HDL-C, and loge triglycerides explained 1.6%, 2.3%, 1.4%, and 
0.6% of the variation in Lp(a) concentration, respectively. The shapes of the 
associations between Lp(a) levels and the lipid correlates were broadly linear and 
similar for male and female participants (Figures 3.4, 3.5, Table 3.5). After 
correcting the LDL-C and non-HDL-C values for the cholesterol content of Lp(a), 
LDL-C and non-HDL-C were no longer correlated of Lp(a) levels. 
 
Association with inflammatory markers 
Lp(a) concentration was higher by 11% per 1-SD higher fibrinogen, by 4% per 1-SD 
higher CRP and by 5% per 1-SD lower albumin levels (Table 3.6). Individually, 
fibrinogen, CRP, and albumin explained 1%, 0.2%, and 0.4% of the variation in Lp(a) 
concentration, respectively. The shapes of the associations between Lp(a) levels and 
the lipid correlates were broadly linear and similar for male and female participants 
(Figure 3.5, Table 3.5). No significant correlations were observed between Lp(a) 
levels and leukocyte count. Parallel analyses performed using z-transformed loge 
Lp(a) values yielded comparable results for both the categorical and the continuous 
correlates (Table 3.7). 
 
Mutually adjusted correlations 
The associations of Lp(a) level and risk factors was further assessed in mutually 
adjusted multivariable mixed models. To make maximal use of available data two 
mixed models were fitted: model 1 used data from 17 studies involving 66,848 
participants with complete information on age, sex, BMI, history of diabetes, total 
cholesterol, HDL-C, triglycerides, ethnicity, and fibrinogen; model 2 used data from 
9 studies involving 37,564 participants with complete information on all the 
preceding variables plus apo B100, and CRP.  
 
Lp(a) levels were highly significantly associated with all the variables include in 
model 1 (p-value < 0.01), except for age and HDL-C (Table 3.8). Of the variables 
with significant correlations with Lp(a), ethnicity contributed to the largest explained 
variation in Lp(a) concentration (3.3%), followed by non-HDL-C (2.5%) and 
triglycerides (1.1%). The combined association with all the characteristics included 
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in the model explained 8.1% of the variation in Lp(a) levels, of which 4.1% was 
attributable to age, sex and ethnicity, and the remaining 4% attributable to BMI, 
history of diabetes, non-HDL-C, HDL-C, triglycerides, and fibrinogen. There was 
significant heterogeneity in the association of fibrinogen with Lp(a) concentration 
between males and females (p-value=0.01), the association being stronger in 
females. The interaction between BMI and sex observed in the univariate model was 
no longer significant in the multivariable model; however, the association of BMI 
with Lp(a) concentration appeared stronger in males than in females (-4.5% vs. -
2%, respectively).  As in the univariate analysis the correlation of non-HDL-C 
became non-significant after correction for the cholesterol contained in Lp(a) 
particles. The penultimate column in Table 3.8 displays the standard deviation of 
the study random-effect, which is an estimate of the between-study variation in the 
association between log-Lp(a) concentration and the corresponding correlate. The 
parameter is analogous to the tau-squared value in random-effects model meta-
analysis and follows similar interpretation. For example, the average association of 
Lp(a) with non-HDL-C across study in men was 0.19 log mg/dl (i.e., 23%) increase 
per 1-SD higher non-HDL-C level, and the 95% range of values expected for 
individual studies can be estimated as 0.19 +/- 1.96*0.06 log mg/dl. (Please note 
that the random-effect parameters are provided as change in loge Lp(a) levels 
[penultimate column] and as percentage change [final column], while the fixed 
effects are provided as percentage change only.) In model 2, when apo B100 and CRP 
were added after the  nine variables included in model 1 above (using data on 
37,564 participants from 9 studies with complete information on these variables), 
the amount of variation in Lp(a) concentration that was explained by the model 
increased from 5.6% to 6%. Age, sex and ethnicity explained 1.4% of the variation 
in Lp(a) in model 2, with the rest of the variables explaining 5.6% of the Lp(a) 
variation. 
 
Correction for measurement error 
Table 3.9 shows the associations of Lp(a) with the various correlates while 
attempting to take measurement error into account. This was achieved by predicting 
the usual levels Lp(a) and the correlates using information on repeat measures, and 
re-assessing the associations between the predicted usual levels. As can be seen 
from the table, the associations were only modestly strengthened after the 
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correction suggesting that measurement error may not have obscured the correlates 
of Lp(a) concentration. 
 
Discussion 
This meta-analysis of individual data on 126,634 participants from 36 prospective 
studies of general populations has quantified the cross-sectional correlates of Lp(a) 
in more detail and precision than has been previously possible. The analyses 
revealed the presence of large inter-individual variation in Lp(a) levels, with 
relatively smaller between-study variation, which was little explained by measured 
individual level characteristics. Unlike other lipid fractions, Lp(a) levels were largely 
uncorrelated (or weakly correlated) with conventional cardiovascular risk factors 
including smoking, blood pressure and physical activity. However, owing to the 
structural composition and biological properties of the particle, Lp(a) levels were 
significantly (albeit weakly) correlated with certain blood factors, mainly LDL-C, apo 
B100 and fibrinogen. Lp(a) levels were materially higher in Black than in White 
individuals. Post-menopausal women on hormone replacement therapy had lower 
Lp(a) levels. Apart from Black ethnicity which was associated with over 100% higher 
Lp(a) concentration, the other markers were typically associated with about 10% 
difference in Lp(a) concentration per 1-SD change or when compared to reference 
category. Age, sex, and ethnicity accounted for 4% of the variation in Lp(a) level; 
while BMI, history of diabetes, non-HDL-C, HDL-C, triglycerides, and fibrinogen 
accounted for a further 4% of the variation. Overall, the identified correlates 
accounted for only 8% of the variation in Lp(a) levels. By contrast, analyses of the 
ERFC data show that known correlates explain 20% of the variation in non-HDL-C 
(and 28% of that in HDL-C). These findings strengthens the notion that the large 
inter-individual variation in Lp(a) is mainly determined by genetic factors. Due to the 
limited and weak correlation of Lp(a) with other variables, the potential for 
confounding in epidemiological studies of Lp(a)-CHD association should be lower, as 
such confounding effects are in part determined by the degree of correlation. 
However, even minimal correlations could lead to important confounding if the 
correlate has strong association with disease risk (e.g., LDL-C vs. CHD), and 
therefore should be appropriately accounted for. 
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Ethnicity, sex and HRT status 
Lp(a) levels have been reported to vary materially between different ethnic groups. 
This study demonstrated Blacks have over 2-fold higher Lp(a) levels than Whites. 
Although this difference in Lp(a) concentration is believed to be due to genetic 
factors, the specific causal variants have not been reliably determined.27-31 There 
were insufficient data to assess the association of Lp(a) level with other ethnicities. 
Sex hormones (both male and female), and anabolic steroids have been reported to 
influence Lp(a) levels in several epidemiological studies (including clinical 
trials);17;18;32-34 the 13% reduction in Lp(a) levels observed in post-menopausal 
women on hormone replacement therapy is consistent with Lp(a) lowering effect of 
female sex hormones.17;18;34 Unlike other proatherogenic lipids, Lp(a) levels were 
lower in males; hence, based on these data, it might be speculated that male 
hormones have greater Lp(a) lowering effect. Although the biological mechanisms 
have not yet been fully elucidated, it has been hypothesized that growth factors may 
play role in mediating the association between Lp(a) concentration and sex or 
anabolic steroids.17 Observations that Lp(a) levels change in response to treatment 
with hormonal agents suggest the possibility of modifying Lp(a) concentrations 
pharmacologically.33 
 
LDL-C, non-HDL-C, apo B100 
Compared with the other factors, LDL-C, non-HDL-C and apo B100 showed the 
strongest correlations with Lp(a) levels; nonetheless, these correlations were very 
weak (r~0.1). The association observed between Lp(a) concentration and apo B100 
containing lipoproteins (or their cholesterol or protein components) is related to the 
LDL content of Lp(a) particles. The cholesterol (apo B100) contained in Lp(a) particles 
constitutes part of the measured LDL-C (apo B100) values.
7 Hence, measurement 
factors contribute to the observed correlation between Lp(a) and LDL-C (apo B100). 
Correction of LDL-C (non-HDL-C) values for Lp(a) cholesterol attenuated the 
correlations significantly, indicating the importance of this explanation. However, as 
the Lp(a) cholesterol values were not directly measured (but estimated from total 
Lp[a] mass), these data do not provide conclusive evidence that measurement 
factors entirely explain the observed correlations. 
 
In addition, true biological relationships may explain part of the observed correlation 
between Lp(a) and the pro-atherogenic lipoproteins. Since Lp(a) is formed by the 
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covalent bonding of apo(a) molecules and the apo B100 moiety of LDL particles, 
higher LDL levels may lead to greater interaction between the two components, and 
increased production of Lp(a). Consistent with this hypothesis are findings from 
genetic studies demonstrating associations between Lp(a) concentration  and 
variants within the APOB or APOE genes (which are known to influence levels of apo 
B100 containing lipoproteins).
35;36 Such biological models for the correlation Lp(a) and 
LDL have therapeutic implications as they suggest the possibility of altering Lp(a) 
concentration through modulation of LDL (apo B100) levels. For example, 
mipromorsen - an antisense oligonucleotide directed at human apo B100 currently in 
phase 2 clinical trials as an LDL lowering agent - has been shown to reduce Lp(a) 
concentration by 70% in transgenic mice.37 However, these finding will need to be 
replicated in humans. 
 
Fibrinogen, C-reactive protein, albumin 
The current data showed significant positive correlations of Lp(a) with fibrinogen and 
CRP levels and negative correlation with albumin, which are consistent with the 
proposed pro-inflammatory activity of Lp(a). However, the correlations observed for 
Lp(a) were very weak, unlike those reported for typical inflammatory markers (eg, 
CRP, fibrinogen),22;38 perhaps suggesting a different regulation from the established 
acute phase reactant proteins. The correlation of Lp(a) with fibrinogen was stronger 
than that with CRP or albumin, which is consistent with additional biological link 
between Lp(a) and fibrinogen through the blood coagulation cascade (for example, 
in vitro studies have shown that Lp(a) can  interference with thrombolytic processes 
through various mechanisms).4;32;39;40 
 
Triglycerides, fasting blood glucose, diabetes and adiposity markers 
There were significant and inverse correlations between Lp(a) and each of 
triglycerides, fasting blood glucose, BMI and waist-hip ratio. Although the weak 
inverse correlation of Lp(a) with triglycerides has been observed by several studies, 
the mechanism of this relationship has not been determined. Higher triglycerides 
concentrations are associated with increased levels of very-low-density lipoprotein 
(VLDL).41 In such hypertriglyceridemic states, VLDL (instead of LDL) may 
preferentially bind with apo(a) molecules to form lower density Lp(a) particles.42;43 It 
has been hypothesized that VLDL containing Lp(a) particles may have higher 
clearance rate accounting for the inverse association between Lp(a) and triglycerides 
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levels.7 The observed inverse correlations with fasting blood glucose, BMI and waist-
hip ratio may be explained by the effect of triglycerides. Lp(a) levels were also lower 
in people with diabetes. The correlations between Lp(a) and BMI or waist-hip ratio 
were significantly different between males and females. However, the biological 
basis for this sex difference is not clear. 
 
Strengths and limitations 
The present analyses, involving data on up to 127,000 individuals, are the most 
comprehensive and detailed study of the cross-sectional correlates of Lp(a) 
concentration, with adequate power to make reliable assessment of magnitudes and 
shapes of associations within relevant subgroups such as in males and females. Any 
distortion in Lp(a) concentration (or in level of the correlates) due to prevalent 
disease was minimized as individuals with known cardiovascular disease at baseline 
survey were excluded from analyses. Average Lp(a) levels were highly variable 
across the studies, and little of the variation was explained by available data on 
study characteristics (including blood handing and measurement methods). The 
between study variability has been compounded by the expression of Lp(a) 
concentration in weight per unit volume (e.g., mg/dl) in most studies, as the apo(a) 
moiety of Lp(a) is known to have variable molecular weight. Limited information was 
available on certain important aspects of the Lp(a) assays, such as the standard 
used to calibrate the Lp(a) values and whether the assays were sensitive to apo(a) 
isoform variation. However, despite this considerable scope for variation, sensitivity 
analyses on standardised loge Lp(a) values demonstrated the robustness of the 
principal analyses which were carried on loge Lp(a) levels. Attempts were made to 
take measurement error into account by predicting usual levels of the variables 
using data on repeat measurements. However, such correction was limited as 
information on repeat measurements was available only in a subset of the 
participants and as existing regression-based statistical methods are not sufficient to 
handle measurement error in both predictor and dependent variables. The ERFC has 
collated information on several individual level characteristics from the contributing 
studies allowing the current analyses to assess a wider range of variable in relation 
to Lp(a) concentration. The results could have been more informative if further data 
were available on haemostatic factors (e.g., tissue plasminogen activator [tPA], 
plasminogen activator inhibitor [PAI] antigen), oxidative by-products (e.g., oxidized 
phospholipids), and proximal inflammatory mediators (e.g., interleukin-6). 
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Conclusion 
Lp(a) levels were highly variable between participants, but were only modestly 
associated with available individual traits, including several known cardiovascular 
risk factors. The identified correlates were weakly associated with Lp(a) 
concentration and together accounted for only 8% of the total variation in circulating 
Lp(a) levels (in contrast to other lipid factors where up to 28% of variation in levels 
are explained by known correlates). Levels were materially higher in Black 
individuals, perhaps reflecting differences in population genetic structures. Lp(a) 
concentration was modestly associated with non-HDL-C, apo B100 and HRT, perhaps 
indicating the possibility of modulation of levels through lipid or hormonal factors. 
Overall, the findings strengthen the notion that the high inter-individual variation in 
Lp(a) concentration is largely due to genetic factors. Due to the limited and weak 
correlation of Lp(a) with other traits, the potential for confounding in epidemiological 
studies of Lp(a)-CHD association should be lower than that seen in markers with 
more extensive correlations (e.g., CRP).  
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Table 3.1: Summary of data available for analyses of Lp(a) correlates in the ERFC, displayed by marker. 
 
Factor 
No. with Baseline 
measurements 
No. with at least 1 
repeat measurement 
Mean (SD) time to 1st 
repeat survey, years 
Total No. of repeat 
measurements 
Maximum no. 
of surveys 
Lp(a) 126634 6357 8.6 (4.8) 6397 7 
Diabetes History 120141 32886 6.2 (3.2) 80962 21 
BMI 122753 36047 6.0 (3.6) 103208 21 
Total cholesterol 125127 46021 5.8  (3.7) 109608 21 
HDL-C 113889 43718 5.9 (3.7) 94792 21 
Triglycerides 123256 44930 5.8 (3.7) 104781 21 
Fibrinogen 101346 23384 6.4 (3.3) 36639 14 
CRP 77510 18076 7.6 (5.2) 20283 4 
Apo B100 92432 19573 6.5 (4.8) 20066 17 
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Table 3.2: Summary of the baseline characteristics of participants included in Lp(a) analyses. 
 
Summary statistics by thirds of 
baseline Lp(a) levels 
Overall summary statistics 
Bottom 
Third 
Middle 
Third 
Top 
Third 
Variable 
No of 
studies 
No of 
subjects 
Mean (SD) 
or % 
Mean (SD) 
or % 
Mean (SD) 
or % 
Mean (SD) 
or % 
Log Lp(a) (mg/dl) 36 126634 2.37 (1.25) 1.00 (0.74) 2.44 (0.32) 3.71 (0.47) 
Age at survey (yrs) 36 126634 57 (8) 57 (8) 57 (8) 57 (8) 
Sex       
    Male 34 66250 52% 54% 52% 51% 
    Female 21 60384 48% 46% 48% 49% 
Ethnicity       
    White 26 85046 93% 98% 93% 88% 
    Black 11 6223 7% 2% 7% 12% 
Smoking status       
    Never / former 35 89658 73% 73% 73% 73% 
    Current 34 33336 27% 27% 27% 27% 
Alcohol status       
    Never / former 29 42184 38% 36% 38% 39% 
    Current 26 70253 62% 64% 62% 61% 
Physical activity       
    Not active 20 20357 50% 50% 49% 50% 
    Active 8 20616 50% 50% 51% 50% 
History of diabetes       
    No 35 113991 94% 93% 95% 95% 
    Yes 34 7036 6% 7% 5% 5% 
HRT status       
    Never / former 11 36255 70% 67% 71% 72% 
    Current 10 15626 30% 33% 29% 28% 
SBP (mmHg) 35 120643 134 (18) 134 (18) 134 (18) 135 (18) 
DBP (mmHg) 35 122302 82 (10) 82 (10) 81 (10) 82 (10) 
BMI (kg/m2) 35 123740 26 (5) 27 (4) 26 (4) 26 (5) 
Waist/hip ratio 11 43839 0.92 (0.09) 0.93 (0.09) 0.92 (0.09) 0.92 (0.09) 
Fasting glucose (mmol/l) 17 53200 9.7 (3.0) 7.9 (3.2) 7.9 (3.0) 9.1 (2.7) 
 
Lipid Markers 
      
Total cholesterol (mmol/l) 36 126128 5.9 (1.1) 5.8 (1.1) 5.9 (1.1) 6.0 (1.1) 
HDL-C (mmol/l) 33 114889 1.27 (0.38) 1.27 (0.39) 1.27 (0.38) 1.29 (0.38) 
LDL-C (mmol/l) 9 42449 3.70 (0.85) 3.60 (0.84) 3.75 (0.83) 3.79 (0.86) 
Non-HDL-C (mmol/l) 33 114876 4.62 (1.09) 4.49 (1.08) 4.62 (1.07) 4.74 (1.09) 
Log triglycerides (mmol/l) 35 124232 0.37 (0.51) 0.40 (0.54) 0.35 (0.50) 0.35 (0.49) 
Apo AI (g/l) 21 91480 1.51 (0.29) 1.51 (0.29) 1.50 (0.28) 1.51 (0.28) 
Apo B100 (g/l) 23 93058 1.08 (0.28) 1.05 (0.29) 1.08 (0.27) 1.11 (0.28) 
 
Inflammatory markers 
      
Log CRP (mg/l) 27 78153 0.62 (1.12) 0.58 (1.13) 0.62 (1.11) 0.66 (1.12) 
Fibrinogen (µmol/l) 25 101361 9.7 (2.3) 9.4 (2.1) 9.7 (2.2) 9.8 (2.4) 
White cell count (x10^9/l) 11 33625 6.6 (2.0) 6.6 (2.0) 6.6 (2.0) 6.6 (2.0) 
Albumin (g/l) 13 47865 44 (3) 44 (3) 44 (3) 44 (3) 
 
SBP: systolic blood pressure; DBP: diastolic blood pressure 
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Table 3.3: Lp(a) concentration in 36 studies contributing date to meta-analysis 
 
Study 
No. of 
Observations 
Lipoprotein(a), 
Geometric mean (SD) 
Lipoprotein(a), 
Median (IQR) 
AFTCAPS 902 8.3 (1.07) 7.6 (3.3,17.9) 
ARIC 14033 16.8 (1.17) 18.3 (6.9,43.8) 
ATTICA 1508 11.6 (1.06) 11.4 (4.9,25.2) 
BRUN 798 9.0 (1.16) 8.8 (4.4,21.6) 
CHARL 165 8.5 (1.28) 10.4 (3.4,22.3) 
CHS1 3860 9.1 (1.24) 12.6 (4.8,22.2) 
COPEN 7487 15.6 (1.44) 19.1 (6.9,42.6) 
DUBBO 2008 10.9 (1.22) 11.0 (5.0,27.8) 
EAS 637 8.5 (1.45) 9.2 (3.7,25.4) 
FINRISK 2201 11.9 (1.24) 12.2 (4.5,31.7) 
FRAMOFF 2850 15.0 (1.23) 16.7 (7.1,36.6) 
GOH 638 18.5 (0.84) 17.5 (10.0,37.0) 
GRIPS 5784 11.0 (0.93) 9.0 (4.0,25.0) 
KIHD 1996 8.6 (1.25) 9.6 (3.8,22.1) 
NHANES3 4496 18.6 (1.15) 23.0 (9.0,46.0) 
NPHSII 2375 9.7 (1.35) 10.9 (4.3,29.3) 
PRIME 7441 11.7 (1.11) 10.0 (5.0,30.0) 
PROCAM 3198 5.1 (1.33) 4.0 (2.0,13.0) 
QUEBEC 2012 17.7 (1.22) 19.0 (7.8,47.3) 
SHS 3837 3.4 (1.09) 3.0 (1.1,6.7) 
TARFS 1400 9.7 (1.08) 10.3 (4.0,21.4) 
ULSAM 1866 8.3 (1.27) 8.3 (3.4,22.3) 
WHITE2 7903 22.3 (0.89) 21.0 (12.0,46.0) 
WHS 27791 11.1 (1.31) 10.6 (4.4,32.8) 
WOSCOPS 4617 17.0 (1.34) 17.0 (7.0,50.0) 
ZUTE 305 11.9 (1.28) 12.3 (5.8,28.7) 
BUPA 1505 17.5 (1.36) 19.2 (8.7,47.7) 
FIA 1492 18.0 (1.33) 26.5 (11.8,45.0) 
FLETCHER 689 13.5 (1.82) 20.7 (7.2,59.5) 
HPFS 726 13.0 (1.30) 13.0 (5.6,37.3) 
MRFIT 736 3.3 (1.43) 3.4 (1.2,9.3) 
NHS 705 11.4 (1.24) 9.5 (4.8,28.2) 
BRHS 1561 7.6 (1.09) 6.5 (3.4,16.6) 
GOTO33 128 10.6 (1.18) 10.2 (4.2,32.0) 
REYKCON 6179 6.3 (1.70) 9.3 (2.9,22.8) 
USPHS 805 8.4 (1.47) 9.5 (3.8,24.1) 
TOTAL 126634 11.8 (1.32) 12.6 (4.9,32.1) 
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Table 3.4: Associations of Lp(a) concentration with various categorical traits. 
 
 
 
Percentage difference (95% CI) in Lp(a) concentration 
compared to reference category† 
 
 
 
Male participants‡ Female participants‡ All participants 
Sex    
Male NA NA Ref 
Female NA NA 12% (8 to 16) 
Race    
White Ref Ref Ref 
Black 128% (91 to 172) 143% (123 to 164) 119% (84 to 161) 
Smoking status    
Never / former Ref Ref Ref 
Current 3% (-0 to 7) 3% (-3 to 10) 0% (-2 to 3) 
Alcohol status    
Never / former Ref Ref Ref 
Current -2% (-7 to 4) -6% (-14 to 3) -4% (-8 to 1) 
Physical activity    
Not active Ref Ref Ref 
Active -2% (-28 to 33) -17% (-34 to 3) -8% (-23 to 10) 
History of diabetes    
No Ref Ref Ref 
Yes -11% (-19 to -3) 0% (-12 to 13) -11% (-17 to -4) 
HRT status    
Never / former NA Ref NA 
Current NA -14% (-24 to -4) NA 
 
 
NA: not applicable; Ref: reference category; † Percentage difference in mean Lp(a) levels for 
the category versus the reference for random effects across studies; ‡The analysis of sex-
specific associations was performed in studies that comprised of both male and female 
participants 
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Table 3.5: Correlation coefficients of Lp(a) levels with several continuous trait variables. 
 
 
 
 
†Pearson correlation coefficients between loge Lp(a) and the row variables, pooled across studies 
using random effects meta-analysis; ‡ The analysis of sex-specific associations was performed in 
studies that comprised of both male and female participants. § Corrections for cholesterol content 
of Lp(a) particles were made assuming that cholesterol comprises 15% of the total Lp(a) mass.  
 
 
 
 
 
 
 
 
 
 
Pearson correlation r (95% CI)† 
 
 
 
Males participants‡ 
Females 
participants‡ 
All participants 
Age at survey 0.01 (-0.01 to 0.03) 0.04 (0.02 to 0.06) 0.01 (0.00 to 0.02) 
Systolic blood pressure 0.00 (-0.01 to 0.02) 0.03 (0.01 to 0.05) 0.01 (-0.01 to 0.02) 
Diastolic blood pressure 0.01 (-0.02 to 0.03) 0.03 (0.00 to 0.05) 0.00 (-0.01 to 0.02) 
Body mass index -0.03 (-0.05 to -0.01) 0.02 (-0.02 to 0.05) -0.02 (-0.04 to -0.00) 
Waist/hip ratio -0.05 (-0.11 to 0.00) 0.01 (-0.01 to 0.04) -0.04 (-0.06 to -0.02) 
Fasting glucose -0.04 (-0.07 to -0.02) -0.02 (-0.06 to 0.03) -0.04 (-0.07 to -0.01) 
 
Biophysical markers 
   
Total cholesterol 0.11 (0.09 to 0.13) 0.15 (0.13 to 0.16) 0.12 (0.10 to 0.13) 
HDL-C 0.03 (-0.00 to 0.06) 0.01 (-0.02 to 0.03) 0.03 (0.02 to 0.04) 
LDL-C 0.07 (-0.03 to 0.18) 0.08 (-0.04 to 0.18) 0.11 (0.06 to 0.16) 
Non-HDL-C 0.10 (0.07 to 0.13) 0.14 (0.12 to 0.16) 0.11 (0.09 to 0.13) 
Log triglycerides -0.06 (-0.10 to -0.02) -0.03 (-0.07 to 0.01) -0.05 (-0.07 to -0.02) 
Apo AI 0.04 (0.00 to 0.08) 0.01 (-0.02 to 0.04) 0.02 (-0.00 to 0.04) 
Apo B100 0.13 (0.08 to 0.17) 0.14 (0.11 to 0.18) 0.11 (0.09 to 0.13) 
Total cholesterol – corrected§ 0.04 (0.02 to 0.06) 0.07 (0.05 to 0.09) 0.04 (0.02 to 0.06) 
LDL-C – corrected§ 0.00 (-0.10 to 0.11) -0.01 (-0.12 to 0.10) 0.00 (-0.09 to 0.10) 
Non-HDL-C – corrected§ 0.03 (-0.00 to 0.05) 0.07 (0.04 to 0.09) 0.03 (0.00 to 0.05) 
 
Inflammatory markers 
   
Log C-reactive protein 0.04 (0.01 to 0.06) 0.03 (0.02 to 0.05) 0.03 (0.01 to 0.05) 
Fibrinogen 0.09 (0.07 to 0.11) 0.12 (0.09 to 0.16) 0.08 (0.06 to 0.10) 
White cell count -0.03 (-0.08 to 0.02) -0.03 (-0.07 to 0.00) -0.02 (-0.05 to 0.01) 
Albumin -0.05 (-0.09 to -0.01) -0.05 (-0.10 to 0.01) -0.04 (-0.07 to -0.01) 
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Table 3.6: Associations of Lp(a) concentration with several continuous trait variables. 
 
 
† Percentage difference in mean Lp(a) levels for the category versus the reference for random 
effects across studies. ‡ The analysis of sex-specific associations was performed in studies that 
comprised of both male and female participants. § Corrections for cholesterol content of Lp(a) 
particles were made assuming that cholesterol comprises 15% of the total Lp(a) mass.  
 
Percentage difference (95% CI) in Lp(a) concentration 
compared to reference category† 
 
 Male participants‡ 
Female 
participants‡ 
All participants 
Age at survey  1% (-2 to 3) 5% (2 to 8) 2% (0 to 3) 
Systolic  blood pressure 0% (-2 to 3) 4% (1 to 7) 1% (-0 to 2) 
Diastolic  blood pressure 1% (-2 to 3) 4% (1 to 7) 0% (-1 to 2) 
Body mass index -5% (-8 to -2) 2% (-1 to 6) -4% (-6 to -1) 
Waist/hip ratio -6% (-11 to -1) 1% (-2 to 4) -5% (-7 to -2) 
Fasting glucose  -8% (-12 to -2) -3% (-8 to 3) -8% (-13 to -3) 
 
Lipid markers 
   
Total cholesterol  15% (13 to 18) 20% (17 to 22) 16% (14 to 18) 
HDL-C  3% (-0 to 7) 1% (-2 to 5) 4% (2 to 6) 
LDL-C  9% (-7 to 27) 9% (-7 to 27) 16% (8 to 24) 
Non-HDL-C  13% (11 to 16) 19% (15 to 22) 14% (12 to 17) 
Log triglycerides  -8% (-11 to -4) -4% (-8 to 1) -6% (-9 to -3) 
Apo AI  5% (0 to 9) 1% (-3 to 5) 1% (-1 to 4) 
Apo B100  16% (11 to 22) 18% (12 to 24) 15% (11 to 18) 
Total cholesterol - corrected§ 5% (2 to 8) 10% (7 to 12) 4% (0 to 8) 
LDL-C - corrected§ 0% (-14 to 17) -1% (-15 to 16) -1% (-17 to 18) 
Non-HDL-C - corrected§ 3% (-0 to 6) 9% (6 to 12) 2% (-2 to 7) 
 
Inflammatory markers 
   
Log CRP  5% (1 to 9) 4% (2 to 6) 4% (2 to 6) 
Fibrinogen  11% (8 to 14) 17% (12 to 22) 11% (8 to 15) 
White cell count  -4% (-9 to 1) -4% (-7 to 0) -2% (-5 to 1) 
Albumin  -6% (-11 to -1) -6% (-11 to 0) -5% (-8 to -2) 
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Table 3.7: Associations of z-transformed Lp(a) levels with several categorical and 
continuous trait variable. 
 
  
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in 
Lp(a) concentration per 1 SD 
increase or compared to reference 
category‡ 
Age at survey (yrs) 0.01 (0.00 to 0.02) 1% (0 to 3) 
Sex   
    Male  Ref 
    Female  9% (6 to 13) 
Race   
    White  Ref 
    Black  98% (74 to 126) 
Smoking status   
    Never / former  Ref 
    Current  0% (-1 to 2) 
Alcohol status   
    Never / former  Ref 
    Current  -3% (-7 to 1) 
Physical activity   
    Not active  Ref 
    Active  -6% (-19 to 9) 
History of diabetes   
    No  Ref 
    Yes  -9% (-14 to -3) 
HRT status   
   Never / former  Ref 
   Current -0.04 (-0.06 to -0.02) -11% (-17 to -4) 
Systolic blood pressure 0.01 (-0.01 to 0.02) 1% (-0 to 2) 
Diastolic blood pressure 0.00 (-0.01 to 0.02) 0% (-1 to 2) 
Body mass index -0.02 (-0.04 to -0.00) -3% (-5 to -1) 
Waist/hip ratio -0.04 (-0.06 to -0.02) -4% (-6 to -2) 
Fasting glucose  -0.04 (-0.07 to -0.01) -6% (-10 to -2) 
 
Lipid markers 
  
Total cholesterol  0.12 (0.10 to 0.13) 13% (11 to 15) 
HDL-C  0.03 (0.02 to 0.04) 3% (2 to 5) 
LDL-C  0.11 (0.06 to 0.16) 12% (7 to 18) 
Non-HDL-C  0.11 (0.09 to 0.13) 12% (10 to 14) 
Log triglycerides  -0.05 (-0.07 to -0.02) -5% (-7 to -2) 
Apo AI 0.02 (-0.00 to 0.04) 2% (-0 to 4) 
Apo B100 0.11 (0.09 to 0.13) 12% (9 to 15) 
 
Inflammatory markers 
  
Log C-reactive protein 0.03 (0.01 to 0.05) 3% (2 to 5) 
Fibrinogen  0.08 (0.06 to 0.10) 9% (7 to 12) 
White cell count  -0.02 (-0.05 to 0.01) -2% (-4 to 1) 
Albumin  -0.04 (-0.07 to -0.01) -4% (-7 to -1) 
 
†Pearson correlation coefficients between loge Lp(a) and the row variables, pooled across 
studies using random effects meta-analysis; ‡Percentage change in Lp(a) levels per 1-SD 
increase in the row variable (or for categorical variables, the percentage difference in mean 
Lp(a) levels for the category versus the reference) adjusted for sex and age and allowing for 
random effects 
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Table 3.8: The mutually adjusted associations of the correlates with Lp(a) concentration in multivariable mixed models. 
 
Change in Lp(a) concentration†, % (95% CI) Female-male interaction Study random effect‡ 
  Male participants Female participants Difference %(95% CI) P-value SD % change 
Age  0.01 (-0.22,0.24) 0.06(-0.11,0.24) 0.05(-0.22,0.33) 0.70 0.001 0.06 
Body mass index -4.52 (-7.06,-1.91) -1.99(-4.35,0.44) 2.65(-0.13,5.51) 0.06 0.005 0.62 
Non-HDL cholesterol 22.56(17.04,28.35) 25.18(19.42,31.21) 2.13(-0.81,5.16) 0.16 0.058 7.54 
HDL-C 0.34 (-2.78,3.55) 0.31(-2.72,3.44) -0.03(-2.97,3.01) 0.99 0.082 10.84 
Log-triglycerides -11.92 (-16.08,-7.55) -14.69(-18.88,-10.28) -3.15(-6.45,0.27) 0.07 0.126 17.12 
Fibrinogen 9.08 (5.16,13.14) 13.55(9.35,17.91) 4.10(0.93,7.37) 0.01 0.020 2.47 
Race (Black vs. White) 164.4 (146.9,183.0) 150.4 (137.7,163.7) -5.30(-12.66,2.68) 0.19 0.011 1.4 
Model 1 
Diabetes  (Yes vs. No) -10.98(-17.85,-3.53) -10.52(-16.87,-3.67) 0.52(-8.35,10.25) 0.91 0.044 5.63 
Age 0.10(-0.31,0.52) -0.05(-0.27,0.17) -0.15(-0.62,0.32) 0.52 0.000 0.05 
Body mass index -6.53(-10.98,-1.86) -1.57(-5.41,2.43) 5.31(-0.42,11.37) 0.07 0.005 0.65 
Non-HDL cholesterol 14.49(7.52,21.90) 14.67(11.21,18.24) 0.16(-6.53,7.33) 0.96 0.006 0.71 
HDL-C 2.11(-1.58,5.93) 0.68(-1.09,2.47) -1.40(-5.33,2.70) 0.50 0.008 1.03 
log-triglycerides -14.11(-19.05,-8.87) -14.34(-19.28,-9.09) -0.27(-6.36,6.23) 0.93 0.085 11.26 
Fibrinogen 1.80(-5.64,9.82) 17.23(8.77,26.34) 15.16(7.25,23.65) 0.0001 0.029 3.67 
Apo B100 12.27(4.06,21.13) 9.47(3.55,15.72) -2.50(-9.87,5.49) 0.53 0.141 19.2 
Log CRP  7.71(4.04,11.51) -2.63(-4.46,-0.76) -9.60(-13.08,-5.98) <0.0001 0.141 19.2 
Race (Black vs. White) 172.8 (109.7,254.9) 152.8 (127.2,181.2) -7.33(-30.05,22.79) 0.60 0.023 2.86 
Model 2 
Diabetes  (Yes vs. No) -11.20(-28.59,10.42) -16.18(-31.22,2.15) -5.61(-28.16,24.04) 0.68 0.117 15.72 
 
Note: Model 1 was based on data from 17 studies and 66,848 participants; model 2 was based on data from 9 studies and 37,564 participants. 
†Percentage change in Lp(a) levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean Lp(a) levels 
for the category versus the reference) with mutual adjustment for other variable in corresponding model and allowing for random effects across 
studies; ‡The study random-effect standard deviation summarizes the variability of the association between Lp(a) and the corresponding correlate 
across the studies. The random-effect parameters are provided as change in log Lp(a) concentration (penultimate column) and as percentage change 
(final column), while the fixed effects are provided as percentage changes only. 
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Table3.9:  The association of Lp(a) with several factors after taking within-person 
variability into account. 
 
 
†Pearson correlation coefficients between loge Lp(a) and the row variables, pooled across 
studies using random effects meta-analysis; ‡Percentage change in Lp(a) levels per 1-SD 
increase in the row variable (or for categorical variables, the percentage difference in mean 
Lp(a) levels for the category versus the reference) adjusted for sex and age and allowing for 
random effects across studies. § Corrections for cholesterol content of Lp(a) particles were 
made assuming that cholesterol comprises 15% of the total Lp(a) mass 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pearson correlation 
r (95% CI)† 
Percentage difference 
(95% CI) in Lp(a) 
concentration per 1 SD 
increase or compared to 
reference category‡ 
Ethnicity (Black vs. White)  120% (83 to 166) 
History of diabetes (Yes vs. No)  -3% (-4 to -2) 
Body mass index  0.00 (-0.02 to 0.02) 0% (-2 to 2) 
 
Lipid markers 
  
Non-HDL-C 0.15 (0.13 to 0.17) 18% (15 to 21) 
HDL-C 0.05 (0.03 to 0.06) 5% (3 to 7) 
Log triglycerides -0.05 (-0.07 to -0.03) -5% (-8 to -3) 
Apo B100 0.20 (0.18 to 0.22) 25% (21 to 30) 
Total cholesterol – corrected §  0.03 (0.01 to 0.06) 2% (-2 to 7) 
Non-HDL-c  - corrected § 0.02 (-0.01 to 0.05) 0% (-4 to 5) 
 
Inflammatory  markers 
  
Fibrinogen 0.07 (0.04 to 0.10) 9% (6 to 13) 
Log C-reactive protein 0.04 (0.02 to 0.05) 5% (2 to 7) 
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Figure 3.1:  Mean Lp(a) levels by cohort and (a) assay method principle, or (b) whether 
the assay method used was sensitive to apo(a) isoform variation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELISA: Enzyme Linked Immunosorbent Assay; ITA: Immunoturbidimetric Assay; INA: 
Immunonephelometric Assay; NS: Not specified. Meta-regression showed no statistically 
significant difference between groups of studies defined by (a) assay method (p=0.10; r2 = 
8%), or (b) isoform sensitivity (p= 0.98; r2 = 0%) 
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Figure 3.2: Mean Lp(a) levels by cohort and (a) fasting status, or (b) type of blood sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS: Not specified. Meta-regression showed no statistically significant difference between 
groups of studies defined by (a) fasting status (p=0.41; r2 = 0%), or (b) type of blood sample 
(p= 0.81; r2 = 0%) 
2
4
8
1
6
3
2
B
R
H
S
U
S
P
H
S
C
H
A
R
L
N
P
H
S
II
G
R
IP
S
N
H
S
F
IN
R
IS
K
Z
U
T
E
F
L
E
T
C
H
E
R
C
O
P
E
N
F
IA
N
H
A
N
E
S
3
M
R
F
IT
S
H
S
P
R
O
C
A
M
R
E
Y
K
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
B
R
U
N
C
H
S
1
T
A
R
F
S
G
O
T
O
3
3
D
U
B
B
O
W
H
S
A
T
T
IC
A
P
R
IM
E
H
P
F
S
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
B
U
P
A
Q
U
E
B
E
C
G
O
H
W
H
IT
E
2
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le
Non-fasted Fasted
(A) Fasting status
2
4
8
1
6
3
2
P
R
O
C
A
M
R
E
Y
B
R
H
S
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
N
P
H
S
II
G
O
T
O
3
3
D
U
B
B
O
G
R
IP
S
A
T
T
IC
A
F
IN
R
IS
K
Z
U
T
E
C
O
P
E
N
B
U
P
A
N
H
A
N
E
S
3
W
H
IT
E
2
M
R
F
IT
S
H
S
U
S
P
H
S
B
R
U
N
C
H
S
1
T
A
R
F
S
W
H
S
N
H
S
P
R
IM
E
H
P
F
S
F
L
E
T
C
H
E
R
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
Q
U
E
B
E
C
F
IA
G
O
H
C
H
A
R
L
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le Serum Plasma NS
(B) Blood sample
2
4
8
1
6
3
2
B
R
H
S
U
S
P
H
S
C
H
A
R
L
N
P
H
S
II
G
R
IP
S
N
H
S
F
IN
R
IS
K
Z
U
T
E
F
L
E
T
C
H
E
R
C
O
P
E
N
F
IA
N
H
A
N
E
S
3
M
R
F
IT
S
H
S
P
R
O
C
A
M
R
E
Y
K
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
B
R
U
N
C
H
S
1
T
A
R
F
S
G
O
T
O
3
3
D
U
B
B
O
W
H
S
A
T
T
IC
A
P
R
IM
E
H
P
F
S
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
B
U
P
A
Q
U
E
B
E
C
G
O
H
W
H
IT
E
2
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le
2
4
8
1
6
3
2
B
R
H
S
U
S
P
H
S
C
H
A
R
L
N
P
H
S
II
G
R
IP
S
N
H
S
F
IN
R
IS
K
Z
U
T
E
F
L
E
T
C
H
E
R
C
O
P
E
N
F
IA
N
H
A
N
E
S
3
M
R
F
IT
S
H
S
P
R
O
C
A
M
R
E
Y
K
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
B
R
U
N
C
H
S
1
T
A
R
F
S
G
O
T
O
3
3
D
U
B
B
O
W
H
S
A
T
T
IC
A
P
R
IM
E
H
P
F
S
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
B
U
P
A
Q
U
E
B
E
C
G
O
H
W
H
IT
E
2
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le
2
4
8
1
6
3
2
P
R
O
C
A
M
R
E
Y
B
R
H
S
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
N
P
H
S
II
G
O
T
O
3
3
D
U
B
B
O
G
R
IP
S
A
T
T
IC
A
F
IN
R
IS
K
Z
U
T
E
C
O
P
E
N
B
U
P
A
N
H
A
N
E
S
3
W
H
IT
E
2
M
R
F
IT
S
H
S
U
S
P
H
S
B
R
U
N
C
H
S
1
T
A
R
F
S
W
H
S
N
H
S
P
R
IM
E
H
P
F
S
F
L
E
T
C
H
E
R
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
Q
U
E
B
E
C
F
IA
G
O
H
C
H
A
R
L
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le
2
4
8
1
6
3
2
P
R
O
C
A
M
R
E
Y
B
R
H
S
A
F
T
C
A
P
S
U
L
S
A
M
E
A
S
K
IH
D
N
P
H
S
II
G
O
T
O
3
3
D
U
B
B
O
G
R
IP
S
A
T
T
IC
A
F
IN
R
IS
K
Z
U
T
E
C
O
P
E
N
B
U
P
A
N
H
A
N
E
S
3
W
H
IT
E
2
M
R
F
IT
S
H
S
U
S
P
H
S
B
R
U
N
C
H
S
1
T
A
R
F
S
W
H
S
N
H
S
P
R
IM
E
H
P
F
S
F
L
E
T
C
H
E
R
F
R
A
M
O
F
F
A
R
IC
W
O
S
C
O
P
S
Q
U
E
B
E
C
F
IA
G
O
H
C
H
A
R
L
G
e
o
m
e
tr
ic
 m
e
a
n
 L
p
(a
),
 m
g
/d
l 
(9
5
%
 C
I)
 -
lo
g
 s
c
a
le
 95 
Figure 3.3: Mean Lp(a) levels by cohort and (a) storage duration, or (b) storage 
temperature of blood samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NS: Not specified. Meta-regression showed no statistically significant difference between 
groups of studies defined by (a) storage duration (p=0.48; r2 = 0%), or (b) storage 
temperature (p= 0.13; r2 = 7%) 
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Figure 3.4:   Mean Lp(a) levels within tenths of systolic blood pressure, body mass index, fasting 
blood glucose, triglycerides, HDL-C or apolipoprotein AI in males and females 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Lp(a) levels are adjusted to age 65 years 
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Figure 3.5:  Mean Lp(a) levels within tenths of total cholesterol, non-HDL-C, Apo B100, 
C-reactive protein, fibrinogen or albumin in males and females 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Lp(a) levels are adjusted to age 65 years 
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Chapter 4: Within-person variability in lipoprotein(a) levels 
 
Chapter summary 
As Lp(a) concentration is known to be largely determined by genetic factors, it is 
thought that the levels remain constant over time within the individual. This chapter 
presents data on over 12,000 serial measurements of Lp(a) concentration in  over 
6000 participants made an average of 8 years apart, providing the most 
comprehensive and detailed assessment to date of the long-term within-person 
variability in Lp(a) levels.  The main finding is that Lp(a) shows high within-person 
consistency, as assessed using the regression dilution ratio (RDR). However, the 
RDR was importantly different at different levels of baseline Lp(a) concentration. The 
RDR for individuals with Lp(a) levels close to the mean of the distribution was 
estimated to be 0.9; RDR values were higher at higher Lp(a) concentrations and vice 
versa. The RDR was not materially different by other characteristics including age, 
sex or length of time interval between baseline and repeat measurement, or on 
adjustment for other cardiovascular risk factors. The high observed RDR suggests 
that the degree of underestimation of the strength of association between Lp(a) and 
disease risk in epidemiological studies is modest. However, as the variability appears 
to depend on the individual’s Lp(a) level, more subtle biases may arise, which 
necessitate appropriate correction for within-person Lp(a) variability. On the other 
hand, some small studies, with several repeated Lp(a) measurements over short 
period of time, have suggested that Lp(a) concentrations show considerable 
biological fluctuations, which may have implication for determination of the 
individual’s Lp(a) level in the clinical setting. This is in contrast to the relevance of 
the RDR to determination of disease associations in population studies. 
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Background 
Within-person variation in levels of a given factor has two components, i) analytical 
variation, and ii) biological variation.1 Analytical variation is the result of 
measurement error and depends on several factors, such as optimization of assays, 
availability of validated reference material for calibration of assays, and 
standardization of conditions in which measurements are carried out. Biological 
variation, on the other hand refers to true intra-individual changes in levels that 
occur as a result of a multiplicity of internal and external exposures such as 
hormonal factors and dietary habits. Biological variability can be short term, 
occurring over a period of hours to weeks (e.g., diurnal variation), or long term, 
occurring over a period of several months to years (e.g., lifestyle changes).2  
 
Due to within-person variability it is not possible to quantify accurately an 
individual’s true level of exposure to a given factor using a single measurement. 
Depending on the magnitude and sources of the within-person variability it might be 
necessary to take two or more measurements of the factor to be able to determine 
an individual’s true level.1;3;4 The indeterminacy of true underlying levels with single 
measurements has implications for both the individual patient seen in clinic, and for 
population based studies conducted in the field. In the clinical setting, where the 
administration of an intervention to an individual may depend upon an assessment 
of their disease risk by comparison of their measured levels with pre-specified cut-off 
values, there is a need to determine an individual’s true underlying exposure level in 
order to maximize the benefit (or minimize the risk) of the intervention. As a 
consequence, repeated measurements may be necessary especially when the 
patient’s value lies close to a cut-off point or when it is known that the particular 
exposure has large within-individual variability.1;3;4 For instance, consideration of 
within-person variability is part of the rationale behind recommendations to make 
several measurements of blood pressure over a certain period of time before 
initiation of anti-hypertensive therapy. 
 
 In epidemiological studies, single measurements of error-prone factors can lead to a 
misclassification of participants with regards to their true level of exposure. For 
studies assessing relationship between a given factor and disease risk such 
misclassification leads to attenuation of the real underlying association. As this error 
is a result of non-directional misclassification of individuals with regards to their 
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‘true’ levels of the exposure, it is considered as a random error. The resulting 
attenuation is known as ‘regression dilution’ bias, as it leads to weaker exposure 
coefficients (i.e., shallower slopes) in regression models.2;5-9 On the other hand, such 
misclassification in potential confounding factors used to adjust the associations of a 
given exposure can lead to error in either direction (strengthening or weakening the 
true underlying association) depending on the effect of confounding.10  
 
As Lp(a) concentration is known to be largely determined by genetic factors, it is 
thought that the levels remain constant over time within the individual.11-13 Current 
information on the within-person variability of Lp(a)  is based on a few studies 
conducted on small number of individuals.  Two of these studies, each based on 
approximately 200 individuals, reported a high correlation between a baseline and 
repeat measurement of Lp(a) taken a few years apart (Pearson’s correlation 
coefficient ~ 0.9).14;15 In the Reykjavik study we found a similarly high within-person 
correlation using repeat measurements from 372 individuals taken 12 years apart 
(Figure 4.1). These values of within-person correlation of Lp(a) levels are higher 
than those reported for other risk factors such as cholesterol and blood pressure.5;16 
 
In addition to the studies that assessed the long-term within-individual correlations 
of Lp(a) concentration over a period of years, there have been a few small scale 
endeavors to determine the short-term within-individual biological fluctuations of 
Lp(a) over a period of weeks.1;3;4;17-20 These studies, involving between six and 40 
participants, used biological coefficients of variation as measures of within-person 
variability, calculated as the ratio of the standard deviation to the mean of several 
repeat measurements. The estimates of the biological coefficient of variation ranged 
from 0% (which implies absence of significant biological fluctuation) to 26% (which 
implies existence of material biological fluctuation) (Table 4.1). These results cannot 
be compared directly with those from studies of long-term variability because the 
biological coefficient of variation relates the variance and mean of serial repeat 
measures within the same individual, and has different interpretation from within-
person correlations estimated in the long-term variability studies.21 In addition, as 
the biological fluctuations were typically studied on a handful of individuals, the 
estimates may lack precision. 
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This chapter assesses long term within-person variations in Lp(a) concentration in 
more detail than has been previously possible, using data on over 6000 participants, 
each with at least 2 serial measurements taken an average of 8 years apart. The 
implication of the findings to epidemiological studies and individual patients is 
discussed.  
 
Methods 
Approaches to estimate within-person variation 
The use of regression dilution ratios (RDRs) to correct observed epidemiological 
associations for the effect of within-person variability is a widely accepted 
approach.2;5;8 As its name implies, the RDR represents the fractional attenuation in 
the regression coefficient of a given exposure-disease association (i.e., the ratio of 
the observed slope to the true underlying slope of association), as a result of within-
person variation, when a single baseline measurement is used. The RDR can take 
values between 0 and 1, with values closer to 1 implying an absence of ‘regression 
dilution’ and vice versa. A simple correction for `regression dilution’ involves division 
of the estimated disease association (e.g., log hazard ratio) by the RDR. 
 
The RDR can be estimated using parametric or non-parametric methods.5;6 In the 
non-parametric method, the RDR is estimated by categorizing individuals using 
quantiles of their baseline measurements, and then comparing the mean values of 
the baseline and repeat measurements for these quantile groups. The RDR is 
calculated by dividing the difference between the means the extreme quantiles of the 
repeat measurements by the corresponding difference for the baseline 
measurements. The method does not make assumptions about the variance of the 
measures and provides a robust estimate of RDR in many different situations. The 
parametric method, on the other hand, assumes equality in the variance of the 
baseline and the repeat measures.5 However, the flexibility of the parametric 
methods and the greater ease of extension to more complex analytic situations (e.g., 
correction for within-person variation in multi-variable models) make the parametric 
method preferable. Thus the work in this thesis is based on parametric estimation of 
RDRs. 
 
Parametric estimation of the RDR can be done in three ways: i) by calculating the 
correlation between repeat and baseline measurements, ii) by calculating the within-
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person intra-class correlation (ICC) for individuals with serial measurements, and iii) 
by regressing repeat measurements on baseline measurements in linear regression 
models and taking the coefficient for the baseline measurement. The later approach 
is used in this chapter and the other approaches are referred to as necessary. 
 
Data source 
Analyses were based on data from the ERFC database, which is a central repository 
for individual participant data from 110 prospective epidemiological studies 
(Chapter 2). Repeat measurements on Lp(a) concentration were available on over 
6000 participants from 7 studies. Serial measurements generally involved a baseline 
and single repeat measurement for each individual. As with the analyses of 
correlates (Chapter 3), Lp(a) values were log-transformed to achieve normal 
distributions before calculation of the RDR. 
 
Stratified regression model 
Study-specific RDRs were estimated by regressing repeat measurements of Lp(a) on 
the baseline measurements as shown in equation 1: 
 
Yij = aj + bj Xij + eij      (1) 
 
where Yij is the repeat Lp(a) measurement for the i
th individual in study j, Xij is the 
baseline Lp(a) measurement for the ith individual in study j, eij ~ N(0,∂
2), and bj  is 
the study-specific RDR. Overall (pooled) RDR was calculated by combining the study-
specific RDRs using random-effects model meta-analysis, as shown in equation 2: 
 
bj = b + uj       (2) 
 
where b is the overall RDR and uj ~ N(0,∂
2) allows for between-study heterogeneity. 
Thus, the overall RDR was calculated using a two-step method. 
 
The overall RDR was also estimated by a one-step method using a linear-mixed 
model which allowed the RDR to vary randomly at the study level, as shown in 
equation 3: 
 
Yij = aj + (b+uj) Xij + eij    (3) 
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where Yij is the repeat Lp(a) measurement for the i
th individual in study j, Xij is the 
baseline Lp(a) measurement for the ith individual in study j, eij ~ N(0,∂e
2),  uj ~ 
N(0,∂u
2),  and b is the overall RDR. 
 
 
Adjusting RDR for covariates 
As the primary purpose of the RDR is to allow an unbiased risk estimation of a 
disease association, the RDR model should be adjusted similarly to the disease risk 
model. For instance, if the association between CHD and Lp(a) was adjusted for 
cholesterol levels, then a cholesterol-adjusted RDR should be used to correct it. 
Adjustment of RDRs was achieved by adding the relevant covariates to equation 3. 
 
Potential modifier of within-person variability 
The ability of some factors, such as baseline Lp(a) concentration, time since baseline 
measurement, assay method, and individual characteristics (e.g., age, sex), to 
modify the within-person variability of Lp(a) was also investigated: 
 
(i) Baseline Lp(a) concentration  
It has been reported previously that the RDR for a given exposure may differ with 
level of the same exposure. For instance, it has been shown that the variability in 
fibrinogen is larger in individuals with higher fibrinogen levels.8 To allow the RDR to 
vary by Lp(a) level, a quadratic term was added to the centered baseline Lp(a) 
concentration as shown in equation (4). 
 
Yij = aj + (b+uj) Xij + c Xij
2 
+ eij  (4) 
 
where Yij is the repeat Lp(a) measurement for the i
th individual in study j, Xij is the 
baseline Lp(a) measurement for the ith individual in study j, eij ~ N(0,∂e
2),  uj ~ 
N(0,∂u
2),  b is the overall RDR at mean Lp(a) concentration, and c represents the 
effect of Lp(a) concentration on the RDR. An Lp(a)-concentration dependent RDR 
may then be calculated as shown in equation (5). 
 
  bx = b + c X      (5) 
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 where bx is the RDR at a given Lp(a) concentration X, b is the RDR at mean Lp(a) 
concentration, and c is the difference of RDR per unit change in L(a) concentration. 
 
(ii) Time since baseline measurement 
To assess whether RDRs vary by time, study-specific RDRs were plotted against the 
average time interval since baseline measurement and visually inspected. The 
significance of time-effect on RDRs was assessed using meta-regression. 
 
(iii) Individual characteristics 
Assessment of the effect of individual characteristics on Lp(a) variability was done by 
fitting an interaction term between baseline Lp(a) levels and the covariates in 
equation (3), also allowing a study-level random effect for the interaction and the 
covariate. The following variables were pre-specified for investigation as potential 
modifiers of Lp(a) variability: age, sex, history of diabetes, BMI, triglycerides, total 
cholesterol and fibrinogen. 
 
(iv) Assay method 
As a single Lp(a) assay was used per-study, exploration of the effect of assay 
method on variability could only involve sub-grouping of study-specific RDRs based 
on the assay method used. This was not carried-out in the current analyses because 
data involved only 7 studies, so meaningful subgrouping of the RDRs was not 
possible. All analyses were performed using Stata Statistical Software, Release 10 
(StataCorp, College Station, Texas, USA). 
 
Results 
Available data from repeat measurements 
Lp(a) concentration was re-measured at least once in 6357 participants from 7 
studies (Table 4.2). For AFTCAPS, almost all the participants with baseline Lp(a) 
measurements also had one repeat measurement; for COPEN, FLETCHER, TARFS and 
ULSAM between 25 and 60% of the participants with available data on baseline Lp(a) 
concentration had one repeat measurement; for REYK and PROCAM individuals with 
Lp(a) re-measurements comprised less than 15% of the participants with baseline 
L(a) values. Although the subsets with repeat Lp(a) measurements were not strictly 
random samples of the studies, they were selected with the intention of being 
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representative of all participants within the respective studies, and had generally 
similar characteristics to those with only baseline Lp(a) measurements (Table 4.2).   
 
A total of 12,754 serial measurements were available, derived from 9 different re-
surveys. The mean time interval between baseline and repeat Lp(a) measurements 
within each study ranged from 1.0 to 21.3 years; the overall mean time interval 
between baseline and repeat was 8.5 years (Table 4.3). Among individuals who 
provided repeat samples, the overall mean (SD) log-Lp(a) concentration at the re-
survey was 2.69 (1.30) log mg/dl, the corresponding value for the baseline survey 
was 2.47 (1.46). In some of the studies (e.g., COPEN), the variance of log-Lp(a) for 
the repeat measurements was materially different from that of the baseline 
measurements (Table 4.3). To fulfill the assumption of equal variance for 
parametric RDR estimation, the repeat measurements were transformed within each 
study to have the same variance as the baseline measurements. 
 
Regression dilution ratio for Lp(a) 
The estimated study-specific RDRs ranged from 0.62 to 0.94. The combined RDR for 
Lp(a), pooled across all studies using random-effects model, was 0.80 (95% CI, 0.74 
to 0.87) (Figure 4.2). The total heterogeneity between the study-specific RDRs had 
a standard deviation of 0.13 (95% CI, 0.07 to 0.24). The addition of quadratic term 
to the model including centered baseline and repeat Lp(a) values was highly 
statistically significant, suggesting that Lp(a) variability differed by level. The 
coefficient of the quadratic term was 0.12 (95% CI, 0.11 to 0.13), which indicates 
that the RDR increased by 0.12 with every 1 log mg/dl higher Lp(a) concentration, 
and vice versa. The overall RDR at mean loge Lp(a) concentration, hitherto referred 
as `mean RDR’, was 0.87 (95% CI, 0.81-0.93) (Figure 4.3). As the RDR varied 
materially by Lp(a) levels, all subsequent RDR analyses included a quadratic term in 
the RDR models, and the reported RDRs refer to the `mean RDR’. Unlike Lp(a) 
concentration, there was no strong evidence that the time interval between baseline 
and repeat measurements influenced the RDR estimate (meta-regression p-value = 
0.47; Figure 4.2, 4.3). Estimation of the RDR using the other parametric 
approaches (i.e., intra-class correlation and Pearson’s correlation) yielded similar 
results. 
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Adjusting for potential confounders 
The overall age- and sex- adjusted mean RDR for Lp(a) was 0.87 (95% CI, 0.78 to 
0.97);  the RDR was virtually unchanged on adjustment for systolic blood pressure, 
smoking status, history of diabetes body mass index, log-triglycerides and total 
cholesterol values. 
 
Predictors of Lp(a) variability 
RDR was not materially affected by several individual levels characteristics pre-
specified to be tested as potential predictors of Lp(a) variability (Table 4.4). 
Notably, Lp(a) mean RDR was not different between males and females, or at 
different levels of triglycerides, total cholesterol or fibrinogen. 
 
Comparison of Lp(a) RDR 
To allow comparison of Lp(a) RDR with that of other cardiovascular risk factors, RDR 
was calculated for each of total cholesterol, HDL-C, triglycerides and systolic blood 
pressure using the maximum available data in the ERFC. (Analyses involved up to 
293,759 serial measurements in 155,027 participants from 35 studies.) The age- and 
sex-adjusted RDRs were considerably weaker for these other exposures than for 
Lp(a): 0.65 (95% CI, 0.62 - 0.67) for total cholesterol, 0.72 (95% CI, 0.70 - 0.75) 
for HDL-C, 0.63 (95% CI, 0.61 - 0.65) for loge triglyceride, 0.52 (95% CI, 0.49 - 
0.55) for systolic blood pressure (Figure 4.4). 
 
Discussion 
This chapter presents data on over 12,000 serial measurements of Lp(a) 
concentration in over 6000 participants taken an average of 8 years apart, providing 
the most comprehensive and detailed assessment of long-term within-person 
variability in Lp(a) levels to date. The main finding is that Lp(a) levels are highly 
consistent within individuals. However, the RDR was importantly different across the 
range of baseline Lp(a) concentrations. The RDR for individuals with average Lp(a) 
concentration was estimated to be 0.9; RDR values were higher at higher Lp(a) 
concentration and vice versa. The RDR was not materially different by age, sex or 
BMI, or by levels of triglycerides, total cholesterol or fibrinogen. In addition, the 
length of the time interval between baseline and repeat measurement did not appear 
to significantly affect the RDR. Adjustment for cardiovascular risk factors did not 
have a material effect on the RDR estimate. 
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The observed high RDR for Lp(a) suggests that in long-term epidemiological studies 
of disease outcomes, regression dilution bias may be less important for Lp(a) than 
for other exposures such as systolic blood pressure.2;5 That the RDR was positively 
associated with Lp(a) concentration indicates that, unlike other cardiovascular risk 
markers such as fibrinogen and HDL-C, within-person variability in Lp(a) tends to 
decrease with increasing Lp(a) concentration.8 Thus, misclassification is likely to be 
particularly lowest at high Lp(a) concentrations where the RDR is also high. On the 
other hand, at lower than average Lp(a) concentration the degree of 
misclassification will be expected to be higher. The difference in variability of Lp(a) 
by its own concentration has implications for assessing the shape of association 
between Lp(a) and disease risk.  As misclassification would be expected to be lower 
with higher Lp(a) concentration, the relative risks for categories with higher Lp(a) 
concentration would be attenuated to a lesser degree than categories with lower 
Lp(a) concentration. In an analysis that does not make appropriate allowance for 
Lp(a) variability, this could lead to an apparent curvilinear, or even threshold, 
association even if the shape of the underlying association was linear. Perhaps 
epidemiological observations of high relative risks for individuals with very high 
Lp(a) concentrations (e.g., >95th percentile) might in part be related to such 
differential misclassifications, as studies did not typically take regression dilution into 
account. Thus, making appropriate adjustment for Lp(a) variability in disease risk 
models is of considerable importance. 
 
The observation of an increase in RDR with increasing Lp(a) concentration is 
consistent with that of  Nakajima et al, who reported that the biological coefficient of 
variation for Lp(a) was inversely related to its concentration.20 This finding may 
reflect a true biological phenomenon, or may relate to the way the RDR or the 
coefficient of variation is calculated. One potential biological explanation is that 
higher Lp(a) concentrations might be under stronger genetic regulation and hence 
have lesser variability. Alternatively, as the RDR is related to the ratio of between-
person to total (between- and within-person) variation, (i.e., the RDR is high when 
the between-person variation is much greater than the within-person variation, and 
vice versa), if between-person variation in Lp(a) concentration were higher at higher 
Lp(a) levels (e.g., due to greater dispersion of the distribution), then the RDR would 
be expected to decrease in the same direction. On the other hand, as the coefficient 
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of variation expresses the within-person variation as a proportion of the mean, 
values would be expected to be lower at high Lp(a) concentrations. 
 
Perhaps it is intuitive to assume that high RDR values always reflect low within-
person variability in a marker. However, as described above, high RDR values may 
be observed even with significant within-person fluctuations if the between-person 
variation is very high. For Lp(a), due to the presence of very large between-person 
variation (up to 1000 fold difference), the concentration may vary considerably 
within the individual despite the high RDR. This is also consistent with the small-
scale observations which highlighted the presence of some degree of short-term 
biological variation in Lp(a) values.3;4;20 For the purpose of epidemiological study, 
the high RDR implies that the ranking of individuals with respect to their values is 
likely to be accurate and the probability of misclassification is low. On the other 
hand, for the purpose of clinical risk-stratification of individuals there may be a need 
for repeat measurements as the actual value is subject to biological variations.3 The 
need for re-measurement may be different for individuals with different Lp(a) 
concentrations as variability appears to vary by level.4;20 
 
The limitations of the current report are worth some consideration. Although this 
report is the most detailed exploration of Lp(a) variability to date, with 6397 repeat 
measurements in 7 studies, data were still somewhat limited, particularly in 
comparison with the other markers studied in the ERFC. The low number of studies 
with repeat measurements meant that it was not possible to investigate study level 
characteristics such as assay method in relation to Lp(a) variability. Although 
estimation of the RDR provides useful information about within-person variation of 
Lp(a) that is particularly relevant to epidemiological studies, it does not enable 
determination of within-person biological fluctuations of Lp(a). Biological coefficient 
of variation may be more relevant for the later. 
 
It is important to discuss the assumptions underlying the use of RDR methods for 
correction of measurement error in epidemiological studies of disease risk. Firstly, 
correction of a disease-exposure association only, using an RDR, assumes that 
confounders are perfectly measured.8;22 In reality, as confounders are also measured 
with error an isolated RDR correction for exposure may amplify residual confounding. 
Therefore, a multivariate extension of the RDR method taking into account 
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measurement error in both exposure and confounders is more appropriate.23;24 This 
approach has been implemented for analyses of Lp(a) disease association (Chapter 
5).  Secondly, RDR correction methods assume that disease risk depends on a single 
underlying long-term average exposure level.25 Therefore the methods are valid if 
disease risk depends on current usual level or if RDRs are constant over the life 
course. On the other hand, if the risk of disease depends on the temporal 
fluctuations in the exposure, then an RDR correction will be less appropriate. 
 
Conclusion 
Lp(a) shows high within-person consistency with a typical RDR of about 0.9 which 
appears to be concentration dependent. The RDR was not materially different by 
other characteristics including age, sex and length of time interval between baseline 
and repeat measurement, or on adjustment for cardiovascular risk factors. The high 
observed RDR suggests that the degree of underestimation of the strength of 
association between Lp(a) and disease risk in epidemiological studies would be low. 
However, as the variability appears to depend on the individual’s Lp(a) level, more 
subtle biases may arise, which necessitate appropriate adjustments for within-
person Lp(a) variation. On the other hand, some small studies, with several 
repeated Lp(a) measurements over short period of time, have suggested that Lp(a) 
concentrations show considerable biological fluctuations, which may have implication 
for determination of the individual’s Lp(a) level in the clinical set-up. This is in 
contrast to the relevance of the RDR to determination of disease associations in 
population studies. 
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Table 4.1:  Short-term within-person variation in Lp(a) concentration assessed 
using biological coefficient of variation* 
 
Study No. of 
subjects 
No. of 
repeat 
measures 
Average time 
interval between 
repeat measures 
Biological 
coefficient of 
variation* 
Albers, 1977 7 8-10  3 week ~0 
Chambless, 1992 40 2 1-2 weeks 3% 
Panteghini, 1992 8 5 1 week 9% 
Marcovina, 1994 20 4 2 weeks 9% -27% 
Mackness, 1996 6 12 1 month 10% 
Nakajima, 1996 16 12 1 month 17% 
Nazir, 1997 22 12 1 month 21% 
 
* Biological coefficient of variation is calculated the ratio of standard deviation to the mean 
of a serial measurement (expressed as percentage). 
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Table 4.2: Some characteristics of studies with serial Lp(a) measurements  
 
 Individuals with available baseline  Lp(a) values Individuals with at least one repeat Lp(a) measurement 
Study N % Male 
Mean 
(SD) age 
Median (IQR) 
Lp(a) N % Male 
Mean 
(SD) age 
Median (IQR) 
Lp(a) 
No. of 
repeats 
N with > 
2 repeats 
AFTCAPS 902 83 59 (7) 7.6 (3.3,17.9) 874 83 59 (7) 7.9 (3.6,18.8) 1 0 
COPEN 7,487 42 59 (14) 19.1 (6.9,42.6) 3,809 41 55 (12) 19.3 (7.0,42.4) 1 0 
FLETCHER 689 79 57(14) 20.7 (7.2,59.5) 216 72 51 (13) 22.6 (5.8,67.6) 1 0 
PROCAM 3,198 71 43 (10) 4 (2.0,13) 454 76 41 (8) 4 (1.0,10) 2 8 
REYKCON 6,179 71 55 (9) 9.3 (2.9,22.8) 366 97 48 (6) 10.5 (2.7,20.7) 1 0 
TARFS 399 43 54 (11) 10.3 (4,21.4) 189 41 53 (10) 11.3 (4.2,23.5) 2 72 
ULSAM 1,866 100 51 (4) 8.3 (3.4,22.3) 449 100 50 (0) 8.6 (4.1,22.5) 1 0 
Overall 20720 63 54 (12) 11.0 (3.7,29.0) 6,357 58 54 (11) 13.5 (5.0,33.6) - 80 
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Table 4.3: Comparison of mean and SD of loge Lp(a) values between baseline and repeat 
measurements within each study providing serial Lp(a) measurements 
 
Baseline measurement Repeat measurement 
Study 
N with 
repeat 
Mean log-
Lp(a) (log 
mg/dl) 
SD log-Lp(a) 
(log mg/dl) 
Mean 
time 
(years) 
Mean log-
Lp(a) (log 
mg/dl) 
SD log-
Lp(a) (log 
mg/dl) 
AFTCAPS 874 2.15 1.05 1.0 2.15 1.09 
COPEN 3,809 2.75 1.44 9.4 3.10 0.98 
FLETCHER 216 2.55 1.98 2.5 2.45 2.01 
PROCAM 454 1.43 1.34 6.2 1.93 1.49 
REYKCON 366 1.83 1.74 11.7 1.33 1.97 
TARFS 189 2.37 1.01 2.8 2.41 1.10 
ULSAM 449 2.19 1.23 21.3 2.43 1.20 
Overall 6,357 2.47 1.46 8.5 2.69 1.30 
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Table 4.4  Regression dilution ratios for Lp(a) by levels of several 
individual-level characteristics 
 
Lipoprotein(a) 
Baseline characteristics 
RDR† (95% CI) 
Interaction 
p-value 
    
Age < 53 yrs 0.87 (0.77-0.97) 0.69 
 > 53 yrs 0.88 (0.77-0.99)  
    
Sex Male 0.88 (0.78-0.98) 0.68 
 Female 0.86 (0.99-0.07)  
    
History of diabetes No 0.87 (0.78-0.97) 0.89 
 Yes 0.86 (1.05-0.15)  
    
Body mass index < 25 kg/m2 0.86 (0.77-0.96) 0.61 
 > 25 kg/m2 0.87 (0.78-0.97)  
    
Triglycerides < 1.5 mmol/l 0.87 (0.77-0.97) 0.39 
 > 1.5 mmol/l 0.85 (0.74-0.95)  
    
Total cholesterol < 5.9 mmol/l 0.89 (0.79-0.99) 0.01 
 > 5.9 mmol/l 0.85 (0.75-0.95)  
    
Fibrinogen < 9.3 µmol/l 0.91 (0.66-1.16) 0.58 
 > 9.3 µmol/l 0.88 (0.62-1.14)  
    
 
Note: RDR models allowed variation in Lp(a) to vary by level; models were 
adjusted for age and sex. †RDR values are for individuals with Lp(a) 
concentrations close to the mean of the distribution. 
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Figure 4.1: Direct comparisons of within-person variability of Lp(a) with that of 
several risk factors in the Reykjavik Study† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Serial measurements were done 12 years apart 
‡RDRs were calculated using the log-transformed variables. 
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Figure 4.2:  Within-person variability in Lp(a) estimated with simple regression 
dilution model† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† RDRs were calculated using simple Rosner models by regressing repeat Lp(a) measurements on 
baseline values. RDRs are adjusted for age and sex. Data shown for repeat measures involving more 
than 25 individuals. The solid and broken lines indicate the overall RDR and its 95%CI, respectively. 
Sizes of data markers are proportional to the inverse of the variance of the study specific RDRs. RDR 
indicates regression dilution ratio; CI confidence interval.  
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Figure 4.3:  Within-person variability in Lp(a) allowing regression dilution ratio to vary 
by Lp(a) concentration† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† The values provided are estimates of RDR at mean log-Lp(a) concentration, as the models allowed 
variation in Lp(a) to vary by level. RDRs are adjusted for age and sex. Data shown for repeat measures 
involving more than 25 individuals. The solid and broken lines indicate the overall RDR and its 95%CI, 
respectively. Sizes of data markers are proportional to the inverse of the variance of the study specific 
RDRs. RDR indicates regression dilution ratio; CI confidence interval.  
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Figure 4.4: Comparison of Lp(a) RDR with that of other cardiovascular risk factors 
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Chapter 5: Lipoprotein(a) concentration and the risk of coronary heart 
disease, stroke, and non-vascular mortality 
 
 
Chapter summary 
 
The aim of this chapter was to make a detailed and reliable assessment of the 
relationship of Lp(a) concentration with risk of major vascular and nonvascular 
outcomes. Individual records were provided on each of 126,634 participants in 36 
prospective studies, without known pre-existing CHD or stroke at baseline. During 1.3 
million person-years of follow-up, 22,076 first-ever fatal or nonfatal vascular disease 
outcomes or nonvascular deaths were recorded. Analyses of data involving over 9000 
incident CHD outcomes revealed broadly continuous associations of Lp(a) with the risk 
of CHD. The relative risk (RR) for CHD, adjusted for age and sex only, was 1.16 
(1.11-1.22) per 1-standard deviation higher Lp(a) concentration, and it was 1.13 
(1.09-1.18) following further adjustment for lipids and other conventional risk factors. 
The RRs did not differ not materially by several clinically relevant characteristics, 
notably, by levels of LDL cholesterol. Lp(a), however, did not appear to improve risk 
prediction significantly, beyond what can be achieved using standard cardiovascular 
risk factors. The corresponding adjusted RRs were: 1.10 (1.02-1.18) for ischaemic 
stroke, 1.01 (0.98-1.05) for the aggregate of nonvascular mortality, 1.00 (0.97-1.04) 
for cancer deaths and 1.00 (0.95-1.06) for nonvascular deaths other than cancer. 
These findings encourage the study of Lp(a) as a risk factor and therapeutic target in 
cardiovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
Background 
As discussed in Chapter 1, many epidemiological studies have shown positive 
associations between Lp(a) concentration the risk of coronary disease. A literature-
based meta-analysis of published data from 31 prospective studies reported a 
relative risk of 1.5 (95% CI, 1.3-1.6) in a comparison of people in the top third 
versus those in the bottom third of the Lp(a) distribution.1 However, such literature-
based reviews1-3 have not been sufficiently detailed to enable reliable 
characterisation of any independent association with CHD, and have not adequately 
addressed possible associations with ischaemic stroke4 and nonvascular outcomes. In 
particular, Lp(a) concentration is correlated with some lipid markers, but published 
studies have not adjusted for them in a consistent way.5;6 It has been suggested that 
Lp(a) is associated with CHD only at very high concentrations,7;8 but this suggestion 
is controversial, indicating that studies with greater power than hitherto are needed 
to characterise the shape of any dose-response relationship reliably. In addition, it 
has been proposed that the vascular risk associated with Lp(a) may be synergistic 
with other markers of dyslipidemia, such as high cholesterol levels.8-10 Some authors 
have even suggested that Lp(a) may be relevant to cardiovascular risk only at high 
LDL cholesterol levels.11;12 However, reliable determination of such effect-
modification requires analyses of large number of incident vascular outcomes, which 
is difficult to accrue within a single prospective study. Finally, to date, it has not been 
possible to determine reliably whether Lp(a) contributes to risk prediction over and 
above the standard cardiovascular risk factors.10;13  
 
The objectives of this chapter were, (i) to produce reliable and detailed estimates of 
associations of Lp(a) with CHD, stroke and nonvascular mortality, incorporating 
adjustment for potential confounding by risk factors, and (ii) to determine whether 
inclusion of Lp(a) measurements may improve the performance of cardiovascular 
risk prediction models. These analyses differ from previous reports on Lp(a) in 
several important ways that enhance their scientific value and reliability. First, it is 
large and comprehensive: the data encompass 36 prospective studies, comprising 
22,076 first-ever incident vascular disease outcomes or nonvascular deaths among 
126,634 individuals (Chapter 2). Second, harmonisation of individual records 
allowed a consistent approach to adjustment for lipids and other potential 
confounders. Third, correction for within-person variation in Lp(a) concentration and 
in potential confounders has been made by use of information on participants with 
serial measurements (Chapter 4). Fourth, individual records are available for each 
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participant, allowing detailed analyses under different circumstances (e.g., at 
different lipid levels). Finally, individuals with known pre-existing CHD and stroke 
have been excluded, limiting any effects of clinically evident disease on Lp(a) 
concentration (i.e. `reverse causality’).  
 
Methods 
Study design  
Details of study selection, data collection, and harmonisation procedures have been 
described in Chapter 2. Thirty-six studies1;8;9;14-46 involving a total of 126,634 
participants who had no known prior history of CHD (i.e., myocardial infarction [MI] or 
angina) or stroke at the initial (`baseline’) examination were included in present 
analyses.  The general characteristics of these studies including methods for Lp(a) 
measurement and outcome ascertainment are described in Chapter 2.  
 
Assay systems and apo(a) isoform sensitivity 
As discussed in Chapter 1 dependence of Lp(a) assay method on apo(a) isoforms 
variation is a potentially important source of bias. Although an investigation conducted 
in 2000 has reported that isoform sensitivity was a widespread problem among 
contemporary assay systems, information on the performance of assays with respect 
to apo(a) isoforms is generally unavailable from most manufacturers.47 (Notably, one 
manufacturer [Denka Seiken] has been reported to produce assays that are not 
sensitive to apo[a] isoforms.)8 For the majority of studies contributing data to the 
current analyses, information on isoform sensitivity was largely unreported in 
publications, and was typically unobtainable through correspondence with 
investigators. As isoform sensitive assays overestimate Lp(a) concentration for larger 
apo(a) isoforms, which correlate with lower Lp(a) concentrations, Lp(a) values would 
be overestimated for individuals with lower Lp(a) levels, and vice versa.  Hence, for 
measurements taken using an isoform sensitive assay, one would expect to have an 
overestimation of the 25th percentile and underestimation of the 75th percentile of the 
Lp(a) distribution. For 23 studies with unavailable information, attempts were made to 
determine the isoform sensitivity status by comparing the distributions of their Lp(a) 
values with those of three studies that used the Denka Seiken assay. Overall, the 
assay systems used in 24 studies appeared to be insensitive to apo(a) isoform 
variation, while the rest were isoform sensitive or indeterminate.  
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Analytic approach 
Normal distributions were achieved by taking natural logarithms (loge) of Lp(a). The 
pooled standard deviation across studies in baseline loge Lp(a) concentration was 
1.25, which corresponds to about a 3.5-fold difference (i.e., e1.25) on the original 
scale of Lp(a) measurement in mg/dl. The primary disease outcome was CHD (i.e., 
first-ever MI or fatal CHD), with subsidiary analyses of stroke and non-vascular 
deaths. Analyses involved a 2-stage approach with estimates of association 
calculated separately within each study before pooling across studies by random-
effects meta-analysis. Parallel analyses were conducted using fixed-effect models. 
For the 26 studies analysed as prospective cohort studies, hazard ratios were 
estimated by survival analysis using Cox’s proportional hazard regression models 
stratified by sex (and, where appropriate, by trial arm). In the survival models, each 
participant contributed only either the first nonfatal outcome or death recorded at 
age 20 years or older (i.e., deaths preceded by nonfatal CHD or stroke were not 
included in the analyses). The assumptions of the proportionality of hazards were 
evaluated within each study by including an interaction term between the exposure 
and time. Study-specific interaction terms were then pooled across studies to provide 
the average interaction term and test statistic. (A significant correlation between 
time and the log-hazard ratio would indicate that the proportional hazards 
assumption is violated.)  The assumptions of the proportionality of hazards for loge 
Lp(a) levels were satisfied (Table 5.1). For the 10 ‘nested’ case-control studies 
within prospective cohorts, odds ratios were calculated using either conditional or 
unconditional logistic regression models, as appropriate. Hazard ratios and odds 
ratios were assumed to approximate one other and are collectively described as 
‘relative risks’ (RRs). RRs were adjusted progressively for age, sex, and several other 
conventional risk factors, with evidence of association indicated by the Wald chi-
squared statistic. Given the substantial variations in average Lp(a) levels across 
available studies, it should be emphasised that the current analyses compare 
participants only within each contributing study. 
 
Correction for measurement error 
Measurement error in exposure leads to underestimation of exposure-disease 
association (i.e., regression dilution), while error in confounders can bias the 
association in either direction leading to residual confounding.48 Regression dilution 
ratios for each characteristic were calculated by regressing serial measurements using 
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linear-mixed models that included random-effects, (i) at the study level (to allow for 
between-study heterogeneity), and (ii) at the individual level (to allow for 
heterogeneity between multiple repeats). These regression calibration models were 
then used to predict conditional expectations of long-term average (i.e., ‘usual’) 
levels of Lp(a) and error-prone confounders. Correction for within-person variation in 
Lp(a) and in potential confounders was achieved by using the predicted ‘usual’ levels 
in assessments of associations with disease risk. As detailed in Chapter 4, the 
regression calibration models allowed variability in Lp(a) to vary by its baseline levels. 
 
Shapes of relationships 
To assess the shape of association, study-specific RRs calculated within quantiles 
(e.g., tenths) of baseline Lp(a) levels were combined by multivariate random-effects 
meta-analysis and plotted against mean usual loge Lp(a) levels within each quantile. 
As the mean value of Lp(a) varies materially across the studies quantiles were 
defined within-each study (subsidiary analyses involved use of overall quantiles). 
95% CIs were estimated from the floated variances that reflect the amount of 
information underlying each group (including the reference group).49 When 
associations were approximately log-linear, regression coefficients were calculated to 
estimate the RR associated with a 3.5-fold (i.e., 1-SD) higher Lp(a). When 
associations appeared non-linear, two approaches were used to assess the statistical 
evidence for using more complex models: (i) quadratic terms were fitted within each 
study, and (along with the main-effects) were pooled across the studies using 
multivariate random-effects meta-analysis; (ii) likelihood-ratio tests were used within 
each study to compare a model with quantiles of Lp(a) fitted as continuous variable 
versus a model with quantiles fitted as dummy variables. The study-specific chi-
squared statistics and degrees of freedom were summed across studies to provide the 
overall chi-squared statistics and total degrees of freedom. The latter approach is 
generally not powerful to test non-linearity, and so the parametric approach was 
preferred.  
 
Effect-modification 
Potential effect modifiers measured at the individual level, such as age or other risk 
markers, were assessed using within-study information.  Interaction terms for the 
potential effect modifier were fitted within each study, and combined using random-
effects meta-analysis. 
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Between-study heterogeneity and publication bias 
In addition to the standard Chi-squared test for heterogeneity, the magnitude of 
between-study heterogeneity was expressed in terms of I2, the percentage of 
variance in the estimated log hazard ratios from each study that is attributable to 
between-study variation as opposed to sampling variation.50 Diversity at the study 
level (such as differences by study design or assay methods) was investigated by 
grouping studies by recorded characteristics and by meta-regression.51 The likelihood 
of publication bias was assessed by determining the effect of study size on risk 
estimates using: (i) Chi-squared tests comparing studies with ≥500 cases versus 
those with <500 cases; (ii) eye-balling of forest and  funnel plots; and (iii) use of 
Egger test for publication bias. 
 
Correction for cholesterol contained in Lp(a)  
Measurement of total cholesterol concentration includes the cholesterol contained in 
Lp(a) particles. As the vascular risk of Lp(a) may be mediated through both its 
protein and cholesterol content, inclusion of uncorrected total cholesterol values in 
risk models may lead to over-adjustment. The magnitude of the bias is related to the 
amount of cholesterol contained in the Lp(a) particles and the coefficient of total 
cholesterol in the risk model (Table 5.2). Thus, a more appropriate model would 
adjust for non-Lp(a) cholesterol values (i.e., total cholesterol – Lp(a) cholesterol). As 
Lp(a) cholesterol was not directly measured in the contributing studies, it was 
estimated from the total Lp(a) mass with the conservative assumption that 
cholesterol contributes to 15% of the total mass52 (compositional studies have 
reported that cholesterol may constitute as much as 30% of the total Lp(a) mass).53  
 
Censoring of outcomes 
For participants who had multiple events (e.g., two CHD events at separate time 
points, or a CHD event followed by another type of event such as a stroke or death 
from cancer), analyses focused on first major nonfatal cardiovascular events. Thus, 
in an analysis of CHD events, participants were followed until their first CHD event, 
or were censored at the time of other nonfatal cardiovascular events, such as stroke 
(in addition to standard censoring at death from other causes or loss to follow-up). 
The rationale for this was that major cardiovascular events may lead to lifestyle and 
other modifications (e.g., medication use) that may alter levels of factors 
significantly and disrupt the association between baseline risk factors and 
 129 
subsequent disease risk. Sensitivity analyses were conducted by implementing 
alternative censoring criteria.  
 
Z-transformation 
As the average Lp(a) levels varied materially across the studies, the loge Lp(a) 
distributions were transformed to a mean of 0 and an SD of 1 (i.e., z-transformed) 
within each study. Parallel analyses were performed on z-transformed Lp(a) values 
and results were compared with untransformed analyses. 
 
Assessment of utility in CHD risk prediction 
Detailed characterization of the association of Lp(a) with CHD risk as described above 
allows understanding of the potential etiological role of the factor in CHD. 
Furthermore, determination of the magnitude of association and the effect of 
adjustment for established cardiovascular risk factors can provide insight into the 
potential utility of Lp(a) in predicting cardiovascular disease risk (for instance, strong 
RR and little attenuation after adjustment for standard risk factors would suggest that 
Lp(a) may be important as risk predictor). Such analyses do not, however, help to 
assess whether Lp(a) has incremental value over and above standard risk factors 
used in existing prognostic models that use (e.g., Framingham risk score) for 
predicting the individual’s risk in clinical set-ups.54  
 
While the optimal approach to assess the utility of risk prediction models is 
controversial, it is generally accepted that discrimination measures provide a useful 
tool to summarize the prognostic ability of prediction models.55;56 (Discrimination is 
how well the model can separate those who do and do not have the disease of 
interest.)57  Discrimination was assessed using Harrell’s C-index among the studies 
with cohort design.55;58 The C-index is a generalization of the area under the receiver 
operating characteristic (AUROC) curve for survival data, which estimates the 
probability that for a randomly chosen pair of participants, the person who develops 
CHD first has the higher predicted risk. All possible pairs of participants within each 
stratum are examined and classified as concordant (i.e., matching in predicted and 
observed order of failure), discordant (opposite in such ranking) or tied. The numbers 
of concordant, discordant and tied pairs within strata are summed to yield a weighted 
average C-index. Standard errors for the C-index were estimated by bootstrapping 
within strata, using 200 bootstrap samples obtained by random sampling with 
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replacement. The interpretation of the C-index is similar to that of the AUROC, 
ranging from 0.5 (no discrimination) to a theoretical maximum of 1 (perfect 
discrimination).57 The regression coefficients for the prediction models were estimated 
from a one-step stratified Cox-model (stratified by cohort and sex), and C-indices 
were calculated within each study. The overall estimate was derived by combining the 
study-specific C-indices weighted by number of events. 
 
Further assessment of the utility of Lp(a) in cardiovascular risk prediction was done 
using the risk stratification table, which is a recently proposed approach focusing on 
the key purpose of the risk prediction model, i.e., to classify individuals into clinically 
relevant risk categories.59-61 Hence, an increased probability that case subjects will 
be categorized as case subjects and a decreased probability that control subjects will 
be categorized as case subjects imply better predictive ability, whereas the opposite 
imply worse predictive ability.  Clinical risk reclassification was assessed by 
comparing the predicted 10-year risk from disease models containing standard 
cardiovascular risk factors to the predicted risk from models that also contained 
Lp(a). The predicted risks from these nested models were classified into four 
categories (<5%, 5-10%, 10-20%, >20% 10-year risk) based on the Adult 
Treatment Panel III (ATP-III) guidelines, and cross-tabulated.62 For each pair of 
models, any changes in predicted risk on addition of Lp(a) were quantified by the Net 
Reclassification Improvement (NRI), that summarizes whether movement between 
risk categories is in the correct direction (ie, to higher risk categories for those who 
develop the event and to lower risk categories for those who do not). However, 
because risk categories are inherently arbitrary, the Integrated Discrimination 
Improvement (IDI) was used additionally, which considers the change in the 
estimated prediction probabilities as a continuous variable ( in contrast to the NRI 
which considers only those changes in estimated prediction probabilities that imply a 
change from one category to another).61 By definition, participants who were 
censored before 10 years were not able to contribute to the reclassification analyses, 
while individuals whose CHD events occurred after 10 years were classed as non-
cases.  
 
All analyses were performed using Stata release 10 (StataCorp LP, College Station, 
Texas). 
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Results 
Mean age at entry of participants was 57 (SD 8) years, 48% were women, 47% were 
European and 50% North American. During 1.3 million person years at risk (mean 
10.2 years to first outcome), there were 9336 CHD outcomes, 1903 ischaemic 
strokes, 338 haemorrhagic strokes, 751 unclassified strokes, 1091 other vascular 
deaths, 8114 non-vascular deaths and 242 deaths of unknown cause (Table 5.3). 
The overall median (inter-quartile range) of Lp(a) at baseline was 12.6 (4.9, 32.1) 
mg/dl. As Blacks had Lp(a) concentrations twice those of Whites (Chapter 3), they 
were examined separately in subanalyses.  
 
CHD event rates 
Figure 5.1 is an overall and sex-specific a CHD free survivor plot for the cohort 
studies. The overall CHD rate was 4.8 (95% CI, 4.7-5.0) per 1000 person-years at 
risk. The rate among male and female participants was 7.5 (7.3-7.8) and 2.5 (2.4-
2.7), respectively, per 1000 person-years at risk. The rates of CHD among 
participants in top and bottom thirds of baseline Lp(a) distributions were 5.5 (95% 
CI, 5.4-5.9) and 4.4 (4.2-4.6), respectively, per 1000 person-years at risk (Figure 
5.2). 
 
Associations with CHD 
In analyses adjusted for age and sex only, there were continuous associations of 
Lp(a) with risk of CHD, potentially consistent with a curvilinear shape, which was 
little altered on further adjustment for other covariates (Figure 5.3, 5.4). Statistical 
tests of the compatibility of the data with a linear versus a quadratic model 
suggested a better fit with a curvilinear shape (P=0.003; Table 5.4). In analyses 
restricted to participants with complete information on relevant covariates, the age- 
and sex- adjusted RR for CHD per 3.5-fold higher Lp(a) levels was 1.16 (1.11-1.22), 
and it was 1.13 (1.09-1.18) following further adjustment for systolic blood pressure, 
smoking, history of diabetes and total cholesterol (Table 5.5). There was moderate 
heterogeneity among studies contributing to the fully adjusted CHD model (I2=49%; 
95% CI, 22-66%: Table 5.5). Adjustment for non-HDL-C and HDL-C instead of total 
cholesterol yielded similar results. As expected, alternative adjustment with 
correction of total cholesterol for the cholesterol content of Lp(a) particles gave a 
higher RR (Table 5.6). Findings were broadly similar in subanalyses: of coronary 
death and nonfatal MI (Figure 5.5 and 5.6); adjusted for apoAI and apo B100 
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(instead of total cholesterol); and with further adjustment for fibrinogen or C-
reactive protein (Table 5.6). The association was slightly attenuated in analyses that 
did not adjust regression dilution (Table 5.7). Findings were qualitatively similar 
after exclusion of the first 5 years of follow-up (Figure 5.7). The RR, adjusted for 
several conventional risk factors, was 1.27 (1.17-1.38) in a comparison of those in 
the top third with those in the bottom third of baseline Lp(a) concentration (Table 
5.7). A forest plot of the study-specific estimates did not reveal the presence of 
extreme RRs in the smaller studies; the combined RR for studies with > 500 cases 
was not significantly different from those for the studies < 500 cases (p=0.36). 
Fixed-effect model meta-analysis yielded similar results to the random-effects model 
meta-analysis (Figure 5.8).  
 
The RRs for CHD did not vary importantly by sex, non-HDL-C, HDL-C, triglycerides, 
blood pressure, diabetes or body mass index (Figure 5.9). There was no convincing 
evidence of major variations in RRs of studies using isoform sensitive versus isoform 
insensitive assays, or with other features of study design recorded (Figure 5.10). 
Subsidiary analyses restricted to people of European continental ancestry (>90% of 
the participants) yielded very similar findings to the overall findings; but analyses of 
RRs in Black people, involving only 4546 participants and 261 incident CHD cases 
among 3 studies, was uninformative due to limited data  (Figure 5.10). In a 
common set of participants, the adjusted RR for CHD per 1-SD higher Lp(a) 
concentration was considerably weaker than the corresponding RR with non-HDL-C 
(1.14 v 1.66, respectively: Figure 5.11).  
 
Associations with stroke  
In analyses adjusted for age and sex only, the shape of association of Lp(a) with the 
risk of ischaemic stroke was indistinct (Figure 5.3). Assuming a log-linear 
association with risk, the age- and sex- adjusted RR for ischaemic stroke was 1.11 
(1.02-1.20) per 3.5 fold higher usual Lp(a) levels, in analyses restricted to 
participants with complete information on relevant covariates (Table 5.5). The RR 
was 1.10 (1.02-1.18) following further adjustment for systolic blood pressure, 
smoking, history of diabetes and total cholesterol (Table 5.5). There was no clear 
evidence of heterogeneity among studies contributing to ischaemic stroke (I2=30%, 
0-64%). The adjusted RRs per 3.5 fold higher usual Lp(a) levels were 1.01 (0.92-
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1.12) for unclassified stroke and 1.06 (0.90-1.26) for haemorrhagic stroke (Figure 
5.5).  
 
Associations with nonvascular mortality 
The adjusted RR for the aggregate of nonvascular mortality was 1.01 (0.98-1.05: 
Figure 5.5). The adjusted RRs were 1.00 (0.97-1.04) for all cancer deaths and 1.03 
(0.97-1.09) for smoking-related cancer deaths. The adjusted RR for other 
nonvascular deaths other than cancer was 1.00 (0.95-1.06). There were too few 
cases of particular types of cancer (or other nonvascular outcomes) to enable reliable 
analyses by subtype. Adjusted RRs for major vascular and nonvascular outcomes 
were qualitatively similar in subsidiary analyses that looked at fatal outcomes 
without censoring previous nonfatal cardiovascular events (Figure 5.12). Subsidiary 
analyses conducted on z-transformed Lp(a) concentration yielded very similar results 
as the main analyses for both vascular and non-vascular outcomes.  
 
Lp(a) and CHD risk prediction 
Data on up to 95,522 individuals from 21 cohort studies were used in the CHD risk 
prediction analyses. The C-index for CHD, which was 0.6113 (95% CI, 0.6033-
0.6194) in a model containing information on age and sex only, increased to 0.6785 
(95% CI, 0.6710-0.6861) upon addition of information on smoking status, systolic 
blood pressure and history of diabetes. This improvement is equivalent to correct 
prediction of the order of CHD for an additional 67 out of 1000 pairs of participants 
screened. Further addition of total cholesterol and HDL-C increased the C-index to 
0.7036 (95% CI, 0.6962-0.7109), which is equivalent to correct prediction of the 
order of CHD for an additional 25 out of 1000 pairs of participants screened. To 
assess its impact on performance of the CHD prediction models Lp(a) was added to 
the above models in three functional forms: (i) as a continuous variable [i.e., loge 
Lp(a)], (ii) as a dichotomous variable with a cut-off at the 75th percentile [Lp(a)_75] 
and, (iii) as a dichotomous variable with a cut-off at the 90th percentile [Lp(a)_90]. 
The rationale for using the last two forms was due to the observation that the shape 
of relationship between Lp(a) and the risk of CHD is curvilinear, which suggests that 
Lp(a) may be more predictive at the higher range of the values.  Addition of 
information on Lp(a) to risk factors significantly increased risk discrimination, 
although the gains diminished in magnitude as Lp(a) was added to models with 
increasing numbers of risk factors (Table 5.8). The predictive ability of Lp(a)  was 
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maximal when introduced as a dichotomous variable with a cut-off at the 75th 
percentile (Table 5.8). Addition of Lp(a)_75 to model containing all of the variables 
in the Framingham risk score (ie, age, sex, smoking, systolic blood pressure, history 
of diabetes, total cholesterol and HDL-C) increased the C-index from 0.7036 to 
0.7055 (P<0.004), equivalent to correct prediction of the order of CHD in an extra 2 
out of 1000 pairs of participants screened.  Among participants in the cohorts with 
≥10 years of follow-up, 41,482 who remained uncensored after 10 years of 
monitoring and 2306 who suffered fatal or non-fatal CHD event during follow-up 
were eligible for inclusion in analyses using measures of reclassification for 10-year 
risk categories. Addition of Lp(a)_75 to the Framingham risk factors did not improve 
CHD risk stratification significantly (Table 5.9). In total, 1610 participants (3.7%) 
were reclassified, of whom 38 more were reclassified correctly giving an overall NRI 
of 0.58% (95% CI, -0.56 to 1.73%; p=0.32). Consistent with the NRI, the IDI 
showed a very small (although statistically significant) overall improvement of 
0.00082 (p=0.002), equivalent to less than 0.1% improvement in absolute risk 
prediction.  
 
 
Discussion 
Contrary to previous suggestions of steep threshold effects, the current analysis of 
over 126,000 individuals and over 9000 incident events has demonstrated broadly 
continuous associations of Lp(a) concentration with the risk of CHD.7;8 As these 
associations were only slightly reduced after adjustment for long-term average levels 
of lipids and other established risk factors, it increases the likelihood that Lp(a) is an 
independent risk factor for CHD. Lp(a) concentration is, however, a relatively modest 
coronary risk factor, being only about one-quarter as strong overall as is non-HDL-C, 
though Lp(a) becomes proportionally more important to CHD at very high 
concentrations owing to its curvilinear risk relationship. Furthermore, the significant 
increase in Lp(a) RR upon correction of total cholesterol values for Lp(a) cholesterol 
content indicates that the relevance of Lp(a) for coronary disease may be 
considerably more important than suggested by epidemiological studies (which 
typically do not make such corrections). By contrast to previous reports of potentially 
important joint-effects of Lp(a) with markers of dyslipidemia, the current much 
larger analyses did not reveal any material effect-modifications by levels of non-HDL-
C, HDL-C, or triglycerides.8;9  As associations of higher Lp(a) concentration with CHD 
were similar at both above- and below- average non-HDL-C concentrations, the 
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absolute benefits of cholesterol-lowering should be greater if Lp(a) concentration is 
high (or when absolute risk is high for some other reason). Whereas previous 
literature-based reviews of Lp(a) have focused only on CHD,1-3 the current individual 
participant meta-analysis also investigated stroke subtypes and cause-specific 
mortality, including nonvascular deaths. Although current data in relation to Lp(a) 
concentration and stroke were somewhat sparser and less distinct than those for 
CHD, they were broadly similar to those for CHD. By contrast, Lp(a) concentration 
was unrelated to the aggregate of nonvascular mortality, including cancer and 
noncancer deaths. Hence, Lp(a) appears more specifically associated with vascular 
outcomes than are a number of systemic markers of inflammation, including 
fibrinogen and C-reactive protein, that have been strongly associated with both 
vascular and nonvascular outcomes.63;64  
 
These findings of continuous, independent and specific associations of Lp(a) 
concentration with vascular outcomes increase priority for investigation of Lp(a) as a 
causal factor in CHD and potential therapeutic target. As the current findings show 
that Lp(a) concentration is a relatively modest risk factor for CHD, however, 
interventions capable of much more powerful and specific Lp(a)-lowering than 
currently available may be required to demonstrate any vascular benefits in 
randomised trials. Substantial modification of Lp(a) concentration has been difficult 
to achieve without pharmacological agents.65 Niacin and certain inhibitors of 
cholesteryl ester transfer protein (CETP) can each reduce Lp(a) by about 20% and 
about 40%, respectively.66;67 Large randomised trials of these agents in the 
secondary prevention of CHD are already in progress.68;69 Such studies may not, 
however, enable causal inferences because − in addition to Lp(a)-lowering − the 
drugs raise HDL-C and lower LDL-C and triglyceride concentrations. On the other 
hand, contradictory findings have been reported about the effect of statins on Lp(a) 
concentration,10;70 and it remains uncertain whether statin usage attenuates the CHD 
risk associated with Lp(a) concentration.11;12;71 Concomitant with the quest to assess 
the reversibility of Lp(a)-associated vascular risk through interventions with 
pharmacologic agents, studies of CHD in relation to genetic variants specifically 
related to Lp(a) concentration should help to judge causality (Chapter 7).  
 
Even though the first epidemiological study of Lp(a) and CHD was reported in 
1972,72 this lipoprotein’s investigation as a potential cardiovascular risk factor has 
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been hampered by the lack of consistent approaches to its measurement. 
International reference material for Lp(a) laboratory standardisation emerged only in 
200073 and was accepted by the WHO in 2003.74 Even with methods that use the 
same standard, however, there is significant variability in measured Lp(a) 
concentration if assays are sensitive to apo(a) isoform variation.75 Hence, in 2003 an 
expert panel recommended use of assay systems not sensitive to apo(a) isoforms.10 
Population differences also contribute to variation in Lp(a) concentration, particularly 
since values differ substantially between individuals and are highly heritable.76-78 
Nevertheless, pooled analyses of individual data from prospective studies should 
remain informative, provided that, as in the current study, analyses compare cases 
and noncases only within each study and explore potential diversity across groups of 
studies using similar assay methods.  
 
Despite considerable scope for such diversity, it is notable that there is relatively 
moderate heterogeneity among the 36 studies based in 15 different Western 
countries contributing to the current findings, an observation that supports the ability 
to generalise these data to such populations. As >90% of the participants in the 
current study were of European continental ancestry, however, further studies are 
needed in nonwhite racial groups, particularly in Black and South Asian populations 
which have different Lp(a) concentrations to Whites (Chapter 6).79;80 The RRs in the 
current analysis were not strongly different between studies using assays sensitive 
and insensitive to Apo(a) isoforms (although there was, of course, some 
heterogeneity within each of these groups of studies). Although the findings did not 
differ appreciably in subgroups defined by the laboratory and population features 
recorded, further studies are needed that can explore in greater depth such potential 
sources of heterogeneity and joint effects with other novel lipid markers. For 
example, large studies are needed to assess whether Lp(a) particles with smaller-
sized apo(a) isoforms confer even higher RRs for CHD (Chapter 8).81;82 Similarly, 
studies are needed to assess proposed synergy in the promotion of vascular disease 
through oxidative damage (Chapter 9).83-85 (Such assessments were not possible in 
the ERFC because it lacked concomitant data on apo(a) isoforms, oxidised 
phospholipids or lipoprotein associated phospholipase A2 [LpPLA2].)  
 
Assessment of performance in coronary risk prediction models showed that Lp(a) 
may improve discrimination beyond what is achievable using the Framingham risk 
 137 
score. That the incremental discriminative value of Lp(a) was maximal when it was 
introduced as a dichotomous variable with a cut-off point at the 75th percentile of the 
baseline distribution indicates the relevance of the curvilinear shape of the 
relationship to clinical risk prediction. However, the discriminative benefit of 
measuring Lp(a) was modest with only two additional pairs having correct prediction 
of the order of CHD for every 1000 pairs of individuals screened. In addition, Lp(a) 
did not appear to improve 10-year CHD risk stratification of individuals with respect 
to the ATP-III risk categories. This is in part a reflection of the modest RR for CHD 
observed for Lp(a), further highlighting the need for investigation of potential 
markers of heterogeneity such as apo(a) isoform variation and level of oxidized 
phospholipids that may help to amplify the epidemiological signal associated with 
Lp(a). 
 
Conclusion 
Under a wide range of circumstances, there are continuous, independent and modest 
associations of Lp(a) concentration with risk of CHD and stroke that appear to be 
specific to vascular outcomes. These findings encourage the study of Lp(a) as a risk 
factor and therapeutic target in cardiovascular disease. 
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Table 5.1:   Test of proportional hazard assumption for the association of 
Lp(a) with CHD, by cohort 
 
Cohort 
No of 
participants 
No. of 
events 
Time dependence 
coefficient‡ 
AFTCAPS 902 21 0.061(-0.237 to 0.359) 
ARIC 14033 850 -0.003 (-0.020 to 0.014) 
BRUN 798 53 -0.045 (-0.113 to 0.024) 
CHARL 165 19 -0.098 (-0.316 to 0.12) 
CHS1 3860 592 0.002 (-0.022 to 0.025) 
COPEN 7487 283 0.034 (-0.027 to 0.095) 
DUBBO 2008 273 -0.030 (-0.060 to 0.000) 
EAS 637 54 -0.001(-0.074 to 0.072) 
FIA 1492 519 0.028 (-0.008 to 0.065) 
FINRISK 2201 92 0.047 (-0.014 to 0.107) 
FRAMOFF 2850 109 0.004 (-0.051to 0.058) 
GOTO33 128 16 0.068 (-0.150 to 0.285) 
GRIPS 5784 299 -0.011 (-0.052 to 0.03) 
KIHD 1996 386 0.004 (-0.014 to 0.021) 
NHANES3 4496 107 0.043 (-0.052 to 0.138) 
NPHSII 2375 157 -0.040 (-0.087 to 0.006) 
PRIME 7441 115 -0.069 (-0.212 to 0.074) 
PROCAM 3198 94 0.015 (-0.024 to 0.054) 
QUEBEC 2012 53 0.156 (-0.038 to 0.350) 
SHS 3837 416 -0.025 (-0.052 to 0.003) 
ULSAM 1866 485 -0.003 (-0.013 to 0.007) 
WHITE2 7903 170 0.017 (-0.078 to 0.112) 
WHS 27791 227 -0.028 (-0.075 to 0.020) 
WOSCOPS 4617 299 -0.013 (-0.087 to 0.062) 
ZUTE 305 42 0.013 (-0.099 to 0.126) 
Overall† 110182 5731 -0.005 (-0.012 to 0.002) 
 
†Estimates were combined using random-effects model meta-analysis; there was no 
significant heterogeneity across studies (I2: 30%; 95% CI, 0-54%); ‡Time 
dependence coefficient tests the correlations between the log-hazard ratio for Lp(a) 
and time. A significant correlation between time and the log-hazard ratio indicates 
that the proportional hazards assumption is violated; as can be seen from table the 
coefficient was not significant, overall and in each study 
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Table 5.2:  Rationale for correcting total cholesterol values for Lp(a)-cholesterol in 
disease models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
As the cholesterol contained in Lp(a) particles is thought to contribute to disease 
risk, adjustment for non-Lp(a) cholesterol  (as opposed to total cholesterol) in 
disease models would be appropriate (equation 1): 
 
logHR = b1 Lp(a) + b2 non-Lp(a)-C  (1) 
 
As non-Lp(a)-C is derived from total cholesterol (TC) and Lp(a) cholesterol 
[Lp(a)-C], equation (1) can be re-written as: 
 
  logHR = b1 Lp(a) + b2 [TC – Lp(a)-C]  (2) 
 
When Lp(a) cholesterol is not directly measured, values may be calculated from 
Lp(a) total mass. Taking the conservative estimate that cholesterol constitutes 
15% of the total Lp(a) mass, equation (2) can be re-written as: 
 
  logHR = b1 Lp(a) + b2 [TC – 0.15*Lp(a)]  (3) 
 
Re-arranging equation (3) gives the following: 
   
  logHR = b1 Lp(a) + b2 TC – 0.15*b2 Lp(a) 
    
   = (b1-0.15*b2) Lp(a) + b2 TC  (4) 
 
Comparison of equations (1) and (4) demonstrates that, when total cholesterol 
is included in disease models, the coefficient for Lp(a) will be underestimated by 
an amount equal to 15% of the coefficient of TC.  
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Table 5.3: Characteristics of 36 prospective studies contributing data to the current analyses 
 
Study acronym , 
Publication year 
Participants 
no. (Male %)  
Age at survey 
mean (sd), yr 
Lp(a) (mg/dl) 
median (IQR) 
Median follow-
up (5th & 95th 
percentiles) 
Non-fatal 
MI / CHD 
death 
CHD 
death 
Non-
fatal 
 MI 
Fatal 
MI 
Ischae-
mic 
stroke 
Haemorr-
hagic 
stroke 
Uncla-
ssified 
stroke 
Non- 
CVD 
deaths 
Cohort studies 
AFTCAPS 902 (83) 59 (7.1) 7.6 (3.3 , 17.9) 5.7 (4.5 , 6.8) 21 1 20 1 3 0 0 7 
ARIC,  2001 14033 (43) 54 (5.7) 18.3 (6.9 , 43.8) 14.1 (5.0 , 15.7) 850 190 660 114 431 52 16 947 
ATTICA 1508 (52) 51 (11.1) 11.4 (4.9 , 25.2) 5.0 (5.0 , 5.0) 0 0 0 0 0 0 0 16 
BRUN, 1999 798 (48) 58 (11.4) 8.8 (4.4 , 21.6) 15.3 (3.9 , 15.5) 53 31 22 19 24 14 0 120 
CHARL 165 (100) 70 (7.5) 10.4 (3.4 , 22.3) 6.8 (1.2 , 7.5) 19 3 16 2 0 2 7 15 
CHS1, 2003 3860 (38) 72 (5.2) 12.6 (4.8 , 22.2) 12.1 (2.0 , 12.9) 592 212 380 212 367 62 36 797 
COPEN, 2008 7487 (42) 59 (13.6) 19.1 (6.9 , 42.6) 7.4 (2.4 , 8.9) 283 36 247 0 184 39 94 525 
DUBBO, 2002 2008 (42) 68 (6.7) 11.0 (5.0 , 27.8) 14.1 (1.8 , 14.9) 273 56 217 0 73 19 81 315 
EAS, 2001 637 (51) 64 (5.6) 9.2 (3.7 , 25.4) 15.1 (2.3 , 15.6) 54 25 29 18 0 2 34 123 
FINRISK92, 2005 2201 (46) 54 (6.2) 12.2 (4.5 , 31.7) 11.8 (4.4 , 11.9) 92 21 71 10 45 18 0 114 
FRAMOFF, 1996 2850 (46) 54 (9.8) 16.7 (7.1 , 36.6) 12.0 (5.7 , 14.4) 109 12 97 0 52 6 0 182 
GOH 638 (48) 71 (6.7) 17.5 (10.0 , 37.0) 3.9 (0.3 , 6.9) 0 0 0 0 0 0 0 0 
GRIPS, 1997 5784 (100) 48 (5.1) 9.0 (4.0 , 25.0) 9.8 (4.8 , 10.0) 299 0 299 0 0 0 103 158 
KIHD 1996 (100) 53 (5.3) 9.6 (3.8 , 22.1) 19.2 (2.9 , 23.1) 386 11 375 6 104 34 3 239 
NHANES3 4496 (43) 54 (15.7) 23.0 (9.0 , 46.0) 7.5 (3.9 , 9.0) 107 107 0 38 0 0 46 321 
NPHSII, 2001 2375 (100) 57 (3.4) 10.9 (4.3 , 29.3) 8.3 (3.5 , 10.4) 157 18 139 16 28 7 17 97 
PRIME, 2002 7441 (100) 55 (2.9) 10.0 (5.0 , 30.0) 5.2 (5.0 , 7.3) 115 13 102 10 24 3 3 92 
PROCAM, 1996 3198 (71) 43 (10.4) 4.0 (2.0 , 13.0) 17.4 (5.3 , 18.6) 94 23 71 8 12 4 2 98 
QUEBEC, 1998 2012 (100) 56 (6.9) 19.0 (7.8 , 47.3) 5.3 (4.3 , 5.6) 53 5 48 4 0 0 9 45 
SHS, 2002 3837 (39) 56 (8.0) 3.0 (1.1 , 6.7) 12.5 (2.1 , 14.3) 416 133 283 62 8 8 177 750 
TARFS  1400 (48) 54 (10.5) 10.1 (4.2 , 21.6) 2.2 (1.2 , 4.5) 3 3 0 3 0 0 3 12 
ULSAM  1866 (100) 51 (4.5) 8.3 (3.4 , 22.3) 27.1 (5.9 , 35.8) 485 124 361 60 164 42 30 457 
WHITE2  7903 (69) 49 (6.0) 21.0 (12.0 , 46.0) 7.6 (3.8 , 8.2) 170 23 147 18 1 0 3 86 
WHS, 2006 27791 (0) 55 (7.1) 10.6 (4.4 , 32.8) 10.2 (8.4 , 10.8) 227 10 217 4 229 25 1 540 
WOSCOPS, 2000 4617 (100) 55 (5.6) 17.0 (7.0 , 50.0) 5.0 (2.8 , 6.0) 299 60 239 0 0 0 61 83 
ZUTE 305 (100) 75 (4.5) 12.3 (5.8 , 28.7) 9.1 (1.1 , 10.1) 42 13 29 9 1 1 25 65 
SUBTOTAL 112,108 (49) 55 (9.5) 12.9 (5.0 , 32.7) 9.7 (3.6 , 15.7) 5199 1130 4069 614 1750 338 751 6204 
Nested case-control studies (individually matched) 
BUPA, 1994 1505 (100) 53 (7.2) 19.2 (8.7 , 47.7) 23.7 (4.5 , 26.9) 208 208 0 170 0 0 0 173 
FIA, 1998 1492 (72) 55 (7.6) 26.5 (11.8 , 45.0) 3.7 (0.5 , 8.6) 519 118 401 118 0 0 0 0 
FLETCHER,  2007 689 (79) 57 (14.3) 20.7 (7.2 , 59.5) 5.6 (2.2 , 6.4) 140 - - 0 0 0 0 0 
HPFS 726 (100) 63 (8.3) 13.0 (5.6 , 37.3) 7.7 (3.0 , 8.5) 220 35 185 9 0 0 0 18 
MRFIT, 2001 736 (100) 47 (5.6) 3.4 (1.2 , 9.3) 7.1 (6.0 , 7.8) 246 19 227 13 0 0 0 5 
NHS, 2005 705 (0) 60 (6.5) 9.5 (4.8 , 28.2) 8.0 (1.4 , 8.8) 234 27 207 27 0 0 0 10 
SUBTOTAL 5853 (78) 55 (9.6) 16.0 (5.5 , 40.5) 7.0 (1.3 , 25.9) 1567 407* 1020* 337 0 0 0 206 
Nested case-control studies (frequency matched) 
BRHS 1561 (100) 52 (5.3) 6.5 (3.4 , 16.6) 20.3 (3.7 , 23.6) 461 169 292 122 0 0 0 221 
GOTO33,  1993 128 (100) 51 (0.2) 10.2 (4.2 , 32.0) 12.8 (1.7 , 13.1) 16 7 9 4 0 0 0 7 
REYK,  2008 6179 (71) 55 (9.0) 9.3 (2.9 , 22.8) 20.3 (3.3 , 33.5) 1850 810 1040 228 0 0 0 1476 
USPHS, 1993 805 (100) 60 (9.0) 9.5 (3.8 , 24.1) - 243 22 221 22 153 0 0 0 
SUBTOTAL 8673 (79) 55 (8.6) 8.7 (3.2 , 21.8) 20.1 (3.4 , 32.9) 2570 1008 1562 376 153 0 0 1704 
TOTAL 126,634 (52) 55 (9.4) 12.6 (4.9 , 32.1) 9.8 (3.5 , 21.3) 9336 2545* 6651* 1327 1903 338 751 8114 
 
IQR: inter-quartile range; *Numbers do not add because 1 study (FLETCHER) did not provide separate data on CHD death and non-fatal MI  
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Table 5.4:  Results from quadratic models for the association between usual Lp(a) 
levels and the risk of CHD 
 
Study 
No. of 
observations 
No. of 
cases 
Association with CHD risk: 
RR (95% CI) per 3.5 fold higher level 
   __Main effect__ __Quadratic term__ 
Cohort studies  
AFTCAPS43 902 21 1.15(0.72,1.84) 1.04(0.73,1.47) 
ARIC20  2001 14033 850 1.15(1.05,1.25) 1.05(0.96,1.14) 
BRUN22 1999 798 53 1.10(0.74,1.63) 1.05(0.76,1.43) 
CHARL24 165 19 0.73(0.37,1.45) 0.66(0.29,1.52) 
CHS123  2003 3860 592 1.01(0.91,1.13) 0.98(0.87,1.10) 
COPEN25 2008 7487 283 1.16(1.03,1.32) 1.12(1.01,1.23) 
DUBBO26 2002 2008 273 1.26(1.07,1.47) 0.91(0.79,1.05) 
EAS27 2001 637 54 1.41(0.97,2.07) 0.80(0.51,1.25) 
FINRISK9228 2005 2201 92 1.03(0.80,1.33) 1.05(0.82,1.33) 
FRAMOFF29 1996 2850 109 1.35(1.03,1.76) 0.98(0.76,1.27) 
GRIPS31 1997 5784 299 1.31(1.13,1.51) 1.14(1.04,1.23) 
KIHD32  1996 386 1.01(0.90,1.15) 1.18(1.06,1.32) 
NHANES333 4496 107 1.26(0.99,1.61) 1.02(0.79,1.32) 
NPHSII34 2001 2375 157 1.12(0.92,1.37) 1.04(0.81,1.35) 
PRIME35 2002 7441 115 1.44(1.12,1.86) 0.90(0.74,1.10) 
PROCAM36 1996 3198 94 1.67(1.07,2.60) 0.84(0.60,1.18) 
QUEBEC37 1998 2012 53 1.15(0.81,1.64) 0.95(0.66,1.38) 
SHS38 2002 3837 416 1.11(0.97,1.27) 1.01(0.94,1.07) 
TARFS39  1400 3 0.82(0.21,3.12) 1.49(0.31,7.16) 
ULSAM40  1866 485 1.14(1.03,1.26) 1.09(1.00,1.19) 
WHITE241  7903 170 1.27(1.03,1.57) 1.03(0.89,1.20) 
WHS15 2006 27791 227 0.92(0.78,1.09) 1.33(1.15,1.53) 
WOSCOPS44 2000 4617 299 1.02(0.89,1.18) 1.00(0.87,1.16) 
ZUTE42 305 42 1.11(0.75,1.66) 1.06(0.72,1.55) 
Nested case-control studies (individually matched) 
BUPA45 1994 1184 208 1.55(1.24,1.93) 1.03(0.82,1.28) 
FIA46 1998 1454 510 1.34(1.10,1.64) 1.27(0.95,1.69) 
FLETCHER47 2007 372 134 1.31(0.94,1.82) 1.02(0.76,1.38) 
HPFS48 691 220 1.15(0.94,1.40) 0.93(0.76,1.14) 
MRFIT49 2001 736 246 0.90(0.73,1.10) 0.97(0.80,1.17) 
NHS50 2005 687 234 1.27(1.00,1.61) 1.00(0.83,1.20) 
Nested case-control studies (frequency matched) 
BRHS51 1561 461 1.06(0.91,1.23) 1.06(0.97,1.16) 
GOTO3352 1993 128 16 1.28(0.66,2.46) 2.01(0.95,4.22) 
REYK10 2008 5771 1850 1.30(1.21,1.39) 1.00(0.93,1.09) 
USPHS53 1993 652 243 1.19(0.97,1.46) 1.06(0.84,1.33) 
Overall† 123,198 ‡ 9321 1.16 (1.11,1.21) 1.05 (1.02,1.08)* 
 
Risk ratios are adjusted for baseline age and, where appropriate, stratified by sex and trial 
arm. † Overall effect calculated by combining study specific estimates for main effect and 
quadratic terms for the log-Lp(a) using multivariate random-effects meta-analysis. ‡Overall 
number is less than study total because 2 studies (ATTICA and GOH) did not contribute CHD 
endpoints.*P-value for comparison of the linear versus the quadratic model = 0.003.  
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Table 5.5: Risk ratios for a) coronary heart disease and b) ischemic stroke 
per 3.5 fold (ie, 1-SD) higher usual Lp(a) levels with progressive 
adjustment for usual levels of confounders†.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Analyses were restricted to participants with complete information on sex and all 
confounding variables. Risk ratios are stratified by sex and trial arm where 
appropriate. Studies with fewer than 10 cases for CHD or ischemic stroke outcomes 
were excluded from the analyses of that outcome.  
Note: I2 is a measure of consistency across studies: the percentage of variance in 
estimated log RRs that is attributable to between study variations as opposed to 
sampling variation. Values of I2 close to 0 indicate lack of evidence of heterogeneity. 
a) Coronary heart disease : 106645 individuals, 8362 cases, 30 studies 
 
With adjustment for... RR (95%CI) Wald
2
1
χ  I2 (95% CI) 
Age & sex 1.16 (1.11 , 1.22) 46 57 (36 , 72) 
Plus systolic blood pressure 1.16 (1.11 , 1.21) 43 57 (36 , 71) 
Plus smoking status 1.16 (1.11 , 1.21) 42 57 (36 , 72) 
Plus history of diabetes 1.17 (1.12 , 1.22) 47 58 (37 , 72) 
Plus body mass index 1.17 (1.12 , 1.23) 51 57 (36 , 71) 
Plus total cholesterol 1.13 (1.09 , 1.18) 36 49 (22 , 66) 
    
b) Ischaemic stroke :  69539 individuals, 1684 cases, 13 studies 
 
With adjustment for... RR (95%CI) Wald
2
1
χ  I2 (95% CI) 
Age & sex 1.11 (1.02 , 1.20) 6 46 (0 , 72) 
Plus systolic blood pressure 1.09 (1.01 , 1.17) 6 31 (0 , 64) 
Plus smoking status 1.09 (1.01 , 1.17) 6 30 (0 , 64) 
Plus history of diabetes 1.10 (1.02 , 1.17) 7 26 (0 , 62) 
Plus body mass index 1.10 (1.03 , 1.18) 8 25 (0 , 61) 
Plus total cholesterol 1.10 (1.02 , 1.18) 7 30 (0 , 64) 
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Table 5.6:  Risk ratios for CHD for 3.5 fold (ie. 1-SD) higher usual levels of Lp(a), further adjusted for usual values of  various 
potential confounding factors. 
 
 
 
†Analysis was restricted to participants with complete information on sex, trial arm and respective confounding variables for each subset. ‡Basic 
adjustment includes age and usual values of systolic blood pressure, smoking, history of diabetes and body mass index. Risk ratios are stratified 
by sex and trial arm where appropriate. Studies with fewer than 10 events were excluded from these analyses.  § Correction was made by 
subtracting estimated Lp(a) cholesterol values from total cholesterol; Lp(a) cholesterol was estimated from Lp(a) total mass using the following 
equation: Lp(a)-C (mg/dl) = 0.15*Lp(a) (mg/dl)+1.24 (Clinical Chemistry 1998; 44(8):1629-40) 
 
Subset Adjustment  No. of 
studies 
No. of 
subjects 
No. of 
cases 
RR (95% CI) Wald
2
1
χ  
Lipid markers† Basic ‡  Plus total cholesterol 26 96675 5728 1.13 (1.08 , 1.19) 23 
 Basic ‡  Plus Non-HDL-C & HDL-C    1.15 (1.09 , 1.21) 25 
 Basic ‡  Plus  Non-HDL-C, HDL-C & log-triglycerides    1.14 (1.08 , 1.20) 25 
 Basic ‡  Plus total cholesterol  corrected  for Lp(a) cholesterol§    1.17 (1.11 , 1.24) 30 
       
Apolipoproteins† Basic ‡  Plus Non-HDL-C & HDL-C 15 75560 3540 1.21 (1.12 , 1.31) 22 
 Basic ‡  Plus Apo-B & Apo-AI    1.18 (1.09 , 1.27) 18 
       
Fibrinogen† Basic ‡  Plus Non-HDL-C & HDL-C 19 87708 4227 1.16 (1.09 , 1.24) 20 
 Further adjustment for fibrinogen    1.13 (1.06 , 1.21) 12 
       
CRP† Basic ‡  Plus Non-HDL-C & HDL 19 55146 3375 1.09 (1.04 , 1.15) 11 
 Further adjustment for CRP    1.09 (1.04 , 1.13) 13 
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Table 5.7:  Parallel analyses of the association of Lp(a) with disease risk: (a) per 3.5 fold (ie. 1-SD) higher baseline level, 
and (b) for comparison of individuals in extreme thirds of baseline  level distributions. 
 
 Coronary heart disease 
106645 individuals 8362 cases 30 cohorts 
 Ischaemic stroke 
69539 individuals 1684 cases 13 cohorts 
 Risk ratio 
(95% CI) Wald
2
1
χ  
I2 
(95% CI) 
 Risk ratio 
(95% CI) Wald
2
1
χ  
I2 
(95% CI) 
 
a) Per 3.5 fold higher baseline Lp(a) level 
With adjustment for...        
Age & sex 1.13 (1.09 , 1.18) 33 62 (43 , 74)  1.08 (1.00 , 1.17) 4 52 (9 , 74) 
Plus systolic blood pressure 1.14 (1.09 , 1.19) 34 62 (44 , 75)  1.07 (1.00 , 1.15) 4 38 (0 , 68) 
Plus smoking status 1.13 (1.09 , 1.18) 32 63 (45 , 75)  1.08 (1.00 , 1.15) 4 37 (0 , 67) 
Plus history of diabetes 1.14 (1.09 , 1.19) 35 64 (46 , 75)  1.08 (1.01 , 1.16) 6 33 (0 , 65) 
Plus body mass index 1.15 (1.10 , 1.20) 38 63 (46 , 75)  1.09 (1.02 , 1.16) 6 31 (0 , 64) 
Plus total cholesterol 1.11 (1.07 , 1.16) 25 59 (39 , 73)  1.08 (1.01 , 1.16) 5 35 (0 , 66) 
 
b) Top vs. bottom thirds of Lp(a) distribution 
With adjustment for...        
Age & sex 1.33 (1.23 , 1.45) 46 42 (11 , 63)  1.19 (1.01 , 1.41) 5 17 (0 , 56) 
Plus systolic blood pressure 1.34 (1.23 , 1.45) 47 42 (11 , 63)  1.17 (1.01 , 1.36) 4 0 (0 , 57) 
Plus smoking status 1.33 (1.23 , 1.45) 45 44 (13 , 63)  1.17 (1.01 , 1.36) 4 0 (0 , 57) 
Plus history of diabetes 1.35 (1.24 , 1.47) 49 45 (15 , 64)  1.19 (1.02 , 1.38) 5 0 (0 , 57) 
Plus body mass index 1.35 (1.25 , 1.47) 50 42 (10 , 63)  1.19 (1.03 , 1.38) 6 0 (0 , 57) 
Plus total cholesterol 1.27 (1.17 , 1.38) 33 40 (6 , 62)  1.18 (1.02 , 1.37) 5 0 (0 , 57) 
        
 
Analyses were restricted to participants with complete information on sex and all confounding variables. Risk ratios are stratified by 
sex and trial arm where appropriate. Studies with less than 10 events were excluded from analysis. Note: I2 is a measure of 
consistency across studies: the percentage of variance in estimated log RRs that is attributable to between study variations as 
opposed to sampling variation. Values of I2 close to 0 indicate lack of evidence of heterogeneity 
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Table 5.8: Assessment of incremental predictive value of Lp(a) to standard CHD risk factors 
 
Model Variables C-index (95% CI) 
Change in  C-index 
compared to reference 
model 
P-value for 
change in  
C-index 
Model A Age + Sex 0.6113 (0.6033, 0.6194) Ref NA 
 Model A + log-Lp(a) 0.6183 (0.6103, 0.6264) 0.0070 (0.0032, 0.0108) <0.001 
 Model A + Lp(a)_75 0.6209 (0.6129, 0.6290)  0.0096 (0.0061, 0.0130) <0.001 
 Model A + Lp(a)_90 0.6170 (0.6089, 0.6250) 0.0056 (0.0029, 0.0083) <0.001 
     
Model B Model A + Smoking status 0.6412 (0.6334, 0.6490)  Ref NA 
 Model B + log-Lp(a) 0.6458 (0.6380, 0.6536) 0.0046 (0.0020, 0.0072) <0.001 
 Model B + Lp(a)_75 0.6477 (0.6399, 0.6555) 0.0065 (0.0039, 0.0091) <0.001 
 Model B + Lp(a)_90 0.6452 (0.6374, 0.6530) 0.0040 (0.0020, 0.0060) <0.001 
     
Model C Model B + Systolic blood pressure 0.6658 (0.6582, 0.6734) Ref NA 
 Model C + log-Lp(a) 0.6683 (0.6607, 0.6759) 0.0025 (0.0008, 0.0042) 0.004 
 Model C + Lp(a)_75 0.6698 (0.6622, 0.6774) 0.0040 (0.0020, 0.0059)  <0.001 
 Model C + Lp(a)_90 0.6686 (0.6611, 0.6762) 0.0028 (0.0012, 0.0044) <0.001 
     
Model D Model C + history of diabetes 0.6785 (0.6710, 0.6861) Ref NA 
 Model D + log-Lp(a) 0.6812 (0.6737, 0.6888) 0.0027 (0.0010, 0.0045)  0.002 
 Model D + Lp(a)_75 0.6825 (0.6749, 0.6900) 0.0039 (0.0020, 0.0059)  <0.001 
 Model D + Lp(a)_90 0.6813 (0.6738, 0.6889)  0.0028 (0.0012, 0.0044)  0.001 
     
Model E Model D + total cholesterol 0.6915 (0.6840, 0.6989) Ref NA 
 Model E + log-Lp(a) 0.6932 (0.6858, 0.7006)  0.0017 (0.0006, 0.0028) 0.003 
 Model E + Lp(a)_75 0.6940 (0.6865, 0.7014) 0.0025 (0.0011, 0.0039) <0.001 
 Model E + Lp(a)_90 0.6928 (0.6854, 0.7002) 0.0014 (0.0003, 0.0024)  0.012 
     
Model F Model E  + HDL-C 0.7036 (0.6962, 0.7109) Ref NA 
 Model F + log-Lp(a) 0.7048 (0.6975, 0.7121) 0.0013 (0.0002, 0.0024)  0.026 
 Model F + Lp(a)_75 0.7055 (0.6982, 0.7128) 0.0019 (0.0006, 0.0033) 0.004 
 Model F + Lp(a)_90 0.7046 (0.6973, 0.7119) 0.0010 (0.0000, 0.0020) 0.044 
 
Note: Analyses were restricted to 95,522 individuals from 21 cohort studies with available information 
on age, sex, smoking status, systolic blood pressure, history of diabetes, total cholesterol and HDL-C. 
NA = not applicable 
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Table 5.9: Reclassification of participants between predicted 10-year CHD risk categories 
on addition of Lp(a) to Framingham risk factors 
 
    
  Predicted 10-year risk 
with Framingham risk factors plus Lp(a)† 
 
 
  < 5 % 5 to 10 % 10 to 20 % > 20 %  
< 5 % 546 28 0 0 
5 to 10 % 37 532 36 0 
10 to 20 % 0 25 614 31 
> 20 % 0 0 21 436 
 
CHD cases 
n = 2,306 
      
< 5 % 30,525 352 0 0 
5 to 10 % 409 5701 258 0 
10 to 20 % 0 260 3,014 93 
 
 
Predicted 10-year 
risk using 
Framingham  
risk factors‡ 
> 20 % 0 0 60 810 
 
Controls  
n = 41,482 
       
  NRI, 0.58% (95% CI: -0.56 to 1.73)  p=0.32 
IDI, 0.00082 (95% CI: 0.00029 to 0.00134) p=0.002 
 
 
† Lp(a) was introduced in model as continuous variable. ‡ Framingham risk factors are: age, 
sex, smoking status, systolic blood pressure, history of diabetes, total cholesterol and HDL-C. 
IDI, Integrated Discrimination Index; NRI, Net Reclassification Index; All analyses were 
stratified by study and trial arm (where appropriate) 
Note: The shaded region shows participants whose ATP-III category did not change in either 
direction with the addition of Lp(a) to the Framingham prediction model; upward re-classification 
for CHD cases and downward re-classification for controls indicate better predictive ability. 
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Figure 5.1: Kaplan-Meier survivor plot for CHD†: (a) overall and (b) by sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Analysis involved 111,700 participants and 5200 cases from 26 cohorts 
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Figure 5.2: Kaplan-Meier survivor plot for CHD by thirds of Lp(a)† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Analysis involved 111,700 participants and 5200 cases from 26 cohort studies 
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Figure 5.3: Risk ratios of CHD by fifths of usual Lp(a) concentration  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sizes of data markers are proportion to the inverse of the variance of the risk ratios. Confidence 
intervals (CIs) were calculated using floating absolute risk technique. Studies involving fewer than 
10 cases were excluded form analysis. † Further adjustment for systolic blood pressure, smoking 
status, history of diabetes, body mass index, and total cholesterol 
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Figure 5.4: Risk ratios of coronary heart disease, ischaemic stroke and non-vascular 
death by quantiles of usual Lp(a) levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the variance of the 
risk ratios. CIs were calculated using floating absolute risk technique. †Further adjustment for systolic blood 
pressure, smoking status, history of diabetes, body mass index and total cholesterol. Studies involving fewer 
than 10 cases of any outcome were excluded from the analysis of that outcome.  
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Figure 5.5: Risk ratios for various vascular and non-vascular endpoints per 3.5 fold (ie. 1-SD) 
higher usual Lp(a) levels adjusted for cardiovascular risk factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the variance 
of the risk ratios. Risk ratios are adjusted for age, and usual levels of systolic blood pressure, smoking 
status, history of diabetes, body mass index and total cholesterol, and stratified, where appropriate, 
by sex and trial arm. Studies involving fewer than 10 cases of any outcome were excluded from the 
analysis of that outcome. † These subtotals do not add to the total number of CHD outcome in the 
first row because some nested case-control studies did not subdivide outcomes into coronary death or 
non-fatal MI 
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Figure 5.6:  Age- and sex- adjusted risk ratios for various vascular and non-vascular endpoints 
per 3.5 fold (i.e., 1-SD) higher usual Lp(a) levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the 
variance of the risk ratios. Risk ratios are adjusted for baseline age and stratified, where 
appropriate, by sex and trial arm.  Studies involving fewer than 10 cases of any outcome were 
excluded from the analysis of that outcome. † These subtotals do not add to the total number of 
CHD outcome in the first row because some nested case-control studies did not subdivide outcomes 
into coronary death or non-fatal MI 
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Figure 5.7:   Risk ratios for coronary heart disease by fifths of usual Lp(a) levels, after excluding 
the first 5 years of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. CIs were calculated using floating absolute risk technique. 
†Further adjustment for systolic blood pressure, smoking status, history of diabetes, body mass 
index and total cholesterol. Sizes of data markers are proportional to the inverse of the variance of 
the risk ratios. 
 
 
 
 
 
 
 
 
 
 
R
is
k
 r
a
ti
o
 a
n
d
 9
5
%
 C
I 
(l
o
g
 s
c
a
le
)
Usual  Lp(a) (mg/dl)
Geometric mean (log scale)
Non-fatal MI and coronary death: 5717 Cases
a) Adjustment for age and sex only
Usual  Lp(a) (mg/dl)
Geometric mean (log scale)
Non-fatal MI and coronary death: 5237 Cases
b) Further adjustment†
.9
1
1.2
1.4
1.6
1.8
2
3 6 12 24 48 96 192
.9
1
1.2
1.4
1.6
1.8
2
3 6 12 24 48 96 192
R
is
k
 r
a
ti
o
 a
n
d
 9
5
%
 C
I 
(l
o
g
 s
c
a
le
)
 154 
 
Figure 5.8: Study-specific adjusted risk ratios for CHD, corresponding to the adjusted risk 
ratio in Table 5.5† 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†adjusted for age, sex, systolic blood pressure, smoking status, history of diabetes, body mass 
index, and total cholesterol. CI indicates confidence interval. Sizes of data markers are 
proportional to the inverse of the variance of the risk ratios.  
 
Note: The overall adjusted RR in studies with greater than 500 CHD cases (1.09, 1.03-1.16) was 
not significantly different from that of studies with less than 500 cases (1.15, 1.09-1.21) 
(heterogeneity p-value=0.36).  
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Figure 5.9: Risk ratios for coronary heart disease per 3.5 fold (ie. 1-SD) higher usual Lp(a) 
levels, by age and by thirds of some individual level characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the variance of 
the risk ratios. Adjusted for age, and usual levels of systolic blood pressure, smoking status, history of 
diabetes, body mass index and total cholesterol, and stratified, where appropriate, by sex and trial arm. 
Studies with fewer than 3 cases per stratum were excluded from analyses. †Correction was made by 
subtracting estimated Lp(a) cholesterol values from total cholesterol; Lp(a) cholesterol was estimated 
from Lp(a) total mass using the following equation: Lp(a)-C (mg/dl) = 0.15*Lp(a) (mg/dl)+1.24 
(Clinical Chemistry 1998; 44(8):1629-40) 
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Figure 5.10:  Risk ratios for coronary heart disease per 3.5 fold (ie. 1-SD) higher usual 
Lp(a) levels, by strata of various study level characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the variance of 
the risk ratios. Risk ratios are adjusted for age, and usual levels of systolic blood pressure, smoking 
status, history of diabetes, body mass index and total cholesterol, and stratified, where appropriate, by 
sex and trial arm. †Although a total of 30 studies have contributed to the analyses, for different 
characteristics different number of studies had relevant data; for Storage duration 4 studies, for Storage 
temperature 3 studies, and for Assay method 2 studies did not have relevant data. For Race, the no. of 
studies do not add to 36 because 4 studies contributed to 2 categories. ‡Isoform sensitivity refers to 
whether the result of an assay is affected by apo(a) isoform variation. 
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Figure 5.11:  Direct comparison of adjusted risk ratios for CHD between Lp(a), non-HDL-C, 
HDL-C and triglycerides for a 1-SD difference† baseline or usual levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the 
variance of the risk ratios.* † RRs presented are for 1-SD higher loge lp(a), loge triglycerides, or 
non-HDL-C levels, or for 1-SD lower HDL-C levels. Analyses were based on data from 26 cohorts 
involving 97,049 and 5766 cases. Risk ratios were mutually adjusted for each other, and 
baseline age, and usual levels of systolic blood pressure, smoking status, history of diabetes, 
body mass index and HDL-C  
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Figure 5.12: Association of Lp(a) with  fatal vascular and non-vascular outcomes in analyses 
that did not censor for nonfatal events† – RRs are per 3.5 fold (ie. 1-SD) higher 
usual Lp(a) levels adjusted for cardiovascular risk factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CI indicates confidence interval. Sizes of data markers are proportional to the inverse of the variance of 
the risk ratios †Compared to the corresponding main analyses (Figure 5.5), analyses that did not 
censor for non-fatal events involved additional 1917 vascular and 1122 non-vascular fatal outcomes. 
Risk ratios are adjusted for baseline age, smoking status, systolic blood pressure, history of diabetes, 
body mass index and total cholesterol, and stratified, where appropriate, by sex and trial arm. Studies 
involving fewer than 10 cases of any outcome were excluded from the analysis of the outcome. 
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Chapter 6: Lipoprotein(a) concentration and the risk of myocardial 
infarction in South Asians  
 
Chapter summary 
While available evidence shows that circulating Lp(a) levels are independently and 
continuously associated with the risk of CHD in people of European ancestry, data 
are limited in South Asians, a population with a large cardiovascular disease burden. 
Analyses of data based on 1800 cases with first ever myocardial infarction (MI) and 
1800 age and sex matched controls from the Pakistani Risk of Myocardial Infarction 
Study yielded an odds ratio of 1.19 (95% CI, 1.09-1.26) per 1-SD higher Lp(a) 
concentration. The association was almost completely unaltered by adjustment for 
smoking status, history of diabetes and total cholesterol. The corresponding adjusted 
odds ratio comparing individuals in the top vs. bottom fifths of the distribution of 
Lp(a) concentration was 1.59 (95% CI, 1.38 to 1.83).  This retrospective case-
control study suggests that circulating Lp(a) levels are significantly and 
independently associated with risk of MI in Pakistanis. Large prospective studies are 
needed to reliably assess the association and determine its relevance to the 
cardiovascular disease burden in this population.  
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Background 
As South Asia is a region with a large and rapidly increasing cardiovascular disease 
burden, there is interest in studying the distributions and associations of established 
and novel vascular risk factors in this population.1-5 The need for studying novel 
markers, such as Lp(a), in South Asians is particularly heightened  because 
established vascular risk factors, such as smoking and elevated LDL-C level, do not 
appear to explain the excess cardiovascular risk observed in this population.6-12 It has 
been previously proposed that, along with higher insulin resistance and lower HDL-C 
levels, elevated Lp(a) concentration may account for part of the excess risk observed 
in south Asians.5;10;13-17  In support of this hypothesis, small-scale comparative studies 
have indicated that Lp(a) levels are significantly higher in South Asians than in 
Whites.18-20 In addition, a number of case control studies of CHD, typically involving 
less than 100 angiographically detected coronary stenosis patients, have reported 
associations with high Lp(a) concentration.10;13;15  It has also been suggested that 
Lp(a) may be particularly important in segments of the south Asian population with 
high rates of premature coronary disease.5;11;21 
 
However, in contrast to the considerable epidemiological evidence available for people 
of European origin (Chapter 5), there is limited data on circulating Lp(a) levels and 
their association with CHD among people living in South Asia.17;22;23 The previous 
largest study of Lp(a) from this region involved only 734 participants (254 
angiographically proven CHD cases and 480 age- and sex- matched controls).24 
Although, this study reported a significant difference in the Lp(a) concentration 
between the CHD cases and disease-free controls, it was not sufficiently powered to 
provide an informative relative risk estimate. Furthermore, as the range of covariates 
measured in the study were too limited to enable adequate adjustment for potential 
confounders, it was not possible to determine whether the observed associations were 
independent of established cardiovascular risk factors. This chapter reports the first 
comprehensive and large-scale study of circulating Lp(a) levels in relation to the risk 
of first-ever myocardial infarction (MI) and other cardiovascular risk markers / factors 
among people living in South Asia.  
 
 
 
 
 167 
Methods 
Study design 
This chapter present data on a subset of the Pakistani Risk of Myocardial Infarction 
Study (PROMIS) with information available on Lp(a) concentration.25 PROMIS is an 
ongoing case-control study of acute MI recruiting in six centres in urban Pakistan. 
Cases were individuals with no previous history of cardiovascular disease in whom MI 
was diagnosed based on the following criteria: (i) sustained clinical symptoms 
suggestive of MI; (ii) typical ECG characteristics; and (iii) elevated troponin levels. All 
cases were enrolled within 24 hours of onset of chest symptoms, with close to 80% 
recruited within 12 hours of chest pain. Symptom free individuals without self-
reported history of cardiovascular disease, frequency-matched to cases by sex and 
age in 5 year age bands, were concurrently identified to serve as healthy controls. 
The controls were recruited in the same hospitals as index cases in the following order 
of priority: (i) visitors of patients attending the outpatient department; (ii) patients 
attending the outpatient department for routine noncardiac complaints, or (iii) non 
blood related visitors of index MI cases. Controls with recent illnesses or infections 
were excluded. A locally-piloted and validated epidemiological questionnaire was 
administered to participants by medically qualified research officers. The 
questionnaire included >200 items of information in relation to: ethnicity (e.g. 
personal and parental ethnicity, spoken language, place of birth and any known 
consanguinity); demographic characteristics; lifestyle factors (e.g., tobacco and 
alcohol consumption, dietary intake and physical activity); personal and family history 
of cardiovascular disease; and medication usage. Non-fasting blood samples were 
drawn from each participant and centrifuged within 45 minutes of venipuncture. 
Serum samples were stored at -80 ºC. PROMIS has received approval from the ethics 
committee of the Centre for Non-Communicable Diseases (CNCD), Karachi, Pakistan 
and informed consent has been obtained from each participant (including consent to 
use samples in genetic, biochemical and other analyses). 
 
Measurement of Lp(a) and lipids 
All samples underwent Lp(a) and lipid analyses in the Lipids Metabolism Laboratory, 
Human Nutrition Research Centre on Aging, Tufts University, Boston USA. Lp(a)  
concentration was measured with an immunoturbidimetric assay using reagents and 
calibrators from Denka Seiken (Niigata, Japan). This is the only commercially 
available assay that is not sensitive to apo(a) isoform size heterogeneity.26 Total 
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cholesterol, HDL-C and triglyceride concentrations were measured using enzymatic 
methods (Roche Diagnostics, USA). LDL-C was calculated using Friedewald’s formula. 
The laboratory staff measuring levels of Lp(a) and lipids were unaware of the disease 
status of the participants.  
 
Statistical analysis 
The Lp(a) values were natural log transformed to achieve an approximately 
symmetrical distribution. The correlates of Lp(a) were assessed using Pearson’s 
correlation coefficient and regression of the loge Lp(a) value on the covariates. The 
association of Lp(a) with the covariates was then expressed as the percentage change 
in Lp(a) concentration per 1-SD higher level of the correlate for continuous variables 
or with respect to the reference group for categorical variables.  Comparison of the 
characteristics of cases and controls was done using the Student’s t-test (for 
continuous variables) and chi-squared test (for categorical variables). To determine 
the effect of the acute phase on Lp(a) concentration among the MI cases we 
regressed the loge Lp(a) concentration on the time interval between blood drawing 
and onset of chest pain. Unconditional logistic regression was used to calculate odds 
ratios (ORs) and 95% confidence intervals (CIs), progressively adjusted for age, sex, 
tobacco use, history of diabetes and total cholesterol.  Alternative adjustments were 
made for other lipids and lipoproteins. The association was further characterized by 
categorizing Lp(a) into fifths based on Lp(a) values in controls; for the purpose of 
graphical display, the corresponding 95% CIs were estimated from floated variances 
that reflect the amount of information underlying each group (including the reference 
group).  As the present study has a retrospective case-control design, we stratified 
the logistic regression analyses by thirds of time since onset of chest pain to assess 
whether the observed OR was biased by any drift in Lp(a) concentration in the cases 
subsequent to the onset of MI. All analyses were performed using Stata release 10 
(StataCorp LP, College Station, Texas). 
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Results 
Study description  
Table 6.1 displays some socio-demographic characteristics and biochemical 
measurements in the cases and controls. The mean (SD) age of the cases was 54 
(12) years. Eighty percent of the cases were males and 21% had a history of 
diabetes. As would be expected, the prevalence of established CHD risk factors such 
as self-reported diabetes, family history of MI, tobacco consumption and levels of 
LDL-C were higher in MI cases than in controls. 
 
Correlates of circulating Lp(a) levels 
The median (Inter-quartile range) of the Lp(a) concentration among the control 
participants was 6.7 (2.7-13.9) mg/dl. Lp(a) levels were significantly higher in MI 
cases than in controls (p-value < 0.0001). Circulating Lp(a) levels were significantly 
correlated with levels of total cholesterol (r= 0.06; 95% CI, 0.02 to 0.11), LDL-C (r= 
0.15; 0.11 to 0.20), Apo B100 (r= 0.21; 0.16 to 0.25), loge triglycerides (r= -0.16; -
0.20 to -0.11), and waist to hip ratio (r= -0.05; -0.01 to -0.001) (Table 6.2). No 
significant correlations were observed between Lp(a) concentration and age, tobacco 
use, systolic blood pressure, BMI, gender, family history of MI, or history of diabetes 
(Table 6.2). 
 
Lp(a) concentration and time since onset of chest pain  
Figure 6.1 shows the mean concentrations of loge Lp(a), C-reactive protein, 
albumin, and HDL-C by thirds of time interval between chest pain onset and blood 
drawing. The mean loge Lp(a) levels increased significantly as time since onset of 
chest pain increased (p-value = 0.02). However, the magnitude of the change was 
small (r = 0.08). 
 
Lp(a) concentration and the risk of MI 
 The OR for MI per one standard deviation higher loge Lp(a) concentration, adjusted 
for age and sex was 1.19 (95% CI, 1.09 to 1.26). The association was only slightly 
attenuated on further adjustment for tobacco consumption, self-reported history of 
diabetes and total cholesterol (OR: 1.17; 1.09 to 1.26; Table 6.3). The association 
was not materially altered with alternative adjustment for LDL-cholesterol and HDL-
cholesterol, or for apolipoproteins-AI and –B100, instead of total cholesterol. 
Comparable odds ratios were obtained when the analyses were stratified by thirds of 
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time since onset of chest pain; although the association appeared stronger among 
individuals with longer duration between blood drawing and time of onset of chest 
pain, the differences were not statistically significant (p-value = 0.4: Figure 6.2). 
Analyses of data by fifths of Lp(a) concentration suggested that the ORs for MI 
increased continuously with increasing Lp(a) levels (Figure 6.3). The adjusted OR 
for MI in a comparison of individuals in top versus bottom fifths of Lp(a) 
concentrations was 1.59 (95% CI, 1.38 to 1.83).  
 
Discussion 
This first large-scale study of MI in Pakistan investigating circulating levels of Lp(a) in 
1800 cases and 1800 controls demonstrated that Lp(a) levels are independently 
associated with risk of MI in South Asians. The magnitude of the association found in 
this study was comparable to that observed for people of European ancestry. 
Analyses of individual participant data in the ERFC, which was comprised of 
predominantly European populations, yielded an adjusted relative risk for CHD of 
1.13 (1.09-1.18) per 1 SD higher loge Lp(a) concentration (Chapter 5). The 
corresponding relative risk in the present study was 1.17 (1.09-1.26).  In addition, 
as for people of European ancestry, the relationship between Lp(a) concentration and 
the risk of CHD appeared continuous in this South Asian population. However, direct 
comparison of the findings of the present study with that of the ERFC is difficult 
because of differences in case definitions (first-ever MI in the current study versus a 
broader definition of CHD in the ERFC), age of participants (young age of participants 
in the current study compared with the older age of participants in the ERFC), study 
design (retrospective for the current study versus prospective for studies included in 
the ERFC), and study scope (a single moderately-powered study versus collaborative 
analyses of 36 studies involving 127,000 participants).  
 
Although studies have reported that Lp(a) levels tend to rise in response to stress 
(eg, MI, surgery), the acute phase nature of the particle is not fully established.27-29  
Any such stress-responsiveness in Lp(a) has particular relevance to retrospective 
case-control studies where blood samples are drawn from the MI cases after the 
onset of chest pain, as an upward drift in Lp(a) concentration in the cases may bias 
the observed association between Lp(a) and the risk of MI. In the current study the 
average Lp(a) concentration was not materially different between groups of MI cases 
with different durations between onset of chest pain and time of blood drawing. 
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Stratifying our analyses by thirds of time interval between onset of chest pain and 
time of blood drawing did not show important differences, suggesting that major 
reverse causation bias arising from acute phase mediated drift in Lp(a) concentration 
may not be likely. Nonetheless, it is acknowledged that these are blunt sensitivity 
analyses and it is possible that the observed odds ratios might have been modestly 
inflated by the acute phase response. 
 
South Asians account for one-fifth of all cardiovascular deaths worldwide.5 Several 
studies suggest that South Asians from the Indian subcontinent (including India and 
Pakistan) have an increased risk of developing CHD when compared with European 
populations.2;8;11;30 It is notable that the average age of the MI cases in the present 
study was substantially lower than that observed in Western populations, indicating 
the higher risk of premature cardiovascular disease among South Asians (for 
instance, the average age of onset of CHD was 67 years in the ERFC compared to a 
mean age of 53 years for MI cases in the current study).11;17;21  High prevalence of 
insulin resistance and type 2 diabetes mellitus, along with high triglycerides and low 
HDL-C levels are thought to contribute to the elevated risk of CHD in South Asians. 
5;6;9;17 In addition, a number of studies have shown that emerging risk factors, 
including Lp(a), may be higher among South Asians compared with Europeans, 
which may contribute to part of the excess cardiovascular risk in this population.18-20 
The current study suggests that Lp(a) is probably similarly important in South Asians 
as in people of European descent. However, the average Lp(a) concentration did not 
appear to be significantly higher in this population compared to Europeans as 
previously reported. This may be due to the presence of a similar distribution of the 
factor in the two populations, which suggests that Lp(a) may not contribute to the 
observed cardiovascular risk differences. Comparison of Lp(a) levels across studies, 
however, is very difficult due to significant variability in Lp(a) assay methods 
(Chapter 1, 2). This may be addressed by conducting simultaneous measurement of 
Lp(a) concentrations in representative samples from the two populations using the 
same measurement method. 
 
The strengths and potential limitations of the present study merit consideration. 
First, this is the largest epidemiological study to date of MI in South Asians providing 
the most precise estimate of the relationship between Lp(a) concentration and the 
risk of CHD in this population. Second, the PROMIS population has been well 
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phenotyped, with measurements of a broad set of socio-demographic, biophysical, 
and lipid markers allowing us to make appropriate adjustment for potential 
confounders. On the other hand, being of retrospective design and with the putative 
acute-phase role of Lp(a), the present study may be limited by potential biases. 
However, sensitivity analyses using data on the time interval between onset of chest 
pain and time of blood drawing did not yield strong evidence for the presence of such 
biases. Second, despite its considerable size, the present study was not sufficiently 
powered to determine the shape of the relationship between Lp(a) and the risk of MI 
or to make a reliable determination of the association within clinically relevant 
subgroups. In addition, lack of concomitant measurement of putative factors that 
may contribute to Lp(a) heterogeneity (such as apo(a) isoforms, Chapter 8) may 
limit the contributions of the study to current understanding of the role Lp(a) in 
cardiovascular disease in South Asians. Nonetheless, the present study is important 
because it extends several epidemiological observations of Lp(a) and CHD risk from 
Western populations to South Asians. 
 
Conclusion 
In summary, this report has provided the first demonstration that circulating levels 
of Lp(a) are independently and significantly associated with risk of MI in South 
Asians. The strength of association was as strong in South Asians as previously 
observed in Europeans. Future prospective studies with larger sample size and with 
information on apo(a) isoforms and other potential co-mediators of the coronary 
effect of Lp(a), will help to fully characterize the role of this factor in CHD. 
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Table 6.1: General characteristics of cases and controls in PROMIS 
 
 
 
 
‡ Median (inter-quartile range) presented for non-normally distributed variables; values were 
log-transformed for statistical tests of significance between cases and controls. 
IQR indicates inter-quartile range 
 
 
 
 
 
 
 
 
 
 
 
 Cases Controls  
Characteristics N 
Mean (SD), 
Median (IQR) or % 
N 
Mean (SD), 
Median (IQR) or % 
P value 
 
Conventional risk 
factors           
Lp(a) (mg/dl)
‡
 1736 8.3 (3.4-17.3) 1807 6.7 (2.7-13.9) <0.0001 
Age (yrs) 1717 54 (12) 1795 53 (10) matched 
Male 1455 84 1390 77 matched 
Waist to hip ratio 1320 0.94 (0.05) 1708 0.93 (0.07) 0.12 
Family history MI 354 21 183 10 <0.0001 
History of diabetes 350 21 271 15 <0.0001 
Current tobacco user 894 54 654 36 <0.0001 
 
Lipids      
Total cholesterol (mmol/l) 1650 4.60 (1.30) 1733 4.51 (1.30) 0.058 
HDL cholesterol (mmol/l) 1642 0.83 (0.24) 1167 0.88 (0.27) <0.0001 
LDL cholesterol  (mmol/l) 1734 2.97 (1.15) 1805 2.79 (1.44) <0.0001 
Apo AI (g/L) 1720 1.15 (0.26) 1807 1.26 (0.29) <0.0001 
Apo B (g/L) 1721 0.90 (0.26) 1807 0.82 (0.25) <0.0001 
Triglycerides (mmol/L)
‡
 1736 1.62 ( 1.14-2.28) 1805 1.62 ( 1.16-2.27) 0.82 
 
Inflammatory markers      
Albumin (g/L) 1736 47 (8) 1807 50 (7) <0.0001 
 
Ethnicity      
Urdu 844 49 869 48 
Punjabi 284 16 252 14 
Other 608 35 686 38 
0.062 
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Table 6.2: Cross-sectional correlates of lipoprotein(a) levels in controls 
 
Variables 
Pearson correlation 
r (95% CI)┼‡ 
Percentage difference (95% 
CI) in Lp(a) levels per 1 SD 
increase or compared to 
reference category‡ 
z values‡ 
Age (yrs) -0.01 (-0.05 to 0.04) -1% (-6 to 5) -0.3 
Waist to hip ratio -0.05 (-0.10 to -0.00) -6% (-12 to -0) -2.1* 
BMI (kg/m2) -0.03 (-0.08 to 0.02) -4% (-9 to 2) -1.2 
SBP 0.04 (-0.01 to 0.09) 5% (-1 to 11) 1.6 
Sex    
    Male  Ref Ref 
    Female  4% (-9 to 19) 0.6 
Family history MI    
    No  Ref Ref 
    Yes  19% (-1 to 43) 1.9 
History of diabetes    
    No  Ref Ref 
    Yes  10% (-6 to 29) 1.2 
Tobacco use    
    Never  Ref Ref 
    Ex  7% (-11 to 30) 0.7 
    Current  14% (1 to 29) 2.1* 
 
Lipids 
   
   Total cholesterol 0.06 (0.02 to 0.11) 8% (2 to 14) 2.6* 
    HDL cholesterol  -0.06 (-0.11 to 0.00) -7% (-13 to 0) -1.9 
    LDL cholesterol 0.15 (0.11 to 0.20) 20% (14 to 27) 6.5*** 
   Apo AI  -0.01 (-0.06 to 0.04) -1% (-7 to 5) -0.5 
   Apo B 0.21 (0.16 to 0.25) 28% (22 to 35) 9.0*** 
   Triglycerides† -0.16 (-0.20 to -0.11) -17% (-22 to -13) -6.8*** 
 
Inflammatory markers 
Albumin  0.04 (-0.01 to 0.09) 5% (-1 to 11) 1.7 
 
Ethnicity 
   
    other Ref Ref  
    Urdu 0.07 (0.02 to 0.12) 18% (4 to 33) 2.7* 
    Punjabi 0.04 (-0.02 to 0.11) 13% (-5 to 34) 1.4 
 
┼Pearson correlation coefficients were calculated for continuous variables only, ‡Adjusted for age 
and sex; †Non-normally distributed variables were log-transformed 
***P<0.001, *P<0.05 
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Table 6.3:  Odds ratios for myocardial infarction per 1-SD higher log-Lp(a) levels 
with progressive adjustment for confounders 
 
 
a) Adjustment for age, sex, tobacco use, history of diabetes 
and total cholesterol† 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) Adjustment for Age, sex, tobacco use, history of diabetes, 
LDL cholesterol, HDL cholesterol and triglycerides‡ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†Analyses involved 1691 myocardial infarction cases and 1817 controls 
‡Analyses involved 1682 myocardial infarction cases and 1251 controls 
OR: odds ratios; CI: confidence intervals 
 
 
 
 
 
 
 
 
 
 
Model OR (95% CI) x2 
No adjustments 1.16 (1.09, 1.22) 24 
Age 1.15 (1.09, 1.22) 22 
plus sex 1.16 (1.09, 1.22) 23 
plus tobacco use 1.15 (1.08, 1.22) 21 
plus history of diabetes 1.14 (1.08, 1.21) 19 
plus total cholesterol 1.14 (1.07, 1.21) 19 
Model OR (95% CI) x2 
No adjustments 1.27 (1.19, 1.35) 54 
Age 1.27 (1.19, 1.35) 52 
plus sex 1.27 (1.19, 1.36) 54 
plus tobacco use 1.26 (1.18, 1.34) 48 
plus history of diabetes 1.25 (1.17, 1.34) 46 
plus LDL cholesterol 1.23 (1.15, 1.32) 37 
plus HDL cholesterol 1.22 (1.14, 1.30) 33 
plus triglycerides 1.21 (1.13, 1.29) 30 
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Figure 6.1: Mean levels of various factors by thirds of time since onset of 
myocardial infarction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: r indicates Pearson’s correlation coefficient; p-values were calculated from linear 
regression models adjusted for age and sex. Analyses involved 878 cases of myocardial 
infarction (845 for HDL-C) in which time difference between onset of chest pain and 
phlebotomy was recorded. 
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Figure 6.2: Odds ratios for myocardial infarction by time since onset of chest pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The odds ratios were not significantly different by time since onset of chest pain (p = 0.40) 
OR: odds ratio; CI: confidence interval 
 
 
 
 
 
 
 
 
 
Time since
chest pain
onset, hrs
Lp(a) value
Median (IQR), 
mg/dl
OR (95% CI)
All participants
No information 
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Figure 6.3: Odds ratio of myocardial infarction by fifths of Lp(a) concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Further adjustment for smoking status, history of diabetes and total cholesterol 
Analyses involved 1,691 myocardial infarction cases and 1817 controls; fifths were calculated in based 
on Lp(a) distribution in controls. Confidence intervals were calculated using floating variances. Sizes of 
data markers are proportional to inverse of variances. CI: confidence interval. 
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Chapter 7: Assessing the causal relevance of lipoprotein(a) to coronary 
disease using an integrative genetic study 
 
Chapter summary 
Individual participant data meta-analysis of observational epidemiological studies has 
shown that Lp(a) is continuously, independently and specifically associated with the 
risk of CHD. Integrative genetic studies can help judge whether this association is 
likely to represent a causal relationship. A nested case-control study within the EPIC-
Norfolk cohort was conducted to assess the association between circulating Lp(a) 
levels, tagging SNPs at the LPA locus and the risk of CHD in up to 2175 cases and 
2175 controls matched for age, sex and study enrolment date.  The odds ratio for 
CHD per 1-SD higher loge Lp(a) concentration, after adjustment for cardiovascular 
risk factors, was 1.37 (95% CI, 1.20-1.56).  Tagging SNPs rs10455872 and 
rs11751605 (minor allele frequency: 8% and 18%, respectively) were associated 
with 207% (95% CI, 188 - 227%) and 38% (95% CI, 31 - 46%) higher Lp(a) 
concentrations per copy of minor allele, respectively. These SNPs accounted for 35% 
and 5% of the variation in circulating Lp(a) levels, respectively, and were associated 
with an odds ratio for CHD of 1.34 (95% CI, 1.14-1.58) and 1.17 (95% CI, 1.04-
1.33), respectively. The observed SNP-CHD associations were consistent with 
expected odds ratios corresponding to the Lp(a) effect of the SNPs. The disease 
association was abolished on adjustment for Lp(a) concentration. These data 
corroborate with recent reports from genetic association studies of the LPA gene, and 
are consistent with the causal role of Lp(a) in CHD. The findings have implications for 
understanding the impact of currently available Lp(a) lowering medications such as 
niacin on cardiovascular risk reduction.  
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Background 
As presented in Chapter 5 comprehensive and detailed analysis of individual records 
on more than 126,000 participants from 36 prospective studies demonstrated that 
there are independent and continuous associations of Lp(a) concentration with the 
risk of CHD and stroke which appear to be specific for vascular outcomes.  The 
findings of independence from established cardiovascular risk factors, graded 
increase in risk with increasing concentration, specificity for vascular outcomes, and 
consistency across several studies are suggestive that Lp(a) may be a causal risk 
factor for atherosclerotic vascular diseases. However, it is not possible to make a 
definitive causal inference using these data as observational epidemiological studies 
are inherently limited by residual confounding and reverse causation.1;2 Although 
efforts were made to minimise confounding  and other potential biases (by 
harmonising data across studies, conducting only within-study comparisons prior to 
pooling, consistently adjusting risk estimates for a common set of potential 
confounders, and correcting for within-individual variation in both Lp(a) and 
confounders), observational studies cannot reliably determine whether all residual 
confounding and bias has been eliminated.3  
 
The highest level of evidence for establishing causality comes from demonstration of 
the reversibility of vascular risk in randomized controlled trials of pharmacologic 
agents that lower Lp(a) concentration.4 However, existing Lp(a)-lowering agents 
(e.g., niacin and certain cholesteryl ester transfer protein inhibitors) do not provide 
adequate tools for assessing the causality of Lp(a) as they concomitantly alter the 
levels of other lipids, such as LDL and HDL cholesterol levels.5-8 Moreover, clinical 
trials of available Lp(a)-lowering agents that are currently underway are not 
expected to report for the coming several years.9-11  
 
In the absence of definitive evidence from clinical trials, study of Lp(a)-related 
genetic variants as proxies for Lp(a) concentration provides a complementary 
approach to making causal inference.1;2;12 This approach, known as ‘Mendelian 
randomization’, utilizes Mendel’s second law of genetics which states that allocation 
of `genes’ from parents to offspring occurs randomly at conception. Study of genetic 
variants that specifically alter Lp(a) concentration can help judge causality because, 
by contrast to associations observed in traditional epidemiological studies, 
associations between  genetically mediated differences in Lp(a) concentration and 
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disease risk are not likely to be affected by confounding or reverse causation. The 
LPA gene, which codes for apo(a), has been regarded as an excellent tool for 
`Mendelian randomization experiment’ as it explains much of the population 
variation in Lp(a) concentration (Chapter 1).13-17 In particular, the copy number 
variant (CNV) that codes for the repeating kringle-4 (KIV) domain in apo(a) explains 
a considerable proportion of the genetic variation related to Lp(a). 16-18 The 
identification of the LPA gene as risk locus for CHD in a recent genome-wide 
association study (GWAS) further increases its priority for detailed investigation.19  
 
The spectrum of genetic variation in the LPA gene influencing circulating Lp(a) levels 
has not been fully characterized to date.20;21 In particular, studies of single nucleotide 
polymorphisms (SNPs) of the LPA gene have generally not involved comprehensive 
coverage of the LPA locus (typically being limited to a handful of candidate variants), 
not been adequately powered, and/or not made concomitant assessment of gene-
marker and gene-disease associations.22-28 To help advance current understanding 
about the nature of relationship between Lp(a) and vascular disease, this chapter 
presents comprehensive assessment of SNP variation at the LPA locus in a 
prospective case-control study of coronary disease in which subsets had available 
data on Lp(a) concentration. 
 
Methods 
Study design 
This report is based on a nested case-control study of participants of the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort.29 The 
EPIC-Norfolk is a prospective population-based study of 25,663 men and women 
resident in Norfolk, identified using general practice registers between 1993 and 
1997. Participants, aged between 45 and 79 years at time of baseline survey, 
completed a detailed health and lifestyle questionnaire; biophysical data were 
collected by trained nurses. Nonfasting blood samples were obtained by venipuncture 
into plain and citrate bottles. All participants had been flagged for cause-specific 
mortality by the UK Office of National Statistics and linked with the ENCORE 
database (East Norfolk Health Authority) for hospital discharge diagnoses codes 
recorded throughout England and Wales. Trained nosologists assigned the underlying 
cause of death or hospital admission based on the International Classification of 
Diseases (ICD) codes. CHD was defined as ICD-9 codes 410 to 414 or ICD-10 codes 
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I20-I25.  Between 1993 and 2006, 2175 incident CHD cases were recorded. Controls 
were selected among participants who remained free of cardiovascular disease 
during follow-up.  One control was matched to each case by age (within 5 years), 
sex and date of baseline survey (within a range of 3 months). The study was 
approved by the Norwich District Health Authority Ethics Committee, and all 
participants gave written informed consent. 
 
Biochemical analyses 
Measurements of lipoproteins and C-reactive protein were carried out on nonfasting 
serum samples collected at baseline and stored at -80oC for an average of 11 years.  
Lp(a) concentration was measured with an immunoturbidimetric assay (ITA) using 
polyclonal antibodies directed at epitopes in apo(a).  Both the assay kit and the 
standard were obtained from Denka Seiken (Niigata, Japan). (Denka Seiken is the 
only commercially available Lp(a) assay that is not sensitive to apo(a) isoform 
variation.)30 Apolipoprotein A-I and B100 levels were measured using 
immunonephelometric assay (Behring Nephelometer BNII, Marburg, Germany). High 
sensitivity C-reactive protein (hsCRP) levels were measured using an in-house 
sandwich-type enzyme linked immunosorbent assay (ELISA). Levels of oxidized 
phospholipids were measured with chemiluminescent ELISA, using a murine 
monoclonal antibody developed in Professor Tsimikas’ laboratory (University of 
California San Francisco, USA).  Total cholesterol, HDL-C and triglycerides were 
measured on fresh serum samples using a RA-1000 analyzer (Bayer Diagnostics, 
Basingstoke, UK). LDL-C values were calculated using the Friedwald formula. 
 
Tagging SNPs for the LPA gene 
To capture the variation at the LPA locus comprehensively, information from the 
published literature (identified through a systematic search of Medline: Table 7.1) 
was combined with data from two publicly available genetic resources for SNP 
tagging, HapMap V2 data (http://www.hapmap.org) and re-sequencing data from 
the SeattleSNPs initiative (http://pga.gs.washington.edu/finished_genes.html) of the 
University of Washington. In SeattleSNPs database, 117 SNPs were reported to be 
polymorphic among people of European ancestry in a region spanning 136 kb (chr 6: 
160,871–161,008,280). In HapMap V2 database, 83 SNPs were reported to be 
polymorphic among people of European ancestry in a region spanning 145 kb (chr 6: 
160,867,506–161,012,397, including 5kb flanking regions either side of the LPA 
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gene) (Figures 7.1A, 7.1B). Thirty SNPs were common between the two databases 
(Table 7.2 shows a comparison of the minor allele frequencies between the two 
databases). On literature review, 11 SNPs considered to be relevant for large-scale 
genotyping were identified based on possible functional properties or reported 
association with Lp(a) concentration and/or CHD risk.19;22-28;31-44 (Three of the 11 
SNPs were not reported to be polymorphic among the European populations in 
HapMap V2 or SeattleSNPs databases.) Tagging sets were generated sequentially 
applying standard criteria, first using data from SeattleSNPs and then HapMap V2, 
based on populations of European descent. We used the Tagger program embedded 
in Haploview to generate the tagging SNPs (tSNPs).45;46 The eleven SNPs reported in 
the literature were included in the tagging set. In total, 173 variants in the LPA gene 
were captured with a mean r2 of 0.98 using 56 tSNPs. It was not possible to design 
an assay for 14 tSNPs due to the repetitive nature of the surrounding sequence. 
Therefore eight of these SNPs were replaced with highly correlated SNPs using 
SeattleSNPs or HapMap V2 data, while 6 were uncorrelated with any other SNP and 
so alternative tSNPs could not be selected.  In addition, assays designed for two 
other tSNPs (rs1800769 and rs41266362) failed to work successfully. This left a set 
of 48 tSNPs capturing 162 variants at the LPA locus (Table 7.3). Eleven of these 
SNPs were monomorphic (or had a MAF<0.1%) in the EPIC-Norfolk population 
leaving 38 tSNPs for the current analyses. 
 
Genotyping 
Genomic DNA for the EPIC-Norfolk case-control study was whole genome amplified 
(WGA) prior to genotyping using a REPLI-g Midi Kit from Qiagen following the 
manufacturer’s instructions. WGA DNA was normalised using a Quant-iT PicoGreen 
dsDNA kit (Invitrogen). Concordance checks were conducted with genomic DNA 
using a panel of three SNPs in separate genomic locations and obtained > 95% 
concordance for these SNPs between WGA and genomic DNA.  Genotyping was done 
by KBioscience (http://www.kbioscience.co.uk) using KASPar technology. Allele 
calling was done using K-biosciences SnpViewer2 program (K-biosciences, UK). 
Cases and controls were randomly allocated across DNA study plates with two 
duplicate samples and two water controls in each 96-well plate. The overall 
concordance between duplicate samples for all the SNPs was > 99%. 
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Statistical analysis 
Baseline characteristics were compared between CHD cases and controls, using the 
Student’s t-test for continuous trait variables and using the χ2 statistic for categorical 
trait variables. Lp(a), triglycerides and CRP values were natural log transformed to 
achieve symmetrical distributions. Pearson’s correlation coefficient and linear 
regression were used to assess the correlates of circulating Lp(a) levels. The 
association between Lp(a) concentration and the risk of CHD was assessed using 
conditional logistic regression.  
 
Deviation from Hardy-Weinberg equilibrium was assessed for each tSNP in control 
participants using the χ2 statistic (tSNPs with p-value less than 0.001 were excluded 
from analyses).  In the primary test for association, linear regression of loge Lp(a) 
levels on tSNPs, adjusted for age, sex and case-control status, was performed in all 
participants assuming an additive effect of the alleles (subsidiary analyses involved 
fitting regression models separately for cases and controls and combining the 
estimates with fixed-effect model meta-regression). The p-value criteria for declaring 
significance was adjusted for multiple testing using Bonferroni correction. Twenty-
five tSNPs were relatively uncorrelated with each other (r2<0.5); accordingly the p-
value threshold was set to be 0.001 (~ 0.05 / 25). 
 
Pairwise correlation (r2) was used to assess the extent of linkage disequilibrium 
among tSNPs in control participants. A stepwise linear regression with backward 
selection method was used to determine which of the statistically significantly 
associated tSNPs had an independent effect on circulating Lp(a) levels. The starting 
model for the backward selection contained all tSNPs that showed significant 
univariate associations with Lp(a) concentration at the adjusted p-value threshold 
(p<0.001). Age, sex, case-control status and the lead tSNP were included as fixed 
terms in the stepwise regression model, and the p-value criterion for exclusion of a 
SNP from the model was 0.1. 
 
A genetic score was built using each of the SNPs having independent associations 
with Lp(a) levels.47 Before making the genetic score, the reference groups of the 
SNPs with negative correlation with Lp(a) levels were changed so that all the SNPs 
had the same directional effect. Two types of genetic scores were generated: (i) an 
un-weighted score was constructed by directly adding together the number of rare 
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alleles for each SNP, which assumes an equal and additive effect of the individual 
SNPs; (ii) a weighted score was constructed by adding the number of rare alleles for 
each SNP weighting them by the effect size. The lower confidence limit of the effect 
size was used for weighting in order to obtain conservative estimate of the weights. 
To make the values of the weighted genetic score comparable with those of the un-
weighted one, the weighted score was rescaled by multiplying by a factor involving 
the ratio of the number of SNPs and the sum of the weights (ie, k / ∑wi, where k is 
the total number of SNPs and ∑wi is the sum of the weights of the SNPs). The 
relationship of the genotype score with circulating Lp(a) levels or the risk of CHD was 
investigated using linear regression and conditional logistic regression models, 
respectively. The scores were categorized into four equal groups and individuals in 
the top fourth of the genotype score distribution were compared with those in the 
bottom fourth. (Parallel analyses using uncategorized scores yielded similar results.) 
 
To assess for the presence of haplotype associations at the LPA gene with circulating 
Lp(a) levels or risk of CHD, haplotypes were constructed for SNPs showing significant 
associations with circulating Lp(a) levels using the program TagSNPs, which uses an 
expectation-substitution approach to account for the uncertainty caused by unphased 
genotype data.  Individuals with > 50% missing genotype data were excluded; rare 
haplotypes with a frequency of < 2% were pooled together.  For a global test of 
haplotype association with circulating Lp(a) levels or CHD risk, likelihood ratio tests 
were used to compare the model with additive effects for each common haplotype  
with the intercept-only model. The association of each haplotype with circulating 
Lp(a) levels and CHD risk was estimated using  linear and conditional logistic 
regression analyses, respectively.   
 
All analyses were done using Stata 10.1 (Stata Corporation, TX, USA). 
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Results 
Lp(a) concentration and risk of CHD 
The current analyses involved up to 2175 cases and 2175 controls. Sixty-five percent 
of the participants were males, and the mean (SD) age of the participants was 64 (8) 
years. Table 7.4 shows the distribution of cardiovascular risk factors among cases 
and controls.  As would be expected, the cases had more adverse cardiovascular risk 
profiles than the control participants. For the analysis of circulating Lp(a) levels, data 
were available on 929 cases and 1290 controls. The geometric mean of Lp(a) 
concentration among the control population was 10.4 mg/dl (SD = 0.7 log mg/dl).  
Lp(a) concentration was significantly higher in cases than in controls (p<0.001).  
 
The associations of Lp(a) concentration with several established and novel 
cardiovascular risk factors / markers were assessed in linear regression models. As 
shown in Table 7.5 Lp(a) concentration was generally uncorrelated with most  
established cardiovascular risk factors. There were weak positive correlations of 
Lp(a) concentration with levels of total cholesterol, LDL-C and apo B100. Lp(a) 
concentration was 9% higher in women than in men, and 8% higher in individuals 
with a family history of myocardial infarction than in those without such history. 
Lp(a) concentration was not materially different between diabetic and non-diabetic 
individuals, smokers and non-smokers or individuals with various levels of physical 
activity. On the other hand, consistent with recent reports, Lp(a) levels were strongly 
correlated with oxidized phospholipids (r~0.7); levels increased by 66% per 1-SD 
higher oxidized phospholipids concentration. 
 
The age and sex adjusted odds ratio for CHD per 1-SD higher log-Lp(a) levels was 
1.31 (95% CI, 1.18-1.46). The corresponding odds ratio after further adjustment for 
established cardiovascular risk factors (systolic blood pressure, BMI, smoking status, 
diabetes, and LDL and HDL cholesterol) was 1.37 (1.20-1.56). 
 
Association of tagging SNPs with circulating Lp(a) levels 
Of the 38 tSNPs that were eligible for the current analyses, one tSNP (rs1853021) 
showed deviation from Hardy-Weinberg equilibrium (p<0.001) and so was excluded 
from further analysis. Twenty-three tSNPs, with minor allele frequency (MAF) ranging 
between 0.4% and 50% in the controls, were statistically significantly associated 
with Lp(a) concentration at the 10-3 level of significance (Table 7.6). The effect of 
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the SNPs ranged between 10% and 200% change in Lp(a) concentration, accounting 
for 0.5% to 35% of the variation in circulating Lp(a) levels (Table 7.6).  Four SNPs 
(rs10455872, rs3798220, rs41272112, rs11751605) with MAF of 8.2%, 1.6%, 0.4% 
and 17.6%, respectively, were associated with 207% (95%CI, 188 to 227%), 211% 
(162 to 269%), 99% (45 to 174%), and 38% (31 to 46%) higher Lp(a) 
concentration, respectively. Five other SNPs (rs41259144, rs41272114, rs41265930, 
rs9457938, rs6919346) with MAF of 1.0%, 3.5%, 7.3%, 16.1% and 15.9%, 
respectively, were associated with 36% (21 to 49%), 26% (17-35%), 25% (18-
31%), 21% (16 to 25%) and 21% (16 to 25%) lower Lp(a) concentration, 
respectively. The associations observed in the overall analyses were consistent with 
findings from subsidiary analyses conducted for cases and controls separately.  
 
On stepwise regression with backward selection (p-value for eligibility = 0.05, p-
value for removal=0.1), 11 of the 23 tSNPs with significant univariate associations 
with Lp(a) concentration were found to have independent effects (Table 7.7). 
Together, the 11 tSNPs accounted for 49% of the variation in Lp(a) concentration. 
The combined effect of the 11 tSNPs on Lp(a) concentration was assessed using two 
types of genetic scores (ie, un-weighted and weighted scores). (The distribution of 
the genetic scores in the study population is shown in Figures 7.2A, 7.2B.) Lp(a) 
levels increased continuously across the quantiles of the genetic scores (Figure 7.3). 
Individuals in the top fourth of the gene score distributions had 117% (101-135%) 
higher Lp(a) levels when compared with those in the bottom fourth. (Results were 
similar for the weighted and un-weighted scores.) 
 
The 11 independent tSNPs that were selected with stepwise regression were 
assessed for the presence of any haplotype effect on Lp(a) concentration. These 
SNPs defined 11 haplotypes with frequency greater than 2%. The global test for 
haplotypic effect on Lp(a) concentration was highly statistically significant (p = 
3.14x10-177). The haplotype containing the minor alleles of tSNPs rs10455872, 
rs10755578, rs11751605 showed the strongest association with Lp(a) concentration 
(3-fold increase in Lp(a) level, p = 7.85x10-159: Table 7.8).   
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Association of tagging SNPs with CHD risk factors 
Tables 7.9A, 7.9B show the relationships of tSNPs rs10455872 (the lead SNP) and 
rs11751605 with several established CHD risk factors. Unlike circulating Lp(a) levels, 
which showed a degree of correlation with some of the CHD risk factors (eg, LDL 
cholesterol, apo B100), the tSNPs were not materially associated with the known 
cardiovascular risk factors.  On the other hand, oxidized phospholipids levels were 
materially higher among carriers of the rare alleles of either of the tSNPs. In addition 
the rs10455872 variant was associated with significantly higher LpPLA2 
concentration.  
 
Association of tagging SNPs with CHD risk 
The association between the 23 tSNPs with significant effect on Lp(a) concentration 
and the risk of CHD was assessed in up to 1649 cases and 2249 controls. The 
observed SNP-CHD risk associations were generally directionally consistent with the 
SNP-Lp(a) concentration associations (Figure 7.4). The odds ratios for CHD per copy 
of minor allele for tSNPs rs10455872, rs11751605, and rs9457938 were: 1.34 (95% 
CI, 1.14 to 1.58), 1.17 (1.04 to 1.33), and 0.84 (0.75 to 0.95), respectively (Table 
7.6). Based on the EPIC-Norfolk data on the association between circulating Lp(a) 
levels and the risk of CHD (described above), the expected odds ratios for 207% and 
38% higher, and 21% lower Lp(a) concentration (i.e., changes corresponding to the 
effects of rs1045587, rs11751605 and rs9457938) were 1.61 (1.31 to 1.98), 1.15 
(1.08 to 1.22) and 0.91 (0.87 to 0.95), respectively (Figure 7.5). In a subset of 
participants that had information on Lp(a) and oxidized phospholipids (661 CHD 
cases and 661 controls), rs10455872 was associated with 1.62 (1.21 – 2.16),  higher 
risk of CHD per copy of minor allele. This association was abolished on adjustment 
for baseline Lp(a) concentrations (OR: 1.10; 95% CI, 0.78-1.56). The association 
was significantly attenuated when baseline concentration of oxidized phospholipids 
was alternatively included in the model (OR: 1.39; 1.02-1.89) 
 
The association between the genetic scores constructed using the 11 independent 
tSNPs (described above) and the risk of CHD was assessed in logistic regression 
models. The risk of CHD increased continuously across the quartiles of the gene 
scores (Figure 7.6). The odds ratio for CHD in comparison of individuals in the top 
fourth of the genetic risk score distributions with those in the bottom fourth (which 
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correspondence to a 117% higher mean Lp(a) concentration) was 1.32 (95% CI, 
1.11 to 1.57).  
 
The global test for haplotypic association between the 11 independent tSNPs and the 
risk of CHD was statistically significant (p = 0.034). The haplotype with the strongest 
effect on Lp(a) concentration (i.e., haplotype containing the minor alleles of tSNPs 
rs10455872, rs10755578, rs11751605) also showed the strongest association with 
CHD risk (OR = 1.28, p =0.01; Table 7.8).   
 
Discussion 
This present study presents the most comprehensive analysis of Lp(a) concentration, 
CHD risk, and SNP variants at the LPA locus. Using data on up to 2175 CHD cases 
and 2175 age and sex matched controls I identified 23 tSNPs in the LPA gene with a 
significant effect on Lp(a) concentration. Eleven tSNPs with an independent effect in 
a multivariable model accounted for 50% of the variation in Lp(a) concentration. 
Eight tSNPs were significantly associated with CHD risk and comparison of the 
observed odds ratios with those expected based on SNP-Lp(a) and Lp(a)-CHD 
associations suggested the existence of a causal relationship between circulating 
Lp(a) levels and the risk of CHD. While these findings are consistent with the recent 
report by Kamstrup et al, where the authors applied a Mendelian randomization 
framework to analyse the KIV repeat polymorphism at the LPA locus in relation to 
Lp(a) concentration and CHD risk, the present study usefully complements the 
previous one by extending the analyses to a comprehensive set of SNPs.48;49   
 
In particular, the tagging SNP rs10455872 (MAF, 8%) was associated with over 
200% higher Lp(a) concentration per copy of minor allele, explaining 35% of the 
variation in circulating Lp(a) levels. The corresponding odds ratio for CHD (1.34; 
95% CI, 1.14 to 1.58) was consistent with that expected based on the SNPs effect 
on Lp(a) concentration (1.61; 95% CI, 1.31 to 1.98). The observed disease 
association was abolished on adjustment for Lp(a) concentration demonstrating that 
the CHD effect of the SNP is mediated by Lp(a). Despite its important association 
with both Lp(a) concentration and CHD risk the SNP has not been described to date 
as previous studies did not measure the variant. The strength of the observed signal 
and the lack of strong correlation with neighbouring SNPs suggests that rs10455872 
may be a causal variant. However, located in the intronic region of the LPA gene, the 
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mechanism underlying the effect of this synonymous SNP on Lp(a) concentration 
remains unclear. While the SNP may be in linkage disequilibrium with the KIV2 
repeat polymorphism, 50;51 the observed 3-fold increase in Lp(a) concentration is 
unlikely to be fully explained by correlation with a short KIV2 repeat only. Further 
fine mapping of the region and functional studies will help to elucidate the potential 
mechanisms underlying the observed association. Carriers of the rs10455872 mutant 
alleles had 2-fold higher concentrations of oxidized phospholipids. The association of 
rs10455872 with CHD attenuated significantly on adjustment for oxidized 
phospholipid levels. These findings are consistent with the strong correlation 
observed between Lp(a) concentration and oxidized phospholipids,52;53 and suggest 
that oxidized phospholipids may play a role in the relationship between Lp(a) and 
coronary disease (Chapter 9).  The differential attenuation of the association on 
adjustment for baseline Lp(a) or oxidized phospholipid concentrations may indicate 
differences in the biological importance of the factors in mediating the SNP’s effect, 
or may be due to differences in within-person variability of the factors (Chapter 9). 
 
The association between LPA gene SNPs and circulating Lp(a) levels may be 
mediated by various mechanisms: (i) some of the SNPs may be in linkage 
disequilibrium with the KIV repeat polymorphism which has been shown to explain 
approximately 50% of the genetic variation in Lp(a) concentration; (ii) certain SNPs 
may directly influence the transcriptional and/or translational processes of the LPA 
gene (for example,  rs41272114, which is located at the splice donor site for KIV 
type 8, alters the splicing of the LPA gene transcript leading to the synthesis of a 
short non secreted protein);36 and (iii) some non-causal SNPs may be in linkage 
disequilibrium with SNPs having causal effect on Lp(a) concentration. Therefore, the 
associations observed in the present study are likely to represent, in part, the direct 
effect of the genotyped SNPs, and in part, the effect of other unmeasured correlated 
variants in the region. 
 
Combination of information from several independent SNPs using genetic scores or 
haplotype analyses yielded consistent results with those of the individual SNP 
analyses. Lp(a) concentration and the risk of CHD increased comparably across 
quantiles of the genetic score. Similarly, haplotypes that were significantly associated 
with Lp(a) concentration showed comparable associations with CHD risk. The 
consistency of findings between the individual and the combined SNP analyses 
 193 
indicates the robustness of the conclusion that Lp(a) is likely to play a causal role in 
CHD. Determining the nature of the association between Lp(a) and CHD is useful for 
understanding the aetiology of coronary disease and provides novel approaches to 
reducing cardiovascular risk. As existing lipid lowering medications such as niacin 
and anacetrapib reduce Lp(a) levels by up to 20-40%, the current findings will have 
implications for understanding the cardiovascular effect of these agents.6;7 
 
The strengths and limitations of the present study merit consideration. This is the 
first study to perform comprehensive analyses of SNPs at the LPA locus using 
information from multiple genome databases and reported data in the literature for 
selection of the genotyped SNPs. Accordingly, we were able to describe several SNPs 
with a material effect on Lp(a) concentration that have not been previously described 
in the literature. Second, we prospectively determined the association between Lp(a) 
concentration and the risk of CHD within the same study, which allowed us to make 
a within-study comparison of gene-marker, gene-disease and marker-disease 
associations providing an un-biased dataset for `Mendelian randomization’. Third, 
levels of several established and novel cardiovascular risk factors have been 
measured in the EPIC-Norfolk study allowing optimal adjustment for confounders in 
assessing the Lp(a)-CHD associations, and detailed investigation of the correlates of 
circulating Lp(a) levels and those of LPA gene variants. 
 
Regarding the limitations, first, as the current analyses is based on data from a 
single study involving approximately 2000 CHD cases, there was not sufficient power 
to determine the CHD associations of several SNPs with modest effect on Lp(a) 
concentration. Expansion of the current analyses to a larger population subset should 
enable a more powerful test of associations, and provide an opportunity to determine 
the replicability of positive findings. Second, lack of concomitant measurement of the 
KIV repeat polymorphism did not allow assessment of its role in the observed SNP 
associations. Third, as the data are solely based on people of European descent, it is 
not clear whether the findings will hold true for other populations such as South 
Asians and Blacks. Fourth, complete coverage of the LPA gene was not possible as 
several tSNPs were left unmeasured due to technical difficulties (eg, location in a 
repeat region) or because they were not sufficiently polymorphic in the study 
population (ie, MAF<0.1%). However, the present study presents the most 
comprehensive analyses to date of the LPA locus using a SNP tagging approach. A 
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large-scale study of Lp(a) concentration, SNPs at the LPA locus, and the KIV2 repeat 
polymorphism, involving several thousands of participants of European and South 
Asian ancestry, is currently underway and should help to provide a more definitive 
data on the determinants of Lp(a) concentration and the nature of the relationship 
between Lp(a) and vascular disease (Chapter 10). (Concomitant genotyping of SNPs 
at LPA locus and the KIV2 CNV is likely to yield fruitful results, as a recent study has 
demonstrated an additive effect of the two in explaining Lp(a) variation.)51 
 
Clarke et al recently reported comparable results to the present study using a novel 
gene chip analysis of Lp(a) levels among 3145 CHD cases and 3352 controls from 
the Precocious Coronary Artery Disease (PROCARDIS) study.50;54 The study, 
published after completion of the write-up of this chapter, identified LPA variants 
associated with both an increased Lp(a) concentration and an increased risk of 
coronary disease. The identified genetic variants are the same as those described in 
this chapter further highlighting the robustness of the findings. 
 
Conclusion 
The present study showed that single nucleotide polymorphisms with material effects 
on Lp(a) concentration were significantly associated with the risk of CHD. The data 
are consistent with the a causal role of Lp(a) in CHD, and have implications for 
understanding the impact of currently available Lp(a) lowering medications such as 
niacin on cardiovascular risk reduction. 
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Table 7.1: Description of 16 SNPs in / near the LPA gene identified through 
literature search† 
 
No Location  ( 5'——3') Common name rs number MAF 
1 PLG-LPA inter-gene region ‡ -1712  g>t rs7760010 NA 
2 PLG-LPA inter-gene region ‡ -1617 c>a rs7758766 NA 
3 PLG-LPA inter-gene region ‡ -1557 a>t NA NA 
4 PLG-LPA inter-gene region ‡ -1230 a>g rs9347440 NA 
5 5' flanking sequence -914 g>a  (aka -772 g>a) rs1800589 0.53 
6 Near transcription start site -49 c>t (aka +93 c>t) rs1853021 0.18 
7 5' UTR -21 g>a  (aka  +121 g>a) rs1800769 0.2 
8 Kr 4 type-7 exon 2 L/V3847* rs7765803 0.36 
9 Kr 4 type-7 exon 2 L/V3861* rs7765781 0.36 
10 Kr 4 type-8 exon 1 T3888P rs41272110 0.15 
11 Kr 4 type-8 exon 1 R3910Q rs41272112 0.02 
12 Kr 4 type-8   intron 1, +1 g>a +1 in KIV-8 rs41272114 0.04 
13 Kr 4 type-10 intron 2 NA rs10755578 0.48 
14 Kr 4 type-10 exon 2 M4168T rs1801693 0.39 
15 Intronic NA rs7767084 0.14 
16 Protease-like domain I4399M rs3798220 0.03 
 
† SNPs studied in relation to Lp(a) concentration and/or coronary disease among people of 
European ancestry were identified through a systematic search of literature through March 
2009: 11 were included in the tagging SNP set (4 were difficult to genotype due to 
location in repeat region, 2 were in perfect linkage disequilibrium); ‡ Located in a long 
interspersed nuclear element 20 kb upstream of the LPA gene - genotyping was not 
possible; *these SNPs are in perfect linkage disequilibrium - rs7765803 arbitrarily selected 
for genotyping. M4168T, also reported as Met/Thr KIV 37, Thr/Met KIV 10, or T/C +12 
605. MAF: minor allele frequency in Europeans as reported in NCBI dbSNP; NA: not 
available; Kr: Kringle; UTR: untranslated region 
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Table 7.2:  Comparison of minor allele frequencies† of polymorphisms which 
were common to both SeattleSNPs and HapMap databases. 
  
 
 † Minor allele frequency in Europeans as reported in NCBI dbSNP 
‡ The chromosome locations are based on HaMap data Re/ 22 / Phase II, April 2007, on 
NCBI B36 Assembly, dbSNP b126 
 
Minor allele frequency† 
No. 
Reference 
SNP number 
Chromosome 
location‡ SeattleSNPs HapMap 
1 rs3127596 160873025 0.30 0.31 
2 rs6919346 160880349 0.21 0.18 
3 rs7767084 160882493 0.11 0.14 
4 rs11751605 160883220 0.15 0.14 
5 rs1801693 160889619 0.39 0.28 
6 rs3798221 160918138 0.22 0.18 
7 rs6455689 160926978 0.36 0.31 
8 rs7765781 160927486 0.36 0.33 
9 rs7765803 160927528 0.36 0.33 
10 rs7771801 160928105 0.37 0.32 
11 rs10455872 160930108 0.04 0.08 
12 rs7453899 160930756 0.37 0.33 
13 rs6921516 160935752 0.37 0.32 
14 rs9456552 160937110 0.39 0.39 
15 rs6913833 160937441 0.39 0.37 
16 rs6926458 160939856 0.24 0.26 
17 rs9365179 160944838 0.41 0.37 
18 rs6902102 160945278 0.39 0.37 
19 rs6932014 160946505 0.34 0.38 
20 rs7770685 160989643 0.19 0.24 
21 rs10945682 160989931 0.39 0.38 
22 rs1569933 160991202 0.39 0.38 
23 rs1321196 161001832 0.38 0.38 
24 rs1652507 161002451 0.18 0.13 
25 rs1367211 161002685 0.16 0.30 
26 rs1367210 161002789 0.18 0.13 
27 rs1367209 161002837 0.18 0.31 
28 rs1321195 161004146 0.17 0.17 
29 rs9346833 161004632 0.48 0.43 
30 rs783148 161007859 0.17 0.17 
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Table 7.3: A list of 56 SNPs proposed to be genotyped in Lp(a) genetics studies 
 
No. 
Tagging SNPs in 
SeattleSNPs 
No. 
Tagging SNPs 
in HapMap 
No. 
Tagging SNPs 
in both  
1 rs41265930 34 rs1358754 49 rs10455872 
2 rs9346833 35 rs4708871 50 rs11751605 
3 rs1800769† 36 rs6415084‡ 51 rs1321196 
4 rs1853021 37 rs6455697 52 rs1367211 
5 rs3124784 38 rs6919346 53 rs1801693 
6 rs3798221 39 rs6939089‡ 54 rs3127596 
7 rs41259144 40 rs12175867 55 rs7765803 
8 rs41264334 41 rs783149 56 rs7767084 
9 rs41265938* 42 rs9355816   
10 rs41266352* 43 rs9364559   
11 rs41266362† 44 rs9365200   
12 rs41266375 45 rs9457933   
13 rs41266379 46 rs10755578   
14 rs41266381 47 rs3798220   
15 rs41266385* 48  rs9457937   
16 rs41269133*     
17 rs41272130     
18 rs41269864*     
19 rs41269872     
20 rs41269886     
21 rs35600881     
22 rs41270978     
23 rs41270982     
24 rs41270990     
25 rs41271030*     
26 rs41272078     
27 rs9347407     
28 rs41272110     
29 rs41272112     
30 rs41272114     
31 rs41272120     
32 rs9365169     
33 rs9457938     
 
† It was not possible to design a successfully working assay for this SNP; ‡These SNPs are 
located in a repeat region; no replacement SNP was found for them, but an ABI pre-designed 
assay is available; *These SNPs are located in a repeat region, and neither a replacement SNP 
nor an ABI pre-designed assay is available for them 
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Table 7.4: Baseline characteristics cases and controls in EPIC-Norfolk 
 
Summary Statistics 
Cases Controls 
Variable 
N Mean (SD) 
or % 
N Mean (SD) 
or % 
Log-Lp(a) (mg/dl) 929 2.52 (0.78) 1290 2.34 (0.68) 
Age* 2175 65 (8) 2175 64 (8) 
Sex*     
    Male 1412 65% 1412 65% 
    Female 763 35% 763 35% 
Smoking history     
    Current 310 14% 171 8% 
    Former 1134 53% 1088 51% 
    Never 708 33% 892 41% 
Diabetes history     
    Yes 123 6% 42 2% 
    No 2049 94% 2132 98% 
Physical activity     
    Inactive 907 42% 717 33% 
    Moderately inactive 548 25% 605 28% 
    Moderately active 419 19% 461 21% 
    Active 301 14% 392 18% 
Family history of MI     
    Yes 959 44% 766 35% 
    No 1213 56% 1409 65% 
 
Biophysical markers 
    
Systolic blood pressure (mmHg ) 2171 144 (19) 2172 138 (17) 
Body mass index (kg/m2) 2174 27 (4) 2172 26 (4) 
Waist-hip ratio 2171 0.90 (0.08) 2173 0.89 (0.09) 
 
Lipid markers 
    
Total cholesterol (mmol/l) 2105 6.5 (1.2) 2132 6.3 (1.2) 
LDL cholesterol (mmol/l) 1982 4.23 (1.04) 2056 4.04 (1.00) 
HDL cholesterol (mmol/l) 1980 1.28 (0.37) 2056 1.38 (0.40) 
Log-triglycerides (mmol/l) 2105 0.65 (0.50) 2132 0.51 (0.51) 
Apolipoprotein B (mg/dL) 1102 139 (33) 1382 129 (31) 
Apolipoprotein A1 (mg/dL) 1042 155 (29) 1302 161 (28) 
 
Inflammatory markers 
    
Log-C-reactive protein (mg/L) 1195 0.85 (1.18) 1477 0.40 (1.13) 
Plasma fibrinogen (g/L) 2042 3.17 (0.83) 2063 2.98 (0.74) 
White blood cell count (103/µl) 1594 6.9 (1.9) 1632 6.5 (1.7) 
Lp-PLA2 activity (nmol/min per ml) 1219 54 (17) 1494 51 (15) 
OxPL/apoB (relative light units) 929 3055 (3820) 1290 2550 (3204) 
 
Note: P-value for case-control difference <0.001 for each variable (except for matching 
variables); *Participants were matched on age and sex; MI: myocardial infarction 
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Table 7.5: Correlations between Lp(a) concentration and several established and emerging 
cardiovascular risk factors 
 
 
†Percentage change in Lp(a) levels per 1-SD increase in the row variable (or for categorical variables, the 
percentage difference in mean Lp(a) levels for the category versus the reference) adjusted for sex and age 
Variable 
No of 
subjects 
Mean (SD) or 
% 
Pearson correlation 
 r (95% CI) 
Percentage difference 
(95% CI) in Lp(a) 
levels per 1 SD 
increase or 
compared to 
reference category† 
Log-Lp(a) 2219 2.42 (0.73)   
Age 2219 65 (8) 0.00 (-0.04 to 0.04) -1% (-4 to 2) 
Sex     
    Male 1440 65%  Ref. 
    Female 779 35%  9% (2 to 16) 
Smoking history     
    Never 809 37%  Ref. 
    Former 1153 52%  -2% (-6 to 16) 
    Current 235 11%  5% (-6 to 15) 
Diabetes history     
    No 2135 96%  Ref. 
    Yes 82 4%  6% (-10 to 20) 
Physical activity     
    Inactive 823 37%  Ref. 
    Moderately inactive 602 27%  -9% (-16 to -1) 
    Moderately active 440 20%  -7% (-15 to 1) 
    Active 354 16%  -5% (-13 to 5) 
Family history of MI     
    No 1331 60%  Ref. 
    Yes 887 40%  8% (2 to 13) 
 
Biophysical markers 
    
Systolic blood pressure (mmHg) 2215 140 (18) -0.05 (-0.09 to -0.01) -3% (-6 to 0) 
Body mass index (kg/m2) 2216 27 (4) -0.02 (-0.07 to 0.02) - 2% (-5 to 1) 
Waist-hip ratio 2216 0.89 (0.08) -0.06 (-0.10 to -0.01) -3 % (-7 to 2) 
 
Lipid markers 
    
Total cholesterol (mmol/l) 2193 6.4 (1.2) 0.13 (0.09 to 0.17) 9% (6 to 13) 
LDL cholesterol (mmol/l) 2093 4.12 (1.02) 0.15 (0.10 to 0.19) 11% (8 to 15) 
HDL cholesterol (mmol/l ) 2091 1.34 (0.39) 0.01 (-0.03 to 0.06) 0% (-4 to 3) 
Log-triglycerides (mmol/l) 2193 0.58 (0.50) -0.01 (-0.06 to 0.03) -1% (-4 to 2) 
Apolipoprotein B (mg/dL) 2009 132 (32) 0.11 (0.06 to 0.15) 8% (4 to 11) 
Apolipoprotein A1 (mg/dL) 1867 159 (29) 0.01 (-0.04 to 0.05) -1% (-4 to 3) 
 
Inflammatory markers 
    
Log-CRP (mg/l) 2193 0.57 (1.17) 0.05 (0.01 to 0.09) 4% (0 to 7) 
Fibrinogen (g/L) 2150 3.10 (0.77) 0.07 (0.03 to 0.11) 5%  (2 to 9) 
Leucocyte count (103/µl) 1912 6.7 (1.9) 0.00 (-0.04 to 0.05) 0% (-3 to 4) 
Lp-PLA2 activity (nmol/min/ml) 2218 52 (16) 0.05 (0.01 to 0.09) 4% (1 to 8) 
OxPL/apoB (relative light units) 2219 2762 (3483) 0.69 (0.67 to 0.72) 66% (63 to 70) 
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Table 7.6: Association with Lp(a) concentration and CHD risk of 23 tagging SNPs* in the LPA gene 
 
SNP 
N 
Total 
MAF 
 N with 
Lp(a) 
Lp(a) effect,     
% (95% CI) 
P-value for 
Lp(a) effect 
R-sq 
(%) 
 N 
Cases† 
Odds ratio 
(95% CI) 
P-value 
for OR 
rs10455872 4078 8.2  2095  207(188,227) 0.00E+00 34.9  1912 1.34(1.14,1.58) 4.67E-04 
rs3798220 4110 1.6  2109  211(162,269) 6.93E-39 7.3  1943 1.24(0.87,1.77) 2.32E-01 
rs11751605 4050 17.6  2083  38(31,46) 3.69E-28 5.4  1888 1.17(1.04,1.33) 9.41E-03 
rs3124784 3929 28.5  2027  22(16,29) 2.08E-15 2.9  1781 1.08(0.97,1.21) 1.40E-01 
rs35600881 4042 21.2  2073 -19(-24,-15) 5.08E-15 2.8  1883 0.96(0.86,1.08) 4.96E-01 
rs9457938 4001 16.1  2049 -21(-25,-16) 7.53E-15 2.8  1841 0.84(0.75,0.95) 7.15E-03 
rs6919346 3925 15.9  2022 -21(-25,-16) 8.12E-15 2.8  1772 0.83(0.73,0.94) 4.19E-03 
rs3127596 4031 31.4  2068  19(13,24) 2.54E-12 2.2  1868 1.11(1.00,1.22) 4.81E-02 
rs41265930 4082 7.3  2095 -25(-31,-18) 3.70E-11 2  1918 1.08(0.90,1.28) 4.18E-01 
rs1853021 4045 12.7  2075 -19(-24,-13) 1.99E-09 1.6  1883 1.05(0.91,1.21) 4.87E-01 
rs3798221 3932 17.8  2038 -16(-21,-11) 2.34E-09 1.6  1780 0.98(0.87,1.11) 7.59E-01 
rs10755578 3996 49.1  2046  14(9,19) 1.16E-08 1.5  1838 1.12(1.02,1.23) 1.60E-02 
rs1321196 4035 35.0  2067 -11(-15,-7) 2.53E-07 1.2  1879 0.97(0.89,1.07) 5.79E-01 
rs9347407 4035 49.3  2077 -11(-15,-7) 4.10E-07 1.2  1872 0.95(0.87,1.05) 3.12E-01 
rs41272114 4050 3.5  2066 -26(-35,-17) 4.82E-07 1.1  1892 0.83(0.65,1.07) 1.46E-01 
rs9347438 4022 44.5  2071 -11(-14,-6) 8.45E-07 1.1  1859 0.96(0.88,1.06) 4.39E-01 
rs9365200 3523 44.4  1797 -11(-15,-6) 3.29E-06 1.1  1454 0.96(0.86,1.06) 4.23E-01 
rs9346833 3952 44.6  2039 -10(-14,-6) 8.76E-06 0.9  1797 0.95(0.87,1.04) 2.78E-01 
rs9365169 3783 49.5  1945 -10(-14,-5) 1.90E-05 0.9  1649 0.87(0.79,0.96) 7.76E-03 
rs41272112 4112 0.4  2110  99(45,174) 2.00E-05 0.8  1946 1.00(0.47,2.13) 9.98E-01 
rs41259144 4101 1.0  2099 -36(-49,-21) 3.38E-05 0.8  1933 1.08(0.70,1.68) 7.22E-01 
rs7765803 4041 32.5  2075 -8(-13,-4) 2.26E-04 0.6  1884 1.00(0.91,1.11) 9.52E-01 
rs1801693 3998 30.9  2061 -8(-13,-4) 2.78E-04 0.6  1840 0.90(0.82,1.00) 4.43E-02 
 
*Of the total 37 SNPs analysed, 23 SNPs showed a significant association with Lp(a) concentration at the pre-specified 10-3 p-value 
threshold; †CHD cases were individually matched on age and sex to disease free controls in a 1:1 ratio; R-sq = R-squared value, 
refers to the proportion of variation in Lp(a) concentration that is explained by the respective SNP; MAF = minor allele frequency 
Note: The table is sorted by the p-value for the Lp(a) effect 
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Table 7.7: Result of stepwise backward regression on 23 SNPs with significant 
correlation with Lp(a) levels 
 
SNP 
Effect on Lp(a) level:  
X-fold (95% CI) 
P-value 
rs10455872 3.97(3.59,4.38) 0.00E+00 
rs3798220 2.73(2.31,3.23) 3.71E-32 
rs11751605 0.75(0.69,0.81) 1.00E-12 
rs41272114 0.75(0.67,0.84) 8.01E-07 
rs9347438 1.15(1.10,1.21) 4.30E-08 
rs1801693 1.09(1.01,1.17) 2.37E-02 
rs6919346 0.86(0.80,0.93) 8.78E-05 
rs41272112 2.69(2.06,3.51) 3.37E-13 
rs41259144 0.78(0.64,0.96) 1.79E-02 
rs3798221 0.81(0.76,0.86) 8.08E-11 
rs10755578 1.09(1.02,1.16) 1.24E-02 
Constant 6.55(4.95,8.66) 0.00E+00 
 
Note: The 11 SNPs explained 49% of the variation in Lp(a) levels. Analysis involved 
1117 individuals who had information available on Lp(a) levels and all the 23 SNPs. 
Analysis was adjusted for age, sex and case-control status. P-value for eligibility in the 
stepwise regression was 0.001 and p-value for removal was 0.05 
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Table 7.8:  LPA gene haplotype analysis results for association with circulating 
Lp(a) levels and risk of CHD. 
 
 
 
 
 
 
Haplotype Frequency Βeta (se) † P-value  OR (95% CI) ‡ P-value 
       
h00000001001 0.15 -0.28 (0.031) 1.78 x 10-18  0.85 (0.74- 0.96) 0.01 
h00000010000 0.13 -0.061 (0.035) 0.08  1.03 (0.89- 1.18) 0.72 
h10000000000 0.12 -0.006 ( 0.037) 0.87  1.01 (0.87- 1.17) 0.92 
h10000110000 0.11 -0.20 (0.039) 5.77  x10-7  1.01 (0.86- 1.18) 0.90 
h10000010100 0.07 -0.28 (0.046) 1.14 x 10-9  1.001 (0.84- 1.20) 0.99 
h00100010100 0.07 1.10 (0.038) 7.85 x 10-159  1.28 ( 1.071- 1.52) 0.01 
h00000001000 0.06 -0.009 (0.053) 0.87  1.11 ( 0.90- 1.37) 0.33 
h00000000000 0.06 -0.12 (0.055) 0.02  0.91( 0.73- 1.13) 0.40 
h10000010000 0.04 0.21 (0.074) 0.004  1.22 ( 0.91- 1.63) 0.18 
h10000001000 0.04 -0.01 (0.070) 0.86  0.74 ( 0.54 – 1.01) 0.06 
h00000110000 0.02 -0.19 (0.094) 0.04  0.95 ( 0.67- 1.34) 0.76 
Rare <0.02 each 0.07 (0.035) 0.05  1.013 ( 0.88 - 1.16) 0.85 
Global test   3.14 x 10-177   0.034 
       
In the haplotypes, 0 corresponds to the common allele for each SNP and 1 to the minor allele. 
SNP order in haplotypes is 5’-3’ of the LPA gene, as follows:  rs9347438 rs41259144 rs10455872 
rs41272112 rs41272114 rs3798221 rs10755578 rs1801693 rs11751605 rs3798220 rs6919346 
† Tests for association between haplotypes and circulating Lp(a) levels were conducted in up to 1290 
controls  and 929 cases using linear regression of log-Lp(a) concentration on each haplotype with 
adjustment for case-control status; ‡ Tests for association between haplotypes and CHD risk were 
conducted in up to 2068 cases and 2075 controls using conditional logistic regression analysis with no 
covariate adjustment. OR: Odds ratio; CI: confidence interval. 
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Table 7.9A:  Association of tSNP rs10455872 with cardiovascular risk factors 
 
rs10455872 
Common 
homozygote 
rs10455872 
Heterozygote / rare 
homozygote Variable 
No of 
subjects 
Mean (SD) or 
% 
No of 
subjects 
Mean (SD) 
or % 
P-value 
Log-Lp(a) (mg/dL) 1774 2.22 (0.59) 321 3.43 (0.55) <0.0001 
Age 3437 65 (8) 641 64 (8) 0.017 
Sex     0.78 
    Male 2234 65% 413 64%  
    Female 1203 35% 228 36%  
Smoking history     0.053 
    Current 360 11% 88 14%  
    Former 1770 52% 315 50%  
    Never 1271 37% 232 37%  
Diabetes history     0.99 
    Yes 129 4% 24 4%  
    No 3305 96% 617 96%  
Physical activity     0.21 
    Inactive 1298 38% 223 35%  
    Moderately inactive 918 27% 163 25%  
    Moderately active 687 20% 140 22%  
    Active 534 16% 115 18%  
Family history of MI     0.17 
    Yes 1340 39% 268 42%  
    No 2095 61% 372 58%  
 
Biophysical markers 
     
Systolic blood pressure (mmHg) 3431 141 (18) 640 140 (18) 0.17 
Body mass index (kg/m2) 3434 27 (4) 640 27 (4) 0.67 
Waist-hip ratio 3432 0.90 (0.09) 640 0.89 (0.08) 0.45 
 
Lipid markers 
     
Total cholesterol (mmol/l) 3350 6.4 (1.2) 625 6.4 (1.2) 0.51 
LDL cholesterol ( mmol/l) 3187 4.14 (1.02) 602 4.14 (1.01) 0.99 
HDL cholesterol (mmol/l) 3185 1.33 (0.39) 602 1.33 (0.38) 0.83 
Log-triglycerides (mmol/l) 3350 0.58 (0.51) 625 0.58 (0.50) 0.85 
Apolipoprotein B (mg/dL) 1978 133 (33) 354 135 (30) 0.49 
Apolipoprotein A1 (mg/dL) 1859 158 (28) 341 158 (28) 0.82 
 
Inflammatory markers 
     
Log-C-reactive protein (mg/l) 2126 0.61 (1.17) 386 0.61 (1.19) 0.95 
Fibrinogen 3245 3.07 (0.78) 607 3.11 (0.85) 0.23 
White blood cell count (103/µl) 2569 6.7 (1.8) 467 6.8 (1.7) 0.21 
Lp-PLA2 activity (nmol/min / ml) 2158 52 (16) 392 54 (16) 0.027 
OxPL/apoB (relative light units) 1774 2332 (3153) 321 5065 (4321) <0.0001 
 
 
 204 
Table 7.9B: Association of tSNP rs11751605 with cardiovascular risk factors 
 
rs11751605 
Common 
homozygote 
rs11751605 
Heterozygote / rare 
homozygote Variable 
No of 
subjects 
Mean (SD) or 
% 
No of 
subjects 
Mean (SD) or 
% 
P-value 
Log-Lp(a) (mg/dl) 1431 2.30 (0.66) 652 2.66 (0.81) <0.0001 
Age 2748 65 (8) 1302 64 (8) 0.026 
Sex     0.95 
    Male 1780 65% 842 65%  
    Female 968 35% 460 35%  
smoking history     0.091 
    Current 287 11% 162 13%  
    Former 1424 52% 638 49%  
    Never 1007 37% 490 38%  
diabetes history     0.98 
    Yes 110 4% 41 3%  
    No 2636 96% 1260 97%  
Physical activity     0.92 
    Inactive 1028 37% 482 37%  
    Moderately inactive 733 27% 340 26%  
    Moderately active 559 20% 267 21%  
    Active 428 16% 213 16%  
Family history of MI     0.74 
    Yes 1076 39% 517 40%  
    No 1670 61% 784 60%  
Systolic blood pressure (mmHg) 2743 141 (18) 1300 140 (18) 0.37 
Body mass index (kg/m2) 2745 27 (4) 1301 27 (4) 0.13 
Waist-hip ratio 2744 0.90 (0.09) 1300 0.89 (0.08) 0.56 
Total cholesterol (mmol/l) 2679 6.4 (1.2) 1267 6.4 (1.2) 0.54 
LDL cholesterol (mmol/l ) 2555 4.13 (1.02) 1206 4.16 (1.03) 0.36 
HDL cholesterol (mmol/l) 2554 1.33 (0.39) 1205 1.34 (0.38) 0.71 
Log-triglycerides (mmol/l) 2679 0.57 (0.51) 1267 0.58 (0.51) 0.67 
Apolipoprotein B (mg/dL) 1568 133 (33) 750 134 (31) 0.57 
Apolipoprotein A1 (mg/dL) 1482 158 (28) 706 159 (28) 0.41 
Log-C-reactive protein (mg/l) 1698 0.60 (1.16) 798 0.61 (1.18) 0.94 
Fibrinogen (g/L) 2585 3.07 (0.78) 1237 3.09 (0.82) 0.40 
White blood cell count (103/µl) 2066 6.7 (1.8) 959 6.7 (1.8) 0.43 
Lp-PLA2 activity (nmol/min/ml) 1720 52 (16) 814 52 (16) 0.55 
OxPL/apoB (relative light units) 1431 2632 (3565) 652 3058 (3368) 0.010 
 
 205 
 
 
Note:  the LD blocks shown were predicted using Haploview V4.1 (Barrett JC, 
et al. Bioinformatics. 2005). The colour scheme reflects the r-squared values. 
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Figure 7.2: Distribution of (A) raw and (B) weighted genetic scores 
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Figure 7.3: Lipoprotein(a) levels by fourths of genetic score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The weighted genetic risk score was constructed by adding 11 SNPs with independent 
effect on Lp(a) concentration identified in stepwise regression. The SNPs were weighted by 
their effect sizes. Error bars are 95% confidence intervals. Confidence intervals were 
calculated using floating absolute risk. 
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Figure 7.4: Associations of 23 tagging SNPs with Lp(a) concentration and CHD risk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The changes in Lp(a) concentration (loge mg/dl) or the odds ratio for CHD shown are for 
each additional minor allele, ie, assuming additive effect of the variants. The x-axes were 
plotted on the log-scale. Error bars are 95% Confidence intervals. 
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Figure 7.5: Comparison of observed vs. expected odds ratios for 3 tagging SNPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Expected odds ratios for the SNPs were calculated from the observed effect of the SNPs 
on Lp(a) concentration and from the observed association between Lp(a) concentration and the 
risk of CHD, within the EPIC-Norfolk study. If Lp(a) is a causal factor in CHD then it would be 
expected that such genetically elevated Lp(a) level will be associated with disease risk. 
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Figure 7.6: Odds ratios for CHD by fourths of genetic score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The weighted genetic risk score was constructed by adding 11 SNPs with 
independent effect on Lp(a) concentration identified in stepwise regression. The SNPs were 
weighted by their effect sizes. Error bars are 95% confidence intervals. Confidence 
intervals were calculated using floating absolute risk. 
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Chapter 8: Sources of lipoprotein(a) heterogeneity: apolipoprotein(a) 
isoforms and the risk of vascular disease 
 
Chapter summary 
Although Lp(a) is a likely causal risk factor in coronary disease, the magnitude of 
the observed association is modest. Hence, considerations of factors that 
potentially amplify its effect are important to enhance its usefulness in clinical 
practice. Studies have shown that smaller apo(a) isoforms are associated with 
higher Lp(a) concentration. In addition, it has been proposed that Lp(a) particles 
with smaller apo(a) isoforms may be more pathogenic than those with larger 
isoforms. Literature-based meta-analysis of data from 36 published studies showed 
that individuals with smaller apo(a) isoforms have about 2-fold higher risk of CHD 
or ischemic stroke compared to those with larger isoforms.  This relative risk (RR) 
is substantially stronger than that observed in the comparison of individuals in top 
versus bottom third of Lp(a) distribution (RR~1.3) supporting the hypothesis that 
Lp(a) particles with smaller apo(a) isoforms confer greater vascular risk.  
Individuals with small apo(a) isoforms could therefore be potentially exposed to 
two elements of Lp(a) associated risk, ie, higher Lp(a) concentration of small 
apo(a) isoform type. Further study is needed to fully characterize the relationship 
between Lp(a), apo(a) isoforms and vascular risk. 
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Background 
As discussed in Chapter 7, Lp(a) is a likely causal factor in coronary disease. 
However, as the magnitude of the association is modest (the risk associated with 
Lp[a] concentration being only about one-quarter of that for non-HDL-C)1, translation 
of these findings to clinical practice may be difficult. Such considerations might 
change if specific Lp(a) subtypes were shown to confer much higher risks. It is 
therefore important to study factors that contribute to heterogeneity in Lp(a) particles 
- such apo(a) size heterogeneity -  in relation to disease risk, to identify ways of 
amplifying the observed epidemiologic signal. In particular, it has been proposed that 
Lp(a) particles with smaller apo(a) isoforms may be more pathogenic because they 
appear to have:  1) increased capacity to bind oxidized phospholipids; 2) greater 
propensity to localize in blood vessel walls through enhanced lysine-binding ability 
and interaction with fibrin; and 3) greater thrombogenic effect through increased 
inhibition of plasmin activity.2-5  It has also been suggested that smaller apo(a) 
isoforms may act synergistically with other novel biomarkers such as small-dense LDL 
and oxidized LDL particles.2;5-7 As described in Chapter 1, the basis for apo(a) size 
heterogeneity relates to a copy number variation in one of its protein domains, 
kringle IV type 2 (KIV2), which exists in 5 to 50  identically repeated copies. This 
copy number variation confers marked heterogeneity in the molecular mass of apo(a) 
isoforms, which can range between 200 and 800kD (Table 8.1).8-10 Apo(a) is coded 
by the LPA gene, which contains a 5.6 kb long segment existing in multiple repeats 
(KIV2 repeat polymorphism) that is responsible for the apo(a) isoform variation.11;12  
 
Many studies13-17 have reported on the association of apo(a) isoform size variations 
with the risk of vascular disease. Although they have reported apparently divergent 
relative risks (RRs), these studies have tended to be small and reported wide 
confidence intervals. Their interpretation has been complicated by differences in 
relation to: (i) populations studied (e.g., people of European, Asian or African 
ancestry), as apo(a) characteristics tend to vary by ethnicity;18 (ii) methods used to 
measure apo(a) isoforms (e.g., genotypic versus phenotypic methods; and among 
the latter, quantitative versus semi-quantitative approaches); (iii) vascular disease 
outcomes recorded (e.g., myocardial infarction [MI], coronary stenosis, stroke); and 
(iv) analytical approaches used (e.g., different cut-offs chosen to define smaller 
apo(a) size). Studies have also differed in adjustment for covariates, particularly in 
relation to circulating Lp(a) concentration, higher levels of which tend to be 
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associated with smaller apo(a) isoforms.19-21 To help clarify the evidence, this chapter 
presents a systematic review and meta-analysis of epidemiological studies reporting 
on the association between apo(a) isoforms and coronary disease or ischemic stroke 
outcomes. 
 
Methods 
Study selection 
 Studies published between January 1970 and June 2009 that reported on the 
association between apo(a) isoforms and coronary or stroke outcomes were identified 
by systematic searches of MEDLINE, scanning the reference lists of original reports, 
and discussions with investigators. Electronic searches used MeSH terms and free 
texts related to vascular disease and apo(a) isoforms (e.g., “Cardiovascular ” [MeSH], 
“Lipoprotein(a)"[MeSH], "Protein Isoforms"[MeSH], “apolipoprotein(a)”, “Isoforms”, 
“coronary heart disease”, “stroke”). Studies were eligible for inclusion if they: 1) were 
broadly population based, i.e., did not select participants or controls on the basis of 
pre-existing comorbidity or cardiovascular risk factors (such as end-stage renal 
disease, diabetes or high LDL cholesterol levels); 2) had used a well-described assay 
to measure apo(a) isoforms; 3) recorded CHD (defined as MI, angina, coronary 
stenosis or revascularization) or ischemic stroke outcomes using accepted criteria (ie, 
MI using World Heath Organization or similar criteria; or coronary stenosis using 
quantitative angiography and typically defined as at least one coronary artery with 
≥50% coronary stenosis; or ischemic stroke using brain CT scan); and 4) provided 
findings that could be used to calculate an odds ratio for vascular disease. 
Retrospective and cross-sectional study designs were eligible for inclusion as apo(a) 
isoforms are determined by copy number variation in the LPA gene8;11 and are 
therefore unlikely to be altered by prevalent vascular disease. In cases of apparent 
duplicate publication, investigators were contacted to confirm whether such studies 
contained unique participants; in case of no response, the report with the greatest 
number of participants was used. The total number of publication identified and 
reasons for exclusion are summarized in Figure 8.1. Accordingly, 40 unique studies 
were included in this review. 
 
Data extraction 
The following information was extracted from each article by using a standardized 
abstraction form: study population (including population source and the sampling 
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method employed); geographical location; year of baseline survey; age range of the 
participants at baseline; percentage of male participants; mean duration of follow-up 
(for prospective studies); vascular disease outcome definition; assay methods and 
standards used; type of blood sample used; mean Lp(a) concentration at baseline; 
RR estimates for risk of CHD or ischemic stroke; cut-off level used to categorize 
apo(a) isoforms as smaller or larger; and degree of statistical adjustment for any 
potential confounders used (+ denoting no adjustment, ++ denoting adjustment for 
age, sex and some standard vascular risk factors, +++ denoting adjustment for the 
preceding plus Lp[a] concentration).  
 
Statistical analysis 
Relative risks for vascular disease were calculated by comparing individuals with 
smaller-sized apo(a) isoforms with those with larger isoforms. Cut-off levels to define 
smaller versus larger isoforms were taken as reported in each contributing study. 
Apo(a) isoforms have been reported to have a bimodal distribution in European 
populations with a trough in the distribution around 22 KIV2 repeats (approximately 
40% of the general White population has fewer than 22 repeats).18 This value has 
been used as the cut-off in most studies that used quantitative electrophoretic 
approaches to measure apo(a) isoform size (although some studies have used 
different cut-offs, eg, 25 or 27 KIV2 repeats). Studies that used semi-quantitative 
approaches generally involved comparable cut-off values. In the studies that used 
electrophoretic methods, RRs were estimated assuming a dominant effect of the risk 
phenotype, ie, by comparing people who expressed at least 1 small apo(a) isoform 
with individuals having 2 large apo(a) isoforms or who did not express apo(a). Four 
studies that used genotypic (ie, quantitative polymerase chain reaction or pulsed-field 
gel electrophoresis) methods were analysed separately because they measured the 
sum of KIV2 repeats on both alleles, which involves assumptions about additivity of 
the effects of KIV2 repeats (see Discussion).   
 
When RRs were not reported in publications, they were calculated based on the 
numbers of cases and controls falling into categories of smaller or larger apo(a) 
isoforms using Fisher’s exact method. Summary RRs for CHD or ischemic stroke were 
calculated by pooling study-specific estimates using a random effects model meta-
analysis (parallel analyses involved fixed-effect models). All analyses were performed 
using only within-study comparisons to limit possible biases. Consistency of findings 
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across studies was assessed by standard χ2 tests and the I2 statistic.22 Sources of 
heterogeneity were investigated by comparing results from studies grouped according 
to pre-specified study-level characteristics using meta-regression. Evidence of 
publication bias was assessed using funnel plots, Egger’s test,23 and by comparing 
pooled results from studies involving at least 500 CHD cases with pooled results from 
smaller studies. All analyses were performed using Stata release 10 (StataCorp, 
College Station, Texas). Statistical tests were two-sided and used a significance 
threshold of P < 0.05. 
 
Results 
A total of 40 relevant studies4;6;13;15;16;19;24-55 reporting on 58,334 individuals were 
identified (Table 8.2). Twenty-seven studies were based in Europe, 5 in East Asia, 2 
in the USA, 3 in South Asia and 2 in the Middle East; and 1 study was multinational 
(with centers in Austria, Germany, Israel, Wales, China and India). Overall, 57% of 
the participants were male, and the weighted mean age at baseline was 56 (SD 10) 
years. Thirty-six studies used electrophoresis to characterize apo(a) isoform size; of 
these, 15 compared apo(a) gel migration speed against that of apolipoprotein-B100 
(apo B100), 17 measured the number of KIV2 repeats (9 of which dichotomized the 
isoforms at 22 KIV2 repeats, while the remainder used cut-off values of 20, 25, 26 or 
27 repeats), and 4 studies measured the molecular weight of apo(a). Table 8.1 
summarises the approximate relationships between these measures. A further four 
studies used genotyping methods, characterizing apo(a) isoforms as total number of 
KIV2 repeats. 
 
Thirty studies4;6;13;15;16;19;24-48;55 that used broadly comparable phenotyping and 
analytical methods assessed CHD (7382 cases and 8514 controls). Using a random-
effects model, the combined RR for CHD was 2.08 (95% CI: 1.67-2.58) in a 
comparison of individuals with smaller versus those with larger apo(a) isoforms; the 
corresponding RR in a fixed-effect model was 1.88 (1.74-2.04; Figure 8.2). Only 3 of 
these studies, however, reported RRs adjusted for Lp(a) concentration. In these 
studies (463 CHD cases and 298 controls), the combined RR reduced from 2.26 
(1.13-4.54) to 1.48 (0.97-2.26) with such adjustment. There was evidence of 
substantial heterogeneity among the 30 studies contributing to the CHD total (I2 = 
85%, 80-89%). A considerable portion of this heterogeneity was accounted for by 
recorded study characteristics, notably differences in definitions used for smaller 
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versus larger apo(a) isoforms (which explained 53% of the observed between study 
variation, P<0.001) and type of assay method used (P=0.04; Figure 8.3). There was 
limited power to detect differences in some of the subgroups of interest; for example, 
it was not possible to explore ethnicity-related differences because most of the 
available data related to people of European continental ancestry. Analyses by study 
size, funnel plots and Egger’s test did not reveal evidence for the presence of 
publication bias (Figure 8.3 and Figure 8.4). In the 4 studies47;55 that used 
genotypic methods (3296 cases and 36,787 controls), the combined relative risk for 
CHD was 1.19 (1.06-1.33) for smaller vs. greater number of KIV2 repeat sum.  
 
Six studies49-54 that used broadly comparable electrophoretic assay methods focused 
on ischemic stroke (718 cases and 1637 controls). Using a random-effects model, the 
combined RR for ischemic stroke was 2.14 (1.85-2.97: Figure 8.5) in a comparison 
of individuals with smaller versus those with larger apo(a) isoforms; the 
corresponding RR in a fixed-effect model was 2.35 (1.86-2.97). Again, there was 
considerable heterogeneity among the studies contributing to this estimate (I2= 62%, 
8-85%). Data on ischemic stroke were too sparse to attempt subgroup analyses.  
 
Discussion 
As discussed in preceding chapters, findings from observational and genetic studies 
suggest that Lp(a) concentration is a likely causal factor in CHD, but the association 
is comparatively moderate in magnitude: that is, a RR of about 1.3 in a comparison 
of people in the top third with those in the bottom third of the population 
distribution.1 Consequently, there is interest in whether certain subtypes of Lp(a) may 
be more strongly associated with disease risk. Meta-analysis of published data from 
36 studies, involving over 18,000 participants, indicates that people with smaller 
apo(a) isoforms have about a 2-fold higher risk of CHD (and ischemic stroke) than 
those with larger proteins. This approximately relates to a comparison of people with 
22 or fewer KIV2 repeats versus those with >22 repeats (or, analogously, an apo(a) 
molecular weight of <640kD versus ≥640kD). These two groups encompass about 
40% and 60%, respectively, of the general White population,25;51;53 respectively. 
Furthermore, although the current meta-analysis focused on studies of general 
populations, associations of similar magnitude have been observed for vascular risk 
with apo(a) isoforms in high risk populations such as patients with hypertension,56 
hypercholesterolemia,30 or diabetes.57 Hence, available data encourage study of 
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apo(a) isoforms in cardiovascular risk prediction and in randomized trials of agents 
that can lower Lp(a) concentration (e.g., niacin or certain inhibitors of cholesteryl 
ester transfer protein).58;59 
 
An important limitation, however, is the general lack of adjustment for Lp(a) 
concentration in studies reporting on the association between apo(a) and CHD risk. In 
people of European continental ancestry, apo(a) isoform polymorphism contributes 
between 40% and 70% of the variation in Lp(a) concentration, with fewer number of 
KIV2 repeats being associated with higher Lp(a) concentration.
19-21 It is likely, 
therefore, that at least part of the association observed between apo(a) isoforms and 
CHD risk in the current review is mediated by Lp(a) concentration. As only three of 
the available studies had adjusted associations of apo(a) isoform with CHD for Lp(a) 
concentration, however, it remains difficult to judge to what extent the association of 
apo(a) isoforms with vascular disease depends on Lp(a) concentration.50;60 Although 
it is clear that large-scale studies of CHD are needed with concomitant assay of 
apo(a) isoforms and Lp(a) concentration, a potential difficulty is the labour-intensive 
nature of conventional methods to measure apo(a) isoforms. Furthermore, 
interpretation of data on apo(a) isoform phenotypes may be complicated by: (i) 
difficulty in detecting apo(a) isoforms with less than 15 KIV2 repeats (which 
encompass about 3% of the general White population);18 (ii) potential difficulties in 
distinguishing heterozygotes with similarly sized isoforms; and (iii) potential 
difficulties in distinguishing between non-expressed alleles and homozygous 
phenotypes. One approach to address these limitations is to use supplementary 
information on KIV2 repeat polymorphisms in the LPA gene, such as by employing 
real time PCR assays (an approach that also facilitates higher-throughput assay).61 
Use of this genotypic approach alone, however, is potentially limited because it 
measures the sum of KIV2 repeats in both alleles (rather than the number of repeats 
in each allele), which implies an additive effect of the number of repeats. This 
assumption is inconsistent with observations that different KIV2 repeats are not 
equally expressed: for example, alleles with fewer than 22 KIV2 repeats are 
expressed in over 90% of individuals, whereas those with >22 repeats are expressed 
in about 50% (with the expression rate decreasing as the number of repeats 
increases).17 Hence, this genotypic approach to apo(a) isoform assessment may be 
liable to important misclassification of isoform size categories, potentially leading to 
underestimation of the true associations. Such assay considerations could account for 
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the considerably lower RRs for CHD seen in the current analysis with studies that 
used real time PCR compared with those that used conventional electrophoretic 
methods. More generally, analytical and assay differences between available studies 
accounted for much of the heterogeneity noted in the current analysis. Hence, further 
work is needed to optimise approaches to apo(a) isoform assessment in large studies.  
 
Although this literature-based meta-analysis has provided the most comprehensive 
assessment yet of apo(a) isoforms and risk of vascular disease, it has relied on 
aggregated published data. As such it was not possible to adjust consistently for 
potential confounding factors, nor investigate vascular medication usage. Large new 
studies are, therefore, needed to evaluate potentially important features of this risk 
relationship, such as the shape of any dose-response curve and, most importantly, 
the extent of independence of apo(a) isoforms from Lp(a) concentration. It is not 
possible to discount completely the influence of selective reporting on the current 
review, despite the lack of strong evidence for publication bias. For example, it may 
be that in some studies cut-off levels for apo(a) isoform size were chosen only after 
exploration of the data. Although apo(a) isoforms are determined by copy number 
variation in the LPA gene (and hence not likely to be affected by cardiovascular 
disease status), the retrospective design of many of the studies included in this 
review could be a source of other types of biases, such as selection bias. Evaluation 
of apo(a) isoforms in prospective studies in the future will provide more robust data.  
In addition, there is a need for detailed phenotyping of participants to help assess 
potential joint effects of apo(a) isoforms with circulating levels of small-dense LDL 
and oxidized phospholipids.2;5-7 As Lp(a) concentrations tend to vary considerably 
across different ethnic groups,36;62 further studies are needed in nonwhite populations 
(such study is currently underway in South Asians using blood samples obtained from 
participants of the Pakistani Risk of Myocardial Infarction Study: Chapter 10).  
 
Conclusion 
People with smaller apo(a) isoforms have about a 2-fold higher risk of CHD or 
ischemic stroke than those with larger proteins. Further study is needed to fully 
characterize the relationship between Lp(a), apo(a) isoforms and vascular risk. 
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Table 8.1: Relationship between various approaches used to express 
apo(a) isoform sizes. 
 
Apo(a) isoform size expressed as: 
No. of KIV2 repeats Gel migration speed Molecular weight  
11-13 F < 400 kD 
14-16 B 460 kD 
17-19 S1 520 kD 
20-22 S2 580 kD 
23-25 S3 640-655 kD 
> 25 S4 > 700 kD 
 
kD denotes kilodaltons; For gel migration speed, F denotes mobility 
faster than apo B100, B denotes mobility equal to apo B100, and S1-
S4 denote different levels of mobility slower than apo B100 .  
Relevant references: 17;20;24;28;38;41;63 
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Table 8.2:  Summary of 40 epidemiological studies that assessed the association between apolipoprotein(a) isoforms and the risk of 
cardiovascular disease. 
 
Study Country Male % Age 
N 
cases 
N 
controls 
Case definition 
Blood 
sample 
Apo(a) method † Comparison‡ (cut point) 
Studies of coronary heart disease that used phenotyping methods 
Kraft, 1996 Austria 80 51 69 69 MI, CAD Plasma SDS-PAGE § KIV repeat (20) 
Klausen, 1997* Denmark 100 Ns 74 190 MI,  AP Plasma SDS-PAGE Migration speed (S2) 
Emanuele, 2004 Italy 65 65 83 94 MI,  AP Plasma SDS-Agarose KIV repeat (25) 
Parlavecchia, 1994 Italy 100 <55 83 96 MI, CAD Plasma SDS-PAGE Migration speed (S2) 
Martin, 2002 Spain 100 < 50 91 99 MI Plasma SDS-Agarose KIV repeat (25) 
Simo, 2001 Spain 100 <50 95 95 MI Plasma SDS-Agarose § KIV repeat (22) 
Geethanjali, 2002 India Ns 53 104 104 CAD Plasma SDS-Agarose Migration speed (S2) 
Qin, 1995 China Ns Ns 105 102 MI, CAD  ns SDS-PAGE Migration speed (S2) 
Zeljkovic, 2009 Serbia 61 56 109 102 CAD  Plasma SDS-Agarose KIV repeat (22) 
Calmarza, 2004 Spain 100 < 60 111 99 MI Serum SDS-PAGE Migration speed (S2) 
Akanji, 2000 Kuwait 73 55 128 140 MI, CABG Serum SDS-PAGE Migration speed (S2) 
Katsouras, 2001 Greece 72 61 131 33 MI, AP Plasma SDS-Agarose KIV repeat (26) 
Gazzaruso, 1997 Italy 83 60 142 264 MI, CAD, AP CABG Plasma SDS-Agarose Molecular weight (640 kD) 
Sandholzer, 1991 Singapore 80 58 162 210 CAD Plasma SDS-PAGE Migration speed (S2) 
Sandholzer, 1991 Singapore 80 58 193 189 CAD  Plasma SDS-PAGE Migration speed (S2) 
Rifai, 2004* USA 100 40-84 195 195 AP Plasma SDS-Agarose KIV repeat (22) 
Emanuele, 2004 Italy 84 55 210 105 MI, UAP Plasma SDS-Agarose KIV repeat (25) 
Gambhir, 2008 India 87 < 40 220 160 CAD  Plasma SDS-Agarose KIV repeat (22) 
Zorio, 2006 Spain 89 < 51 222 199 MI Plasma SDS-Agarose Migration speed (S2) 
Kalina, 2001 Hungary Ns ns 263 97 CAD  ns SDS-Agarose KIV repeat (22) 
Bigot, 1997 France 84 38-88 267 259 CABG Serum SDS-PAGE Migration speed (S2) 
Paultre, 2000 USA 61 56 289 283 CAD Serum SDS-Agarose § KIV repeat (22) 
Gazzaruso, 1999 Italy 88 52 335 370 MI, CAD, AP, CABG Plasma SDS-Agarose Molecular weight (640 kD) 
Emanuele, 2003 Italy 76 62 337 103 MI, CAD, AP, CABG  Plasma SDS-Agarose Molecular weight (640 kD) 
Kark, 1993 Israel 44 54 365 397 MI Plasma SDS-PAGE Migration speed (S2) 
Abe, 1992 Japan 86 50 470 465 CAD  Serum SDS-PAGE Migration speed (S2) 
Brazier, 1999 Ireland, France 100 25-64 481 519 MI ns SDS-Agarose KIV repeat (27) 
Holmer, 2003 Germany 62 51 834 1548 MI Serum SDS-PAGE KIV repeat (22) 
Sandholzer, 1992 Multi-center 86 50-59 1013 1570 CAD Plasma SDS-Agarose Migration speed (S2) 
Gazzaruso, 2001 Italy 52 59 201 358 CAD  Plasma SDS-Agarose Molecular weight (640 kD) 
Studies of coronary heart disease that used genotyping methods 
Geethanjali, 2003 India 70 52 480 254 CAD Plasma PFGE  KIV repeat  sum (55) 
Kamstrup, 2009* Copenhagen 39 55 599 8038 MI Serum QPCR KIV repeat  sum (41) 
Kamstrup, 2009 Copenhagen 39 59 986 22,265 MI Serum QPCR KIV repeat  sum (41) 
Kamstrup, 2009 Copenhagen 39 60 1231 1230 MI Serum QPCR KIV repeat  sum (41) 
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Studies of ischemic stroke 
Yingdong, 1999 China 50 67 42 85 Ischemic stroke Serum SDS-PAGE Migration speed (S2) 
Kronenberg, 1999* Italy Ns ns 64 826 CVD Plasma SDS-Agarose KIV repeat (22) 
Peynet, 1999 France 50 17-54 90 84 Ischemic stroke Serum SDS-Agarose KIV repeat (22) 
Zambrelli, 2005 Italy 67 70 94 188 Ischemic stroke Plasma SDS-Agarose KIV repeat (26) 
Milionis, 2006 Greece 54 77 163 166 Ischemic stroke Serum SDS-Agarose KIV repeat (27) 
Jurgens, 1995 Austria 34 51 265 288 
Ischemic  Stroke or 
TIA 
Serum SDS-Agarose Migration speed (S2) 
 
AP = angina pectoris; CAD = Coronary artery disease; CABG = Coronary Artery Bypass Graft; CHD = Coronary heart disease; CVD = Cardiovascular 
disease; MI = Myocardial infarction; ns = not stated; na = not applicable;  PFGE = Pulsed Field Gel Electrophoresis; SDS QPCR = quantitative 
polymerase chain reaction; SDS-Agarose = Sodium Dodecyl Sulfate Agarose Gel Electrophoresis; SDS-PAGE = Sodium Dodecyl Sulfate Polyacrylamide 
Gel Electrophoresis; TIA = Transient Ischemic Attack; UAP = Unstable angina pectoris; †SDS-Agarose, and SDS-PAGE refer to apo(a) isoform 
phenotyping techniques using electrophoresis, PFGE is apo(a) isoform genotyping technique using electrophoresis; ‡comparisons were made between 
individuals with small and large apo(a) isoforms expressed as  number of  KIV-2 repeats, sum KIV-2 repeats in both alleles, speed of migration on gel 
(F, B,S1, S2, S3,S4,0), molecular weight in kilodaltons (kD) or isoform size quantiles; § these studies used PFGE to validate apo(a) isoform phenotype 
measurements; * prospective studies. 
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Figure 8.1: Study flow diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†These studies reported a total of 1838 CHD cases, approximately 15% of the total included in the 
current review; ‡the number of studies exceeds the number of articles because 1 publication 
presented data from 3 studies 
 
885 citations identified in MEDLINE and 
through search of reference lists of 
relevant articles
837 excluded on basis of title, 
abstract or full text
48 relevant publications identified
40 unique studies‡ were included in 
analyses
•34 studies with coronary outcome
•6 studies with ischemic stroke outcome
2 publications were duplicates
4 studies† were not included because 
sufficient data was not provided
4 studies† used quantile-based 
comparisons and could not therefore 
be combined informatively with other 
studies
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Figure 8.2: Apolipoprotein(a) isoform size and risk coronary heart disease among 30 studies that 
used comparable phenotyping methods and analytical approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Size of data markers is proportional to the inverse of the variance in each study. CI = confidence interval; RR = 
relative risk. Assessment of heterogeneity: I2 = 85% (p<0.001). 53% of this variation was explained by the 
apo(a) isoform size comparison groups (p<0.001). †Migration speed comparisons were between individuals 
having isoforms with F, B, S1 or S2 gel mobility versus those having S3 or S4 mobility or null allele; the 
molecular weight comparisons used a cut-off value of 640 kD. Degree of adjustment: + unadjusted; ++ 
adjustment for standard risk factors (e.g. age, sex, conventional lipids); +++ adjustment for preceding plus 
Lp(a) concentration 
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Figure 8.3:    Apolipoprotein(a) isoform size and coronary heart disease risk grouped by recorded 
study level characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Size of data markers is proportional to the inverse of the variance in each study. CI = Confidence interval; MI 
= Myocardial infarction; RR = Relative risk; SDS-Agarose = Sodium Dodecyl Sulfate Agarose Gel 
Electrophoresis; SDS-PAGE = Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis; PFGE = Pulsed 
Field Gel Electrophoresis. For the ethnicity, sex and age subgroups, studies may have contributed data to 
more than one category. *P-values for heterogeneity from meta-regressions.  † Two studies contributed to 
more than 1 category of ethnicity. ‡ Two studies did not provide information on age, 2 studies provided 
information on both categories of age 
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Figure 8.4: Funnel plot – apolipoprotein(a) isoforms and CHD risk 
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Figure 8.5:   Apolipoprotein(a) isoform size and risk ischaemic stroke among 6 studies that used 
comparable phenotyping methods and analytical approaches.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Overall I2 = 62%, p-value=0.02; RR = relative risk; CI = confidence interval; Size of data markers is 
proportional to the inverse of the variance in each study. *Migration speed comparisons were between 
individuals having isoforms with F, B, S1 or S2 gel mobility versus those having S3 or S4 mobility or null 
allele. + Unadjusted; ++ adjustment for standard risk factors (e.g. age, sex, conventional lipids); +++ 
adjustment for preceding plus Lp(a) concentration. † About half of the patients had ischemic stroke or 
transient ischemic attack. ‡ Outcome included transient ischemic attack 
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Chapter 9: Sources of lipoprotein(a) heterogeneity: Oxidized LDL and the 
risk of vascular disease 
 
Chapter summary 
Oxidized LDL (OxLDL) is believed to play a role in the initiation and progression of 
atherosclerosis. The observation that oxidized phospholipids (the major components 
of OxLDL) accumulate in Lp(a) particles has led to the suggestion that the two 
markers act together in producing vascular injury. The aim of this chapter was to 
explore the relationship between OxLDL, Lp(a) and the risk of CHD using a 
systematic literature review and analyses of new prospective data. In a literature 
based meta-analysis of 10 prospective epidemiological studies (10,000 participants, 
1500 CHD cases), individuals in the top third of the distribution of baseline OxLDL 
levels had a relative risk (RR) of 1.83 (95% CI, 1.35 – 2.47) compared to those in 
the bottom third. There was evidence of important heterogeneity in the RR across 
studies likely due to differences in OxLDL assay methods, which measure different 
types of oxidative by-products. Analysis of correlation patterns by OxLDL assay 
method suggested that OxLDL-E06 might be specific for oxidized phospholipids 
(OxPL) that primarily localize in Lp(a) particles.  
 
The relationship between OxPL E06, Lp(a) and CHD risk was further assessed in a 
nested case-control subset of the EPIC-Norfolk study. OxPL E06 was highly 
correlated with Lp(a) concentration, and strongly associated with the risk of CHD 
independent of conventional cardiovascular risk factors. The magnitude of the 
observed CHD association – RR 1.91 (95% CI, 1.42-2.57) for top vs. bottom third 
comparisons – was similar to that obtained in the literature-based meta-analysis. 
This association was no longer statistically significant on adjustment for Lp(a) 
concentration. Conversely, the association of Lp(a) with the risk of CHD was 
moderately attenuated, but remained highly statistically significant, on adjustment  
for OxPL levels. Genetic variants at the LPA locus influenced OxPL and Lp(a) 
concentration in a similar manner. These data provide supportive evidence that OxPL 
E06 is a key component mediating the atherogenicity of Lp(a) particles. 
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Background 
As discussed in Chapter 8, the study of factors related to Lp(a) heterogeneity can 
help to identify circumstances in which Lp(a) particles may confer greater vascular 
risk. The blood concentration of oxidized phospholipids (OxPL) is one potential source 
of Lp(a) heterogeneity that has been recently receiving increasing attention.1-5 OxPL 
tend to accumulate in Lp(a) particles rendering them more pathogenic than the 
native particles. Lp(a) particles with greater oxidized phospholipid content are 
thought to have enhanced inflammatory and atherogenic activity.1-3;6-8 Consequently, 
it has been proposed that high levels of Lp(a) and OxPL may interact with one other 
to produce elevated vascular risk.1-3 In addition, as Lp(a) particles with smaller 
apo(a) isoforms show greater affinity for OxPL than those with larger isoforms, there 
is a further possibility of a three-way interaction between Lp(a) concentration, OxPL 
levels, and apo(a) isoform variation in the production of vascular injury.2;8;9 This 
chapter assesses the relationship between OxPL, Lp(a), and vascular risk in two 
sections. The first section is a systematic review and meta-analysis of prospective 
epidemiological studies reporting on the association between oxidized LDL and the 
risk of cardiovascular disease (OxPL are the major components of oxidized LDL). The 
second section is based on analyses of data from the EPIC-Norfolk study in a subset 
of participants with concomitant information on baseline Lp(a) and oxidized 
phospholipid concentrations, and the CHD outcome. 
 
Oxidized LDL and the risk of vascular disease: systematic review  
Oxidized LDL (OxLDL) is a general term used to denote low-density lipoprotein 
particles that contain oxidatively modified lipid (i.e., phospholipids, triglycerides, and 
cholesterol) or protein components.2;10;11 Various in vitro and in vivo studies have 
shown that OxLDL accumulates in atheromatous plaques and can induce monocyte 
chemotaxis and formation of foam cells.12;13 OxLDL has also been shown to up-
regulate pro-inflammatory genes, increase expression of matrix metalloproteinases, 
and promote platelet aggregation and thrombosis, suggesting that it plays an 
important role in the initiation, progression, and destabilization of atherosclerotic 
lesions.12;14;15  Moreover, the observation that OxPL tend to accumulate in Lp(a) 
particles has led to the suggestion that OxLDL and Lp(a) may have a synergistic 
effect on coronary risk.1-3 
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Several cross-sectional and retrospective case-control epidemiological studies have 
generally reported positive correlations between OxLDL levels and the extent of 
atherosclerotic lesions or presence of CHD.16-23 On the other hand, prospective 
evidence has been limited and less consistent.24-30 Observed differences between 
studies are thought to be mainly due to differences in: (i) OxLDL measures, and (ii) 
study populations. OxLDL can be measured using direct or indirect methods.30;31 
Direct methods quantify the amount of oxidized phospholipid contained within LDL 
particles using antibodies that recognize specific lipid oxidation products (e.g. 
oxidized phosphocholine), while indirect methods include a broad array of measures 
of LDL oxidation or oxidizability, such as autoantibodies to OxLDL and oxidized LDL 
immune complexes. Many indirect assays are not specific for LDL oxidation and not 
necessarily comparable to one other, or to the direct methods, which makes 
interpretation of results difficult.30;31 Differences between study populations may also 
contribute to inconsistencies in the findings of epidemiological studies, as OxLDL 
levels can be altered by acute coronary syndrome, revascularization procedures or 
statin therapy.4;32;33  
 
Detailed characterization of the association of OxLDL concentration with the risk of 
CHD would help to assess the potential relevance of OxLDL in coronary risk 
prediction, and as therapeutic target. It might also enable assessment of any joint-
effects of the marker with established and novel cardiovascular risk factors (e.g. 
LDL-C, Lp(a), and LpPLA2). A previous review assessed the relationship of OxLDL and 
two other novel markers with CHD, but the report on OxLDL was based on only 2 
prospective studies.34  This section presents a literature based meta-analysis of the 
association between OxLDL levels and the risk of CHD in 10 prospective studies of 
general populations. 
 
Methods 
Search strategy 
Studies published between January 1970 and August 2008 reporting on associations 
between coronary heart disease (CHD) and markers of LDL oxidation were identified  
by systematic search of electronic databases (MEDLINE and EMBASE) and scanning 
the reference lists of original reports and reviews. Electronic searches used MeSH 
terms and free text terms related to CHD and oxidized LDL (e.g. “myocardial 
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ischemia” [MeSH], “oxidized low density lipoprotein” [MeSH], “coronary heart 
disease”, “ox-LDL”).  
 
Selection criteria 
Studies were eligible for inclusion if they: i) were broadly population based, i.e., did 
not select participants or controls on the basis of pre-existing comorbidity or 
cardiovascular risk factors (such as end-stage renal disease or diabetes); ii) had 
prospective design (cohort or nested case-control); iii) measured one or more 
markers of LDL oxidation; iv) had a minimum follow-up period of 6 months; and v) 
had recorded CHD outcomes (i.e. myocardial infarction, coronary death or 
angiographic coronary stenosis).  Accordingly, of the 912 publications identified using 
the search strategy, 15 relevant studies were considered for inclusion, 10 of which 
had sufficient data available for calculation of risk estimates (Figure 9.1). In case of 
duplicate publications, the one reporting the longest duration of follow up was 
selected.  
 
Data extraction 
The following data were extracted from each report using standardized abstraction 
forms: study design, number of participants and population characteristics; assay 
method; duration of follow up; correlation coefficients between OxLDL and each of 
age, body-mass index (BMI), Lp(a), total cholesterol, LDL-C, HDL-C, triglycerides, 
and C-reactive protein; CHD case definition and number of cases; relative risks (RR) 
for CHD and degree of adjustment for potential confounders. When published data 
were not sufficient to calculate risk estimates, attempts were made to obtain 
supplementary information through correspondence with investigators of studies. Of 
the 6 studies from which supplementary information was sought, one was able to 
provide additional data not available in publications.35 One study that did not provide 
standard errors for its risk estimate;25 instead an average standard error from 
studies of similar size was used.26;35  
 
OxLDL assays 
The assay methods were classified as direct or indirect based on the OxLDL assay 
principle implemented. The direct assays used one of two anti-OxLDL antibodies: i) 
antibody 4E6, which recognizes aldehyde-modified lysine groups (OxLDL values 
measured with 4E6 show strong correlation with LDL-C concentration); or ii) 
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antibody EO6, which recognizes the phosphorylcholine head group of oxidized 
phospholipids (these measurements are independent of LDL-C levels as the OxPL 
content is normalized for apo B100 concentration in each sample, and values are 
expressed as OxPL/ApoB ratio). All but one of the studies that used indirect OxLDL 
assays measured levels of autoantibodies to OxLDL. 
 
Statistical analyses 
Correlation coefficients were combined using random-effects meta-analysis (standard 
errors of the coefficients were calculated after normalization of the distributions using 
Fischer’s z-transformation). Hazard, odds, and risk ratios were assumed to 
approximate the same underlying relationship and are collectively referred to here as 
relative risks (RRs). Reported RRs were rescaled to reflect the risk between the 
bottom and top third of OxLDL levels at baseline, assuming an approximately normal 
distribution for (raw or transformed) OxLDL values, and a log-linear relationship 
between OxLDL and the risk of CHD. To obtain the conversion factors required to 
rescale the RRs, the distance in SDs between the means of the bottom and top thirds 
was determined using the standard normal curve. Accordingly, the log risk ratio of 
CHD among individuals in the top third vs. the bottom third of baseline OxLDL 
distribution was calculated as 2.18 times the log risk ratio for a 1-SD difference in 
OxLDL values, or 2.18/2.54 times the log risk ratio for the comparison of the top and 
bottom fourths, etc. Rescaled RRs were pooled, separately for each assay type, using 
random-effects meta-analysis. By this method, cases were directly compared only to 
controls in the same studies. Statistical heterogeneity was assessed by Cochran’s χ2 
test, the I2 statistic, stratification, and meta-regression.36;37 Potential publication bias 
was assessed by funnel plot and Egger regression analysis. All analyses were 
performed using Stata IC/10.0 (StataCorp, College Station, Texas, U.S.A.). 
Statistical tests were two-sided and used a significance level of p < 0.05. 
 
Results 
Description of studies 
Ten studies involving 1454 cases and 10,193 controls, all conducted in general 
populations, were included in review.24-28;35;38-40 Details of baseline characteristics of 
the studies are provided in Table 9.1. The studies were based in Western Europe 
and North America.  Two of the studies had a cohort design while the rest had a 
nested-case control design. Three studies involved only men, one only women and 
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the rest included both sexes. The average age of the participants ranged from 45 to 
84 years. Participants were followed for an average duration of 4 to 21 years. Six of 
the studies implemented a direct measure of oxidized LDL using antibodies that 
recognize oxidation specific epitopes, while 4 used indirect measure of oxidized LDL 
involving determination of anti-oxidized LDL antibody or lipid peroxide levels. Most 
measurements were done using ELISA (enzyme linked immunosorbent assay) 
method. When measurements were done on stored samples studies generally 
reported storage at temperatures of -700 Celsius or less.  
 
Correlates of oxidized LDL 
The patterns of correlation of OxLDL with other variables were different for the direct 
4E6, direct EO6, and indirect assays. Across the studies that measured OxLDL using 
the direct 4E6 assay method, the marker showed strong positive correlations with 
LDL and total cholesterol, weak to moderate positive correlations with body mass 
index, C-reactive protein and triglycerides, and weak negative correlations with HDL 
cholesterol; OxLDL 4E6 was uncorrelated with Lp(a) concentration (Table 9.2). On 
the other hand, OxLDL measured using the direct EO6 assay method was highly 
correlated with Lp(a) concentration (r = 0.88), and there were also weak correlations 
with LDL-C and triglycerides. OxLDL measured using indirect assay methods was not 
significantly correlated with any of the above mentioned factors.  
 
Association with CHD 
The pooled overall RR for CHD for individuals in the top vs. bottom third of baseline 
OxLDL levels was 1.83 (95% CI, 1.35-2.47) using random-effects model meta-
analysis. There was significant heterogeneity across the 10 contributing studies 
(p=0.001, I2: 67% [35-83%]). The corresponding pooled RR using a fixed-effect 
model meta-analysis was 1.54 (1.31-1.81). Grouping of the studies by type of OxLDL 
assay used (ie direct vs. indirect) showed that most of the heterogeneity was among 
the studies that used indirect assay methods (Figure 9.2). Among studies that used 
direct assays, the pooled RR for CHD for individuals in the top vs. bottom third of 
baseline OxLDL concentration was 1.95 (1.51-2.51), with no significant 
heterogeneity observed across the studies (p=0.48; I2: 0% [95% CI, 0-79%]). The 
corresponding RR for studies that used indirect OxLDL assays was 1.72 (1.02-2.89), 
but here there was substantial heterogeneity across these studies (p=0.001; I2:77% 
[45-91%]) (Figure 9.2). Possible sources of heterogeneity were explored using 
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study-level subgroup analysis. However, little of the heterogeneity was explained by 
available study characteristics, including assay methods and level of adjustment for 
confounders (Figure 9.3). Egger’s test for publication bias was significant 
(p=0.012), and comparison of risk ratios by study suggested that the smaller sized 
studies reported more extreme associations.  
 
Discussion 
The present literature-based meta-analysis of 10 general population studies involving 
over 1,400 incident CHD cases and 10,000 participants has shown that individuals in 
the top third of baseline OxLDL distributions have a 1.8-fold higher risk of CHD 
compared with those in bottom third. There was substantial heterogeneity in RRs 
across studies, which appeared mainly among the studies using indirect OxLDL assay 
methods, while no significant heterogeneity was observed across studies using direct 
OxLDL markers. Indirect assay methods of OxLDL encompass a variety of different 
measures that may not be equivalent to those of direct assays or to one another, 
and this appears to be reflected by quantitative and qualitative differences in the RR 
estimates.30;31 By contrast, more consistent RRs were observed across the studies 
that used direct measures, with a pooled RR of 1.95 (1.51-2.51) highlighting the 
importance of assay method in assessing the relevance of the marker to coronary 
disease. 
 
Differences between the OxLDL measures are further demonstrated by the different 
correlation patterns with various covariates, in particular Lp(a) and LDL-C. OxLDL 
measured with indirect assays were uncorrelated with several lipid and non-lipid 
factors including Lp(a) and LDL-C. OxLDL measured with direct 4E6 assay showed a 
correlation pattern similar to that of LDL-C (a strong correlation with total cholesterol 
and LDL-C, weak to moderate positive correlations with triglycerides, body mass 
index and C-reactive protein, and negative correlation with HDL-C); this 
measurement was uncorrelated with Lp(a) concentration. On the other hand, OxLDL 
measured with direct E06 assay was highly correlated with Lp(a) concentration 
(r~0.9), while showing weak or no correlation with other markers. The later 
observations suggest that antibody E06 is specific for OxPL that accumulate in Lp(a) 
particles.2;4 The correlation of OxLDL 4E6 values with cardiovascular risk factors has 
raised questions about the independence of this measure. In this review, there was 
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no significant difference between studies with different levels of adjustment, 
although the power to detect such effects was limited due to the number of studies. 
 
The potential role of OxLDL in atherosclerosis has been recognized for over 20 
years,12;13 but epidemiological studies have shown inconsistent results because of 
variation in methods of measurement (especially in relation to the indirect assays), 
lack of adequate power in individual studies, and differences in study designs and 
study populations. Large-scale prospective studies using direct assay methods could, 
in the future, help to better characterize the relationship between OxLDL and CHD. 
On the other hand, in vitro and in vivo observations that OxPL accumulate in Lp(a) 
particles have led to interest in investigating the joint-effect of the two markers.3 
Available evidence on the correlation patterns of the various OxLDL markers with 
circulating Lp(a) levels indicates that OxLDL E06 is the best candidate for such 
investigation.  
 
The strengths and limitations of the current review merit some consideration. The 
first strength is that a comprehensive review of the available prospective evidence on 
the association between OxLDL and CHD to date was done through extensive search 
of electronic databases and reference list of relevant studies.  Second, cases were 
directly compared only to controls within the same studies, reducing the possibility 
for bias due to differing assay methods or population characteristics.  Third, it was 
possible to explore potential sources of heterogeneity using available study level 
characteristics, which showed the importance of assay methods in observed between 
study differences. However, the available data was limited by small size of studies 
and variations in assay methods. Second, a significant publication bias was observed 
across the general population studies indicating a need for caution in interpreting the 
results. Third, assessment of the differences between the various OxLDL measures 
was based on indirect comparisons across studies; measurement of OxLDL using 
several different assay methods within the same study in the future will enable direct 
comparisons. 
 
In summary, this review suggests a strong association between OxLDL markers and 
the risk of CHD in prospective studies of general populations. The association was 
more consistent among studies that used direct assay methods. OxPL measured 
using direct E06 assays appeared to be specific for Lp(a) particles. However, the 
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available evidence was limited by sparse data and considerations of heterogeneity 
and publication bias. There is a need to conduct large-scale studies implementing 
direct OxLDL assays, in order to clarify the role of the marker in CHD.  Concomitant 
measurement of Lp(a) concentration and use of antibody E06 can help to assess any 
joint-effects of the markers in relation to CHD risk . (The next section reports new 
data on the relationship between Lp(a),  OxPL measured using E06 antibodies, and 
the risk of CHD.) 
 
Lipoprotein(a), oxidized phospholipids and the risk of coronary heart 
disease: new prospective data 
As discussed above, assessment of OxPL measured using E06 antibody in relation to 
Lp(a) concentration and  the risk of CHD can help to identify the potential role of this 
marker in Lp(a) heterogeneity. This section reports on the relationship between 
circulating OxPL E06 levels, Lp(a) concentration and the risk of CHD using data from 
the EPIC-Norfolk study. 
 
Methods 
Study design 
The design of the nested case-control subset of the EPIC-Norfolk study has already 
been described in Chapter 7. The analyses in this section are based on data from up 
to 915 CHD cases and 1271 controls with concomitant information on OxPL levels, 
Lp(a) concentration, and other covariates. 
 
Laboratory method 
The laboratory methods used to measure Lp(a) and other covariates has been 
described in Chapter 7. Serum concentration of OxPL was measured with 
chemiluminescent ELISA, using murine monoclonal antibody developed in Professor 
Tsimikas’ laboratory (University of California San Francisco, USA).41 This method 
determines the content of OxPL per apo B100 particles (OxPL/apoB). Equal numbers of 
apo B100 particles are captured from each serum sample onto microtiter wells using 
anti-apo B100 antibody MB47. This enables normalization for apo B100 concentration of 
each sample. Then the OxPL content of the captured apo B100 particles is measured 
using monoclonal antibody E06. (E06 binds to the phosphocholine headgroup of 
oxidized but not native phospholipids). OxPL/apoB values are expressed as relative 
light units (RLU). 
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Statistical analyses 
Lp(a), OxPL, triglycerides, and CRP values were natural log-transformed to achieve 
symmetrical distributions. Pearson’s correlation coefficient and linear regression were 
used to assess the correlates of circulating OxPL levels. Linear regression models 
were also used to assess the association between OxPL levels and several SNPs at 
the LPA locus with significant effect on Lp(a) concentration (described in Chapter 7). 
The association of OxPL concentration with the risk of CHD was assessed using 
conditional logistic regression. Parallel analyses of Lp(a)-CHD association were 
conducted in the same subset of individuals. To assess the relationship between 
OxPL and Lp(a) concentration, the markers were mutually adjusted for each other in 
a multivariable model containing other coronary risk markers. Interaction between 
OxPL and Lp(a) was tested in two ways: i) by fitting a continuous interaction in a 
multivariable model; ii) by dichotomizing the variables and testing for categorical 
interaction with dummy variables. All analyses were done using Stata 10.1 (Stata 
Corporation, TX, USA). 
 
Results 
Data on OxPL E06 were available in 915 CHD cases and 1271 controls. The mean 
(SD) age of the controls was 64 (8) years; sixty-five percent were male. As shown in 
Table 9.3, OxPL E06 strongly correlated with Lp(a) concentration (r=0.7); OxPL 
levels increased by 73% (95% CI, 68 -79%) per 1-SD higher loge Lp(a) 
concentration. On the other hand, OxPL levels were virtually uncorrelated with all the 
other available markers. 
 
There was a significant association between OxPL and the risk of CHD. The age- and 
sex- adjusted odds ratio (OR) CHD per 1-SD higher OxPL concentration was 1.24 
(95% CI, 1.10 – 1.40), and 1.35 (1.17 – 1.54) after further adjustment for several 
markers (systolic blood pressure, smoking status, history of diabetes, body mass 
index, LDL-C, HDL-C, and triglycerides: Table 9.4). The corresponding ORs per 1-SD 
higher Lp(a) concentration were 1.34 (1.19 – 1.51) and 1.39 (1.21 – 1.60), 
respectively. The association between OxPL and CHD was no longer statistically 
significant when adjusted for baseline Lp(a) concentration (OR 1.13; 0.93 – 1.37). 
Conversely, Lp(a) remained significantly associated with the risk of CHD after 
adjustment for baseline OxPL concentration, but the OR was moderately attenuated 
to 1.27 (1.04 – 1.55) (Table 9.4).   
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A categorical interaction was tested by dichotomizing the OxPL and Lp(a) values, and 
including them in the multivariate model as dummy variables. The OR for CHD in 
comparison of individuals in top vs. bottom half of the distribution of baseline Lp(a) 
values appeared stronger among participants with greater than average OxPL levels 
(1.47; 95% CI, 1.11 – 1.94) than among those with less than average OxPL levels 
(1.06; 95% CI, 0.70-1.61); but the difference was not statistically significant (p = 
0.31). In addition, the continuous interaction term between Lp(a) and OxPL was not 
statistically significant.  
 
Table 9.5 shows the aassociation between OxPL levels and 6 SNPs known to have 
significant effect on Lp(a) concentration (Chapter 7). As can be seen from the table, 
the associations of the SNPs with OxPL levels mirrored their effect on Lp(a) 
concentration; for instance the lead SNP (rs10455872) was associated with 234% 
(211 to 257%) higher Lp(a) concentration and 136% (115 to 158%) higher OxPL 
concentration. In a subset of participants with available information on rs10455872, 
OxPL and Lp(a) (661 cases and 661 controls), the OR for CHD per copy of minor 
allele of rs10455872 was 1.62 (95% CI, 1.21 – 2.16), which was attenuated to 1.39 
(95% CI, 1.02-1.89) on adjustment for OxPL levels; the association was abolished 
on alternative adjustment for Lp(a) concentration (OR:1.10; 95% CI, 0.78-1.56).  
 
Discussion 
The present analyses of prospective epidemiological data from EPIC-Norfolk study 
have demonstrated that OxPL E06 is associated with the risk of CHD independent of 
known cardiovascular risk factors. In subset of individual with available data on 
covariates (637 CHD cases, 637 controls), the OR for CHD per 1-SD higher OxPL 
levels, adjusted for several lipid and nonlipid factors, was 1.35 (95% CI, 1.17 – 
1.54). The association was no longer statistically significant on further adjustment for 
Lp(a) concentrations. Conversely, the association of Lp(a) with the CHD risk 
remained significant after adjustment for OxPL, but the ORs were moderately 
attenuated. Consistent with the findings of the literature review, OxPL E06 levels 
were highly correlated with Lp(a) concentration. These findings indicate that E06 
detectable OxPL are highly related with Lp(a) particles, and that their vascular effect 
appear dependent on Lp(a) concentration. That the association of Lp(a) with CHD 
was moderately attenuated but still persisted after adjustment for OxPL levels 
suggests that the pathogenic effect of Lp(a) is only partly explained by OxPL. This is 
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consistent with the proposed pathogenic mechanisms for Lp(a) which involve, but 
are not limited to, accumulation of OxPL in the particles.6;7;42 An alternative 
explanation for the differential attenuation between the two highly correlated 
markers on mutual adjustment in multivariable model may be statistical. As Lp(a) 
values show high within-person correlation (r~0.9), compared with the relatively 
lower self-correlation reported for OxPL E06 (r~0.8),8 Lp(a) would be expected to 
pick-up most of the association when the two are mutually adjusted for each other 
using baseline values. Data were not available on repeat measurements to test 
whether this was the case in this instance. Assessment of OxPL in relation to SNPs at 
LPA locus with significant effect on Lp(a) concentration demonstrated that such 
variants also influence OxPL levels further highlighting the close interrelation 
between the two markers. 
 
In summary, there were strong associations of OxPL E06 with the risk of CHD 
independent of the conventional cardiovascular risk factors. The magnitude of the 
observed association (1.91 [95% CI, 1.42-2.57] for top vs. bottom third 
comparisons) was similar to that obtained by pooling published data from 
prospective studies which used direct OxLDL assays (OR: 1.95; 95% CI, 1.51-2.51).  
OxPL EO6 was highly correlated Lp(a) concentration and the associated vascular risk 
was fully explained by Lp(a) levels. Genetic variants at LPA locus influenced OxPL 
and Lp(a) concentrations in a similar manner. These data provide supportive 
evidence that OxPL E06 is key component in mediating the atherogenicity of Lp(a) 
particles. It should however be emphasized that, given the significant heterogeneity 
among OxLDL markers, these conclusions relate specifically to OxPL detected by E06.
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Table 9.1: Summary of 10 studies included in the review of the association between oxidized phospholipids and the risk of 
cardiovascular diseases 
 
Study 
Name 
Author Country 
Baseline 
year 
Population 
source 
% 
Males 
Average 
age 
(yrs) 
Blood 
source 
Storage 
T0C 
Measure of 
OxLDL 
Assay 
source 
Average 
follow-
up (yrs) 
Outcome 
assessed 
HPFS Wu(2006) USA 1993-4 
Male health 
professionals 
100 58 Plasma -150 Direct (4E6) Mercodia 7 MI 
NHS Wu(2006) USA 
1989-
90 
Female health 
professionals 
0 63 Plasma -150 Direct (4E6) Mercodia 8 MI 
CCHS Juul(2004) Denmark 
1976-
78 
General 
population 
44 45 Plasma -80 
Indirect (AA 
OxLDL) 
in-house 21 CAD 
FRAMOFF Wilson(2006) USA 1989-3 
Excluded 
baseline CVD 
46 NS Plasma -70 Direct (4E6) 
Dynex 
Technologies 
8 CAD 
HHS Puurunen(1995) Finland 1981-2 
Dyslipidemic 
middle-aged 
men 
100 47 Serum -20 
Indirect (AA 
MDA-modified 
OxLDL) 
In-house 5 MI 
Health 
ABC 
Holvoet(2004) USA 1997-8 
Age 70-79 
years 
48 74 Plasma -80 Direct (4E6)  4 MI, CAD 
Uppsala 
study 
Wu(1997) Sweden 
1970-
72 
50 year old 
men 
100 50 Serum NS 
Indirect (AA 
OxLDL IgG) 
In-house 20 MI 
Bruneck 
Study 
Kiechl(2007) Italy 1990 
General 
population 
49 62 Plasma -80 Direct (EO6) In-house 10 CVD 
MONICA -
KORA 
Meisinger(2005) Germany 
1989-
90, 
1994-5 
MONICA 
participants 
NS 61 Plasma -80 Direct (4E6) Mercodia 5.6 MI 
- Mezzetti(2001) Italy 1992 
Octa-
nanogenarians 
54 84 NS NS 
Indirect (Lipid 
peroxides) 
In-house 5 CVD 
 
NS = Not stated; MI = myocardial infarction; CVD = cardiovascular disease; CAD = coronary artery disease; OxLDL = oxidized LDL; AA 
OxLDL = autoantibody to oxidized LDL; AA MDA-modified OxLD = autoantibody to malondialdehyde-modified OxLDL; AA Cu-OxLDL = 
autoantibody to copper oxidized LDL; HPFS: Health Professionals’ Follow-Up Study; NHS: Nurses’ Health Study; CCHS: Copenhagen City 
Heart Study; FRAMOFF: Framingham Offspring Study; HHS: Helsinki Heart Study; Health, Aging, and Body Composition Study 
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Table 9.2: Correlations of oxidised LDL with various lipid and non-lipid factors 
 
  a) direct 4E6 assay  b) direct EO6 assay  c) indirect assays 
Factor  
N 
study 
N 
subject r (95% CI) p-value  
N 
study 
N 
subject r (95% CI) p-value  
N 
study 
N 
subject r (95% CI) 
p-
value 
Lipid factors 
Lp(a)  2 1002 0.02 (-0.11, 0.14) 0.806  3 4437 0.88 (0.84, 0.91) <0.001  0 0 NA NA 
TChol  4 1833 0.57 (0.46, 0.66) <0.001  2 4264 0.05 (-0.01, 0.11) 0.123  1 2458 0.00 (-0.04, 0.04) 0.843 
LDL-C  4 1833 0.61 (0.52, 0.68) <0.001  2 4264 0.08 (0.00, 0.16) 0.047  4 764 0.09 (-0.08, 0.25) 0.288 
HDL-C  3 1781 -0.16 (-0.27, -0.04) 0.008  2 4264 0.04 (-0.18, 0.26) 0.722  4 3140 0.00 (-0.12, 0.12) 0.976 
TG  3 1487 0.33 (0.28, 0.37) <0.001  2 4264 -0.15 (-0.18, -0.11) <0.001  2 180 -0.14 (-0.43, 0.18) 0.402 
Non-lipid factors 
Age  2 3379 0.06 (0.02, 0.10) 0.002  1 3481 -0.00 (-0.07, 0.07) 0.934  3 3060 0.06 (-0.05, 0.17) 0.288 
BMI  2 1348 0.12 (0.06, 0.17) <0.001  2 4264 -0.02 (-0.10, 0.06) 0.664  0 0 NA NA 
CRP  4 4433 0.11 (0.08, 0.14) <0.001  2 4264 0.03 (-0.03, 0.10) 0.316  2 564 0.42 (-0.41, 0.87) 0.322 
 
Tchol: total cholesterol; TG: triglycerides; CRP: C-reactive protein; NA: not available 
N study: no. of studies; N subject: number of individuals 
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Table 9.3: Baseline correlates of oxidized phospholipids among noncases. 
 
 
No of 
subjects 
Mean (SD) 
or % 
Pearson correlation 
 r (95% CI) 
Percentage difference 
(95% CI) in lOxPL levels 
per 1 SD increase or 
compared to reference 
category† 
Log-OxPL/apoB (RLU) 1271 7.5 (0.8)   
Log-Lp(a), mg/dl 1271 2.35 (0.69) 0.70 (0.67 to 0.73) 73% (68 to 79) 
Age 1290 64 (8) -0.06 (-0.11 to -0.00) -5% (-9 to -1) 
Sex     
    Male 837 65%   
    Female 453 35%  4% (-5 to 14) 
Smoking history     
    Never / former 1173 92%   
    Current 104 8%  -2% (-21 to 14) 
Diabetes history     
    Yes 21 2%   
    No 1269 98%  -5% (-33 to 33) 
Systolic blood pressure 1287 138 (17) -0.07 (-0.12 to -0.01) -4% (-9 to -0) 
Body mass index 1288 26 (4) -0.03 (-0.09 to 0.02) -2% (-6 to 2) 
Total cholesterol, mmol/l  1277 6.3 (1.2) -0.02 (-0.07 to 0.04) -2% (-6 to 3) 
LDL-C, mmol/l  1231 4.04 (1.00) -0.02 (-0.07 to 0.04) -1% (-6 to 3) 
HDL-C, mmol/l  1231 1.38 (0.40) 0.04 (-0.01 to 0.10) 4% (-1 to 9) 
Log-triglycerides, mmol/l 1277 0.52 (0.50) -0.03 (-0.09 to 0.03) -2% (-6 to 2) 
Apo B100 , mg/dL 1186 128 (32) -0.04 (-0.10 to 0.02) -3% (-7 to 1) 
Apo A1, mg/dL 1105 162 (28) 0.00 (-0.05 to 0.06)  0% (-5 to 6) 
Log-CRP, mg/l 1277 0.38 (1.12) -0.02 (-0.08 to 0.03) -1% (-5 to 3) 
Fibrinogen, g/L 1250 3.00 (0.74) -0.01 (-0.07 to 0.04) -0% (-5 to 4) 
White cell count, 103/µl 1096 6.5 (1.8) -0.02 (-0.08 to 0.04) -2% (-6 to 3) 
Lp-PLA2 activity, 
nmol/min/ ml 
1289 51 (15) -0.03 (-0.08 to 0.03) -2% (-6 to 3) 
 
† adjusted for age and sex; RLU: relative light units 
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Table 9.4: Odds ratio for CHD per 1-SD higher concentration of oxidized phospholipid or 
Lp(a) concentrations with progressive adjustment for covariates 
 
 Oxidized phospholipids Lipoprotein(a) 
Adjustments 
Risk ratio (95% CI) per 1-SD 
higher loge OxPL levels 
Risk ratio (95% CI) per 1-SD 
higher loge Lp(a) levels 
Age and sex only 1.24 (1.10 – 1.40) 1.34 (1.19 – 1.51) 
Plus systolic blood pressure 1.26 (1.12 – 1.43) 1.37 (1.21 – 1.55) 
Plus smoking status 1.26 (1.11 – 1.43) 1.36 (1.20 – 1.54) 
Plus history of diabetes 1.28 (1.13 – 1.46) 1.37 (1.20 – 1.56) 
Plus body mass index 1.30 (1.14 – 1.48) 1.39 (1.21 – 1.59) 
Plus LDL cholesterol 1.31 (1.14 – 1.49) 1.36 (1.19 – 1.55) 
Plus HDL cholesterol 1.35 (1.18 – 1.54) 1.38 (1.21 – 1.59) 
Plus loge triglycerides 1.35 (1.17 – 1.54) 1.39 (1.21 – 1.60) 
Plus loge lipoprotein(a) 1.13 (0.93 – 1.37) - 
Plus loge oxidized 
phospholipids 
- 1.27 (1.04 – 1.55) 
 
Analysis involved 637 CHD cases and 637 individually-matched controls with available information 
on all the covariates 
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Table 9.5: Association between OxPL levels and 6 SNPs known to have significant effect on Lp(a) concentration 
 
Association with lipoprotein(a)  Association with oxidized phospholipids 
Single 
nucleotide 
polymorphism 
No of 
subjects 
% Mean (SD) 
loge Lp(a), 
mg/dl 
Percentage difference 
(95% CI) in Lp(a) levels 
compared to reference 
category† 
z-value  
Mean (SD) 
loge OxPL, 
relative light 
units 
Percentage difference 
(95% CI) in OxPL 
levels compared to 
reference category† 
z-value 
rs10455872  2095         
    Non-carrier 1774 85% 7.4 (0.8) Ref   2.22 (0.59) Ref  
    Carrier 321 15% 8.3 (0.7) 234% (211 to 257) 34.1***  3.43 (0.55) 136% (115 to 158) 18.6*** 
rs11751605  2083         
    Non-carrier 1431 69% 7.5 (0.8) Ref   2.30 (0.66) Ref  
    Carrier 652 31% 7.7 (0.8) 43% (34 to 53) 10.7***  2.66 (0.81) 23% (14 to 33) 5.3*** 
rs3798220  2109         
    Non-carrier 2049 97% 7.5 (0.8) Ref   2.38 (0.69) Ref  
    Carrier 60 3% 8.9 (0.9) 245% (188 to 312) 13.5***  3.61 (0.88) 309% (234 to 400) 13.7*** 
rs41265930  2095         
    Non-carrier 1800 86% 7.6 (0.8) Ref   2.46 (0.75) Ref  
    Carrier 295 14% 7.3 (0.6) -25% (-32 to -19) -6.5***  2.17 (0.53) -23% (-30 to -14) -5.0*** 
rs9457938  2049         
    Non-carrier 1435 70% 7.6 (0.8) Ref   2.49 (0.73) Ref  
    Carrier 614 30% 7.4 (0.8) -21% (-26 to -15) -6.8***  2.25 (0.70) -15% (-21 to -8) -4.0*** 
rs41259144  2099         
    Non-carrier 2054 98% 7.6 (0.8) Ref   2.42 (0.73) Ref  
    Carrier 45 2% 7.2 (0.6) -36% (-48 to -20) -4.0***  1.99 (0.44) -34% (-48 to -16) -3.4** 
 
Non-carrier: refers to individuals having common homozygote genotypes; Carrier: refers to individual having heterozygote or rare 
homozygote genotypes; † Carriers of the mutant allele were compared with non-carriers ; * p<0.05, ** p<0.01, *** p<0.001 
Note: Regression models were adjusted for sage and sex 
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Figure 9.1: Study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
912 citations identified in electronic databases 
and through search of reference lists of 
relevant articles
57 full text articles retrieved were assessed for 
inclusion
855 excluded based on titles and/or 
abstracts due to not fulfilling the 
inclusion criteria (retrospective case-
control or cross-sectional studies, did 
not measure oxidized LDL levels, did 
assess cardiovascular outcomes, 
reviews, etc)
15 studies fulfilled criteria
32 were excluded due to not fulfilling 
inclusion criteria (did not measure 
oxidized LDL levels, did not assess 
cardiovascular outcomes, conducted in 
diseased populations,  reviews, etc ) 
10 studies were included in final analyses
5 studies did not provide sufficient 
information in publications to allow 
calculation of relative risk estimates 
separately for disease- free individuals
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Figure 9.2:  Association between OxLDL markers and the risk of cardiovascular outcome 
in general populations, stratified by assay method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: RRs were pooled using random-effects model meta-analysis 
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Figure 9.3:   Association between OxLDL markers and the risk of Cardiovascular Outcome 
in general population studies, stratified by various study-level characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+ denotes no adjustment; ++ denotes adjustment for age, sex and some nonlipid factors; 
+++ denote adjustment for the preceding plus lipid factors (eg, LDL-C); * 1 study did not 
report the type of blood sample  
Note: p-values for heterogeneity were obtained from random-effects meta-regression model 
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Chapter 10: Discussion 
 
This thesis has used data from several different sources, including newly generated 
genetic data, and employed complementary epidemiological methods to provide the 
most comprehensive assessment to date of the associations of Lp(a) with the risk of  
CHD (and secondarily other cardiovascular disease). This work has yielded several 
findings that importantly advance current understanding of the relationship of Lp(a) 
with CHD. This chapter discusses the main findings, implications, and strengths and 
limitations of the thesis, and outlines currently ongoing research that will advance 
the work presented herein. In addition, suggestions are made for future studies to be 
conducted in the area. 
 
Summary of principal findings 
The Emerging Risk Factors Collaboration (ERFC) collated individual participant data 
from over 100 prospective studies of cardiovascular disease, in which subsets had 
available information on various novel risk markers such as Lp(a), C-reactive protein, 
and fibrinogen (Chapter 2). This thesis is based on a 36-study subset of the ERFC 
database involving about 127,000 participants, without known preexisting 
cardiovascular disease at baseline survey, in whom at least one measurement of 
Lp(a) concentration had been made. 
 
Cross-sectional correlates of Lp(a) 
Analyses of individual data from up to 127,000 participants demonstrated that Lp(a) 
levels are highly variable between individuals, but were only modestly associated 
with available individual traits, including several known cardiovascular risk factors 
(Chapter 3). The identified correlates were weakly associated with Lp(a) 
concentration and together accounted for only 8% of the total variation in circulating 
Lp(a). Levels were materially higher in Black individuals. Lp(a) concentration was 
modestly associated with non-HDL-C, apo B100 and hormone replacement therapy, 
perhaps indicating the possibility of modulation of levels through lipid or hormonal 
factors. Overall, the findings strengthen the notion that the high inter-individual 
variation in Lp(a) concentration is largely due to genetic factors. Due to the limited 
and weak correlation of Lp(a) with other traits, the potential for confounding in 
epidemiological studies of Lp(a)-CHD association should be lower than that observed 
for markers with more extensive and stronger correlations (e.g., C-reactive protein). 
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Long-term within-person variability  
Analyses of data on over 12,000 serial measurements of Lp(a) concentration made 
an average of 8 years apart demonstrated that Lp(a) levels have high within-person 
consistency, as measured by regression dilution ratios (RDRs) (Chapter 4). 
However, the RDR was importantly different at different levels of baseline Lp(a) 
concentration. The RDR for individuals with Lp(a) levels close to the mean of the 
distribution was estimated to be 0.9; RDR values were higher at higher than average 
Lp(a) concentrations, and vice versa. The RDR was not materially different by other 
characteristics including age, sex and length of time interval between baseline and 
repeat measurement, or on adjustment for cardiovascular risk factors. The high 
observed RDR suggests that the degree of underestimation of the strength of 
association between Lp(a) and disease risk in epidemiological studies would be low. 
However, as the variability appears to depend on the individual’s Lp(a) level more 
subtle biases may arise, which necessitate appropriate correction for within-person 
Lp(a) variability. 
 
Association with disease risk 
Over 22,000 first-ever fatal or nonfatal vascular disease outcomes or nonvascular 
deaths were recorded during approximately 1.3 million person-years of follow-up in 
predominantly White populations (Chapter 5). There were broadly continuous 
associations of Lp(a) with the risk of CHD. The relative risk (RR) for CHD, adjusted for 
age and sex only, was 1.16 (95% CI, 1.11-1.22) per 1-SD higher usual Lp(a) 
concentration, and it was 1.13 (1.09-1.18) following further adjustment for lipids and 
other conventional risk factors. The RRs were not materially different by several 
clinically relevant characteristics, notably, by levels of LDL-C. Lp(a), however, did not 
appear to improve risk prediction significantly beyond what can be achieved using 
standard cardiovascular risk factors. The corresponding adjusted RRs were: 1.10 
(1.02-1.18) for ischaemic stroke, 1.01 (0.98-1.05) for the aggregate of nonvascular 
mortality, 1.00 (0.97-1.04) for cancer deaths and 1.00 (0.95-1.06) for nonvascular 
deaths other than cancer. In a separate analysis of a retrospective case-control study 
of myocardial infarction (MI) among South Asians, the odds ratio per 1-SD higher 
Lp(a) concentration was 1.19 (1.09-1.26) (Chapter 6). 
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Assessing causal relevance 
The causal relevance of Lp(a) to CHD was assessed in a nested case-control subset 
of the EPIC-Norfolk cohort (2175 cases and 2175 controls), using a “Mendelian 
randomization” framework (Chapter 7). The odds ratio for CHD per 1-SD higher loge 
Lp(a) concentration, after adjustment for cardiovascular risk factors, was 1.37 (1.20-
1.56).  Tagging SNPs rs10455872 and rs11751605 in the LPA gene (minor allele 
frequency: 8% and 18%, respectively) were associated with 207% (95% CI, 188-
227%) and 38% (31-46%) higher Lp(a) concentrations per copy of the minor allele, 
respectively. These SNPs accounted for 35% and 5% of the variation in circulating 
Lp(a) levels, respectively, and were associated with an odds ratio for CHD of 1.34 
(1.14-1.58) and 1.17 (1.04-1.33), respectively. The observed SNP-CHD associations 
were consistent with expected odds ratios corresponding to the Lp(a) effect of the 
SNPs. The disease association was abolished on adjustment for Lp(a) concentration. 
These data are thus consistent with a casual role of Lp(a) in CHD.  
 
Sources of Lp(a) heterogeneity: apo(a) isoforms and vascular disease 
Meta-analysis of data from thirty-six published studies showed that individuals with 
smaller apo(a) isoforms have about a 2-fold higher risk of CHD or ischemic stroke 
compared to those with larger isoforms. The RRs appear substantially stronger 
than those observed for comparison of individuals in the top versus bottom thirds 
of Lp(a) distribution (RR~1.3) supporting the hypothesis that Lp(a) particles with 
smaller apo(a) isoforms confer greater vascular risk. Individuals with small apo(a) 
isoforms could therefore be potentially exposed to two elements of Lp(a) 
associated risk, i.e., higher Lp(a) concentration of a small apo(a) isoform type. 
Further study is needed to fully characterize the relationship between Lp(a), apo(a) 
isoforms and vascular risk. 
 
Sources of Lp(a) heterogeneity: oxidized phospholipids and vascular disease 
In a literature-based meta-analysis of 10 prospective epidemiological studies (10,000 
participants, 1500 CHD cases), individuals in the top third of the baseline distribution 
of oxidized LDL (OxLDL) levels had a RR of 1.83 (1.35–2.47) compared to those in 
the bottom third. There was material heterogeneity across the studies likely due to 
differences in OxLDL assay methods, which measure different types of oxidative 
products. Analysis of correlation patterns by OxLDL assay method suggested that 
OxLDL-E06 may be specific for oxidized phospholipids (OxPL) that primarily localize 
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in Lp(a) particles. The relationship between OxPL E06, Lp(a) and CHD risk was 
further assessed in a nested case-control subset of the EPIC-Norfolk study. OxPL E06 
was highly correlated with Lp(a) concentration, and strongly associated with the risk 
of CHD independent of the conventional cardiovascular risk factors. The association 
was no longer statistically significant on adjustment for Lp(a) concentration. 
Conversely, the association of Lp(a) with the risk of CHD was moderately attenuated, 
but not completely abolished, on adjustment  for OxPL levels. Genetic variants at the 
LPA locus were associated with OxPL and Lp(a) concentrations in a similar manner. 
These data provide supportive evidence that OxPL E06 is a key component mediating 
the atherogenicity of Lp(a) particles.  
 
Causality of Lp(a) in CHD 
The counterfactual cohort is a hypothetical population in epidemiology that provides 
a conceptual framework for measuring the effect of a given causal factor on disease 
risk (discussed in Rothman).1;2 Disease risk is measured over a certain period of time 
in a population with a defined level of exposure. The effect of the exposure on 
disease risk is then measured by determining what the risk would have been over 
the same period of time had the same population not been subject to the exposure. 
In reality such a counterfactual cohort does not exist, and hence in practice the 
reference population is taken to be a cohort of people who do not have the exposure 
(nonexposed cohort). Therefore in observational epidemiology, the measure of the 
relationship between a certain exposure and outcome is the association between the 
two, and not the actual effect of the exposure on the outcome. The extent to which 
the disease risk varies between the nonexposed cohort and the counterfactual cohort 
determines the amount of confounding/bias present in a given measure of 
association. 
 
In the absence of a definitive evidence of an effect, a practical approach that is 
widely employed by epidemiologists to make an assessment of causality is use of 
the Bradford Hill criteria.3 Originally proposed by Sir Austin Bradford Hill, the 
criteria have been used to make an `aetiological assessment’ of epidemiological 
associations by considering the various aspects of an observed relationship. 
Detailed characterization of the association of Lp(a) with the risk of CHD in this 
thesis has made possible such aetiological investigation of the epidemiological 
relationship in the following ways: 
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i) Temporality refers to the necessity that the cause precedes the effect in time. 
That the individual participant data meta-analysis reported in this thesis included 
only prospective epidemiological studies where Lp(a) concentration was 
measured at baseline, and participants were followed for occurrence of disease 
prospectively, provides a degree of reassurance about temporality. However, 
even in prospective studies, prevalent clinical or subclinical disease can lead to 
higher levels of Lp(a) among participants who have a CHD event subsequently. 
The possibility of such reverse-causation bias was minimized in the ERFC through 
exclusion of participants with known pre-existing CHD or stroke at the time of 
baseline survey. Furthermore, subsidiary analyses excluding events occurring 
during the first five years of follow-up yielded similar associations. Nonetheless, 
since CHD is a chronic disease with a long pre-clinical period spanning decades, 
reverse causality cannot be completely ruled out as a possibility. 
 
ii) Biological-gradient refers to a monotonous relationship between a cause and 
its effect. Although this criterion was proposed with the expectation that higher 
level of a causal exposure would lead to a higher risk of the outcome, it is 
conceivable that causal associations with threshold (or even “J” shaped) 
relationships may exist. This thesis demonstrated the presence of a monotonous 
relationship between Lp(a) concentration and the risk of CHD (in contrast to 
previous suggestions of a steep threshold relationship). The data were consistent 
with a curvilinear shape of association indicating that Lp(a) may be increasingly 
important at higher concentrations. Although the physiological role of Lp(a) is 
unknown, it has been suggested that the particle may serve as a preferential 
acceptor of oxidized phospholipids and play a role in detoxifying their deleterious 
effects.4;5 Accordingly it has been proposed that Lp(a) may be protective at low 
concentrations and become increasingly pathogenic at higher concentrations.5;6 
An alternative explanation for the observed curvilinear association may be the 
variation in within-person variability of Lp(a) by baseline concentration. High RDR 
at higher Lp(a) concentration means that there is less regression dilution at high 
concentrations, and vice versa, which can lead to observation of a nonlinear 
relationship even when the underlying association has a linear shape. 
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iii) Specificity states that a cause leads to a single effect and not multiple effects. 
Unlike previous studies which generally focused on the association of Lp(a) with 
the risk of CHD, this disease assessed the relationship of Lp(a) with both vascular 
and nonvascular outcomes. The findings indicate that the associations of Lp(a) are 
specific for ischemic vascular outcomes, unlike other novel cardiovascular risk 
markers such as C-reactive protein or fibrinogen.  
 
iv) Stronger associations are thought to provide more compelling evidence for 
causality than weak ones, as weak associations may easily result from residual 
confounding due to unmeasured confounders or error in measured confounders. 
The magnitude of association observed for Lp(a) was a modest increase in CHD risk 
of 15% per a 1-SD higher concentration. However, as the association has a 
curvilinear shape, the RR becomes stronger at higher concentrations. A more 
robust assessment for the presence of residual confounding is to evaluate the 
change in RR estimates with progressive adjustment for putative confounders. In 
this thesis attempts were made to reduce residual confounder effects by predicting 
usual levels of confounders using information on serial measurements. Despite 
such a rigorous approach to control for confounding, the associations of Lp(a) were 
only modestly attenuated in fully adjusted models (Figure 10.1). 
 
v) Consistency refers to the repeated observation of an association in different 
populations under different circumstances. By analyzing data collated and 
harmonized from several epidemiological studies worldwide this thesis presents a 
unique opportunity to assess the consistency of the association between Lp(a) and 
CHD risk. The studies consistently showed a positive association of Lp(a) 
concentration with the risk of CHD, and despite considerable scope for variability 
due to differences in exposure measurement, there was only moderate 
heterogeneity observed across the studies. Furthermore, subgroup analyses by 
various individual-level and study-level characteristics demonstrated the presence 
of a consistent association of Lp(a) with disease risk in different circumstances, 
such as between males and females, diabetics and nondiabetics, smokers and 
nonsmokers, etc. 
 
vi) Plausibility refers to the presence of a biological explanation for an observed 
association. As reviewed in Chapter 1, findings from both in vitro and in vivo 
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studies have suggested potential mechanisms for the role of Lp(a) in CHD.4;7-9 
Lp(a) may contribute to the pathogenesis of CHD through deposition in the blood 
vessel wall and promotion of pro-inflammatory and pro-thrombotic activities. 
Studies have demonstrated that apo(a) transgenic mouse models have a 
significantly increased risk of atherosclerosis.7  
 
vii) Coherence states that a causal conclusion should not contradict existing 
knowledge in the area. A cause-and-effect interpretation of the association 
between Lp(a) and CHD does not appear to conflict with current understanding 
about the pathogenesis of CHD or the role of molecular factors in the disease.  
 
viii) Analogy refers to the availability of a similar exposure-outcome association 
where causality has been shown. For instance, evidence from several lines of 
investigation has led to the acceptance of LDL as the major causal factor in CHD. 
As Lp(a) is an LDL like particle sharing several biological properties, it is 
conceivable that it will cause CHD in a manner analogous to LDL.  
 
As can be seen from the above discussion, the association of Lp(a) with CHD fulfils 
most of the Bradford Hill Criteria. However, this does not prove causality as no 
combination of the criteria is sufficient for causality, and none of the criteria (except 
for temporality) is necessary for causality. In a traditional observational study, 
several factors including confounding, reverse causation, and various selection and 
information biases may lead to a discrepancy in event rates between the nonexposed 
cohort and the counterfactual cohort. Therefore, it is not possible to show 
conclusively using such data that an observed association between a given exposure 
and outcome represents the effect of the exposure on the outcome. 
 
Application of genetic methods to observational epidemiology has helped to make 
important advances in causal inference. For a genetic variant that influences a 
certain exposure, individuals with different genotypes will have different levels of the 
exposure. As alleles are assigned randomly at conception from parents to offspring, 
these genotype-determined differences in exposure are less likely to be affected by 
confounding, reverse causality or selection biases. Hence, such genotype-determined 
differences in exposure can provide a closer substitute for the counterfactual cohort 
than the nonexposed cohort of traditional observational epidemiology, providing the 
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basis for a ‘Mendelian randomization’ study.10;11 In this thesis, I made a 
comprehensive assessment of single nucleotide variations at the LPA locus in relation 
to Lp(a) concentration and the risk of CHD outcome. The analyses demonstrated that 
the risk of CHD is higher among individuals who are carriers of genetic variants 
associated with higher Lp(a) concentrations. These observations are highly 
suggestive that the association between Lp(a) concentration and CHD risk is likely to 
represent a cause-and-effect relationship. However, even these genetic findings do 
not provide conclusive evidence due to some potential limitations of `Mendelian 
randomization’ studies. Although it has been mentioned that genotype-determined 
differences in Lp(a) concentration are unlikely to be correlated with other factors, 
this may not always be the case because: i) the variants of interest maybe in linkage 
disequilibrium with other genetic variants that influence different pathophysiological 
processes; ii) the variants may have pleiotropic effects unrelated to their effect on 
Lp(a) concentrations; and iii) individuals who are carriers of the variants may 
undergo developmental compensations that counteract the effect of the 
polymorphism (canalization).11-13  
 
Experimental studies provide the highest level of evidence for causality, as 
randomization of participants to exposed and nonexposed groups affords maximal 
similarity between the nonexposed group and the counterfactual cohort. Randomized 
controlled trials of Lp(a)-lowering agents can therefore provide the most definitive 
answer possible about the nature of the association between Lp(a) and the risk of 
CHD. The major caveat in using randomized controlled trials to assess the causality 
of Lp(a) is the absence of specific Lp(a)-lowering agents. The only currently 
approved medication with significant Lp(a) lowering effect is niacin, now in phase III 
clinical trials of  vascular risk reduction.14;15 At a dose of 2.5 gm/day niacin produces 
about a 25% reduction in Lp(a) concentration. However, at the same dose niacin 
lowers LDL-C and triglycerides levels by 20% and 45%, respectively, and raises HDL-
C levels by 30%.16;17 Similar considerations apply to anacetrapib (a cholesteryl ester 
transfer protein inhibitor currently in phase III clinical trials)18 and mipomersen (an 
antisense apo B100 mRNA inhibitor evaluated in phase II clinical trials).
19 Anacetrapib 
lowers Lp(a) concentration by up to 50% at maximal dose, but also decreases LDL-C 
levels by about 40% and increases HDL-C levels by over 100% at this dose.20;21 
Mipomersen has been reported to lower Lp(a) levels by up to 75% in transgenic 
mouse models, but findings from phase I clinical trials show that the agent also 
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lowers apo B100 and LDL-C levels by up to 50% and 35%, respectively.
19;22 The 
above examples highlight that, although it was once thought to be very difficult, the 
pharmacologic modification of Lp(a) is becoming increasingly achievable; but due to 
the nonspecificity of available Lp(a) lowering agents clinical trials currently underway 
will not enable a definitive causal inference. Nonetheless, post hoc subgroup 
analyses and multivariable modelling should provide some information about the 
contribution of Lp(a) lowering to any reduction in cardiovascular risk that may be 
achieved with these drugs. (The clinical trials are expected to report within the first 
half of this decade.) 
 
Lp(a) heterogeneity 
This thesis showed that Lp(a) is a likely causal factor in CHD. But the magnitude of 
the association is modest, which may limit its clinical and public health implications. 
Study of Lp(a) heterogeneity is an area of investigation that can change these 
considerations through identification of circumstances or Lp(a) subtypes in which the 
associations of Lp(a) with vascular risk is much stronger. Lp(a) is a heterogeneous 
particle with differently sized apo(a) isoforms, a variable degree of lysine-binding 
activity, variable concentrations of oxidized phospholipids (OxPL), and variable 
densities of LDL particle, etc.23-25 Preliminary studies have implicated that several of 
these factors may influence the toxicity of Lp(a) particles. For instance, Lp(a) 
particles with smaller apo(a) isoforms or a greater concentration of OxPL have been 
proposed to have a greater pathogenic role in CHD.6;26 
 
Lp(a) particles with smaller apo(a) isoforms may be more pathogenic because they 
bind oxidised phospholipids, interact with fibrin, and/or inhibit plasmin more strongly 
than do larger isoforms.24;26-28 A meta-analysis of published data on the association 
of apo(a) isoforms with vascular risk in this thesis found that smaller apo(a) isoforms 
are associated with a 2-fold increased risk of CHD or stroke. As smaller apo(a) 
isoforms are associated with increased Lp(a) concentrations, at least part of this 
observed association reflects the higher Lp(a) concentration in individuals with 
smaller apo(a) isoforms. However, the 2-fold increase in risk is much stronger than 
what can be accounted through the effect of apo(a) isoforms on Lp(a) levels. (Based 
on the reported effect of apo(a) isoforms on Lp(a) levels, comparison of smaller 
versus larger apo(a) isoforms mirrors approximately similar difference in Lp(a) 
concentration as that observed between the means of top and bottom thirds of Lp(a) 
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distributions.29-31 But the individual data meta-analysis showed that the RR for CHD 
for top vs. bottom third comparisons of Lp(a) concentration is only about 1.3.) These 
findings suggest that Lp(a) particles with smaller apo(a) isoforms may indeed have 
more toxic effects. Similar suggestions have been made previously, based on 
observations that RRs associated with smaller apo(a) isoforms appear to be stronger 
than expected from their effect on Lp(a) levels, and findings that the association 
persists after adjustment for Lp(a) levels. It remains uncertain, however, to what 
extent associations of apo(a) isoforms and vascular disease depend on Lp(a) 
concentration, as only a handful of studies have reported mutually adjusted 
estimates.  
 
Observations that OxPL preferentially accumulate in Lp(a) particles have led to 
suggestions that the two factors may act in the same causal pathway to produce 
vascular injury.27;32;33 This thesis showed that OxPL levels are highly correlated with 
Lp(a) concentration. Strong associations of OxPL with the risk of CHD were observed, 
which were abolished on adjustment for Lp(a) concentration, but not on adjustment 
for other cardiovascular risk factors. These findings suggest that Lp(a) may promote 
the vascular toxicity of OxPL by carrying and delivering the molecules to vessel walls. 
The presence of any joint-effect between OxPL and Lp(a) was assessed by fitting 
continuous and categorical interaction terms in multivariable logistic models. The 
interaction term did not achieve statistical significance although the odds ratios for 
CHD associated with higher Lp(a) concentrations appeared stronger among 
individuals with greater than average OxPL levels, and vice versa. Interaction was 
assessed on the multiplicative scale as the risk modelling was also carried out on this 
scale. However, it has been suggested previously that testing of modification of 
absolute risk measures may be more relevant for assessing biological interactions.34 
For instance, it is widely believed that smoking and asbestos exposure interact in 
increasing the risk of lung cancer. This interaction, however, is observed on the 
additive scale and not on the multiplicative scale.35 Similarly, assessment of 
modification of absolute risk measures suggests the presence of biological 
interactions between OxPL and Lp(a). (Assessment of interaction on the additive 
scale using logistic regression models was achieved as follows: First, OxPL and Lp(a) 
levels were categorized into halves. A composite variable with four levels was then 
formed by combining the categorized OxPL and Lp(a) values, (i) less than average 
OxPL and Lp(a) concentrations, (ii) less than average OxPL concentration and 
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greater than average Lp(a) concentration, (iii) greater than average OxPL 
concentration and less than average Lp(a) concentration, and (iv) greater than 
average OxPL and Lp(a) concentrations. Taking level (i) as the reference, the odds 
ratios of CHD for individuals in groups (ii), (iii) and (iv) were 1.10 (95% CI, 0.73-
1.67), 1.19 (95% CI, 0.80-1.77), and 2.06(95% CI, 1.49-2.85), respectively.) These 
findings suggest that OxPL and Lp(a) are associated with CHD risk in pathogenic 
mechanisms that involve common causal pathways. 
 
Study of Lp(a) heterogeneity can be useful in elucidating the pathophysiological 
mechanisms by which Lp(a) may cause vascular injury. Such study can also 
contribute to current understanding about molecular pathways involved in the 
aetiology of CHD. In addition, as describe above, it can help to identify 
circumstances or Lp(a) subtypes in which Lp(a) is associated with much higher CHD 
risk, thereby enhancing the utility of the factor in risk prediction. 
 
Lp(a) in CHD risk prediction 
Risk prediction is a potentially important application of the Lp(a)-CHD association. 
The ability to identify individuals who are more likely to develop future disease is 
useful in a clinical setting because it allows institution of early preventive measures 
that are known to reduce risk (e.g., treatment with statins, better control of blood 
pressure). Whether measurement of Lp(a) concentration will have additional value 
over currently available prediction tools (e.g., Framingham risk score) is not clear. In 
this thesis the utility of Lp(a) in risk prediction was assessed using discrimination and 
re-classification measures.36-38 Although the addition of Lp(a) to standard risk factors 
appeared to increase the C-index significantly, the magnitude of improvement was 
very small reducing the clinical significance of the finding. Furthermore, inclusion of 
Lp(a) in the risk prediction models did not result in a significant improvement in re-
classification of participants with respect to their ten year risk of event. This finding 
is perhaps not unexpected given the modest magnitude of the association of Lp(a) 
with the risk of CHD. In the future, inclusion of factors of Lp(a) heterogeneity may 
importantly improve the utility of Lp(a) in CHD risk prediction. For instance, 
measurement of apo(a) isoforms or OxPL in people with Lp(a) concentration may 
help to identify individuals at further elevated risk. However, more work is needed to 
characterize in detail the epidemiological relationship between Lp(a) and the factors 
of Lp(a) heterogeneity before implementation in risk prediction.  
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Strengths and limitations 
This thesis differs from previous reports on Lp(a) and CHD risk in several important 
ways that enhance its scientific value and accuracy. First, the individual participant 
data meta-analysis presented in this thesis is large and comprehensive; the data 
encompass 36 prospective studies comprising over 126,000 individuals thereby 
reducing scope for random error, avoiding undue emphasis on the results of any 
particular study, and enabling reliable and detailed characterisation of the association 
of Lp(a) with CHD outcome. Second, harmonisation of individual records has 
enhanced consistency across studies, and has allowed the use of common outcome 
definitions and consistent approaches to adjustment for potential confounders. Third, 
individuals with known preexisting CHD and stroke were excluded, limiting any 
effects of clinically evident disease on Lp(a) concentration (i.e., minimising any 
reverse causality). Fourth, use of data on several individuals with serial 
measurements has enabled control for within-person variation in Lp(a) and other 
covariates reducing ‘regression dilution’ bias and residual confounding. Fifth, in 
contrast to earlier reports it was possible to reliably examine associations of Lp(a) 
with ischaemic stroke and nonvascular outcome. Sixth, this thesis has used novel 
applications of advanced statistical techniques to individual participant data meta-
analysis enabling rigorous analyses of available data and enhancing the validity of 
the results, such as extension of regression calibration models to a multi-study and 
multivariate setting. Analyses used appropriate statistical methods including the use 
of consistent within-study comparisons and incorporation of between-study 
heterogeneity into the combined RR estimates. Seventh, the thesis has presented 
comprehensive analyses of SNPs at the LPA locus in relation to Lp(a) concentration 
and the risk of CHD, enabling assessment of the causal relevance of Lp(a) to CHD 
using a ‘Mendelian randomization’ framework. Eighth, investigation of two factors 
related to heterogeneity of Lp(a) particles (i.e., apo(a) isoforms and OxPL 
concentration) has enabled assessment of Lp(a) subtypes in which the association 
with CHD may be more important. Ninth, analyses of data from a case-control study 
of MI among South Asians allowed a preliminary assessment of the association in 
nonwhite populations.  
 
The limitations of this thesis also merit consideration. First, some variables of 
interest were not recorded in all of the 36 studies included in the individual 
participant data meta-analysis. For example, information on HDL-C was available for 
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only 26 studies, limiting analyses involving the variable to this subset of studies.  As 
statistical methods to implement multiple imputation techniques in the meta-
analytical setting are currently under development, they were not used in this 
thesis.39 Second, the average Lp(a) concentration varied significantly across studies 
included in the meta-analysis limiting the interpretability of the actual values; 
however, use of quantile-based within-study comparisons has helped to reduce the 
impact of between-study variability in Lp(a) values. Third, in the meta-analysis, 
information was unavailable on certain key characteristics of the Lp(a) assay 
methods used by some of the contributing studies  (e.g., whether the assays were 
sensitive to apo(a) isoform variation); hence, it was not possible to make a reliable 
assessment of their effect on the magnitude of the risk estimates. Fourth, although 
data on Lp(a) variability presented in this thesis represents the most comprehensive 
information available to date, analyses were based on only about 6000 participants, 
highlighting the need for further study (by contrast, analyses of within-person 
variability of triglycerides in the ERFC involved about 150,000 participants). Fifth, as 
analyses of ischemic stroke outcomes involved relatively fewer numbers of events it 
was not possible to make as detailed characterization of the association as in the 
CHD analyses. Sixth, as data on Lp(a) cholesterol values were unavailable in 
contributing studies, primary analyses involved adjustment for total cholesterol 
without correcting for Lp(a) cholesterol. Seventh, the integrative genetic study 
presented in this thesis, based on 2000 CHD cases and 2000 controls, had limited 
power to determine the CHD effects of rarer variants with modest Lp(a) 
concentrations; a further large-scale study is required to enable full characterization 
of the variation at LPA locus in relation to Lp(a) concentration and the risk of CHD 
(Figures 10.2, 10.3). Eighth, it was not possible to assess the complete spectrum 
of variation at the LPA locus as the integrative genetic study presented in this thesis 
was based only on SNP variants, with no information available on copy number 
variations (in particular, on the KIV2 repeat polymorphism which has been reported 
to be a major determinant of Lp(a) concentration among people of European 
descent). Ninth, the analyses of apo(a) isoform size variation as a source of Lp(a) 
heterogeneity was based on aggregate data from published studies, and hence I was 
not able to characterize the relationship in detail or make appropriate allowances for 
Lp(a) concentration. Tenth, although an attempt has been made to assess the 
association of Lp(a) with CHD in South Asians, data were based on a case-control 
study with relatively modest number of cases; furthermore, there were insufficient 
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data in other nonwhite populations, in particular in Blacks. Eleventh, as the data 
presented in this thesis are observational, they cannot of course provide conclusive 
evidence about the causal nature of the association between Lp(a) and CHD. 
 
Ongoing work 
Further characterization of Lp(a) genetics 
Detailed investigation of the genetic regulation of Lp(a) concentration and its effect 
on the risk of CHD is currently underway in a consortium of 12 epidemiological 
studies (Table 10.1). The coordinating centre of the consortium is based at the 
University of Cambridge, Department of Public Health and Primary Care. The stated 
aims of the consortium are: (i) to make a comparative characterization of the 
distribution of Lp(a) concentration in South Asian and White European individuals 
using standardized measurements; (ii) to reliably characterize the spectrum of 
genetic variation (in particular, at the LPA locus) that influences circulating Lp(a) 
levels and; (iii) to determine the associations with the risk of CHD of variants 
identified under objective (ii). (The integrative genetic study presented in this thesis 
is part of the initial work that is being conducted to achieve these objectives.) 
 
To achieve objective (i), measurements of Lp(a) concentrations are already 
underway in 20,000 Europeans from the EPIC-Norfolk study (including 2200 CHD 
cases), and 10,000 South Asians in the LOLIPOP study using assays from Denka 
Sekien (the only  commercially available Lp(a) assay shown not to be affected by 
apo(a) isoform size variations). These measurements will help clarify whether Lp(a) 
levels are increased in South Asians compared with White European populations 
(Chapter 6), as well as form the basis for subsequent analyses under objective (ii). 
Both studies have already conducted genome wide association scans (GWAS) and 
detailed biochemical profiling in the participants. 
 
Objective (ii) will be achieved through genotyping a comprehensive panel of tagging 
SNPs at the LPA locus in participants with completed Lp(a) measurements under 
objective (i) (the selection of tagging SNPs and the method of genotyping is 
described in Chapter 7). The genotyping will be complemented by the GWAS data 
already available in these participants and will help to identify loci other than LPA 
that have association with Lp(a) concentrations.40-42  In addition, the KIV2 copy 
number variation is being measured in a subset of the participants to enable 
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assessment of its interrelation with the SNP variants. The copy number is determined 
using a high-throughput real-time polymerase chain reaction (PCR) system using 
methods developed by Lanktree et al.43 This method measures the sum of KIV2 
repeat polymorphisms on both alleles and has already been implemented in a large-
scale epidemiological study (Chapter 8).  
 
For objective (iii), variants with significant association with Lp(a) concentrations in 
objective (ii) will be carried forward for measurement in a consortium of studies that 
in total comprises about 28,000 CHD cases and 70,000 controls. The LPA gene is a 
unique locus containing both synonymous and nonsynonymous, and common and 
rare SNPs, as well as copy number variants with significant association with Lp(a) 
concentration and the risk of CHD. This consortium will enable detailed 
characterization of the locus in White European and South Asian populations, helping 
to elucidate the regulation of Lp(a) concentration and the role of Lp(a) in CHD 
causation. As illustrated in Figures 10.2 and 10.3, the study will have >90% power 
to detect even very modest effects on Lp(a) concentration and CHD risk. 
 
Further clarification of the role of apo(a) isoform size variation 
To further clarify the relationship of apo(a) isoform size variation with Lp(a) 
concentration and the risk of CHD, assay is underway in samples from 2000 patients 
with confirmed first-ever acute MI and 2000 controls from the Pakistani Risk of 
Myocardial Infarction Study (PROMIS).44 (The design of PROMIS has been described 
in Chapter 6.) The stated objectives of the study are: (i) to quantify associations of 
apo(a) isoforms with risk of MI in South Asians at given levels of Lp(a) 
concentration; (ii) to characterise in detail the distribution and correlates of apo(a) 
isoforms in South Asians in relation to demographic and lifestyle characteristics 
already recorded in this study; (iii) to quantify associations of apo(a) isoforms with 
Lp(a) concentration and several other relevant lipid fractions; and (iv) to quantify 
associations of apo(a) isoforms with Lp(a)-related genetic variants.  
 
Assay detail 
Measurement of apo(a) isoforms and Lp(a) concentration is underway in the 
laboratory of Professor Marcovina at the University of Washington, Seattle, who is an 
international authority on apo(a) isoform and Lp(a) assays. Apo(a) isoform 
phenotyping is carried out using agarose gel electrophoresis, comparing migration of 
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bands against a standard to determine the size of apo(a) isoforms (Figure 10.4).  
Apo(a) isoforms are characterised using a high-resolution sodium dodecyl sulphate-
agarose gel electrophoresis method followed by immunoblotting. The size 
designation relates to each isoform’s number of KIV2 repeats. The coefficient of 
variation (CV) for the assays carried out so far is <10%. Lp(a) concentration is being 
concomitantly measured by a direct-binding double monoclonocal antibody-based 
ELISA. The detection antibody is directed to a nonrepeating epitope present in 
apo(a) KIV type 9, making the assay insensitive to apo(a) isoform size variation. The 
CV of loge Lp(a) levels for the assays carried out so far is about 5%. These methods 
are recognised as the international ‘reference’ methods for apo(a) isoforms and Lp(a) 
concentration, respectively.45-48 To complement information provided by apo(a) 
isoform phenotyping, measurement of Lp(a)-related genetic factors such as the KIV2 
repeat polymorphism and several variants in the LPA gene will be performed in the 
same participants. These assays will be done at the Center for Genetic Epidemiology 
at the Strangeways Research Laboratory in Cambridge, using a real time PCR 
system. Hence, this study will be the first to assess both apo(a) isoforms and KIV2 
repeat polymorphisms on an epidemiological scale, thus addressing potential 
limitations in the interpretation of data restricted to apo(a) phenotypes, namely: (a) 
inability to detect apo(a) isoforms with less than 15 KIV2 repeats; (b) potential 
difficulties in distinguishing heterozygotes with similarly sized isoforms; and (c) 
potential difficulties in distinguishing between non-expressed alleles and homozygous 
phenotypes.49;50 
 
Power considerations 
The sample size requirement was determined based on objective (i). For a population 
with a mean of 23 KIV2 repeats and a standard deviation of 5, study of 2000 MI 
cases and 2000 controls provides 90% power to detect a difference of 0.5 repeats at 
the 5% significance level (Table 10.2). 
 
Preliminary data 
To date, apo(a) isoforms and Lp(a) concentration measurements have been carried 
out in 1500 participants (750 MI cases, 750 controls). The median (inter-quartile 
range) of Lp(a) concentration was 28.9 nmol/l (95% CI, 11.8 – 54.3 nmol/l). As in 
people of European descent about 40% of the population had predominant apo(a) 
isoforms with fewer than 23 repeats (Figure 10.5). As expected, apo(a) isoform size 
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was inversely correlated with Lp(a) concentration (r = -0.5, p<0.0001). The main 
analyses of the data as specified under the objectives will be carried out when 
measurements are completed in all participants. The results will help to advance 
current knowledge on the relationship between KIV2 repeat polymorphism, apo(a) 
isoforms, Lp(a) concentration, and the risk of CHD among South Asians. 
 
Further assessment of Lp(a) heterogeneity: Lp(a) and LpPLA2 
As implied by its name, lipoprotein-associated phospholipase A2 (LpPLA2) is an 
enzyme that sits on lipoprotein particles and catalyzes the hydrolysis of 
phospholipids.51 Recent observations that LpPLA2 molecules can be carried by Lp(a) 
particles have led to suggestions that molecule may modulate the pathogenic effect 
of Lp(a) by breaking down oxidized phospholipids on the particle (Chapter 1).5;24;32 
To make a detailed assessment of the association between Lp(a), LpPLA2 and CHD 
risk measurement of a panel of markers is underway in 19,000 participants 
(including approximately 4000 incident CHD cases) in the Reykjavik Study. The 
Reykjavik study is a population-based prospective study of the residents of 
Reykjavik, Iceland, initiated in 1967.52 (The design of the Reykjavik study has been 
described in Chapter 1). The measurements are being performed in the laboratory 
of Professor Muriel Caslake at the University of Glasgow. Measurements of LpPLA2 
mass are carried out using assays supplied by diaDexus. Merck supplied the kits for 
measuring Lp(a) concentration. Other biomarkers that are under measurement 
include: total cholesterol, HDL-C, apo B100, apolipoprotein AI, and small, dense LDL. 
Pilot studies conducted in late 2008 have confirmed that these measurements are 
feasible in samples that have been stored for up to four decades, and have shown 
generally good agreement between paired samples taken an average of 5 years 
apart. Assays are expected to be completed on the entire cohort by mid-2010.  
 
Recommendations for future studies 
This thesis has helped to advance current understanding about Lp(a) using multiple 
complementary approaches. Several significant projects that will help further 
increase present knowledge on the marker are already underway in the Department 
of Public Health and Primary Care at the University of Cambridge. (I have made 
significant contributions to the conception, initiation and implementation of these 
projects as described in the Acknowledgements section.) I believe that the 
following are future research avenues that are likely to yield fruitful results: (i) 
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detailed study of potential Lp(a) heterogeneity factors, including apo(a) isoforms, 
oxidized phospholipds, lysine binding activity, LpPLA2, and small, dense LDL; (ii) 
study of Lp(a) in relation to vascular outcome among nonwhite populations (in 
particular in South Asians and Blacks); use of GWAS data to explore genetic loci 
other than the LPA that may importantly influence Lp(a) concentration and CHD risk; 
(iv) study of Lp(a) as a therapeutic target and conducting randomized controlled 
trials using drugs with specific effects on Lp(a) concentration (as they become 
available); and (v) assessment of specific Lp(a) subtypes (e.g., Lp(a) with small 
apo(a) isoforms) as predictors of future CHD events. 
 
Conclusion 
Lp(a) concentration is specifically, continuously and independently associated with 
the risk of ischaemic vascular outcomes. Available evidence supports the causal role 
of the particle in CHD. Lp(a) appears to induce vascular damage through causal 
mechanisms that involve apo(a) isoforms and oxidized phospholipids. A 
comprehensive study of factors that contribute to Lp(a) heterogeneity should help to 
understand the full impact of the marker on cardiovascular diseases. In addition, 
further study is needed in nonwhites to assess the relevance of the factor to vascular 
disease risk in these populations. 
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Table 10.1: List of studies collaborating in Lp(a) genetics  
 
 
Studies in grey contribute to the quantitative trait analysis as well as the case-control analysis 
* For the case-control analyses, 2,200 controls will be genotyped for the EPIC-Norfolk study and 4,000 controls for the LOLIPOP study 
Study Location Design N cases 
N 
control 
Age 
range 
% 
male 
Consortium 
No. with 
genome-
wide data 
Chip array Contribution 
EPIC-Norfolk * England 
Prospective 
cohort study 
2,200 20,000 40-78 64 GEM 4,000 
Affymetrix 500K and 
Illumina HumanHap 
300 
Objective 1,2 
LOLIPOP * UK 
Multi-ethnic 
case series 
and cohort 
4,000 30,000 35–65 60 – 5,500 
Affymetrix 500K and 
Illumina HumanHap 
300, Perlegen 
Objective 1,2 
PROMIS Pakistan Case-control 5,000 5,000 30-80 84 – 10,000 
Illumina 610K Quad 
chip, IBC 50K chip 
Objective 1,2 
CoLaus Switzerland Cohort 227 5,773 35–75 48 GEM 6,000 Affymetrix 500K Objective 3 
Northern Finnish Birth 
Cohort 
Finland Cohort 200 5,741 30-31 48 ENGAGE 3,000 
Illumina HumanHap 
300 
Objective 3 
UK Twins UK Twin cohort 149 5,500 18-80 18 ENGAGE 3,500 
Illumina HumanHap 
300 and 550 duo 
Objective 3 
Rotterdam Study Netherlands Cohort 1,845 9,157 >55 40 ENGAGE 9,157 Affymetrix 500K Objective 3 
decode  Iceland Case control 6,000 5,000 
55 
(mean) 
40 ENGAGE 11,000 
Illumina HumanHap 
300 
Objective 3 
English Longitudinal Study 
of Aging (ELSA) 
UK Cohort 500 4,500 >50 46 UCL NA NA Objective 3 
MRC National Survey of 
Health and Development 
(1946 birth cohort) 
UK Cohort 250 2,750 61-62 52 UCL NA NA Objective 3 
Whitehall II UK Cohort 160 3,600 35-85 100 UCL NA IBC 50K chip Objective 3 
Northwick Park Heart-II 
Study 
UK Cohort 103 2,573 50-64 100 UCL NA NA Objective 3 
British Regional Heart 
Study 
UK Cohort 480 4,252 60-79 100 UCL NA NA Objective 3 
BHF/MRC Family Heart 
and GRACE Studies 
(WTCCC) 
UK Case-control 2,000 3,000 TBC 65 – 5,000 
Affymetrix 500K, IBC 
50K chip 
Objective 3 
SHEEP Sweden Case-control 1,200 1,500 45-70 70 – NA NA Objective 3 
Leicester/ Sheffield MI 
Cohort Study 
UK Case-control 753 624 TBC 73 – NA NA Objective 3 
CHAOS England Case-control 800 1,700 TBC TBC – NA NA Objective 3 
GEMS study Multi-centre Case-control 262 1,665 
52 
(mean) 
59 GEM 1,665 Affymetrix 500K Objective 3 
MEDSTAR  case control 
study 
USA Case-control 2,000 1,000 TBC TBC – 3,000 Illumina 1000K Objective 3 
   28,129 69,535       
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Table 10.2:  Study power to detect an association between KIV2 
repeats and myocardial infarction† 
 
 
 
 
 
 
 
 
 
 
 
†Calculated taking a type I error rate of 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample size 
cases / controls 
Power 
Mean (SD) KIV2 
repeat in controls 
Difference in no. 
of KIV2 repeats 
2000 / 2000 90% 23 (5) 0.5 
1000 / 1000 60% 23 (5) 0.5 
500 / 500 35% 23 (5) 0.5 
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Figure 10.1: Risk ratios for top versus bottom third comparison of Lp(a) concentration, 
with progressive adjustment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Analyses involved data from 26 studies and 96,000 participants. 
 
 
 
 
 
 
 
 
  
 
 
0.6 0.8 1 1.2 1.4 1.6 1.8
Age and Sex only 1.37 ( 1.24, 1.51)
Plus systolic blood pressure 1.37 ( 1.23, 1.52)
Plus smoking 1.36 ( 1.22, 1.51)
Plus history of diabetes 1.37 ( 1.23, 1.52)
Plus body mass index 1.37 ( 1.24, 1.51)
Plus LDL cholesterol 1.27 ( 1.14, 1.41)
Plus HDL cholesterol 1.29 ( 1.16, 1.43)
RR (95% CI) for  top vs. bottom thirds 
Adjustment RR  (95% CI)
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Figure 10.2: An illustration of the number of individuals required to detect a range 
of effect sizes at varying minor allele frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Sample size requirement was calculated assuming 90% power and 5% type 
I error rate, under an additive model. 
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Figure 10.3: An illustration the number of cases required to detect a range of effect 
sizes at varying minor allele frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Sample size requirement was calculated assuming 90% power and 5% type I error rate, 
under an additive model, taking a baseline risk for CHD of 4% and a case: control ratio of 1:2 
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Figure 10.4: Determination of apo(a) isoform size using agarose gel electrophoresis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              Marcovina et al, J Lipid Res 1996;37:2569 
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Figure 10.5: Distribution of apo(a) isoforms in 1500 South Asians  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: the no. of KIV2 repeats represent the predominant apo(a) isoform 
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Appendix 2: Relevant activities during PhD 
 
Selected presentations 
 
1. European Diabetes Epidemiology Group annual scientific conference. Glycated 
haemoglobin and risk of lower extremity amputation. Wageningen, the 
Netherlands, May 2009.  
 
2. American College of Cardiology annual scientific conference. Statins and all-
cause mortality. Orlando, FL, USA, March 2009. (Poster) 
 
3. Gates Scholars’ Public Health Symposium.  Lipoprotein(a) and the risk of 
cardiovascular disease. Cambridge, UK, May 2008. 
 
4. Emerging Risk Factors Collaboration Steering Committee Meeting. Association 
between lipoprotein(a) and cardiovascular disease. Cambridge, UK. December 
2007. 
 
5. Cambridge University - GlaxoSmithKline Joint Seminar. Lipoprotein(a) and risk 
of cardiovascular disease. Cambridge, UK. July 2008. 
 
Other relevant activities 
 
1. I was involved in aliquoting and cataloguing of 19,000 serum samples from the 
Reykjavik Study along with a group of four people over a period of 8 weeks. 
 
2. I undertook a 1 week hands-on molecular biology training at Smith College, 
Connecticut, USA in a summer course organized by the New England 
Biosciences Laboratory. 
 
3. I worked on nuclear magnetic resonance (NMR) analysis of 200 serum samples 
form the Pakistani Risk of Myocardial Infarction Study under Dr Jules Griffin 
(Biochemistry Department, University of Cambridge). 
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4. I worked on designing a project to measure central blood pressure and arterial 
stiffness in 200 blood donors, as part of the Cambridge CardioResourse Study. 
 
5. I was involved in laboratory work of genotyping the KIV2 copy number variation 
using real time PCR in 4000 samples from EPIC-Norfolk Study. 
 
6. I undertook the following bioinformatics courses in the Department of Genetics, 
University of Cambridge: Introduction to R, Browsing Genes and Genomes 
using Ensemble, Introduction to Bioinformatics 
 
7. I undertook several courses in transferable skills at the University of 
Cambridge, including courses on: Communication skills, Project Management, 
Assertiveness, Interview skills, Presentation skills  
 
8. I undertook several computing courses at the University of Cambridge, 
including courses on: Unix, Macintosh, Access,  Excel, PowerPoint, SPSS   
 
9. I undertook part-time consultancy work for GSK conducting literature reviews 
on several health related topics, including: Cardiovascular disease comorbidity 
in COPD, Off-label use of psychotropic medications, Epidemiology of diabetic 
neuropathy 
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3. Oon Khye Ben Ch'Hia Tsio or Lander studentship (Downing College, University 
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